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People suffering with depression often do not respond sufficiently to current treatments. A wealth 
of research suggests that mood disorders are associated with higher levels of inflammation, yet 
this literature currently provides an inadequate description of the nature of the depressive 
disorders studied and involves extensive heterogeneity between patients and study 
methodologies.  
 
This thesis comprises three studies examining a broad spectrum of circulating pro-inflammatory 
proteins before and after interventions for depression, to test specific hypotheses that raised 
inflammatory markers predict a poor response to treatment, and to detect inflammatory changes 
in relation to clinical response. Firstly, a systematic review and meta-analysis of inflammatory 
markers and treatment-response was undertaken (Study 1). Subsequently, investigations of 
inpatients with treatment-resistant depression (Study 2) and outpatients undertaking 
psychological therapy (Study 3) assessed 33 biomarkers alongside treatment and clinical 
outcome. 
 
Interleukin-6 (IL-6), Tumour necrosis factor (TNFα) and c-reactive protein (CRP) represent the 
most studied biomarkers. In meta-analyses, these were higher in depressed participants than 
controls and showed decreases with antidepressant treatment. In both subsequent studies, 
numerous biomarkers were higher in depressed patients than a non-depressed control group; 
few were lower in depression. IL-6, CRP and TNFα were predictive of treatment outcomes. Both 
inpatient and outpatient studies indicate increases in inflammatory levels with treatment. Results 
suggest that overall, inflammation is more closely linked with refractory or somatic depression but 
that age and other sociodemographic constructs also affect inflammatory activity. 
 
These results support previous evidence that inflammatory responses are dysregulated in mood 
disorders and provide novel candidates for future study. Reports of psychological interventions 
and those for treatment-resistant populations are scarce. Our findings provide promising 
indications that, if validated in future research, measures of inflammation may be useful in 
identifying patients less likely to respond to standard treatments or defining more homogenous 
subpopulations within affective disorders.  
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  Introduction  
 
 
1.1 Challenges in mental health and mood disorders  
Although psychiatry has a disease-related burden greater than any other medical discipline 
(Prince et al. 2007) a disparity of esteem is still apparent between physical and mental health 
across many domains including research funding (Kingdon and Wykes 2013) and publication 
(Vivekanantham et al. 2016). Among the difficulties that mental health faces are a lack of 
consensus surrounding classification, diagnosis and treatment that stem from an incomplete 
understanding of the processes underlying these disorders. This is highly apparent in mood 
disorders, the subcategory which comprises the single largest burden in mental health. The most 
prevalent mood disorder, Major Depressive Disorder (MDD), is a complex, heterogeneous illness 
in which up to 60% of patients may experience some degree of treatment resistance that prolongs 
and worsens illness episodes (Fava 2003). For mood disorders, and in the broader field of mental 
health, treatment outcomes would likely be improved by the discovery of robust, homogenous 
subtypes within (and across) diagnostic categories, by which treatments could then be stratified. 
In recognition of this, global initiatives to delineate functional subtypes are now in progress (Insel 
et al. 2010): principally, the Research Domain Criteria (RDoC). It has been posited that biological 
markers are priority candidates for subtyping mental disorders (Kapur et al. 2012).   
 
 
1.2 Improving response to treatments for depression 
“We need to begin collecting the genetic, imaging, physiologic, and cognitive data to see how all 
the data – not just the symptoms – cluster and how these clusters relate to treatment response” 
(Insel 2013). 
Despite an extensive range of treatment options for major depression, only approximately a third 
of patients with MDD achieve remission after an initial antidepressant and rates of treatment 
response appear to fall with each new treatment (Gaynes et al. 2009). Furthermore, treatment-
resistant depression (TRD) is associated with increased functional impairment, mortality, 
morbidity and recurrent or chronic episodes in the long-term (Fekadu et al. 2009a, Fekadu et al. 
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2012). Thus, obtaining improvements in treatment-response at any clinical stage might afford 
wider benefits for overall outcomes in depression. Despite this substantial burden attributable to 
TRD, research in this area has been sparse. Definitions of TRD are not standardised, in spite of 
previous attempts (Fava et al. 2003): some criteria require only one treatment trial that fails to 
achieve a 50% symptom-score reduction (from a validated measure of depression severity), while 
others require non-achievement of full remission or non-response to at least two adequately 
trialled antidepressants of different classes within an episode to be considered TRD (Fava 2003, 
Trivedi Madhukar 2008). This inconsistency renders interpreting the research literature on TRD a 
complex task. 
 
In order to improve response to treatments, it is clearly helpful to identify predictive risk-factors of 
non-response. Some general predictors of TRD have been characterised, including a lack of full 
remission after previous episodes, comorbid anxiety, suicidality and early onset of depression, as 
well as personality (particularly low extraversion, low reward dependence and high neuroticism) 
and genetic factors (Bennabi et al. 2015). These findings are corroborated by reviews 
synthesising the evidence separately for pharmacological (Serretti et al. 2007) and psychological 
(Driessen and Hollon 2010) treatment for depression. Antidepressants and cognitive-behavioural 
therapies (CBT) show approximately comparable efficacy (Cleare et al. 2015), but due to their 
differing mechanisms of action might be expected to have different predictors of response. While 
early-life trauma has long been associated with poorer clinical outcomes and reduced responses 
to treatment (Tunnard et al. 2014), early indications suggest that people with a history of childhood 
trauma might respond better to psychological than pharmacological therapies (Nemeroff et al. 
2003). Despite this, uncertainty prevails and little personalisation or stratification of treatment has 
reached clinical practice (Nierenberg 2003). Biomarkers provide a potential target for identifying 
predictors of response to various interventions (Thase 2014); the evidence to date suggests that 
circulating markers in blood (reflecting activity of neurotransmitter, neurotrophic, neuroendocrine 
metabolic and inflammatory systems) can predict mental and physical health outcomes, but these 
reports are far from consistent (Jani et al. 2015). 
 
The overarching aim of this thesis is to identify whether biomarkers of inflammation hold 
translational potential for enhancing response to treatments for depression (or MDD). The 
forthcoming sections begin with a summary of human inflammatory functions (focusing around 
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proteomic cascades that represent inflammation and can be readily measured), leading to the 
rationale for an inflammatory role in depression followed by the evidence supporting this and 
implicating inflammation in treatment response.   
 
 
1.3 The inflammatory response  
Evidence for an inflammatory role in depression is compelling: the routes by which the two relate 
are numerous and have been frequently documented – as shown by the fact that at least three 
review articles have yielded over 1500 citations each (Raison et al. 2006, Dantzer et al. 2008, 
Miller et al. 2009a). It is crucial to understand the fundamental mechanisms of complex immune 
responses and their effects, in conceiving the potential sources of inflammation in depression.  
 
 Inflammatory functions  
The ability to fight pathogenic intruders was clearly imperative early in evolution and although the 
risk of death from infection has dwindled in modern times, its critical role persists. Inflammation is 
the body’s protective response to infection or other unwelcome intruders. It involves an 
amassment of white blood cells (including phagocytes, such as macrophages), proteins and fluid 
at the site of injury or infection. Macrophages trigger the release of pro-inflammatory cytokines 
(messenger proteins of the immune system), which increase blood vessel permeability allowing 
more inflammatory cells to access the site of infection or injury. This feedback loop sustains the 
innate response; a first-line, non-specific response that is short-term. In the longer term, B or T 
lymphocytes (B or T cells) can initiate a specific response against an intruder, when an antigen 
binds to an antigen-specific receptor on the cell surface. This is an adaptive immune response. B 
cells are primarily involved in producing antibodies. Effector T cells display cytotoxic activity 
(killing infected cells), helper activity (through cytokine signalling to maintain the response) and 
regulatory activity (to inhibit non-essential immune responses).  
 
There is much overlap between adaptive and innate immune responses, occurring through 
receptor signalling and the onset of protein cascades in the inflammatory response. Upon receptor 
binding, tyrosine protein kinases are activated and permit onward signal propagation, mediated 
by signal complexes comprised of many proteins. Inflammatory protein cascades importantly 
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contain cytokines (predominantly interleukins, interferons and the tumour necrosis factor family) 
including chemokines, as well as cell-adhesion molecules (including intracellular adhesion 
molecule-1; ICAM1 and vascular adhesion molecule-1; VCAM1) and acute phase proteins (such 
as c-reactive protein; CRP, and serum amyloid alpha; SAA). The acute phase response is one 
important protein cascade which occurs in innate inflammation, initiated from macrophage 
activation. Chemokines are small cytokines with chemoattractant properties; they attract specific 
cell types. As leukocytes travel alongside endothelial cells, chemokines help them to bind with 
the help of cell-adhesion molecules, enabling the leukocytes to cross blood vessel walls and 
directing them towards the site of inflammation. Chemokine activity also occurs in adaptive 
immunity, in secondary lymphoid organs where T cells are activated. Chemokines and cell-
adhesion molecules enable naïve T and B lymphocytes to pass through lymphoid tissues.  
 
A healthy immune system relies on feedback cycles that are well-regulated. Anti-inflammatory 
cytokines are produced in the same cascades as pro-inflammatory cytokines such as IFNγ (Th1 
cells, among others), but suppress further upregulation of innate and adaptive responses. The 
role of regulatory T-cells is mentioned above; these help to reduce an adaptive response through 
lessening the signalling of antigen-presenting cells and produce prominent anti-inflammatory 
cytokines including interleukin-10 (IL-10), which carries out similar functions, inhibiting the 
production of pro-inflammatory cytokines (particularly IL-12). This is required to prevent 
inflammatory responses from damaging the host. If regulatory T-cells do not function adequately, 
cytokines and similar proteins can be abnormally produced causing a chronic inflammatory state, 
found in immune disorders (e.g. rheumatoid arthritis, multiple sclerosis) which are notoriously 
difficult to treat and increase the likelihood of cancers and other medical complications. An 
expansion of specific inflammatory molecule mechanisms can be found below in Section 1.3.4 
and Table 1.1. 
 
As biomarkers of disease, peripherally circulating cytokines can be non-invasively measured in 
plasma or serum from blood. Some can be detected in saliva or urine (Gururajan et al. 2016). 
Their corresponding gene sequences and gene expression can additionally be assessed. More 
invasively, central nervous system (CNS) production of cytokines can be observed, most often in 




1.3.1.1 Peripheral vs. CNS inflammation 
Neuroinflammation occurs where microglial cells in the brain are activated, stimulating cytokine 
production; this can often become chronic. Chronic neuroinflammation promotes permeability of 
the blood-brain barrier (BBB) causing transmission of peripheral and brain inflammation. It was 
long believed that cytokines could not pass the BBB and therefore a separate system must 
operate in the brain. However, after Pryce et al. (1997) demonstrated that inflammation in rats 
can trigger signals enabling T-cells to pass through the BBB there is growing evidence in humans 
that inflammatory molecules do pass through the BBB even in healthy individuals. This 
relationship is reviewed further in Dantzer et al. (2008) who delineate four pathways of interaction 
between peripheral and brain inflammation: cytokines can cross the BBB via active transport on 
other molecules or via saturable transport when cytokine levels are high; through volume diffusion 
in areas without a BBB (such as the circumventricular organs or chloroid plexus); by activating 
other cells lining the cortex (such as IL-1 receptors that produce prostaglandin, sending signals 
onto the brain), and by binding to receptors in critical locations e.g. the vagus nerve where signals 
can access the brain. The fact that inflammatory states increase BBB permeability has substantial 
implications for disease states where even low-grade inflammation is chronic, because as well as 
inflammatory components, this also increases vulnerability for other molecules or bacteria to 
penetrate the brain. 
 
 Interactions between inflammation and other physiological systems  
Numerous associations are present between inflammation and other important biological 
systems, adding to the complexity of understanding specific immune function. Of most relevance 
in affective disorders are the monoamine, neurotrophic and neuroendocrine systems.  
 
1.3.2.1 Serotonin and monoamines 
Inflammation influences monoamine transmission, most prominently serotonin (5-HT) but also 
dopamine and norepinephrine (Reyes-Garcia and Garcia-Tamayo 2009). Elevations in pro-
inflammatory cytokines influence 5-HT via nuclear factor kappa-light-chain-enhancer of activated 
B cells (NFkB) and tryptophan-kynurenine pathways: indoleamine-2-3-dioxygenase (IDO) is 
stimulated by cytokines and increases the metabolism of tryptophan (the precursor to 5-HT) into 
kynurenine, which reduces its progression into serotonin. Some inflammatory molecules also 
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heighten activation of the 5-HT transporter (5-HTT) which reduces the amount of synaptically 
available serotonin. Zhu et al. (2006) demonstrated transiently increased 5-HTT activity in rodents 
stimulated with IL-1β or TNFα. This has recently been supported in human studies; both in healthy 
and psoriatic populations, Krishnadas et al. (2016) demonstrated brainstem 5-HTT availability 
correlating positively with peripheral TNFα levels (although not with other pro-inflammatory 
markers measured) and treatment with the anti-TNFα drug etanercept in patients reduced the 
amount of available brainstem 5-HTT (as well as depression severity, CRP and IL-6). In 
combination, TNFα and 5-HTT availability explained a proportion of the variance in depressive 
symptoms in these subjects (Krishnadas et al. 2016). Correspondingly, serotonin-enhancing 
medications (e.g. venlafaxine, fluoxetine, sertraline) can reduce levels of inflammation (Janssen 
et al. 2010; see Section 1.4.4). 
 
1.3.2.2 The HPA-axis and neuroendocrine system 
As described above, an increase of kynurenine can be caused by tryptophan which has long been 
known to influence glucocorticoids (Curzon and Bridges 1970). Both immune and endocrine 
responses have well-known roles in responding to stress (physiological or psychological) so it is 
not surprising that these two systems influence each other. As reviewed by Horowitz and 
Zunszain (2015), there are complex interactions between the HPA-axis and inflammatory activity. 
Firstly, cytokines can stimulate corticotropin-releasing hormone (CRH) and adrenocorticotropin 
hormone (ACTH) which in turn stimulate cortisol. Where cytokines are elevated, overproduction 
of these hormones can alter glucocorticoid receptor (GR) function which impairs feedback 
mechanisms, leading to chronic HPA-dysregulation (and feedback to inflammation). In a well-
regulated system, it is thought that GRs subsequently suppress cytokine production, inhibiting 
inflammation; if GR function becomes impaired then inflammatory activity may not be regulated 
through this process. GRs also inhibit inflammatory proteins through lessening the transcription 
of NFkB, which is key for pro-inflammatory gene transcription (Zunszain et al. 2011). 
 
Both acute and chronic cortisol elevations have been reported in mood disorders (Herane Vives  
et al. 2015), and particularly elevated cortisol levels may predict a poorer response to 
psychological treatment (Fischer et al., 2017). Successful antidepressant treatment appears to 
affect neuroendocrine processes; importantly GR function, although preclinical, in vitro and in vivo 
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studies have not yet yielded a consistent model of these effects (Carvalho and Pariante 2008, 
Anacker et al. 2011a).   
 
1.3.2.3 Neurotrophic factors 
Cytokine cascades in response to inflammation facilitate the stimulation of other protein surges; 
two prominent examples are the NFkB and mitogen-activated protein kinase (MAPK) cascades. 
The MAPK pathway may be the primary route of interaction between inflammatory and 
neurotrophic functions; through which molecules such as brain-derived neurotrophic factor 
(BDNF) are reduced in chronic inflammatory states (Yang et al. 2012). Impairment of astrocyte 
function and N-Methyl-D-Aspartate (NMDA) receptor over-activation are consequences of 
recurrent inflammation playing key roles in disrupting neurotrophins, as well as the glutamatergic 
system. This reduces neurogenesis and leads to decreased neural plasticity (Miller et al. 2009a). 
This relationship is reviewed in detail by Eyre and Baune (2012) who outline a number of growth 
factors, including vascular-endothelial growth factor (VEGF) and insulin-like growth factor (IGF), 
that appear related to inflammation and dysregulated in depression. 
 
 A systems biology approach to inflammation  
Systems biology seeks to determine complete models of dynamic, complicated biological 
phenomena through simulation and computational modelling techniques. An extremely complex 
and pleiotropic system, inflammation is still insufficiently understood despite recent progress: 
there is thus much promise for a systems biology approach, particularly for non-healthy 
populations where we can expect to see distinct variations of immune imbalances. However, even 
in healthy subjects, and despite significant research effort, analyses still provide insufficiently 
replicated networks of system components (or nodes) that also do not coherently integrate with 
other networks that operate hierarchically in the system (e.g. between protein-protein interactions, 
genomics, transcriptomics, metabolomics). In discussing this progress to date, Subramanian et 
al. (2015) conclude that full explanatory models of inflammation have the potential to be computed 
for healthy and disease states, at the proteomic level as well as for up-stream genetic markers 
and down-stream clinical markers. It is worth noting that a number of features of inflammation 
render this challenging, including the extensive array of molecules involved in this physiological 
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response. Applying a network approach to large biomarker panels is likely to yield informative 
results for future understanding. 
Inflammatory proteins are often considered either ‘pro’ or ‘anti’ inflammatory, based on whether 
they tend to exert activity in the onset or resolution of the inflammatory responses, respectively. 
This somewhat reductionist observation of immune function has likely perpetuated some 
misconstrued or incomplete understanding of the system: Cavaillon (2001) and Banchereau et al. 
(2012) have highlighted a wide array of proteins that contain both pro- and anti-inflammatory 
properties, which are generally assumed to simply amplify inflammatory activity. These include 
IFNα, IFNγ and TNFα.  Similarly, IL-6 is one of the most prominent pro-inflammatory cytokines 
but is now known to also possess anti-inflammatory functions (Xing et al. 1998). Xing et al. 
reported that IL-6 knockout mice exhibited heightened levels of TNFa and macrophage 
inflammatory protein-2 (MIP-2; CXCL2) among other inflammatory proteins, in response to 
endotoxin. The fact that endogenous IL-6 administration ameliorated these differences was 
attributed to an anti-inflammatory role for this cytokine, although this apparently compensatory 
effect highlights the critical nature of IL-6 in local, acute inflammatory responses.   
  
 Inflammatory markers considered in this thesis  
A priori, IL-6, TNFα and CRP were identified as prominent pro-inflammatory markers that appear 
important in depression (see below, Section 1.4) and are functionally relatively well understood. 
In Study 1, as part of a systematic review, all proteomic markers of inflammation are investigated. 
Subsequently, these three a priori markers were measured as part of an array of 33 inflammatory 
proteins in studies 2 and 3. The ability to measure a broader array of biomarkers enables a greater 
insight into the inflammatory network components and interactions between them. Their main 
functions are summarised below in   
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Table 1.1 and Sections 1.3.4.1 – 1.3.4.5.  Most of these inflammatory markers (IMs) have known 
pro-inflammatory functions; those with important regulatory or anti-inflammatory functions are 
grouped together in the final category.  
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TNFα Pro Mainly Th1 induced, by monocytes and macrophages. Can 
stimulate IL-1 and IL-6. Role in programmed cell death; also 
fatigue and anorexic effects in illness. 
+ + ~ TNFα elevations are uncertain 
(Haapakoski et al. 2015). 
IL-6 Pro  Regulates Th1 / Th2 and mediates acute phase response. 
Pleiotropic functions. Stimulates many cytokines. 
+ + + Elevations in depression appear 
robust (Haapakoski et al. 2015). 
CRP Pro  Acute phase protein. Large increase in levels with 
inflammation, triggered by cytokines e.g. IL-6. 
+ + + Elevations in depression appear 
robust (Haapakoski et al. 2015). 
IL-10 Anti  Th2 secreted. Inhibits the synthesis of many cytokines 
(e.g.  IFNγ, TNFα) and Th1 functions. 
+ ~ - No differences identified with 
controls overall (Liu et al. 2012a). 
IL-8  Pro Chemokine. Produced mainly by macrophages. Activates 
neutrophils, basophils. 
+ ~ No differences identified overall 
(Eyre et al. 2016b). 
IL-12 Pro Th1-produced, early in the inflammatory response. 
Upregulates natural killer-cell activity, IL-2 and IFNγ. 
+ Few studies of elevated IL-12 (Kim 
et al. 2002, Sutcigil et al. 2007). 
IL-7 Pro/ 
Anti 
Upregulates T and B cells. Acts in conjunction with IL-2 and 
IL-4. Important role in lymphocyte development. 
+ Few studies where elevated in 
depression (e.g. Dahl et al. 2014). 
IL-15 Pro/ 
Anti 
Stimulates activated T cell growth and natural killer cell 
activity. Shares functions with IL-2. 
+ ~ Higher than (Simon et al. 2008) or 
similar to (Dahl et al. 2014) controls. 
IL-16 Pro Also known as lymphocyte chemoattractant factor (LCF). 
Attracts T-cells and monocytes. Stimulated by IL-1β.  
+ ~ Normal (Lee et al. 2006) or higher in 
MDD (Stelzhammer et al. 2014). 
IL-17 Pro Produced by Th17 cells and other lymphocytes. Regulatory 
function in production of various cytokines. 
+ May be higher in depression and 
anxiety symptoms (Liu et al. 2011). 
MCP1 Pro Chemokine. Supports Th1 & Th2, may modulate neuro-
endocrine function. Stimulates IL-4, IL-6 and IL-8. 
++ Overall, higher in patients than 
controls (Eyre et al. 2016b). 
MCP4 Pro Chemokine, mainly produced from T cells. Supports initiation 
of inflammatory response, activates basophils. 
+ Few studies. Elevated in late-life 
depression (Diniz et al. 2015). 
Mip1b Pro Chemokine, produced by T cells. Stimulated by IL-1 and 
TNFα, inhibited by IL-10 or corticosteroids. Can activate 
cytokine release only in conjunction with Mip1a.  
+ - Elevated (Xiong et al. 2015) or 
reduced (Lehto et al. 2010) in 
depression. 
Eotaxin  Pro Chemokine. Attracts eosinophils and basophils (along with 
IL-5, sICAM1, sVCAM1). May be an important link between 
peripheral and neural inflammation.   
+ Increase in mood disorders 
regardless of current mood 
symptoms (Magalhaes et al. 2014). 
sICAM1 Pro Found on endothelial cells. Upregulates leukocyte activity. Is 
modulated by a number of cytokines e.g. IFNγ, TNFα. 
+ Higher in bipolar and unipolar 
depression (Schaefer et al. 2016). 
sVCAM1 Pro As above. Specifically found on vascular endothelium, and 
may relate more strongly to cytokines than sICAM1. 
+ Few studies. Increases found in 
MDD (Dimopoulos et al. 2006). 
SAA  Pro Acute phase protein, involved in amyloidosis. Strongly 
related to CRP. Increases 100-1000 fold with inflammation. 
+ Few studies, elevated in depression 
(Kling et al. 2007). 
TARC  Pro Chemokine, selectively attracts T-cells. Stimulated by 
cytokines e.g. TNFα and IFNγ. Additional regulatory role in 
inflammatory responses.  
n/a Not studied. Lower in suicide 
attempters, where only one third had 
MDD (Janelidze et al. 2011) 
Tie2 Pro Induced by cytokines e.g. TNFα. May also have an anti-
inflammatory role (Hughes et al. 2003) 
n/a Not studied. Tyrosine may be lower 
in depression (Dwivedi et al. 2003). 
IP-10 Pro Chemokine. Can stimulate sICAM1 production in endothelial 
cells, is induced by cytokines e.g. IFNγ, IL-1, IL-4 & TNFα.  
+ ~ Normal (Simon et al. 2008) or high in 
MDD (Wong et al. 2008) 
IFNγ Pro Prominent Th1 cytokine, may suppress Th2 cells. Has 
antiviral effects and can activate acute phase responses. 
+ + ~ No different from controls when 
meta-analysed (Liu et al. 2012a) 
Eotaxin3 Pro Chemokine. Similar to Eotaxin-1. Attracts eosinophils, 
basophils and neutrophils. Stimulated by IL-4, IL-13, TNFα. 
n/a Not studied. mRNA high in MDD 
non-responders (Powell et al. 2013). 
Mip1a  Pro Chemokine. Similar functions to Mip1b, but can stimulate 
cytokines in the absence of Mip1b. Interacts with basophils. 
+ Few studies, most with higher levels in 
depression (e.g. Simon et al. 2008).  
IL-5 Pro/ 
Anti 
Produced by T cells (Th2). Aids growth of B cells and 
eosinophils. Functions alongside Eotaxin and IL-4.   
+ Few studies, elevated in depression 
e.g. Dahl et al. (2014). 
TNFβ Pro Also known as lymphotoxin. Th1 secreted cytokine closely 
related to TNFα, and inhibited by IL-10. 
+ Few studies, may be higher in MDD 
than controls; Shelton et al. (2011). 
IL-12p70 Pro Part of heterodimer comprising IL-12. + ~ Higher (Simon et al. 2008) or similar 
to controls (Einvik et al. 2012). 
IL-4 Anti  Prominent Th2 cytokine with many sources and targets. 
Inhibits IFNγ.   
+ ~ - No different from controls in meta-
analysis (Liu et al. 2012a). 
IFNα Pro Secreted from infected cells by leukocytes. Has antiviral 
properties. Stimulates cytokine production including IFNγ 
~ Few studies. No different in TRD 
than controls (Carvalho et al. 2013). 
GM-CSF Pro Upregulates monocytes, granulocytes, T cells and cytokines 
e.g. IL-1, TNFα. Similar but distinct from G-CSF which 
activates neutrophils; GM-CSF reduces neutrophil activity. 
(+) G-CSF may be higher in depressed 
than control groups (Simon et al. 
2008, Dahl et al. 2014). 
IL-13 Anti Th2-cytokine. Closely related to IL-4; also to IL-10. 
Downregulates eosinophils and TNFα activity.  
+ Some indications of elevation in 
depression (Simon et al. 2008). 
IL-1β Pro Produced by monocytes. Triggers fever and acute phase 
response, TNFα & IFNγ. Links with appetite regulation. 
+ + ~ Elevations in depression are not 
robust (Haapakoski et al. 2015). 
IL-1α Pro As above. + - Few conflicting studies (Natelson et 
al. 1999, Simon et al. 2008) 
IL-2 Pro/ 
Anti 
Th1 cytokine which supports Treg cells in regulating immune 
responses. Involved in T lymphocyte development 
+ ~ - IL-2R but not IL-2 higher in MDD in 
meta-analyses (Liu et al. 2012a). 
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1 Biomarkers categorised according to their consideration as primarily pro- or anti-inflammatory in function.   
2 Summary of evidence of IM comparisons between depressed versus non-depressed populations. + = higher IM levels 
in depression or MDD, ~ = non-significant differences between depressed and control groups, - = lower levels in 
depression. The number of signs approximately indicates the amount and relative amounts of evidence pertaining to 
each of the three signs.   
IM abbreviations: TNFα = tumour necrosis factor (alpha), IL-6 = interleukin-6, CRP = c-reactive protein, IL-10 = 
interleukin-10, IL-8 = interleukin-8 (CXCL8), IL-12 = interleukin-12, IL-7 = interleukin-7, IL-15 = interleukin-15, IL-16 = 
interleukin-16, IL-17 = interleukin-17, MCP1 = monocyte chemoattractant protein (CCL2), MCP4 = monocyte 
chemoattractant protein 4 (CCL13), Mip1b = macrophage inflammatory protein-1beta (CCL4), sICAM1 = soluble 
intracellular adhesion molecule 1 (sCD54), sVCAM1 = soluble vascular cell adhesion molecule 1 (sCD106), SAA = 
serum amyloid a, TARC = thymus & activation-regulated chemokine (CCL17), Tie2 = Tyrosine kinases with Ig and EGF 
homology domains-2, IP-10 = interferon gamma-induced protein 10 (CXCL10), IFNγ = interferon gamma, Mip1a = 
macrophage inflammatory protein-1alpha (CCL3), IL-5 = interleukin-5, TNFβ = tumour necrosis factor beta, IL-12p70 = 
interleukin-12 p70, IL-4 = interleukin-4, IFNα = interferon alpha, GM-CSF = granulocyte macrophage colony-stimulating 
factor, G-CSF = granulocyte colony-stimulating factor, IL-13 = interleukin-13, IL-1β = interleukin-1beta, IL-1α = 




1.3.4.1 Pro-inflammatory cytokines 
Upon activation, macrophages produce tumour necrosis factor (TNFα) and interleukin-1 (IL-1), as 
well as IL-6, IL-12 and granulocyte colony-stimulating factor (GM-CSF). In turn, these stimulate 
the release of additional key molecules (including additional macrophages themselves).  
The IL-1 family of proteins signals primarily on the NFkB pathway and is largely involved in innate 
responses, activating macrophages but also T cells. IL-1β is often examined, but although highly 
related, IL-1 alpha and beta (IL-1α and IL-1β) are separate proteins and IL-1α is rarely measured 
singularly in depression research. Although IL-1α and β have very similar actions, IL-1α is 
biologically active from its inception, while immature IL-1β is inactive until cleaving (removal of an 
amino peptide) takes place.  
The TNF family has important roles in both innate and adaptive immunity; TNFα is a key player 
in facilitating monocyte (the precursor to macrophage) transmission across the endothelium 
(partly by increasing cell adhesion molecules) in innate immunity, but is also synthesised by 
activated T cells. TNFβ acts very similarly to TNFα but has a key role in regulating cell activity 
and lymph node development.  
IL-6 is a hematopoietic pro-inflammatory cytokine produced early in innate inflammation and 
important for initiating protein cascades, and with adaptive immune functions: IL-6 is also 
produced by T cells and further stimulates T and B cell production and growth. Hematopoietic 
cytokines include a wide variety of proteins (including IL-5 and GM-CSF) that regulate the 
production of stem cells. GM-CSF facilitates neutrophil and monocyte development; other 
cytokines in this category are classed as regulatory cytokines as they are considered to have 
more downregulatory inflammatory effects. It has recently been shown that IL-16 can enhance 
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the production of hematopoietic cells, through CD34 activity (Rofani et al., 2009); this assists with 
their recruitment of T helper cells at the endothelium.  
IL-12 (and its active heterodimer, IL-12p70), also expressed by macrophages, strongly promotes 
IFNγ production through activating innate lymphoid cells. IL-12 and IFNγ are considered potent 
inflammatory markers and jointly activate natural killer cells which enhance phagocytosis. IL-12 
also binds to its receptor on Th1 cells, which activate macrophages and produce cytokines. 
Additionally, IL-12 upregulates Th17 which produce IL-17.  IL-17 facilitates chemokine production 
early in the immune response, assisting with neutrophil recruitment. While type II interferon-γ 
(IFNγ) is critical for early innate responses, type I interferons (prominently IFNα) derive from 
smaller leukocytes and dendritic cells, and are important for antiviral responses.  
 
1.3.4.2 Acute-phase proteins  
IL-1β, TNFα and IL-6 (described above) all have a critical role in inducing fever, by stimulating 
the acute phase response protein cascade (reviewed in Baumann & Gauldie 1994) for which CRP 
is considered the primary biomarker. Increasing strikingly in response to inflammation, both CRP 
and SAA can bind to bacteria, targeting them for phagocytosis (termed opsonisation) as well as 
initiate a further cascade of complement proteins.  
 
1.3.4.3 Chemokines  
When complement activation occurs, further cytokines – including chemokines – are released. 
CXCL and CCL chemokines act on different sets of receptors but have similar functions in innate 
immunity. While CXCL8 (IL-8) is produced by monocytes and macrophages and attracts 
neutrophils, CXCL10 (IP-10) is stimulated by IFNγ but attracts activated T cells as well as B cells 
and endothelial cells. CCL2 (MCP1), CCL3 (Mip1a) and CCL4 (Mip1b) attract monocytes, natural 
killer and T cells. CCL13 (MCP4) functions similarly to MCP1 but also attracts eosinophils and 
basophils, as do CCL11 and CCL26 (Eotaxin and Eotaxin-3). CCL17 (TARC) targets immature 
dendritic cells and regulatory T cells. 
 
1.3.4.4 Other pro-inflammatory signalling proteins  
Cell adhesion molecules and immunoglobulins ICAM1 and VCAM1 work closely with chemokines 
in allowing molecules such as T lymphocytes to cross the endothelium. At the endothelium these 
CAMs are regulated by IL-1 and TNFα. ICAM1 and VCAM1 indeed have many signalling links 
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throughout the immune response, including opsonisation and phagocytosis. In their soluble forms, 
ICAM1 and VCAM1 help prevent lymphocytes adhering to endothelial walls, including at the BBB, 
which reduces the likelihood of neuroinflammation (Rieckmann et al. 1995). They may, therefore, 
be useful therapeutically in blocking endothelial interactions with lymphocytes, but this might be 
limited by their pro-inflammatory actions. These immunoglobulins, and another – Tie2 – have 
angiogenic and signalling functions. Tie2 in particular is critical for the transduction of signals in 
inflammation.  
 
1.3.4.5 Cytokines with regulatory or anti-inflammatory functions  
Even fairly early in infection response, type II innate lymphoid cells produce cytokines which have 
a downregulatory effect on inflammation. These include IL-13, IL-4 and IL-5 (Th2 cytokines), and 
while these lead to some short-term recruitment of additional cytokines, they can also have 
inhibitory effects on pro-inflammatory markers. For example, IL-13, IL-4 and IL-10 can all reduce 
IL-8 activity (Marie et al. 1996), although these findings were heterogeneous for the former two 
cytokines. IL-10 exerts a strong anti-inflammatory effect, inhibiting macrophage activity in part 
through reducing signalling of antigen-presenting cells to prevent maintained T-cell response. 
Similarly, IL-13 has clear suppressive effects on the inflammatory response through inhibiting 
macrophages, and is important for B-cell growth. IL-4 is also a key marker of B cell activity, 
produced in eosinophils. IL-5 is responsible for eosinophil growth and development; eosinophils 
in turn are essential for regulating local inflammatory responses and overproduction occurs in 
allergy states. The regulation of B- and T-cells is affected by IL-7 which promotes growth and 
development of early pre- B and T cells (both Th1 and Th2). IL-7 has been demonstrated to 
function alongside IL-15 and IL-2 in regulating T-cell survival (Rubinstein et al. 2008). IL-2 and IL-
15, as well as IL-7, have been termed T-cell growth factors; IL-2 is particularly critical for Treg cell 
proliferation and function, and IL-15 for endothelium growth. These actions enable the 
inflammatory response to maintain balance and resolve successfully. Despite the mix in functions 
of these cytokines, it can therefore be helpful to categorise markers with direct 
immunosuppressive effects alongside those that promote atopic or allergic-type responses (also 
outlined by Berger, 2000).  
 
It must not be forgotten that these markers described do not represent all of the proteins in this 
system, and as indicated by the above summary of IM functions the network of interactions 
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between them are not simple to determine. However, these 33 markers provide an insight a broad 
range of aspects involved in the inflammatory response. In the following section we outline the 
background and evidence in the field of inflammation and depression. 
 
 
1.4 Inflammatory findings in depression  
Since Smith’s seminal paper outlining the macrophage hypothesis (Smith 1991) a plethora of 
research has investigated psychoneuroimmunological constructs in depression. The theory was 
driven by rationales including the similarity between symptoms of depression and sickness 
behaviour (the co-occurrence of behavioural and physical symptoms with inflammation), and the 
fact that these can be observed when healthy volunteers are stimulated with inflammation. More 
broadly, people experiencing chronic inflammatory states (through autoimmune illnesses or 
treatment with cytokines like IFNα) have an increased prevalence of depression, in which immune 
state appear at least a partially causal factor.  
 
This established literature now shows increased levels of pro-inflammatory markers in depressed 
patients, evaluated in a number of meta-analyses (Howren et al. 2009, Dowlati et al. 2010, Liu et 
al. 2012a, Haapakoski et al., 2015) and numerous reviews (e.g. Raison et al. 2006, Irwin and 
Miller 2007, Dantzer et al. 2008, Miller et al. 2009a, Maes et al. 2011b).  
 
 Pro-inflammatory markers   
Of the many inflammatory markers (IMs), comparatively few have been frequently studied in 
depression. Across three meta-analyses (Howren et al. 2009, Dowlati et al. 2010, Haapakoski et 
al. 2015) comparing depressed and healthy control groups, IL-6 appears the most reliably 
elevated cytokine in depression (p < 0.001 in all meta-analyses; 31 studies included) and CRP 
similarly emerges as consistently higher in depression (p < 0.001; 20 studies). While IL-6 and 
CRP appear elevated even when adjusting for demographic and methodological factors, TNFα 
aberrations in depression are less robust. Heightened TNFα was identified in early studies (p < 
0.001; Dowlati et al. 2010) but substantial heterogeneity rendered this inconclusive when 
accounting for more recent investigations (Haapakoski et al. 2015; 31 studies). Haapakoski et al. 
posit that study quality and other potential confounders (especially of age and metabolic factors) 
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are likely to explain this finding. Although TNFα and IL-6 cause CRP production (see above, 
Section 1.3.4.1 and 1.3.4.2), the latter two markers are perhaps more key in the acute phase 
response and initiating complement activation, while TNFα levels more closely represent its 
function surrounding T cell mediated immunity. For example, Meijer et al. (1993) report that 
although TNFα appears abnormally high in patients with lupus this is not related to disease 
exacerbation while IL-6 and CRP were correlated with one another and with periods of more 
severe illness.   
Interleukin-1 beta (IL-1β) is even more inconclusively associated with depression than TNFα, with 
meta-analyses suggesting higher levels in depression (p = 0.03; Howren et al. 2009), high levels 
only in European studies (Liu et al. 2012a) or no differences between depressed and control 
groups across 15 studies (Haapakoski et al. 2015). Low concentrations of IL-1β in blood 
(particularly serum) may partly explain this null finding. The low levels normally expressed of IL-
1α and IFNα may partly explain the paucity of research investigating these cytokines. 
Unexpectedly, other prominent pro-inflammatory cytokines IFNγ (Dowlati et al. 2010) and IL-8 
(Dowlati et al., 2010; Eyre et al. 2016b) were not significantly different between patients and 
controls in meta-analyses. Another chemokine, monocyte chemoattractant protein 1 (MCP1), was 
found to be significantly higher in depression (Eyre et al. 2016b). However, most chemokines, 
some pro-inflammatory cytokines and other important molecules (immunoglobulins, or the acute 
phase protein SAA) have not yet been scrutinised at a meta-analytic level.  
 
A few studies have now reported larger panels of inflammatory markers. Simon et al. (2008), 
Schmidt et al. (2014) and Dahl et al. (2014) all found higher levels of pro-inflammatory cytokines 
IL-6, IL-1, IL-8, IFNγ, GM-CSF, and regulatory or anti-inflammatory cytokines (IL-4, IL-2, IL-15, 
IL-7) in depressed than non-depressed samples. IL-5 was higher in patients, except in the Simon 
et al. (2008) study. IL-10 and IL-4 were reported higher in MDD by both Simon et al. (2008) and 
Dahl et al. (2014), but not Schmidt et al. (2014), while the latter was the only of these studies to 
find high TNFα in patients. Additionally, many chemokines were assessed by Simon et al (2008) 
and found to be significantly higher in patients. Despite a similar study design, Einvik et al. (2012) 
found no inflammatory proteins to be markedly higher in participants with depression. However, 
in the latter study depression was assessed using only a self-report measure and scores were 
mostly in mild or moderate categories. Einvik et al. also matched patient and control groups more 
closely; for age, gender, metabolic syndrome and the presence of obstructive sleep apnoea 
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(which was experienced by almost half of the sample). Simon et al.’s strongly significant group 
differences (with most inflammatory markers higher in depression even after Bonferroni 
correction) contrast strikingly with Einvik et al.’s absence of differences. The inconsistency could 
be explained by the extent to which these studies accounted for confounding factors: Simon et al. 
(2008) did not match patient and control groups or adjust for additional factors that may affect the 
relationship, while Einvik et al. (2012) matched patients and controls on a number of factors and 
additionally adjusted for physical illness and smoking. 
 
 Anti-inflammatory markers   
Some anti-inflammatory cytokines are included in the above discussion of this literature, and their 
findings appear similar to those of pro-inflammatory cytokines. Schmidt et al. (2014) did not find 
such comparable results for IL-4 and IL-10; unlike in the other studies described above MDD 
patients in this investigation were not taking psychotropic medication, and IL-10 is thought to 
reduce with antidepressant treatment (Hiles et al. 2012b). At the meta-analytic level, cytokines 
with regulatory or anti-inflammatory functions have not been found as significantly different from 
controls: this is the case for interleukins 2 (IL-2), 4 (IL-4) and 10 (IL-10) which have all been 
reported as either higher or lower in MDD, in separate studies (Dowlati et al. 2010; Liu et al. 2012). 
Haapakoski et al. (2015) exclude these markers from their meta-analysis for this reason, but 
perhaps this is not justified: IL-10 and IL-13 in particular have in many investigations been 
identified as higher in depression (e.g. Hernandez et al., 2008.) Similarly, IL-13 has often been 
reported as elevated in MDD (Hernandez et al., 2008; Schmidt et al., 2014). Elevated levels of 
both pro-inflammatory and anti-inflammatory proteins may indicate a system imbalance between 
up-regulatory and suppressive activities in mood disorders (Blume et al. 2011).  
 
 Interpreting inflammatory marker data  
Disentangling the profound inconsistencies found within this literature is a daunting challenge. 
Standardised norms for cytokines and similar markers do not exist or have not been widely 
accepted: IM levels vary with numerable factors (some are considered in Section 1.6) and 
biomarkers act uniquely, often (but not reliably) co-dependent on one another in a difficult-to-
model fashion. Sporadic reports of Principal Component Analysis (PCA) of IM networks have 
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identified contrasting clusters of biomarkers from one another in similar populations (Black & Miller 
2009, Lindqvist et al. 2011). The measurement of inflammation is made more difficult to interpret 
by the fact that many of the copious number of IMs representing different aspects or stages within 
the inflammatory response are often not measured, or are examined in isolation. As Schmidt et 
al. (2011) proposes, examining a varied array of biomarkers simultaneously is an alternative to 
inspecting isolated biomarkers, and is likely to provide a more accurate viewpoint into the complex 
web of the inflammatory system.  
 
 Inflammation as a trait or state phenomenon  
Some longitudinal investigations suggest that inflammation varies over the time-course of 
depressive illness. A meta-analysis by Valkanova et al. (2013) reports that CRP and to a lesser 
extent IL-6 increase even before the onset of depressive symptoms. This appears to be affected 
by a wide range of factors such as sleep and exercise, but these increases in CRP appear to 
remain following adjustment for a number of sociodemographic variables.  
 
Various studies have detected changes in cytokine levels with antidepressant treatments 
(Janssen et al. 2010) and this has been corroborated in meta-analyses. Hannestad et al. (2011) 
found that reductions in IL-1, IL-6 (only in SSRI trials) and non-significantly in TNFα occurred with 
antidepressant treatment, which align with the macrophage hypothesis. Results from the larger 
meta-analysis by Hiles et al. (2012b) concur with this, and indicate non-significant decreases in 
IL-10 with treatment. Although a decrease in an anti-inflammatory cytokine might not be 
anticipated, this could manifest as a normalisation of initially elevated IL-10. Both of these 
longitudinal meta-analyses were relatively selective in terms of inclusion criteria and IMs 
analysed, yet yielded substantial heterogeneity. These comparisons do also not separate 
medication effects from those of clinical response in the attribution of inflammatory changes 
occurring over treatment.  
 
Most studies investigating inflammation both cross-sectionally and longitudinally have assessed 
baseline IMs in unmedicated participants, to reduce heterogeneity. However, many of these 
assessments are taken after a wash-out period from medication which leaves the potentially 
significant confounding factor of residual changes in physiology, exacerbated by the extensive 
range of treatments available that may have had differing effects on inflammation. Some studies 
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have only excluded psychotropic medication use, meaning that other medications could be 
influencing inflammatory activity. In particular, the oral contraceptive pill is frequently permitted in 
research participants and not controlled for in analyses, which has recently been indicated to 
increase inflammatory marker levels (Divani et al. 2015). Statins are another class of medication 
that is frequently prescribed in the general population and likely has some anti-inflammatory 
effects (Shishehbor et al. 2003).  
 
Several studies indicate that antidepressant medications have effects on the inflammatory 
response (Miller et al. 2009a, Janssen et al. 2010, Strawbridge et al. 2015). However, the 
numerous potential treatments for depression have distinct and complex pharmacological 
properties, which suggests there may be discrete inflammatory effects of different treatment 
options. Current data support this, implying that antidepressants do have contrasting effects on 
inflammation from one another (Maes et al. 1997c, Janssen et al. 2010). One report suggested 
that pharmacological and psychological treatments might show opposing relationships between 
inflammation and treatment-response (Harley et al. 2010). Table 1.2 delineates the most common 
pharmacological treatments for depression and summarises evidence of inflammatory alterations 
identified with these. It has been theorised that specific serotonin-targeting medications (i.e. 
SSRI’s) are likely to target Th2-shifts in inflammation, and norepinephrine antidepressants (i.e. 
SNRI’s) to affect a Th1- shift (Hashimoto 2015); tricyclics may also have an immuno-regulatory 
effect (Van West and Maes 1999). Indeed, Th1 cytokines have been downregulated by all classes 
of antidepressants (Eyre et al. 2016a). It is not yet possible to determine the inflammatory effects 
of individual medications. However, conflicting evidence suggests a complex relationship which 
is likely to be mediated by other factors. Inconsistency is also likely to have arisen from different 
treatment lengths (with few trials of long-term use), sample heterogeneity and not stratifying 





Table 1.2   Antidepressant treatment effects on IM levels 
 
     
Antidepressant 
Class 
Treatment Evidence for inflammatory effects 
SSRI Citalopram  Pro: + IL-1β, IL-6, TNF-α and IL-22, in vitro; Munzer et al. (2013) 
 Escitalopram Pro: - IL-22, ~ many cytokines, in vitro; Munzer et al. (2013) 
        - IL-6, IL-1β mRNA (treatment-responders); Cattaneo et al. (2013)  
 Sertraline Pro: -  IL-12; Sutcigil et al. (2007) 
Anti: + IL-4; Sutcigil et al. (2007) 
 Fluoxetine Pro: ~ IL-6, IL-1β; Jazayeri et al. (2010)  
     ~ IL-6; Maes et al. (1995) 
     -  IL-1β (treatment responders); Song et al. (2009) 
     ~ TNFα, IFNγ; Song et al. (2009) 
     -  CRP; Chang et al. (2012) 
     - IFNγ, IFNγ/IL-10 ratio; Kubera et al. (2001)* 
Anti: ~ IL-10, IL-4; Song et al. (2009) 
 Fluvoxamine Pro: - IL-6, TNFα; Hinze-Selch et al. (2000) 
(S)NRI Venlafaxine Pro: - CRP; Chang et al. (2012 ) 
     - IL-1β, TNFα, MCP1; Piletz et al. (2009) 
     - IFNγ/IL-10 ratio; Kubera et al. (2001)* 
     ~ TNF; Kraus et al. (2002) 
 Duloxetine Pro: + IL-6 (responders); Fornaro et al. (2011)  
Other  Bupropion Pro: + IL-8; Eller et al. (2009)  
 Mirtazapine Pro: - TNF; Kraus et al. (2009) 
 
Pro = activity of pro-inflammatory cytokines. Anti = activity of regulatory or anti-inflammatory cytokines  
* This study measured cytokine production in response to LPS stimulation. When measured alone, IL-10 
increased with treatment by fluoxetine, venlafaxine and imipramine; but IFNγ/IL-10 ratio decreased in all 
treatments. 
+ = IM increases identified alongside treatment; ~ = no changes found with treatment; - = decreases found. 
These associations have been reviewed further by (Maes et al. 1997c, Castanon et al. 2002, Kenis and 




1.5 Potential modifiers of inflammation 
Hiles et al. (2012a) examined sources of inconsistency in the literature meta-analytically. 
Accuracy of diagnostic measurement, BMI and comorbid illnesses were indicated as the most 
important factors to account for in assessing inflammation between depressed and non-
depressed groups. The heterogeneity of MDD populations is also an important contributor to 
contrasting findings within the research literature and it is probable that even within diagnoses, 
abnormal inflammation is confined to a subset of people and which may not be stable over time. 
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Many further factors have been reported to alter inflammatory protein levels in patients with 
affective disorders. These include exercise (which may increase inflammation in the short term 
but downregulate inflammatory responses over time; Ambarish et al. 2012), diet (with many 
compounds differently influencing immune features; Hastings et al. 2016), microbiome activity 
(which has recently received much attention; Rea et al. 2016), smoking and other substance use 
(Berk et al. 2013b), as well as health factors (such as comorbid inflammatory disorders or atopy). 
Although heightened inflammation is observed in depressed but otherwise healthy individuals 
than in non-depressed groups, depressed individuals who also have a comorbid ‘inflammatory’ 
condition frequently have even higher levels of cytokines than either those without depression or 
illness (Maes et al. 2011a). Further factors with probable involvement in the relationship between 
inflammation, depression and treatment-response are outlined below. 
 
 Health-related factors 
1.5.1.1 Sickness behaviour 
Sickness behaviour is an adaptive response to immune challenge that developed early in human 
evolution (Miller and Raison 2016). Sickness behaviour due to a variety of sources occurs in 
conjunction with an increase in pro-inflammatory cytokines (particularly pryogens TNFα, IL-6 and 
IL-1) and acute phase proteins. The phenomenological parallels of sickness behaviour and 
depression are easily discernible, to the extent that they can be mistaken for one another (Ratcliffe 
2013). Overlapping symptoms include dysregulated sleep and appetite, fatigue and lassitude, 
aches or pain, anhedonia and cognitive changes. In a review of this association, Maes et al. 
(2012a) propose a model in which sickness behaviour is a manifestation of acute inflammatory 
response while depression is a consequence and perpetuator of chronic inflammation. 
 
1.5.1.2 Medical comorbidity 
Depressive disorders are commonly comorbid with other illnesses and many of the most 
frequently reported comorbid physical disorders are autoimmune or have an inflammatory 
component. These include rheumatoid arthritis, Crohn’s disease, multiple sclerosis (MS), 
cardiovascular disease (CVD), stroke, chronic obstructive pulmonary disease (COPD), diabetes, 
dermatological (most frequently psoriasis, or atopic dermatitis) or allergic disorders, and cancer - 
as reviewed by Maes et al. (2011a). Most commonly reported in CVD populations, the presence 
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of comorbid depression can produce worse physical outcomes (Jani et al. 2016) which is 
putatively explained by elevations in inflammation (Maes et al. 2010). Aberrant inflammatory 
activity has also been identified in some neurological (migraine, epilepsy) and gastrointestinal 
disorders (Evans et al. 2005), particularly inflammatory bowel syndrome (IBS) whose increased 
comorbidity with MDD may be partly attributable to inflammation (Martin-Subero et al. 2016).  
 
A pertinent example of a phenomenologically similar illness to depression is chronic fatigue 
syndrome (CFS): the two share much symptom overlap, and heightened inflammation has been 
illustrated in two systematic reviews (Lyall et al. 2003, Blundell et al. 2015) and a recent meta-
analysis (Strawbridge et al. 2016b). Despite this, patients with CFS frequently show 
hypocortisolemia while MDD is often associated with hypercortisolemia (Cleare et al. 1995) 
suggesting related but distinct biological mechanisms.  
 
In addition to MDD, other psychiatric conditions often include the co-occurrence of depressive 
symptoms and have been independently (although inconsistently) with alterations in inflammatory 
markers: schizophrenia (Baumeister et al. 2014), anxiety disorders (Vogelzangs et al. 2013), 
Parkinson’s (Whitton 2007), dementia (Leonard 2007) and autism (Reus et al. 2015), as well as 
bipolar affective disorders which are expanded on in Section 1.7.3. It is possible that shared 
inflammatory abnormalities across diagnostic categories exist, representing a potential target for 
an RDoC-type approach (as referred to in Section 1.1).  
 
 Effects of immune challenge 
Some cytokines are routinely used as pharmacotherapy for immunodeficient disorders, most 
notably interferon alpha (IFNα). Treatment with pro-inflammatory agents can reliably produce 
depressive symptoms even in individuals with no history of affective disorder (Hepgul et al. 2010) 
and higher inflammation prior to interferon treatment has been found to predict subsequent 
depression (Wichers et al. 2006, Prather et al. 2009). Interestingly, if IFNα treatment is combined 
with a selective serotonin reuptake inhibitor (SSRI) people are less likely to develop depression 
(Capuron et al. 2002). In the preclinical literature, lipopolysaccaride (LPS; an endotoxin that 
induces inflammation) generates depressive behaviours in mice of a strain at-risk for depressive 
type behaviours but not in a healthy strain of mice (Dinel et al. 2014). Healthy human cells in vitro 
show an attenuated LPS-induced inflammatory response in the presence of increased serotonin 
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(Cloëz‐Tayarani et al. 2003). Taken together, the above findings suggest some causality of 
increased inflammation on depressive behaviours in a subgroup of vulnerable individuals, 
possibly mediated by 5-HT.  
 
 Contributions of psychological stress 
Both acute and chronic psychological stressors also act as an immune challenge, accentuating 
inflammatory responses in the short- and longer-term (Steptoe et al. 2007, Miller et al. 2009b). 
Steptoe et al. (2007) meta-analysed the effects of stress in experimental studies on peripheral 
cytokine production and found that IL-6 and IL-1β (and to a lesser extent, CRP) increased 
significantly after acute stress, which is consistent with an early inflammatory response measured. 
These findings were modified by the length of time between the stressor and inflammatory 
assessment. It is likely that the type of stress and the amount of psychological distress associated 
with it also influence the biological effects, and particularly that chronic stress will have different 
inflammatory consequences (supported by Miller et al. 2009b who reported increased NFkB 
activity and sensitivity of IL-6 production). 
 
This finding extends to the experience of early-life stress, which has been associated with adult 
inflammatory elevations that are independent of stress experienced as an adult (Danese et al. 
2007, Danese et al. 2009). Despite this, people with depression and a history of childhood trauma 
may have blunted cortisol responses to stress compared to those with depression and no early-
life trauma (Suzuki et al. 2015).  Early-life stress is consistently linked to a variety of adverse long-
lasting outcomes, including major depression and other psychiatric disorders, as well as physical 
illnesses and socioeconomic disadvantages (Shonkoff et al. 2012). Inflammation might be 
involved in the risk of developing depression following early-life trauma; Danese et al. (2008) 
reported that inflammatory markers were most elevated in people with both depression and early-
life stress and that controlling for trauma rendered patient-control differences in inflammation non-
significant. During childhood traumatic experience, heightened inflammation has also been 
reported only those children who were currently depressed (Danese et al. 2011). Danese and 
McEwen (2012) reviewed supposed inflammatory mechanisms between early-life stress and 
subsequent depression, suggesting that early-life stress disposes some individuals to enduring 
stress reactions in adulthood that are amplified psychologically and/or biologically. While this can 
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explain the occurrence of state-related inflammatory aberrations during depressive episodes in 
some individuals, it is unclear precisely how childhood trauma affects inflammation (and other 
biological systems) in depressed adults.   
 
 Cognitive functioning  
Neurocognitive dysfunctions occur frequently in people with affective disorders, even in 
unmedicated major depressive disorder (Porter et al. 2003) and euthymic bipolar disorder 
(Thompson et al. 2005). Cognitive deficits appear cumulative alongside treatment-resistance 
(Gallagher et al. 2007, Kemp et al. 2008) and as such cognition is increasingly targeted in 
treatment interventions (Bowie et al. 2013, Strawbridge et al. 2016a). Elevated inflammatory 
responses have been linked with cognitive decline, and likely affect cognitive functioning in mood 
disorders (Allison and Ditor 2014, Bauer et al. 2014) including in a euthymic state (Barbosa et al. 
2012) through a variety of mechanisms (Rosenblat et al. 2015). Neurobiologically, the HPA-axis 
(Strawbridge and Young 2016) and neuroplasticity (Pittenger and Duman 2008) are likely to play 
a key role in this relationship. Krogh et al. (2014) proposed that CRP particularly is more closely 
related to cognitive performance than to the core symptoms of depression. Specifically, 
impairments to executive function in euthymic mood disorder may be found alongside elevated 
immune activity (Barbosa et al. 2012). 
 
 Age, Gender and BMI  
The absence or presence, and direction of inflammatory differences between men and women 
have been particularly variable in the evidence to date. Howren et al. (2009) and Hiles et al. 
(2012a) found that controlling for age and gender did not affect patient-control IM differences 
(although the association between IL-6 and depression reduced as age increased, which is 
somewhat in line with theories that inflammation generally heightens with age). However, the lack 
of adjustment for BMI in previous examinations of inflammation and depression appears to 
confound highly significant differences reported between these groups (Howren et al. 2009). 
Enlarged adipose tissue has been definitively demonstrated to stimulate macrophages which 
produce cytokines, and perhaps even directly increase some pro-inflammatory cytokines, 
particularly IL-6 (Fontana et al. 2007). Because psychotropic medications may be associated with 
weight gain and a higher BMI, and these have been associated with treatment-resistance in 
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depression, this is an important area to examine. Adiposity is also associated with the atypical 
depressive subtype.  
 
 
1.6 An inflammatory subtype of depression   
Thus far, no homogenous subgroups within depression episodes or disorders have been 
identified that reliably distinguish between patients based on symptom presentations or treatment 
responsiveness (Arnow et al. 2015). Krishnadas and Cavanagh (2012) specify the case for the 
existence of an ‘inflammatory’ subpopulation of people with depression: namely from findings 
suggesting that about one third of medically healthy people with depression present with high 
markers of inflammation; that people with immune-dysregulated disorders are at an increased 
risk for depression, and that pro-inflammatory treatments can precipitate the onset of depression 
in some individuals (as well as evidence that anti-cytokine treatments may alleviate depressive 
symptoms). The existence of a subgroup in whom immune aberrations are greater would help to 
explain the heterogeneity between previous studies comparing IMs in depressed and non-
depressed groups. Few direct attempts have been made to discover which participants may 
comprise this cohort, though such a subtype is postulated in many articles (Raison and Miller 
2011, Baune et al. 2012, Vogelzangs et al. 2012). 
 
 Symptom-based subtypes  
The most persistent attempt to reduce the heterogeneity within MDD has been the classification 
of melancholic and atypical depression. These have often been contrasted with one another and 
represent in some ways opposite symptom presentations. Atypical depression (typically 
presenting with lethargy, hypersomnia, increased appetite and weight gain) may be a candidate 
for increased inflammation compared to melancholia (where insomnia, appetite-loss and 
anhedonia are often experienced concurrently). Melancholia has been associated with higher 
cortisol but lower inflammation than atypical depression: in the largest study comparing subtypes 
to date, only people with atypical depression had significantly elevated inflammation compared to 
controls. These individuals also reported more extensive metabolic symptoms; controlling for 
metabolic syndrome rendered the differences in CRP and IL-6 non-significant, though TNFα 
remained significant (Lamers et al. 2013). Other clinical factors differing between these groups 
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are of note: atypical depression has been more frequently associated with childhood trauma 
(Withers et al. 2013), chronic life stressors and an early age of onset (Gold and Chrousos 2002), 
and as discussed elsewhere (e.g. Vogelzangs et al. 2012, Section 1.6) these factors have been 
associated with a rise in inflammation. Sleep is a factor differing between these subgroups that 
has recently received much attention in the field of immunology. The extent of research 
investigating inflammation and sleep disturbance is greater for insomnia, but both insomnia (Irwin 
2015) and hypersomnia (Szymusiak and Gvilia 2012) appear to cause elevated cytokine levels. 
Stewart (2007) proposes that atypical depression runs a more chronic course than non-atypical 
depression, in contrast with melancholic depression. However, melancholic subtypes have also 
been linked with a poorer response to antidepressants than other patients, including in the 
STAR*D study (McGrath et al. 2008). In other studies the proportion of treatment-resistant 
patients with atypical and melancholic depression does not differ markedly (Uher et al. 2011). It 
is apparent that the oft-used melancholic and atypical subtypes do not represent the entire 
depressed population and the differing symptoms are not mutually exclusive. Further symptom 
domains of depression have been associated with increased inflammation (Capuron et al. 2008), 
including neurovegetative symptoms (sleep, appetite, libido loss), mood symptoms (including low 
mood, suicidality and irritability) and cognitive symptoms (including affective bias and guilt).   
 
 Biomarker-based subtypes  
In the absence of success subtyping patients by clinical features, biomarkers may represent 
promising candidates. Kunugi et al. (2015) have proposed that different neurobiological systems 
may display clinically relevant subtypes in depression; hypothesised examples include groups 
showing hypercortisolism or hypocortisolism, reflecting melancholic and atypical subtypes 
respectively; a dopamine-related subset of patients who may present prominently with anhedonia 
(and could respond well to aripiprazole, for example); and an inflammatory subtype characterised 
by elevated inflammation. Kunugi et al. do not posit clinical variables which may be found in an 
inflammatory subtype of depression but highlight the extensive interactions (described in Section 
1.3.2) between immune and other (neuro)biological systems. In addition to cortisol (Herane Vives 
et al. 2015), the growth factors VEGF (Cattaneo et al. 2010) and BDNF (Polyakova et al. 2015) 





Clear potential candidates for an inflammatory subtype are the presence of a high ratio of somatic- 
to non-somatic symptoms, or symptoms that are delineated within sickness behaviour. To this 
aim, preliminary work has categorised participants’ symptoms as primarily somatic or cognitive, 
and observed elevations of CRP, IL-6 and TNFα alongside more severe somatic symptoms 
(Duivis et al. 2013). However, this has not been investigated more extensively and is addressed 
in Study 3 (Chapter 4). 
 
 Bipolar disorder 
Evidence now suggests that bipolar illnesses are a multifaceted group of mood disorders existing 
on a continuum (Angst et al. 2003), with bipolar subsyndromal disorder found more prevalently 
than was previously recognised (Merikangas et al. 2011). Inaccurate and/or delayed detection of 
bipolar disorder (BD) has recently been highlighted as a major problem in clinical psychiatry, with 
the average time to correct diagnosis frequently exceeding a decade (Hirschfeld et al. 2003) and 
this delay causing greater severity and cost of overall illness (Young and MacPherson 2011). With 
the majority of bipolar disorder presenting initially with one or more depressive episodes and 
unipolar depression being the most frequent misdiagnosis, the identification of factors that might 
differentiate between unipolar and bipolar depression has substantial implications (Vöhringer and 
Perlis 2016). It is possible that some previous studies of inflammation in MDD may contain 
undetected bipolar spectrum disorder in a subset of participants. 
 
Smatterings of evidence have indicated differentiation of hypothalamic-pituitary-adrenal (HPA) 
axis activity (Markopoulou et al. 2009), increased irritability and cognitive deficits or a more 
prevalent atypical subtype within bipolar depression (Mitchell et al. 2011, Vöhringer and Perlis 
2016) but distinguishing bipolar from unipolar mood disorders is renowned for its difficulty. 
Elevated inflammation has often been demonstrated in bipolar disorder compared to healthy 
controls (Goldstein et al. 2009, Modabbernia et al. 2013, Munkholm et al. 2013)  Inflammatory 
changes between manic, depressive and euthymic states in bipolar disorders have not been 
determined, with very few studies conducting longitudinal comparisons across states (Tsai et al. 
2012). Furthermore, direct comparisons of inflammation between unipolar and bipolar subjects 
are scarce, particularly within the depressed state: two found no statistical differences (Huang 
and Lin 2007, Su et al. 2011) though both showed non-significant elevations in bipolar subjects 
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and sample sizes were very small. In a larger study (Becking et al. 2015) high CRP (but not IL-6 
or TNFα) was associated with bipolarity in currently depressed participants but only in male 
subjects in conjunction with hypercortisolemia. Of note, these subjects did not have a primary 
bipolar disorder diagnosis, which was an exclusion criterion, and neither medication use or 
depression severity was measured in this study. No investigations have yet examined the 
relationship between treatment response and inflammation in unipolar and bipolar depression. 
 
 Treatment-resistance 
Many of the findings discussed so far implicate treatment-resistance as important in the 
bidirectional relationship between inflammation and depression: for instance, people with 
treatment-resistant depression (TRD) are more likely to have physical illness, an older age, BMI, 
metabolic disturbances, chronic stress and take more medications. Raison et al. (2013a) set out 
a promising argument that inflammation in TRD might differ from non-treatment resistant 
depression (non-TRD) and represent an inflammatory subtype. In proportion to its burden, TRD 
has been relatively neglected in research. Prior treatment-resistance is among the strongest 
prospective predictors of treatment-response and associates strongly with many moderators of 
inflammation. This topic is expanded on and addressed in Study 2 (Chapter 3).  
 
 
1.7 Aims & Objectives  
This thesis aims to evaluate and utilise the current evidence that has accumulated associating 
depression and inflammation, such that this path of research can progress into translational uses 
aiming to improve response to treatments. The quantity of evidence that has been published in 
this area and remaining uncertainties (augmented by the complexity and heterogeneity of both 
depression and inflammation) require an amalgamation of the current evidence relating 
inflammation to treatment-response in depression (Study 1; Chapter 2). Focusing on a large panel 
of novel as well as traditional inflammatory markers, Studies 2 and 3 respectively investigate 
inflammatory mechanisms in a treatment-resistant inpatient sample and in a less severely ill 
sample of depressed outpatients undertaking psychological therapy. TNFα, CRP and IL-6 clearly 
represent the most frequently investigated IMs in depression and are considered the most likely 
to be related to treatment outcomes in mood disorders. These are focused on as the main 
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biomarkers of interest in this thesis. Other IMs are less well understood; their relevance in the 
relationship between depression, treatment and treatment response is tested on an exploratory 
basis in this thesis. 
 
In each study, the following research questions are addressed: 
a) Do any IM levels predict response to treatments?   
b) Are IM levels after treatment related to clinical response?  
c) Do IM levels alter longitudinally alongside treatment for depression? 
d) Is inflammation particularly aberrant in a subgroup of depressed individuals e.g. with a 
treatment resistant, bipolar or prominently somatic mood disorder?   
Where possible, IM differences between depressed patients and non-depressed control subjects 
and the impact of potential modifying factors on inflammation will also be assessed.  
 
Three studies will address the following specific objectives in achieving the overall aim; these 
objectives are formed as specific hypotheses in the relevant Chapters: 
Study 1: To synthesise and assess the state of current evidence of the relationship between 
inflammation and response to treatments for depression using a systematic review and meta-
analysis (see Chapter 2);  
Study 2: To investigate inflammation and treatment-response specifically in a population of 
treatment-resistant inpatients before and after combined psychological and pharmacological 
inpatient intervention (see Chapter 3);  
Study 3: To inspect inflammation and response to psychological treatments for depression in a 
community sample of depressed outpatients (see Chapter 4). 
An exploratory comparison of inflammatory protein levels across controls, inpatients and 
outpatients (i.e. from Studies 2 and 3) is undertaken in Chapter 5. 
The findings across all three studies are considered together in Chapter 6, where a critical 




 Inflammation and clinical response to 
treatment in depression: a meta-analysis (Study 1) 
 
This chapter is published as: Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., 
Herane Vives, A., Cleare, A.J. (2015). Inflammation and clinical response to treatment in 
depression: A meta-analysis, European Neuropsychopharmacology, 25(10), 1532-1543.  
Only very minor alterations have been adapted from the published article, to the Method 





The depressive state has been characterised as one of elevated inflammation, which holds 
promise for better understanding treatment-resistance in affective disorders as well as for future 
developments in treatment stratification. Aiming to investigate alterations in the inflammatory 
profiles of individuals with depression as putative biomarkers for clinical response, we conducted 
a meta-analyses examining data from 35 studies that investigated inflammation before and after 
treatment in depressed patients together with a measure of clinical response.  There were 
sufficient data to analyse IL-6, TNFα and CRP. Levels of IL-6 decreased with antidepressant 
treatment regardless of outcome, whereas persistently elevated TNFα was associated with 
prospectively determined treatment resistance. Treatment non-responders tended to have higher 
baseline inflammation, using a composite measure of inflammatory markers.  Our findings 
suggest that elevated levels of inflammation are contributory to treatment resistance. Combining 
inflammatory biomarkers might prove a useful tool to improve diagnosis and detection of 
treatment refractoriness, and targeting persistent inflammation in treatment-resistant depression 
may offer a potential target for the development of novel intervention strategies. 
 
 
2.2 Introduction   
An aberrant inflammatory profile has been widely demonstrated in depressive disorders and is 
believed to contribute to some of the biological mechanisms associated with disease onset and 
treatment response (Smith 1991, Miller et al. 2009a, Dowlati et al. 2010). Recent evidence 
suggests that levels of inflammation might be modifiable with pharmacological treatment (Janssen 
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et al. 2010, Hannestad et al. 2011, Hiles et al. 2012b) and preliminary evidence indicates that 
treatment resistance might be associated with heightened inflammation.  
 
Additionally, non-steroidal anti-inflammatory drugs might be beneficial as adjunctive treatments 
in unipolar (Muller et al. 2006, Akhondzadeh et al. 2009) and bipolar (Nery et al. 2008) disorders 
and the TNFα antagonist infliximab may particularly benefit depressed individuals with a history 
of treatment resistance and high inflammation (Raison et al. 2013b). Treatment non-response 
contributes greatly to the burden of affective illnesses (Gibson et al. 2010); it is common, affecting 
at least a third of patients (Warden et al. 2007), and is generally associated with poorer long-term 
outcomes (Fekadu et al. 2009a). To improve the rate and robustness of clinical response in 
depression there is a need for novel treatment strategies (Kupfer et al. 2012), including enhancing 
the personalisation of treatment provision using stratification. As such, research has been 
increasingly focusing on the importance of effectively screening for predictors of response across 
depressed populations, and using putative biomarker signatures prior to treatment provision may 
help to identify objective biological differences between patients who do or do not respond to 
treatments.  
 
Measuring ‘panels’ of biomarkers may assist with the discovery of biological signatures for 
disorders such as depression (Schmidt et al. 2011), which also may be supported using meta-
analytic techniques that provide enhanced statistical power than individual studies. Combining 
these two approaches may be useful for identifying inflammatory relationships with depressed 
state and response to treatment, particularly as studies measuring different (but similar) data 
points cannot otherwise be compared in a high-powered analysis. We describe a new 
methodology of combining inflammatory data from different biomarkers together to enable a 
substantially higher statistical power.   
 
Another important factor in this relationship is whether inflammatory profiles within a depressed 
state might differ between individuals with unipolar and bipolar diagnoses: although this has not 
been established there is some indicative evidence that inflammation is not elevated in bipolar 




 Aim of the study 
With the aim of expanding on previous work, we investigated studies measuring inflammatory 
biomarkers in depression in relation to treatment response and hypothesised that:  
a) Non-responsive patients would have higher levels of inflammation at baseline than 
responders;  
b) Patients would show a decrease in levels of inflammation after a course of treatment, but 
that;  




2.3 Experimental Procedures 
 Criteria for study inclusion 
A systematic search of the literature was conducted to obtain all studies that measured 
inflammatory responses in depression at baseline and following a course of treatment, and that 
also assessed treatment response. A priori inclusion criteria required eligible studies to be in 
English, measure in vivo at least one peripheral biomarker purporting to measure inflammation in 
human subjects classified as being in a depressive episode according to a clinician-rated 
standardised measure of depression symptomatology (e.g. HAM-D, MADRS, IDS) alongside a 
standardised measure of clinical response to a treatment (and where relevant, a comparison of 
inflammation between responder and non-responder groups at one time point or more). To ensure 
we measured naturally occurring inflammation we excluded any studies which included a 
psychological or physiological stressor, or induced inflammation either by a targeted agent or by 
specific immunomodulatory drugs (e.g. non-steroidal anti-inflammatory drugs; NSAIDs) would be 
excluded, but not psychotropic medications). For this reason we also excluded papers reporting 
relevant comparisons in specifically physically ill samples (though we included studies which did 
not necessarily exclude individuals who had physical illnesses). Subjects were required to be of 




 Systematic search   
We searched the databases PubMED (1960-), EMBASE (1974-), and PsycINFO (1967-), with the 
aim of eliciting all studies measuring peripheral markers of inflammation in patients with unipolar 
or bipolar depression and in relation to treatment response and/or clinical improvement, fulfilling 
our inclusion criteria. The full search process is depicted in Figure 2.1. Studies were retrieved by 
RS and inclusion/exclusion of studies agreed by consensus (with AC, AP).  Studies were also 
scrutinised for potentially relevant citations. In case of incomplete information study authors were 
contacted to request additional data not available in the original manuscript.  
 
 Assessment of quality  
Research reports were assessed using seven criteria, adapted from those developed by the 
Evidence-Based Medicine Working Group that had been modified for use in prognostic 
investigations (Fekadu et al. 2009a) and the Cochrane Collaboration’s Risk of Bias tool for trial 
designs (Higgins et al. 2011). Studies can score either positively (+1), negatively (-1) or neutrally 
(no score change) on each of the following domains: Cohort formation, sample size, trial/follow-
up length, collection of biological data, study completion data, design of treatment provision, 
objective clinical assessment. This resulted in a ranking from -7 to +7 (see Table 2.1), which we 
used as a brief indicator of methodological rigor in individual studies, within the limitations of this 
approach. 
 
 Composite biomarker calculation  
It was clear that the variation between studies of inflammatory biomarkers investigated would lead 
to low-powered meta-analyses of individual biomarkers. Based on the consideration that all 
selected pro-inflammatory biomarkers should measure the same latent construct (inflammation) 
and thus be correlated, we planned analyses to incorporate all possible available data as further 
comparisons, in addition to the main comparisons of assessing individual inflammatory markers. 
This novel method should at present be considered a preliminary test of the predictive validity of 
a combination of biomarkers as a measure of overall inflammatory response. The ‘composite 
measure’ provides a preliminary and perhaps coarse representation of inflammation and its 
relationship with response to treatment in affective disorders, and will therefore require 
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consideration when interpreting results. However, this method not only permits a higher powered 
meta-analysis, but also enables a broader perspective to be taken on the putative relationship 
between inflammatory profiles and clinical response to antidepressant treatments in people with 
depression.   
 
To prevent bias in the composite inflammation analysis towards studies measuring multiple 
biomarkers, one entry per eligible study was required for each analysis. It was also important not 
to bias our results towards particular biomarkers. We therefore employed a method to utilise the 
maximum data available by averaging together all relevant biomarkers within each study prior to 
entering into the meta-analysis. Eligible markers were defined as pro-inflammatory cytokines 
(Hodge-Dufour et al. 1998, Cameron and Kelvin 2000), as follows: tumour necrosis factor (TNFα), 
interferon-α or β (IFNα/IFNβ), interleukin 1-α or β (IL-1α/IL-1β) or 6 (IL-6), c-reactive protein (CRP) 
which was also included as a direct marker of inflammation. 
 
For each included study, mean data values for each eligible biomarker were first converted into 
pg/ml (except for CRP which was converted into mg/L), and then all relevant variables pooled to 
create the ‘composite’ measure using a pooling method embedded in the software 
Comprehensive Meta-analysis (version 2.2.021), for merging multiple data points within subjects 
(using the mean of the selected outcomes). The composite data calculated for each study, roughly 
representing the levels of inflammation for each comparison, provided a single-entry per study 
into each meta-analysis.  
 
 Statistical analysis      
Meta-analyses were conducted where sufficient data were available in at least 3 studies for each 
primary comparison. For each possible biomarker, the comparisons conducted were as follows:  
a) Responder versus non-responders at baseline (pre-treatment) 
b) Inflammatory changes alongside treatment in responders 
c) Inflammatory changes alongside treatment in non-responders 
Additional secondary comparisons that were conducted on the above biomarkers were patients 
versus controls at baseline and inflammatory change in all patients over treatment (not 




Aside from the effect-size calculations for the composite analyses, statistical analysis 
methodology was conducted using Stata 11.0 (Stata Corp, College Station, Texas) and 
supplemented by ‘Metan’ software downloadable from the Centre for Statistics in Medicine, 
Oxford, UK, as reported previously (Arnone et al. 2009). Standardised mean differences were 
calculated using Cohen’s d statistic and standardised effect sizes were then combined using the 
inverse variance method. Random effects analyses (DerSimonian and Laird 1986) were used 
throughout to weight each study. The presence of heterogeneity was tested using the Q-test and 
its magnitude estimated using I2, which can be interpreted as the proportion of effect size variance 
due to heterogeneity (Higgins et al. 2003). Publication bias, which describes the tendency of small 
studies to report large effect sizes, was examined using the Egger’s test (Egger et al. 1997) with 
the significance level set at p<0.05. To further investigate causes for heterogeneity, meta-
regression analyses were performed in the primary analyses (outlined below). Potential 
confounders considered were; gender (%), age, baseline symptom severity, clinical setting 
(inpatient/outpatient), medication status on study-entry, standardised/naturalised treatment in 
study, length of treatment, study year, and study quality assessment. The STATA module 
"metareg" was used throughout and the REML (restricted maximum likelihood) method used to 
estimate the model parameters. 
 
 
2.4 Results  
The literature search yielded a total of 2053 articles, of which 35 met inclusion criteria (see Figure 
2.1 and Table 2.1 for details and reasons for exclusion). All included studies investigated unipolar 
major depression except for one that only included bipolar diagnosed patients in a depressive 
episode (Tsai et al. 2014), and three that included both bipolar and unipolar depression (Maes et 
al. 1995, Landmann et al. 1997, Himmerich et al. 2006) but did not compare inflammation between 
the two groups.  
 
Three biomarkers were sufficiently researched to be included in primary analyses: interleukin-6 
(IL-6) in 12 studies (Maes et al. 1995, Frommberger et al. 1997, Maes et al. 1997a, Kubera et al. 
2000, Lanquillon et al. 2000, Mikova et al. 2001, Basterzi et al. 2005, Marques-Deak et al. 2007, 
Yoshimura et al. 2009, Fornaro et al. 2011, Carvalho et al. 2013, Yoshimura et al. 2013), TNFα 
in 11 studies (Landmann et al. 1997, Lanquillon et al. 2000, Mikova et al. 2001, Tuglu et al. 2003, 
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Himmerich et al. 2006, Eller et al. 2008, Eller et al. 2009, Piletz et al. 2009, Song et al. 2009, 
Yoshimura et al. 2009, Fornaro et al. 2013) and CRP in 8 studies (Lanquillon et al. 2000, Tuglu 
et al. 2003, O'Brien et al. 2006, Piletz et al. 2009, Harley et al. 2010, Chang et al. 2012, Tsai et 
al. 2014, Uher et al. 2014).  
 
  
Records identified through 
database searching 
(n = 2573) 
Additional records identified 
through other sources 
(n = 8) 
Records after duplicates removed 
(n = 2053) 
Records screened 
(n = 2053) 
Records excluded 
(n = 1959) 
Full-text articles assessed 
for eligibility 
(n = 94) 
Full-text articles excluded  
(n = 59): 
Lack of clinical response measure 
(n=17) 
Ineligible sample characteristics 
(n=15) 
Ineligible biomarkers reported 
(n=11) 
Non-longitudinal design         
(n=7) 
Studies included in meta-
analysis 
(n =  35) 
Figure 2.1   Flow chart of selection process for inclusion of studies 
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Response rate Markers measured 
Basterzi et al. (2005) MD 23 2 74% IL-6 
Basterzi et al. (2010) MD 69 2 64% CD3, CD4, CD8, CD45, CD19 
Carvalho et al. (2012) MD 19 1 33% Il-6, IL-10, IL-4 
Chang et al.(2012) MD 149 4 43% CRP 
Eller et al. (2008) MD 100 3 74% sIL-2R, IL-8, TNFα 
Eller et al. (2009) MD 28 5 64% sIL-2R, IL-8, TNFα 
Fornaro et al. (2011) MD 16 0 56% IL-6 
Fornaro et al. (2013) MD 38 4 40% IL-1β, IL-2, IL-4, IL-10, IL-12, IFNγ, TNFα 
Frank et al. (2004) MD 16 3 56% NKCA, NKCN 
Frommberger et al. (1997) MD 12 1 All IL-6 
Harley et al. (2010) MD 346 4 Improvement only CRP 
Hernandez et al. (2008) MD 31 1 All IL-2, IFNγ, IL-4, IL-13, IL-10, IL-1β 
Himmerich et al. (2006) 
MD&         
BD 
70 1 57% TNFα, sTNFR p55, sTNFR p75 
Himmerich et al. (2010) MD 16 1 Improvement only Lymph. 
Kook et al. (1995) MD 24 1 79% NKCA 
Kubera et al. (2000) MD 9 2 Improvement only IL-6, IL-1RA, IL10 
Landmann et al. (1997) 
21MD/ 
1BD 
22 1 27% Gran., Lymph., Mono., TNFα, IFNγ, CD14 
Lanquillon et al. (2000) MD 35 4 58% Lymph., Mono., CRP, IL-6, TNFα 
Maes et al. (1995) 
53MD/ 
8BD 
61 3 All IL-6, sIL-6 R, sIL2R 
Maes et al. (1997a) MD 25 0 60% Il-6, IL-6 R, IL-1RA, sCD8 
Maes et al. (1997b) MD 36 4 65% DPP-IV 
Marques-Deak et al. (2007) MD 46 2 All IL-1β, IL-6, IFNγ 
Mizruchin et al. (1999) MD 15 5 Improvement only NKCA 
Mikova et al. (2001) MD 28 1 60% IL-8, IL-6, TNFα, IL-2 R, CC16 
O'Brien et al. (2006) MD 20 1 Improvement only CRP 
Pariante & Miller (1995) MD 15  47% NKCA 
Piletz et al. (2009) MD 22 3 All TNFα, IL-1β, MCP1, CRP, CD40 
Schleifer et al. (1999) MD 21 1 Improvement only 
Lymph, CD4, CD8, CD29, CD45RA, 
CD56, NKCA 
Seidel et al. (1996) MD 33 3 36% 
Leuk, Neut, Eos, Baso, CD4, CD8, CD19, 
lymph, mon 
Song et al. (2009) MD 95 4 47% IL-1β, TNFα, IFNγ, IL4, IL10 
Tsai et al. (2014) BD 32 4 All CRP, sIL-2R, sIL-6R, IL-1RA 
Tuglu et al. (2003) MD 26 1 All CRP, Leuk, TNFα 
Uher et al. (2014) MD 241 3 Improvement only CRP 
Yoshimura et al. (2009) MD 51 4 61% IL-6, TNFα 
Yoshimura et al. (2013) MD 118 4 49% IL-6 
 
Abbreviations: MD = major depression; BD = bipolar depression; IL = interleukin; CD = cluster of 
differentiation; CRP = c-reactive protein; sIL-2R = soluble IL-2 receptor; TNFα = tumour necrosis factor; 
NKCA = natural killer cell activity; NKCN = natural killer cell number; sTNFR p55 & p75 = soluble TNFα 
receptors p55 & p75; IFNγ = interferon gamma; Lymph = lymphocyte count; IL-1RA = IL-1 receptor 
antagonist; Gran = granulocytes, Mon = monocytes, DPP-IV = dipeptidyl-peptidase-4; MCP1; monocyte 
chemoattractant protein-1; Leuk = leukocytes; Neut = neutrophils; Eos = eosinophils; Baso = basophils.





 Description of studies 
All 35 studies were longitudinal in design, measuring inflammatory markers at baseline and 
following up patients over the course of treatment. All but two studies (Carvalho et al. 2013, Uher 
et al. 2014) repeated inflammation measurements after treatment. Most articles dichotomised 
patients at study-end into responders and non-responders (Kook et al. 1995, Pariante and Miller 
1995, Seidel et al. 1996, Landmann et al. 1997, Maes et al. 1997a, Maes et al. 1997b, Lanquillon 
et al. 2000, Mikova et al. 2001, Frank et al. 2004, Basterzi et al. 2005, Himmerich et al. 2006, 
O'Brien et al. 2006, Eller et al. 2008, Eller et al. 2009, Song et al. 2009, Yoshimura et al. 2009, 
Basterzi et al. 2010, Fornaro et al. 2011, Chang et al. 2012, Carvalho et al. 2013, Fornaro et al. 
2013, Yoshimura et al. 2013). For these studies, the criterion for response was ≥ 50% reduction 
of score on the adopted depression severity rating scale. Seven studies reported results in 
responders only (Maes et al. 1995, Frommberger et al. 1997, Tuglu et al. 2003, Marques-Deak 
et al. 2007, Hernandez et al. 2008, Piletz et al. 2009, Tsai et al. 2014), and seven studies 
described clinical improvements using a continuous outcome measure (Mizruchin et al. 1999, 
Schleifer et al. 1999, Kubera et al. 2000, O'Brien et al. 2006, Harley et al. 2010, Himmerich et al. 
2010, Uher et al. 2014). Studies were heterogeneous in terms of inflammatory biomarkers 
measured and patient samples, including the presence of psychiatric comorbidity, the degree of 
baseline treatment refractoriness and medication status at baseline.   
 
All studies investigated only pharmacological treatment, except one that compared 
pharmacological with psychological interventions (Harley et al. 2010); this found that high CRP 
was associated with good clinical response in antidepressant therapy but with poor response after 
psychotherapy. There were insufficient studies to compare inflammatory markers in unipolar and 
bipolar depression.  
 
Meta-analyses largely demonstrated significant levels of heterogeneity (I²) and lack of publication 








 Baseline inflammation and subsequent treatment-response 
Elevated baseline inflammation was found in depression vs. healthy controls with all three 
inflammatory markers: IL-6 (p = 0.003), TNFα (p = 0.02) and CRP (p < 0.0001), as well as the 
composite analysis (p = 0.017).  
However, no significant differences in levels of baseline inflammation were identified between 
those subsequently responding or not responding to treatment: this was shown in TNFα (p = 
0.57), CRP (p = 0.76), and IL-6 (p = 0.19), though the latter was numerically higher in non-
responders. The composite measure of inflammation at baseline showed higher levels were 
present in people subsequently not responding to treatment, which approached statistical 
significance (p = 0.073). This finding remained when confining the analysis solely to unipolar 
patients (i.e. removing the study which contained some bipolar depressed patients (Himmerich et 
al. 2006); p = 0.071). We performed a meta-regression on the composite measure which showed 
that the effect of elevated inflammation on treatment non-response was more accentuated in 
outpatient vs. inpatient settings (b = -0.494, p = 0.012), and in studies with a higher quality rating 
(b = 0.137, p = 0.009). 
 
 Effects of treatment and treatment-response on inflammation  
There was no change evident in TNFα levels when simply looking at the effects of treatment i.e. 
when responders and non-responders were grouped together (p = 0.42).  However, there was a 
differential effect when treatment response was taken into account: levels of TNFα significantly 
decreased in treatment responders (p = 0.008) but not in non-responders (p = 0.9); see Figure 
2.2.  These analyses included one study where both unipolar and bipolar patients were included 
(Himmerich et al. 2006); exclusion of this study did not alter TNFα results (responders, p = 0.008; 
non-responders, p = 0.66). Meta-regression analyses suggested that decreased levels of TNFα 
in responders positively correlated with year of publication, suggesting a stronger effect in more 















Figure 2.2   TNFα change in responders vs. non-responders 
 
  
NOTE: Weights are from random effects analysis
































Figure 2A: TNFa change over treatment in responders
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Figure 2B: TNFa change over treatment in non-responders
Eller et al., 2008
Himmerich et al., 2006
Lanquillon et al., 2000
Yoshimura et al., 2009




Egger’s test for publication bias: p=0.27, I2 test for heterogeneity: p<0.001 
Figure 2.2B: Forest plot of TNFα change during treatment in non-responders  
         Egger’s test for publication bias: p=0.07, I2 test for heterogeneity: p<0.001 







In the studies measuring IL-6, there was an overall reduction following treatment irrespective of 
treatment response (p = 0.03; see Figure 2.3). When separate analyses were conducted for 
responders and non-responders however, non-significant decreases were seen after treatment 
in both responders (p = 0.53) and non-responders (p = 0.11). IL-6 analyses included 8 patients 
diagnosed with bipolar depression (Maes et al. 1995); exclusion of the study containing these 
patients (as within-study bipolar/unipolar patient data was unavailable) from the analyses did not 
change the responders’ subgroup results (p = 0.8), and no non-responders were included in this 
article, but the overall analysis showed a slightly lowered significance value (k = 9, ES= -0.54, 
95% CI’s 1.12/0.03, p = 0.06).  
 
Meta-regressions indicated a correlation in responders between age and IL-6 change over 
treatment; studies with a higher mean age report smaller reductions in IL-6 levels with treatment 
(b = 0.113, p = 0.011). In non-responders the degree of change in measured IL-6 levels was more 
significant in older studies (b = 0.236, p = 0.024).  
 
 
  Egger’s test for publication bias: p=0.47, I2 test for heterogeneity: p<0.001 
 
Figure 2.3   IL-6 alterations over treatment 
 
 
NOTE: Weights are from random effects analysis






































Figure 3: IL-6 change over treatment in all patients
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There was no effect of treatment, or of treatment-response, on levels of CRP or on the composite 
inflammation measure. However, meta-regressions run on the composite analyses unanimously 
suggested that studies in which not all subjects were unmedicated at baseline showed greater 
variance in inflammatory changes alongside treatment: (for all depressed subjects: b = 1.23, p = 
0.017; for responders only: b = 1.101, p = 0.432; for non-responders only: b = 1.215, p = 0.053.) 
 
 






ES (95% CI’s) Signiﬁcance value 
R vs. NR baseline: composite      13 0.59 (0.06, 1.36)  p=0.073    
R vs. NR baseline: IL-6        5 0.83 (0.41, 2.07)  p=0.19   
R vs. NR baseline: TNFα        5 0.08 (0.34, 0.17) p=0.57 
R vs. NR baseline: CRP        4 0.03 (0.22, 0.16) p=0.76 
R baseline vs. end: composite      17 0.10 (0.40, 0.60)  p=0.70   
R baseline vs. end: IL-6        7 0.19 (0.78, 0.41) p=0.53 
R baseline vs. end: TNFα        8 0.73 (1.28, 0.19) p=0.008 
R baseline vs. end: CRP        3 0.54 (0.31, 1.50)  p=0.27   
NR baseline vs. end: composite      10 0.17 (0.86, 0.52) p=0.63 
NR baseline vs. end: IL-6        4 1.11 (2.45, 0.24) p=0.11 
NR baseline vs. end: TNFα        5 0.04 (0.58, 0.51) p=0.9 
NR baseline vs. end: CRP        3 0.03 (2.00, 2.07)  p=0.98   
All patients baseline vs. end: composite      23 0.07 (0.55, 0.42) p=0.79 
All patients baseline vs. end: IL-6      10 0.57 (1.09, 0.04) p=0.03 
All patients baseline vs. end: TNFα        9 0.18 (0.63, 0.27) p=0.42 
All patients baseline vs. end: CRP        5 0.41 (1.84, 1.01) p=0.57  
MD vs. HC baseline: composite      20 0.68 (0.12, 1.24)  p=0.017   
MD vs. HC baseline: IL-6      10 1.02 (0.34, 1.69)  p=0.003   
MD vs. HC baseline: TNFα      10 1.18 (0.18, 2.17)  p=0.02   
MD vs. HC baseline: CRP        5 1.26 (0.63, 1.90)  0.0001   
 





 Unipolar and bipolar depression 
Only Tsai et al.(2014) included solely bipolar diagnosed patients who were in a depressive 
episode and it was not possible to undertake a meta-analysis comparing unipolar vs. bipolar 
depression in the four studies identified (Maes et al. 1995, Landmann et al. 1997, Himmerich et 
al. 2006) due to disparate study methodologies or insufficient information being available. Tsai et 
al. (2014) identified a non-significant increase in levels of inflammation from acute depression to 
euthymia. In Maes et al. (1995), eight patients of the 61 included were bipolar patients in a 
depressed mood state, and the authors reported no correlations between bipolarity, IL-6 and 
depression severity (Maes et al. 1995). The other two articles including bipolar depressed patients 
did not report results separately nor any comparisons between the unipolar and bipolar diagnosed 
subjects. As can be seen above, removal of bipolar subjects from primary meta-analyses did not 
substantially affect the results. 
 
 
2.5 Discussion    
To our knowledge this is the first meta-analysis to investigate systematically the relationship 
between inflammation and treatment resistance in depression, both as a predictive marker and in 
maintenance of the illness. We found that prospectively-determined treatment resistance is 
associated with continued elevations in inflammation, in that there is a decrease in TNFα levels 
over time in treatment-responsive but not in treatment-resistant patients. We also examined a 
novel method for merging related inflammatory biomarker data, and its relation to treatment-
resistance in affective disorders, finding a trend towards higher inflammation being associated 
with a poorer response to antidepressant treatment.   
 
 Inflammation and major depression 
Although not the primary focus of the study, we have replicated previous findings that depression 
as a whole is associated with increased inflammation. Inflammatory elevations in depression have 
been reliably demonstrated across numerous reviews (Miller et al. 2009a, Dowlati et al. 2010, 
Hannestad et al. 2011, Hiles et al. 2012b) and there exist many plausible mechanisms by which 
this may occur. The causative effect of psychological and physiological stress on the inflammatory 
response has been well documented and this system interacts bidirectionally with other systems 
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implicated in mood disorders, including HPA-axis activity and cortisol release (Miller et al. 1999), 
serotonergic pathways (Maes et al. 2011b), neurogenesis and neuroinflammation (Harry and 
Kraft 2012). There is additional evidence that inflammation is a causal factor in the onset of 
depression, supported by replicated findings that administration of inflammatory cytokines 
(particularly IFNα treatment for hepatitis C) can induce depressive symptoms or clinical 
depression in many patients (Raison et al. 2005). 
 
An important area of uncertainty is the degree to which depression occurring as part of a bipolar 
disorder may differ compared to a unipolar disorder.  There is a paucity of research to this end, 
and we were not able to identify sufficient studies to test the hypothesis that inflammatory markers 
may differentiate between unipolar and bipolar disorder. There is clear evidence of differential 
treatment strategies being appropriate in unipolar and bipolar depression (Pacchiarotti et al. 2013) 
and due to the unanswered question of whether raised levels of inflammation are more specific 
to unipolar depression, therapeutic intervention in this domain may not be appropriate in bipolar 
depression. This is clearly an area which requires further investigation.  
 
 Inflammation and treatment resistance 
The results of the meta-analysis demonstrate a role of inflammation in treatment-resistant 
depression: there were significant decreases in TNFα (towards control levels) seen only in 
treatment responders, whereas treatment resistance was associated with persistently elevated 
TNFα.  This implies that maintenance of heightened levels of inflammation may at least contribute 
to treatment refractoriness, and thus that anti-inflammatory agents might provide a mechanism 
for treatment resistance in individuals with persistent high levels of TNFα. This is strengthened by 
recent preliminary findings that a TNFα antagonist, infliximab, can improve depression in some 
treatment-resistant patients (Raison et al. 2013b); when stratified by pre-treatment levels of 
inflammation, infliximab appears to be most anti-depressant in those with higher pre-treatment 
inflammation.  This association between TNFα modification and response may account for the 
lack of significant findings in a previous meta-analysis (Hannestad et al. 2011) which did not 
consider differential patterns of alteration in responders vs. non-responders.   
 
We also found that, regardless of treatment response, antidepressant treatment can have anti-
inflammatory effects, notably a reduction in IL-6. This may also occur in bipolar depression (as 
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indicated by the reduced significance found when removing Maes et al. (1995) whose sample 
was partly comprised of bipolar patients. The anti-inflammatory effects of antidepressants have 
been reported in preclinical (Connor et al. 1999) and in vitro (Xia et al. 1996) studies as well as 
clinical samples (Hannestad et al. 2011, Hiles et al. 2012b). Indeed, it has been suggested that 
these anti-inflammatory effects may be one of the many mechanisms by which antidepressants 
exert their therapeutic effect (Janssen et al. 2010). It may be, therefore, that this anti-inflammatory 
effect of antidepressants is sufficient in many cases to reverse the overall inflammatory response 
seen in depression. However, in those with more severe or chronic illnesses, this effect may not 
in itself be sufficient to normalise the inflammation, which may then in turn act as a maintaining 
factor in the illness.  
 
Most studies did not assess a placebo-arm control group and we could therefore not examine 
whether inflammatory changes were related to antidepressant effects or the amelioration of 
depressive symptoms. However, within the studies assessed, Song et al. (2009) only reported IL-
1β reductions in the active treatment arms (acupuncture and fluoxetine) but not placebo groups, 
whereas Frank et al. (2004) found that inflammation did not change differently between patients 
receiving an SSRI from those prescribed a placebo drug. It should also be noted that 
psychological interventions alone have also been reported to reduce inflammation alongside 
depressive symptoms (Thornton et al. 2009). 
 
 Composite biomarker measurement  
While meta-regressions conducted on individual biomarkers may have been insufficiently 
powered to illustrate factors important in modifying the comparisons, the composite meta-
regressions highlight the potential importance of medication status in the relationship between 
inflammation and treatment-resistance in depression. Our findings may also suggest that specific 
medications and their mechanisms might explain some of the heterogeneity within results, 
something that we were not able to explore further. A comprehensive understanding of 
pharmacological effects on inflammation, and treatment-response, will require substantially larger 
samples of depressed individuals before, during and after treatment with a range of separate 




Although not biologically specific, the composite measures showed that patients with higher levels 
of inflammation responded less well to subsequent treatment, though this finding did not reach 
statistical significance. Despite the lack of significant results from the composite analyses, we 
suggest this approach is still worthwhile; due to the complexity of interactions between human 
biomarkers (as well as the heterogeneity of affective disorders), it is arguable that such methods 
will be more likely to detect robust and clinically useful biological indicators to predict the likelihood 
of treatment successes. There may be a number of methods for calculating this composite 
measurement, and identification of an optimal approach requires further investigation. We 
particularly highlight the difficulty surrounding which biomarkers should be classified as those 
representing inflammation, and inconsistencies within the literature on this subject. We believe 
that this can evolve through the use of large datasets, advanced modelling techniques, and/or 
new discoveries made in biochemical mechanisms.   
 
 Clinical Implications 
As outlined earlier, treatment resistance is a common clinical problem in affective disorders, and 
it is likely that there are several contributing factors in each individual patient.  An important 
approach is to rule out alternative diagnoses that may explain the depressive symptoms, and to 
evaluate organic factors that may be of relevance.  The results of this meta-analysis add to the 
suggestion that it may also be important to evaluate the presence of raised levels of inflammation. 
We have shown that elevated inflammatory markers predict a poorer response to 
antidepressants, and that those who do not respond to antidepressant treatments show 
persistently elevated inflammation. We suggest that there is now a clear imperative for research 
to investigate whether targeting this elevated inflammation will improve the outcome in treatment 
resistant depression, and if so, in which particular groups of patients.    
 
Studies have rarely measured all potential inflammatory markers, and we do not yet know whether 
there are specific aspects of the inflammatory response that are relevant to depression or whether 
an approach such as that taken here of combining measures of inflammation is most likely to be 
of clinical relevance.  We also suggest that inflammation is likely to represent just one of several 
potential novel treatment targets in these difficult to treat cases of depression, and that other 
approaches based upon other maintaining factors such as HPA axis disturbance (Juruena et al. 
2009, Markopoulou et al. 2009) may also suggest differential treatment approaches on an 
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individual level.  Indeed, combining a range of inflammatory and other markers might be useful in 
enhancing treatment personalisation and diagnostic accuracy in the future, and complements 
current strategies to link clinical syndromes more closely to underlying neurobiological and other 
substrates (Insel 2014). The benefits of this approach have been comprehensively outlined by 
Schmidt et al. (2011), which advocates the investigation of ‘panels’ of biomarkers (including for 
inflammatory, neurogenesis, endocrine and other systems) in order to improve the recognition of 
different patient subtypes and ultimately increase treatment response. 
 
 Limitations 
There are several limitations in the interpretation of findings from this work. Our assessments 
using Egger’s test indicate that our analyses are not likely to have been influenced by publication 
bias. However, due to the relatively small number of studies included in this work it is not possible 
to fully exclude the possibility of selective publication of positive studies. It is also notable that 
there were a large range of treatments, inflammatory markers and variation in patient 
characteristics between included studies, limiting the conclusiveness and generalisability of the 
present findings. In particular, the treatments studied were almost exclusively pharmacological, 
and therefore the results may not apply to other forms of treatment.    
 
In addition, depression is a highly diverse condition and this was evident in the significant levels 
of heterogeneity present in analyses, with factors including severity, depressive subtype, and 
degree of treatment resistance likely contributing to variation in inflammatory profiles. We 
explored possible sources of heterogeneity with meta-regression analyses and found some 
associations with effect sizes, notably those present in the composite analyses, and that IL-6 
reductions with treatment were more prominent in younger samples. This may be a proxy for an 
earlier stage within the longitudinal course of affective illness or a representation of treatment 
naivety; both of these factors are associated with improved clinical response (Kornstein and 
Schneider 2001). However, it is important to bear in mind that heterogeneity could only partially 
be explained by the confounders we considered in meta-regressions; indeed, it is likely that there 
is significant heterogeneity due to the very nature of depression itself.  Moreover, this reinforces 
our message that further progress will be facilitated by defining more homogeneous groups for 




Utilising standardised treatment approaches, and the inclusion of psychological treatments as 
well as pharmacological, could improve our understanding of how different treatments can resolve 
inflammation. Furthermore, the relationship between inflammatory and other biological systems 
is clearly complex and multifaceted. Concurrent assessment of some of the parameters 
interacting with the inflammatory response in depression, such as the endocrine system, might 





   An exploration of inflammation and 
treatment response for inpatients with treatment-
resistant depression (Study 2) 
 
 
3.1  Abstract   
Approximately one third of those with MDD develop treatment-resistant depression (TRD) and 
this is an important subpopulation in whom there are clear unmet treatment needs. The ability to 
identify individuals who are more likely to manifest treatment non-response a priori would facilitate 
early, optimised care tailored to individuals. Some research suggests that inflammation may be 
related to treatment response, and TRD patients may display particularly elevated inflammatory 
markers. This study compared 28 IMs between TRD treatment responders and non-responders 
on admission and discharge from a specialist service alongside examination of bipolar features 
and sociodemographic factors.  
36 patients with TRD were investigated longitudinally during the inpatient treatment program and 
after discharge. In addition to blood collection for IM levels, data regarding symptom severity, 
demographic and clinical details were obtained before and after treatment. Treatment outcomes 
were calculated from depression severity scores at these time points and at a long-term follow-
up 3-12 months after discharge.   
Levels of inflammation frequently differed between TRD patients and matched controls. 56% of 
the TRD group responded to treatment in the short-term, and 50% showed a good outcome in 
the longer-term. High IM levels after treatment predicted a poorer long-term outcome (IL-6, IL-8, 
and to a lesser extent TNFα, CRP and Mip1a). A number of markers showed small increases 
during treatment, regardless of clinical outcome (IL-10, MCP1, sICAM1 and IFNγ). Age, level of 
cognitive impairment and retrospective treatment-resistance were particularly associated with 
high markers of inflammation. 
The results of this study suggest a complex relationship between TRD and inflammation, which 
requires replication in larger samples that includes an optimised measure of treatment outcome. 
If a predictor or predictors of response in TRD are identified, improved and targeted care might 
be more reliably provided to this vulnerable population. 
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3.2 Introduction 
Treatment-resistance is a serious problem in affective disorders (Keller 2005, Fekadu et al. 
2009a), with TRD patients frequently not responding to numerous treatments and presenting with 
chronic debilitating mood disorder that is often comorbid with many physical and mental disorders. 
Evidence now suggests that even the most treatment-resistant patients can achieve remission 
with a highly specialist, multidisciplinary, intensive and careful intervention program (Wooderson 
et al. 2011). Particularly in conjunction with a strong social support network, clinical remission can 
also be sustained in the longer-term (Fekadu et al. 2012, Wooderson et al. 2014). Identifying 
further factors that relate to treatment-response for different interventions will be extremely useful 
for improving individualised treatment choices in both bipolar and unipolar depression, and for 
identifying potential new targets for novel treatments. Due to the burden of TRD, an improvement 
to outcomes in this population has particular scope to reduce the wider costs associated with 
depressive disorders (Fineberg et al. 2013). It has been suggested that TRD might have distinct 
characteristics from non-TRD (Kornstein and Schneider 2001); as such, research should assess 
TRD and non-TRD as separate groups.  
 
Inflammation may be a factor that distinguishes TRD from non-TRD patients (Raison et al. 2013a). 
As part of a detailed rationale for this, Raison et al. have emphasised the well-documented links 
between physical health factors, and both TRD and elevated inflammation. Many additional 
variables associated with inflammation have been related to treatment-resistance in mood 
disorders. These include depression severity, chronicity and/or recurrence which are core 
elements of TRD (Anisman et al. 1999, Duivis et al. 2011, Maes et al. 2012b), as well as cognitive 
impairments (Allison and Ditor 2014), psychosis (Hope et al. 2009), an older age of onset 
(Vogelzangs et al. 2012), early life trauma (Danese et al. 2011), obesity, bipolar diathesis, and 
comorbid anxiety or personality disorder (Raison et al. 2013a). Age and BMI may confound this 
relationship (Howren et al. 2009) and are frequently not adjusted for in research investigating 
inflammatory activity in depression. However, even when controlling for confounding factors, 
inflammatory responses seem aberrant in approximately one third of patients with depression 
(Raison and Miller 2011, Krishnadas and Cavanagh 2012). As also outlined in Chapter 1, 
undetected bipolar symptoms may contribute to the heterogeneity observed in previous work, 
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although a manic state may co-occur with inflammatory increases more than depressive episodes 
(Bai et al. 2014) and may be higher in bipolar than unipolar depression (Becking et al. 2015). 
Patients classified as TRD can be found to have undetected symptoms of bipolar disorders 
(Hirschfeld et al. 2003); it is therefore important that careful examinations of these factors are 
undertaken to determine classification of participants with maximum accuracy.  
 
Inflammatory effects of medication are especially important in TRD populations, where patients 
are frequently taking multiple medications of different classes on a long-term basis. Titrating TRD 
patients off medication has clear implications for wellbeing and should generally be avoided 
except where clinically indicated. The vast majority of research investigations have measured 
unmedicated depression at baseline in non-TRD samples, both in comparisons between 
depressed and control groups and in longitudinal studies of short-term inflammatory effects. This 
enables an insight only into the initial inflammatory effects of antidepressants. Hernandez et al. 
(2008) suggest that there are different effects seen after one year of taking antidepressants 
compared to those occurring at either 5 or 20-week time points. The authors found that both IL-2 
and IFNγ increased over the 12-months after an initial decrease in levels, while IL-10 and IL-13 
decreased gradually between each assessment, IL-1β rose after an initial lack of change, and IL-
4 fluctuated markedly between measurements. This study included a sample size that was small 
(particularly at follow-up), where all participants were unmedicated at baseline and in clinical 
remission at endpoint, having received non-standardised treatment. Therefore, it is not clear 
whether IM changes are attributable to medication, clinical improvement or other factors. A 
prospective and naturalistic study where participants are medicated at baseline and can be 
distinguished by the achievement of treatment-response would permit an indication of the 
confluence between clinical outcomes and inflammation in an ecologically valid sample of 
individuals.  
 
Inpatient treatment for TRD typically comprises multiple antidepressant trials (including dose 
escalation and switching of drug) in conjunction with occupational and psychological therapies, 
over a longer treatment period than most previous investigations. Although Study 1 (Chapter 2) 
suggested that IM elevations predict response in outpatient but not inpatient treatment settings, 
most of the included studies involved a short-term treatment programme (in most cases, 5-12 
weeks). It is not clear whether this finding extends to a depressive disorder that is considered 
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treatment-resistant in the longer term. Few studies have specifically investigated inflammation in 
patients defined as TRD, but T lymphocytes, IL-6 and IL-10 may be elevated in this group (Maes 
et al. 1997a, Maes et al. 1997b, Carvalho et al. 2013).  
 
In contrast to previous studies, we explored changes in relation to naturalistic treatment for 
depression using an array of 33 IMs in patients who were all medicated and treatment-resistant 
at study-entry. After baseline, participants undertook an individualised package of specialist, 
multidisciplinary inpatient treatment lasting an average of 6 months. As well as measuring short-
term treatment response (at discharge from the inpatient service) a long-term assessment of 
outcome (depression severity at 3-12 months following discharge) was conducted to provide a 
measure of enduring treatment effects. A comprehensive clinical formulation and assessment of 
other potentially mediating factors was undertaken at admission.   
 
 Hypotheses  
In response to the existing evidence examining the relationship between inflammation, 
depression and treatment-response, the following null hypotheses were proposed: 
Main null hypotheses: 
1) At baseline, IM levels will not differ between patient and control subjects; 
2) After treatment, IM levels will not differ between patient and control subjects; 
3) Inflammation before inpatient treatment will not differ between treatment responders and 
non-responders; 
4) Following treatment, markers of inflammation will not differ between treatment responders 
and non-responders;  
5) After treatment, patients’ inflammatory levels will not have changed significantly, and 
change will not differ between responders and non-responders;   
Exploratory null hypotheses:   
6) IMs will not significantly differ between bipolar and unipolar TRD patients (either before or 
after treatment);  
7) IMs will not differ based on long-term treatment outcomes (either before or after 
treatment); 
8) Inflammation will not correlate with depression severity scores (at either time point);  
70 
 
9) Additional factors will not significantly associate with treatment-response and/or 
inflammation. Additional factors inspected are: physical illness severity, traumatic 
experiences in childhood, prior treatment-resistance, current cognitive impairment, 
psychotic symptoms experienced, and age of depression onset. Medication factors 
(number taken regularly and number of changes in regular medication), age, gender and 
BMI are also examined; 
10) IMs will not be related to one another. 
 
Given the number of biomarkers studied and the exploratory nature of the IM panel in this 
population, it is expected that our hypotheses will be true for some but not all biomarkers. Being 
uncertain of the precise inter-relationships between IMs is part of the rationale for measuring a 
large panel of biomarkers of the examined system (Schmidt et al. 2011). The markers that, based 
on existing evidence, are predicted to show differences in relation to treatment-response are 
TNFα, CRP and IL-6. Other pro-inflammatory cytokines (IFNγ, IL-12, IL-12p70, IL-15, IL-16, IL-
17, TNFβ, IFNα, IL-1α, IL-1β and GM-CSF), chemokines (IL-8, IP-10, MCP1, MCP4, Mip1a, 
Mip1b, Eotaxin, TARC, Eotaxin-3), acute phase protein SAA, immunoglobulins (sICAM-1 and 
sVCAM1) and Tie2, would be anticipated to represent pro-inflammatory activity and thus be more 
elevated in TRD patients, specifically non-responders. For anti-inflammatory cytokines (IL-10 and 
IL-13) or those with regulatory functions (IL-2, IL-4, IL-5, IL-7), the directionality of expected 




 Study Design 
This study was a naturalistic inpatient investigation of individuals with treatment-resistant 
depression who were admitted to the National Affective Disorders Unit (ADU), at the Bethlem 
Royal Hospital within the South London and Maudsley NHS Foundation Trust (SLaM), UK. The 
ADU provided a specialist, multi-disciplinary intervention programme individualised for people 
with treatment-resistant mood disorders, incorporating pharmacological, psychological (most 
frequently CBT and/or couple therapy), occupational and physical therapies where relevant as 
well as group activities. The majority of patients undertook multiple treatment modalities during 
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the treatment period, between the two study assessments of admission and discharge from the 
unit (also referred to as pre- and post-treatment). A case-control design element was additionally 
employed to compare people with TRD to a control group who did not have depression.  
 
 Sample Characteristics   
Separate ethical approval was obtained for the TRD (Camberwell & St Giles NHS Research 
Ethics Committee, reference 322/03) and matched non-depressed control group (SELCoH study; 
King's College London Research Ethics Committee, reference CREC/07/08-152).All participants 
provided fully informed written consent before providing data. 
 
TRD group (n = 36): Patients admitted as an inpatient to the ADU were considered eligible for the 
study if they met diagnostic criteria for an affective disorder and were currently depressed. 
Affective disorder diagnosis (defined as DSM-IV codes 296 or ICD-10 F30-39) was assessed 
using the Mini International Neuropsychiatric Interview: MINI, Sheehan et al. (1998), and validated 
by two psychiatrists and screening of patient records. These methods were also used to define 
bipolar disorder and lifetime or current psychotic symptoms, as well as age of depression onset. 
Current depression was identified as a score of >8 on the Hamilton Rating Scale for Depression 
(HAM-D; Hamilton 1960). Treatment completion was defined as >4 weeks of inpatient 
intervention. All participants completed both pre- and post-treatment clinical assessments (n = 
36). However, 7 participants did not complete the blood test after treatment, leading to a reduced 
sample of IM data (n = 29). In all cases this was due to unavailability of participants for 
venepuncture appointment at time of discharge.   
 
Control group (n = 36): Non-depressed volunteers were age-, gender- and BMI-matched 
individuals with no current psychiatric disorder, verified using the Clinical Interview Schedule-
Revised (Lewis et al. 1992) and no current depression assessed by the Patient Health 
Questionnaire (PHQ9; Kroenke and Spitzer 2002) with a score <10. Patients and controls were 
matched as closely as possible, but to a maximum of 2 years difference in age and 5 units in BMI. 
The control group were participants in phase III of the SELCoH study (Hatch et al. 2011) which 
was a large community investigation. Blood collection and analysis techniques, and demographic 





Outcome measurements are reported for the TRD group only, unless otherwise specified. 
Depressed mood was assessed using the Hamilton Rating Scale for Depression (HAM-D; 17-
item version, Hamilton 1960) at admission (pre-treatment) and discharge (post-treatment), as well 
as at a follow-up assessment 3-12 months after discharge. Depression outcome following 
treatment was therefore examined in the short-term and in the longer-term: this later time point 
may more accurately reflect everyday wellbeing following the treatment program, while at 
discharge HAM-D scores can sometimes dip due to the large change in life that occurs in the 
period surrounding discharge from inpatient services (Wooderson et al. 2011). 
a) Short-term response: defined as a HAM-D score reduction of >50% between admission 
and discharge, or if the participant met criteria for remission (HAM-D score <8).  
b) Long-term outcome: A measure of long-term outcome was conducted to determine those 
who remained out of depressive episode following discharge, as an exploratory 
assessment. This compared participants with absent or sub-threshold depression (‘good 
outcome’) to those with mild, moderate or severe depression (‘poor outcome’), using 
standardised HAM-D17 score categories: 0-7 = absent, 8-13 = sub-threshold, 14-18 = 
mild, 19-22 = moderate, 23+ severe depression; National Institute for Health and Clinical 
Excellence (NICE 2009).  
 
Further outcomes were examined at admission (pre-treatment) only. 
Treatment-resistance within the current episode was examined using the Maudsley Staging 
Method - MSM (Fekadu et al. 2009b). The MSM has a possible score range of 3-17, with higher 
scores indicating greater treatment-resistance. A cut-off score of 7.5 has been proposed to define 
treatment-resistant depression (Trevino 2012).  
Physical health problems were evaluated using the Modified Cumulative Illness Rating Scale - 
MCIRS (Miller et al. 1992). The total score of all items except the mental health item ranges from 
13-65 (with higher scores indicating a greater severity of illness). 
Experience of childhood trauma was measured with the Childhood Trauma Questionnaire - CTQ 
(Bernstein et al. 1994), where scores range from 28 to 140 with higher scores indicating more 
extensive trauma experienced. 
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The Mini-Mental State Examination - MMSE (Folstein et al. 1983) was used to inspect current 
level of cognitive impairment. On this measure a greater score demonstrates less cognitive 
impairment (range 0-30).  
The number of pharmacological (psychotropic and non-psychotropic) treatments were calculated 
as a count (for each medication taken at least once daily). Changes in treatment between 
admission and discharge were calculated: a count was added for any medication either stopped 
or started during admission (modifications in dose were not accounted for, due to incomplete 
records of this information). 
 
Biological Measures:  
Blood was collected to measure inflammation from serum (1 x 5ml tube) in the morning (between 
9-11am where possible), using a syringe and butterfly needle. Following complete clotting, the 
tubes were centrifuged and serum extracted, transferred into cryovials and frozen (between -40 
and -80°C). Serum concentrations of biomarkers were then assayed in duplicate with ultra-high 
sensitivity Meso Scale Discovery (MSD) kits (Meso Scale Diagnostics, Maryland, USA). The 33 
biomarkers measured in this study were: CRP, IFNα, IFNγ, IL-10, IL-12, IL-12p70, IL-13, IL-15, 
IL-16, IL-17, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), TNFα, TNFβ, Eotaxin (CCL11), 
Eotaxin-3 (CCL26), GM-CSF, IP-10 (CXCL10), MCP1 (CCL2), MCP4 (CCL13), Mip1a (CCL3), 
Mip1b (CCL4), SAA, sICAM1 (sCD54), sVCAM1 (sCD106), TARC (CCL17) and Tie2. With the 
exception of TNFα, IL-6 and CRP, which had been hypothesised a priori to play a role in response 
to treatment for depression, the examination of this array was exploratory. The assays used were 
the MSD V-PLEX Plus Human Biomarker 40-Plex kit (which also contained some non-
inflammatory growth factors not considered here), and a customised kit assaying IFN-α. These 
quantified the proteins simultaneously using a multiplex ELISA-derived, electrochemiluminescent 
method of analysis and assays were run according to the manufacturer’s guidelines. The MSD 
has been shown to provide a reliable measurement of protein levels in healthy and diseased 
populations (Dabitao et al. 2011). Dabitao et al. reported standard curves and limits of protein 
detection that on the MSD were comparable to (or improved, for IL-8) a cytometric bead array 
method. At recovering low levels of TNFα and IL-12p70, MSD also outperformed the comparator 





 Data Analysis 
Inflammation was assessed on one occasion only for healthy controls, and before and after 
treatment in patients.  
 
Data Cleaning:  
The raw IM data distributions and rates of detection were inspected. Incomplete data were 
imputed with half the lowest level of detection (LLOD) value - LLOD/2 – as recommended by 
Hornung and Reed (1990) and Marques-Vidal et al. (2011) as it is considered likely that these 
‘non-detected’ levels were below the limit of detection by the assay. While imputation with 
LLOD/√2 may introduce less bias (Croghan & Egeghy 2003), this provides asymmetrical 
imputation based on the LLOD (which in this study range from 0.01 to 2.41) with values below 1 
giving a higher imputed value than LLOD. Croghan & Egeghy (2003) suggest that where 25% of 
values are non-detected, LLOD/2 provides 4-5% discrepancy with true values and from >50% 
non-detected, the discrepancy exceeds 10%. Therefore, IMs with >50% undetected data points 
were considered uninterpretable and were excluded from analyses.  
For each biomarker, normality of data distribution was assessed, and IM levels were standardised 
using a log base 10 transformation prior to parametric test analysis. In order to determine 
normality of distributions, all variables were examined using multiple methods: skewness and 
kurtosis values, frequency distribution (histogram plots), stem and leaf plots, P-P (probability-
probability) plots, Q-Q (quantile-quantile) plots and box plots, as well as the Kolmogorov-Smirnov 
test. In order to deal with slightly non-normal distributions, account for potential outlier effects and 




To address the main hypotheses, the main comparisons focused on inflammatory associations 
with treatment outcomes, over time, and between patients with TRD and non-depressed controls. 
For all IMs analysed, the following comparisons were conducted:   
a) Pre-treatment (admission time point) IM levels were compared between the TRD and 
control participants (hypothesis 1). This was conducted using logistic regressions of each 
IM level (independent variable; IV) between the two groups (dependent variable: DV). 
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Unadjusted (univariate) regression was supplemented by a multivariate logistic regression 
including age, gender and BMI in addition to IM to indicate whether adjusting for these IVs 
altered the strength of the prediction of group status (TRD vs. control) by inflammation. 
b) Post-treatment (discharge) comparisons of IMs between TRD and control groups 
(hypothesis 2). The same statistical tests were carried out as above. 
All remaining analyses were conducted within the TRD patient group only. 
c) Whether IMs before treatment could predict response (hypothesis 3) was assessed using 
a univariate logistic regression. Response status was included as the DV (outcome 
variable), and IM as the IV (predictor variable). Due to small numbers this analysis was 
not adjusted for additional factors. 
d) Post-treatment comparisons of IMs between responders and non-responders (hypothesis 
4) were conducted using the same tests as above (for hypothesis 3). 
e) To assess whether inflammation changed with inpatient treatment (hypothesis 5), 2 x 2 
mixed-factorial design ANOVA analyses were conducted, comparing TRD patients’ IM 
levels between admission and discharge measurements, by treatment response group. 
This examined whether inflammatory changes over time differed between responders and 
non-responders. As exploratory comparisons, mixed-model ANOVA also assessed long-
term outcome and bipolar disorder as the between-subjects factor in separate analyses of 
IM change over time. 
Each of the main comparisons outlined above were subjected to a control for multiple 
comparisons; Simes. This is a Bonferroni-based method which is modified for correlated variables 
to be less conservative but maintain practicability (Simes 1986). To denote when Simes-adjusted 
(as opposed to the initial, uncorrected p) value is reported, we use the term ‘corrected’ p. For any 
inflammatory markers significant in any main comparison following control for multiple 
comparisons, a heat-map was constructed to display how levels were distributed across the 
sample before and after treatment.  
 
Exploratory comparisons: 
f) Independent-samples t-tests compared inflammatory markers between bipolar and 




g) Independent-samples t-tests also compared IMs (both pre- and post-treatment) between 
patients who had a good versus poor long-term depression outcome (hypothesis 7). 
h) In line with hypothesis 8, further insight into the association between depressive state and 
inflammation was sought by examining Pearson’s correlations between depression 
severity (total HAM-D score) at both pre- and post-treatment with IM levels pre- and post-
treatment. 
i) Associations between IM levels and additional factors that may alter inflammation 
(potential modifying factors) were assessed (hypothesis 9). Continuous factors were 
compared with IMs using Pearson’s correlations and included age, BMI, number of 
medications taken at baseline, number of changes in medication during admission, 
childhood trauma, prior treatment-resistance, current cognitive impairment, and age of 
depression onset. Gender, physical ill health and psychotic symptoms were dichotomous 
factors that were compared with IMs using independent samples t-tests. 
j) Relationships between all analysed IMs were examined using correlations both pre-
treatment and post-treatment (referred to as inter-IM correlations); hypothesis 10. For 
each marker, the relationship between levels over time (intra-correlation) was also 
inspected.  
 
Finally, an all subsets regression approach (Lawless and Singhal 1987) was undertaken to 
explore the potential for baseline measurements to predict depression outcome at discharge from 
the inpatient unit. In accordance with this technique, all variables with a potential role in predicting 
treatment outcome were included (both IM and non-IM data). IM data were complete, following 
imputation of non-detected values. Non-biological variables where >10% data was missing were 
excluded from the all subsets analysis, and where variables contained less than 10% of data 
missing, these were imputed with the mean to maintain a full sample size. This is based on the 
assertion that completeness of >90% is not likely to induce substantial bias into analyses (Bennett 
2001). All subsets regression explores all possible models and information criteria values indicate 
the optimal model: Akaike’s Information Criterion (AIC; Akaike 1973) has been demonstrated to 
show the most predictive model but has been criticised for overfitting; the Bayesian Information 
Criterion (BIC; Schwarz 1978) addresses this and is likely to provide the most parsimonious model 
(Lindsey and Sheather 2010). All-subsets regression approaches have been recommended 
where there are a large number of potential predictive variables but there is no consensus on 
77 
 
methodology for optimal model selection. An exploratory approach including the use of BIC, AIC, 
r2 and theoretical or clinical merit has been indicated (Sullivan et al. 1989), and was employed (in 
addition to inspection of collinearity statistics). Collinearity was assessed using the Durbin-
Watson statistic; non-substantial multicollinearity was anticipated where the Durbin-Watson value 
falls between 1 and 3 (Field 2009). 
For all analyses, we considered p values < 0.05 to indicate significant findings.  
  
 
3.4 Results   
 TRD patient characteristics 
On admission, all patients were treatment-resistant (defined by exceeding a score of 7.5 on the 
MSM measure; Trevino 2012). See Table 3.1 for characteristics of the sample.  
20 of the patients (56%) were classified as treatment responders and 16 (44%) as non-
responders. At baseline, the mean HAM-D score was 22.9 for non-responders and 20.5 for 
responders. At discharge responders’ mean HAM-D was 7.5 and non-responders’ mean HAM-D 
was 16.3. In the long-term, 14 patients had absent or subsyndromal depressive symptoms only 
(mean HAM-D = 9.4) and were considered to show a good clinical outcome, while 14 were mild, 
moderate or severely depressed (mean HAM-D = 19.0) and were grouped as having a poor 
clinical outcome. Data were missing for the remaining 8 patients; thus a good outcome was found 
in 50% of individuals. 24 patients experienced unipolar depression and 12 had bipolar disorder 
but were currently in a depressive episode. There were 6 responders and 6 non-responders with 
bipolar depression. The 7 participants without IM data after treatment were all categorised as 
unipolar; post-treatment IM data were present for 17 responders and 12 non-responders (n = 29). 
Of these, long-term outcome data were complete for 11 with a good outcome and 11 with a poor 
outcome (n = 22). As detailed in Table 3.1, responders and non-responders did not differ in terms 
of bipolarity, age, gender, BMI, number or changes in medication during admission, physical 
illness severity, age of onset, prior treatment-resistance, childhood trauma or psychotic 
symptoms. Non-responders were more likely to have a poorer outcome in the long-term, but only 
a small trend (p < 0.1) was observed between responders and non-responders for differences in 
long-term follow-up HAM-D severity score. There were also no significant group differences 









n = 36 
TRD  
n = 36 
Responders 
n = 20 
Non-
responders  




n female (%)  21 (58%)  21 (58%)  11 (55%)  10 (63%)  
 
    
Age  
Mean age (range) 54.5 (28-80)  53.8 (26-82)  55.8 (40-78)  51.1 (26-82)  
 
BMI 
Mean BMI (range) 28.2 (20-42)  29.1 (18-46)  29.4 (21-46)  28.6 (18-44)  
 
Regular medications  
Mean number (range)   
  
5.6 (3-10)a 5.6 (3-10)  5.5 (3-10)  
 
Medication changes ** 
Mean number (range)  4.2 (1-9)b 3.9 (1-6)  4.6 (1-9)  
 
Baseline depression severity 
Mean HAM-D score (range)  21.8 (10-32)  20.5 (10-32)  22.9 (12-32)  
 
Discharge depression severity 
Mean HAM-D score (range)  12.2 (0-22)  7.5 (0-16)  16.3 (10-22)  
 
<0.001 
Long-term depression severity 
Mean HAM-D score (range)  
 
14.2 (5-29)c 10.7 (5-19)  17.27 (10-29)  
 
 
Long-term good/poor outcome 
n good outcome (%)  14 (50%)c 10 (71%)  4 (29%)  
 
  0.028 
Treatment-resistance 
Mean MSM score (range)  11.8 (8-15)  11.4 (8-14)  12.1 (8-15)  
 
Age of onset (mood disorder) 
Mean age (range)  33.1 (9-61)  38.7 (11-61)  28 (9-49)  
 
Lifetime psychosis  
n psychosis (%)  20 (55%)  11 (55%)  9 (56%)  
 
Childhood trauma severity 
Mean CTQ score (range)   57.1 (34-123)d 50.7 (36-77)  66.1 (34-123)  
 
Physical illness  
n illness(%)   17 (47%)  10 (50%)  7 (44%)  
 
Cognitive performance   
Mean MMSE score (range)  27.4 (18-30)  26.5 (18-30)  28.1 (20-30)  
 
  
Measurements reported from baseline assessment unless otherwise stated.  
* p value, denoting difference between groups (either TRD versus control, or responder versus non-
responder; the only significant differences in characteristics were between responders and non-responders). 
In this column, differences are non-significant unless stated. 
** number of changes in medication with inpatient treatment (i.e. starting or stopping any medication adds 1 
to the count).  
a n = 35 (20 responders, 15 non-responders) 
b n = 32 (17 responders, 15 non-responders) 
c n = 28 (14 responders, 14 non-responders)  






 Treatment characteristics 
All patients were taking medication on admission and experienced medication changes during 
the inpatient intervention. One participant only was not taking psychotropic medication on 
admission to the unit. Antidepressant medication use in responders and non-responders at both 
time points is detailed in Table 3.2, containing drugs considered to target depression (including 
antipsychotic and mood stabiliser medications but not anxiolytics or hypnotics). The most 
frequently used class of psychotropic medication was mood stabilisers, and within this class most 
frequently quetiapine, lamotrigine and then lithium. After treatment, an increase in antipsychotic 
medication use could be observed, particularly in non-responder patients. The mean number of 
changes in psychiatric medication (number of agents started or stopped during the inpatient stay) 
was 3.5 for non-responders and 2.1 for responders. Many patients also undertook psychological, 
occupational or physical therapies. These were recorded only sparsely and the data are not 
sufficiently complete to report these results or incorporate them into analyses. No controls were 
taking NSAIDs. One responder was taking aspirin at both time points. Main comparisons were 
conducted both with and without this patient; no substantial changes in findings occurred, i.e. 
converting between p < 0.05 and p > 0.05. Therefore, this participant was kept included to 





Table 3.2   TRD antidepressant medication use before and after inpatient treatment  
 
 Pre-treatment  Post-treatment 
  SSRI SNRI TCA MS AP Other SSRI SNRI TCA MS AP Other 
R  1  2 1     2 1  
R    1   1   1   
R    1    1  1 1  
R  1  2 1    1 2   
R   1 1  1 1 1  1   
R 1  1 1 1  1  1 1 1  
R  1  2  1  1  2  1 
R    2 1 2  1  2   
R    2 1        
R  1  1 1 1  1  1  1 
R    1 1     1 1 1 
R    2    1  2   
R*       1      
R    3 1     3 1  
R 1    1 1 1   2  1 
R  1  2  1      1 
R   1  1    1 1 1  
R 1   1 1  1   2 1  
R    1 1     2 1  
R  1      1  1 1  
NR 1   2 1       1 
NR 1   1 1     2 1  
NR  1  2  1   1 2 1  
NR   1      1  1  
NR    3    1  1 1  
NR    3      3 1  
NR   1 2    1   1 1 
NR   1 1    1   1  
NR    2 1       1 
NR    1      2 1  
NR    2      2   
NR     1 1  1   1  
NR  1        2   
NR  1  1 1   1  1 1  
NR  1  2 1     2 1  
 
The number in each column represents how many medications within each class the participant was taking 
at each time point. Each participant is represented by one row (n = 20 responders, n = 15 non-responders 
complete data; 1 non-responder, data missing at both time points). 
*At baseline, 1 responder was taking no psychotropic medication.  
R = responder, NR = non-responder. 
 
Medication categories:  
SSRI = Selective Serotonin Reuptake Inhibitors: includes citalopram, sertraline, fluoxetine, escitalopram. 
SNRI = Serotonin-Norepinephrine Reuptake Inhibitors: includes venlafaxine, duloxetine.  
TCA = Tricyclic antidepressants: includes clomipramine, amitriptyline, lofepramine, nortriptyline.  
MS = Mood Stabilisers: includes lithium and anticonvulsants lamotrigine, sodium valproate, carbamazepine. 
AP = Antipsychotics: includes both typical (chlorpromazine) and atypical antipsychotics (quetiapine, 
olanzapine, aripiprazole).  
Other = includes mirtazapine (noradrenergic and specific serotonergic antidepressant), bupropion 
(norepinephrine dopamine reuptake inhibitor), trazodone (serotonin antagonist). No patients were taking 




 Inflammatory marker characteristics  
Of the 33 biomarkers, 13 had undetected values: IFNγ and Eotaxin-3 had <10% undetected, 
Mip1a, IL-5, TNFβ, IL-12p70, IL-4 and IFNα had <50% undetected and these non-detected values 
were imputed with LLOD/2. GM-CSF, IL-13, IL-1β, IL-1α and IL-2 had >50% undetected and were 
excluded from analyses (28 IMs analysed). At discharge a slightly lower proportion was 
undetected for each IM than at baseline: see Supplementary Table 3.1 for non-detection rates 
and imputation methods of IM data. For all incompletely-detected markers, non-detection was 
more frequent in control than TRD participants, suggesting lower levels in this group and this 
aligns with findings, detailed below. Between responders and non-responders no clear difference 
in detection rates were apparent, although IL-2 was more often undetected in non-responders. 
IL-2 was not analysed due to high rates of undetected IM levels: this regulatory inflammatory 
marker was present only in 6/36 controls (17%), at pre-treatment in 11/20 (55%) responders, 3/16 
(19%) non-responders and after treatment in 11/17 (65%) responders, 4/12 (33%) non-
responders. This suggests that IL-2 is highest in responder participants, but that patients may 
undergo an increase in IL-2 alongside treatment especially in those deriving reduced clinical 
benefits. However, these observations are tentative.  
Following transformation, most IM variables were normally distributed. Three cytokines 
demonstrated non-normal distributions: IL-8 (kurtosis >3), IL-10 (kurtosis >3) and IL-4 (skewness 
>1, kurtosis >3). Bootstrapping is utilised on all comparisons to deal with this issue, as this has 
demonstrated comparable accuracy of findings for normal and non-normal data (Sufahani & 
Ahmad 2012).  All continuous non-IM variables were normally distributed except for physical 
illness severity (MCIRS score), which was dichotomised according to a median split (median 
score = 16, responder range = 13-29, non-responder range = 14-19).   
 
 Main Comparisons 
Inflammation results are displayed in Tables 3.3 - 3.7 below and then categorised by biomarker 
(28 IMs) in text. IL-6, CRP and TNFα were identified a priori as the most pertinent biomarkers 
based on existing evidence and are described first, followed by the more exploratory array of IMs. 
IMs with any non-detected (imputed) values are described last (in order from the largest to 
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smallest proportion detected). Due to the high number of comparisons, a Simes correction was 
conducted on main comparisons and only significant effects prior to Simes correction 
(uncorrected p < 0.05) are reported in text below.  As detailed in tables and the text below, the 
main findings were as follows. 
At pre-treatment, 13 markers were significantly different between patient and control groups after 
Simes correction (IL-8, IL-16, MCP4, TARC, Tie2, IP-10, Mip1a, Eotaxin, Eotaxin-3 and IL-5 were 
higher in TRD while sICAM1, sVCAM1 and TNFβ were lower in TRD than control participants; 
Table 3.3). When adjusting for age, gender and BMI these findings were comparable 
(Supplementary Table 3.2); age, gender and BMI did not affect the association between any 
inflammatory markers and group status. After inpatient treatment, the same markers were 
significantly different between TRD and control groups, except TNFβ which was no longer 
significantly lower in TRD; IL-12, Mip1b and IL-4 were elevated in TRD patients only at post-
treatment (Table 3.4). Similarly, adjustment for age, gender and BMI did not affect these results 
(Supplementary Table 3.3). Pre-treatment IM levels did not predict response when correcting for 
multiple comparisons (Table 3.5), although IL-7 was lower in responders prior to Simes 
adjustment. After treatment, responder and non-responder IM levels did not differ from one 
another (Table 3.6). Over time, levels of four IMs increased (IFNγ, sICAM1, MCP1 and IL-10), but 





Table 3.3   Pre-treatment inflammation in TRD and control groups 
 
    IM 
Control group TRD group  
   r2      OR 
95% CI 
Lower   Upper 
    p cor. p 
lg-mean   SD   lg-mean   SD 
TNFα 0.376 0.163 0.370 0.188 0.000 0.826 -3.228 2.813 0.875 0.907 
IL-6 -0.140 0.315 0.016 0.400 0.062 3.538 -0.130 3.058 0.058 0.102 
CRP 6.570 0.568 6.415 0.697 0.020 0.674 -1.496 0.288 0.345 0.483 
IL-10 -0.641 0.408 -0.498 0.300 0.054 3.465 -0.179 4.375 0.220 0.326 
IL-8 0.935 0.176 1.348 0.592 0.311 39.095 1.981 6.981 0.002 0.006 
IL-12 2.001 0.222 2.110 0.249 0.070 7.749 -0.086 4.733 0.040 0.074 
IL-7 1.165 0.222 1.142 0.183 0.004 0.577 -3.158 1.815 0.649 0.757 
IL-15 0.319 0.093 0.341 0.135 0.012 5.437 -2.861 7.013 0.453 0.577 
IL-16 2.228 0.168 2.352 0.219 0.131 38.153 0.977 8.281 0.017 0.037 
IL-17 0.157 0.402 0.157 0.348 0.000 1.000 -1.264 1.664 1.000 1.000 
MCP1 2.406 0.188 2.313 0.159 0.093 0.042 -7.098 -0.350 0.035 0.070 
MCP4 1.800 0.222 2.135 0.252 0.430 236.996 3.432 9.720 0.001 0.003 
Mip1b* 2.083 0.153 2.129 0.298 0.013 2.343 -1.396 3.661 0.415 0.553 
Eotaxin 1.969 0.179 2.252 0.166 0.536 12108.259 6.214 16.256 0.001 0.003 
sICAM1 5.824 0.267 5.577 0.134 0.352 0.003 -10.393 -3.576 0.001 0.003 
sVCAM1 5.905 0.289 5.602 0.128 0.454 0.001 -13.107 -4.787 0.001 0.003 
SAA 6.826 0.516 6.671 0.719 0.021 0.665 -1.611 0.309 0.328 0.483 
TARC 2.282 0.237 2.464 0.336 0.122 9.083 0.974 4.763 0.011 0.026 
Tie2 3.577 0.123 3.666 0.080 0.210 5352.372 3.678 18.457 0.006 0.015 
IP-10 2.200 0.166 2.533 0.206 0.581 11176.348 6.218 16.332 0.001 0.003 
IFNγ 0.740 0.310 0.752 0.265 0.003 1.362 -1.379 1.742 0.688 0.760 
Eotaxin3 0.315 0.491 1.252 0.279 0.870 140342.049 8.255 285.114 0.001 0.003 
Mip1a 0.413 0.447 1.338 0.439 0.669 87.215 2.733 12.045 0.001 0.003 
IL-5 -1.110 0.627 -0.275 0.532 0.444 9.848 1.448 4.267 0.001 0.003 
TNFβ -0.990 0.439 -1.271 0.392 0.138 0.201 -3.182 -0.560 0.001 0.003 
IL-12p70 -1.214 0.524 -1.290 0.476 0.008 0.730 -1.300 0.691 0.511 0.622 
IL-4 -2.025 0.371 -1.964 0.762 0.004 1.193 -0.481 1.885 0.706 0.760 
IFNα* -0.308 0.472 -0.429 0.262 0.039 0.382 -3.558 0.345 0.254 0.395 
 
Results of unadjusted univariate logistic regressions of inflammation (IV) on TRD versus control group (DV) 
before inpatient treatment. Bold IM names and p values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons. 
Note that some of the OR’s are large; this is due to the levels at which markers were expressed and the 
variability across the sample.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. When adjusting for age, gender 
and BMI each regression model fit was satisfactory. All other regression models were adequately fitted 
according to the Hosmer-Lemeshow test.  




Table 3.4   Post-treatment inflammation in TRD and control groups 
 
IM 
Control group TRD group 
r2  OR 
95% CI 
Lower   Upper 
p cor. p 
lg-mean   SD lg-mean  SD 
TNFα 0.376 0.163 0.413 0.182 0.016 3.666 -1.670 4.586 0.382 0.446 
IL-6 -0.140 0.315 0.040 0.323 0.103 6.764 0.137 4.523 0.043 0.075 
CRP 6.570 0.568 6.452 0.582 0.014 0.692 -1.642 0.501 0.456 0.511 
IL-10 -0.641 0.408 -0.376 0.278 0.185 15.398 0.534 9.133 0.093 0.145 
IL-8 0.935 0.176 1.562 0.695 0.482 108.174 2.698 9.362 0.002 0.006 
IL-12* 2.001 0.222 2.139 0.217 0.123 19.871 0.691 5.812 0.008 0.020 
IL-7 1.165 0.222 1.179 0.219 0.001 1.361 -1.952 3.310 0.800 0.830 
IL-15 0.319 0.093 0.348 0.127 0.025 12.858 -2.777 8.636 0.295 0.393 
IL-16 2.228 0.168 2.353 0.206 0.138 42.881 1.091 8.620 0.014 0.028 
IL-17* 0.157 0.402 0.208 0.274 0.007 1.528 -0.852 2.763 0.585 0.630 
MCP1 2.406 0.188 2.397 0.171 0.001 0.753 -3.189 2.657 0.848 0.848 
MCP4 1.800 0.222 2.217 0.228 0.591 1572.173 5.165 13.134 0.001 0.004 
Mip1b 2.083 0.153 2.190 0.221 0.104 24.594 0.498 6.784 0.026 0.049 
Eotaxin* 1.969 0.179 2.334 0.223 0.591 6043.150 4.978 19.607 0.002 0.006 
sICAM1 5.824 0.267 5.607 0.159 0.259 0.011 -8.419 -2.021 0.001 0.004 
sVCAM1 5.905 0.289 5.623 0.145 0.382 0.002 -11.126 -3.791 0.001 0.004 
SAA 6.826 0.516 6.661 0.539 0.033 0.541 -1.915 0.341 0.242 0.339 
TARC 2.282 0.237 2.537 0.336 0.229 27.092 1.227 7.831 0.011 0.026 
Tie2 3.577 0.123 3.684 0.084 0.271 17454.720 5.240 17.549 0.001 0.004 
IP-10 2.200 0.166 2.578 0.164 0.765 7553578.615 11.328 32.339 0.001 0.004 
IFNγ 0.740 0.310 0.878 0.276 0.065 5.018 -0.177 4.014 0.080 0.132 
Eotaxin3 0.315 0.491 1.270 0.248 0.880 292160.454 8.762 283.054 0.001 0.004 
Mip1a 0.413 0.447 1.378 0.348 0.683 1902.646 5.100 21.418 0.001 0.004 
IL-5 -1.110 0.627 -0.275 0.532 0.194 6.338 0.519 4.712 0.012 0.026 
TNFβ -0.990 0.439 -1.078 0.336 0.018 0.544 -2.068 -1.339 0.315 0.410 
IL-12p70 -1.214 0.524 -1.099 0.593 0.019 1.563 -0.525 1.555 0.360 0.438 
IL-4 -2.025 0.371 -1.663 0.417 0.238 10.306 1.125 4.131 0.001 0.004 
IFNα -0.308 0.472 -0.500 0.268 0.076 0.279 -3.715 0.008 0.120 0.177 
 
Results of unadjusted univariate logistic regressions of inflammation (IV) on TRD versus control group (DV) 
after inpatient treatment. Bold IM names and p values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons. 
Note that some of the OR’s are large; this is due to the levels at which markers were expressed and the 
variability across the sample.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. When adjusting for age, gender 
and BMI each regression model fit was satisfactory. All other regression models were adequately fitted 










 lg-mean   SD 
Non-responders 
 lg-mean     SD 
r2 OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.325 0.157 0.427 0.212 0.103 0.035 -9.665 0.899 0.085 0.750 
IL-6 0.000 0.381 0.035 0.433 0.003 0.796 -2.481 1.615 0.821 0.962 
CRP 6.309 0.714 6.548 0.675 0.040 0.599 -1.665 0.526 0.295 0.751 
IL-10 -0.547 0.307 -0.437 0.288 0.046 0.265 -4.038 1.181 0.223 0.751 
IL-8 1.249 0.467 1.472 0.715 0.048 0.510 -2.460 0.795 0.251 0.751 
IL-12 2.118 0.241 2.100 0.267 0.002 1.341 -2.423 3.900 0.822 0.962 
IL-7 1.199 0.136 1.072 0.213 0.162 85.531 0.841 10.517 0.022 0.616 
IL-15 0.370 0.121 0.303 0.145 0.085 61.993 -0.631 10.761 0.077 0.751 
IL-16 2.347 0.217 2.359 0.228 0.001 0.776 -4.760 3.329 0.892 0.962 
IL-17 0.162 0.268 0.151 0.438 0.000 1.098 -3.166 2.356 0.934 0.962 
MCP1* 2.296 0.133 2.333 0.188 0.019 0.211 -8.183 2.902 0.534 0.935 
MCP4 2.133 0.223 2.137 0.292 0.000 0.937 -3.739 3.494 0.962 0.962 
Mip1b 2.147 0.213 2.108 0.386 0.006 1.576 -2.244 3.781 0.723 0.962 
Eotaxin 2.271 0.103 2.227 0.222 0.024 5.298 -3.590 7.239 0.473 0.935 
sICAM1 5.548 0.134 5.612 0.130 0.076 0.022 -10.874 1.135 0.125 0.751 
sVCAM1 5.578 0.136 5.634 0.114 0.064 0.026 -10.729 2.239 0.204 0.751 
SAA 6.647 0.748 6.700 0.704 0.002 0.900 -1.316 0.934 0.827 0.962 
TARC 2.459 0.353 2.471 0.325 0.000 0.894 -2.772 2.268 0.906 0.962 
Tie2 3.682 0.073 3.646 0.086 0.071 612.925 -3.310 21.133 0.137 0.751 
IP-10 2.535 0.199 2.531 0.221 0.000 1.110 -3.655 4.947 0.936 0.962 
IFNγ 0.787 0.272 0.709 0.258 0.030 3.244 -1.971 4.306 0.366 0.854 
Eotaxin3 1.246 0.270 1.259 0.300 0.001 0.845 -2.647 2.883 0.895 0.962 
Mip1a 1.243 0.401 1.449 0.491 0.072 0.306 -5.498 0.526 0.229 0.751 
IL-5 -0.323 0.475 -0.215 0.606 0.013 0.573 -2.737 3.860 0.521 0.935 
TNFβ -1.258 0.375 -1.287 0.423 0.011 0.620 -2.955 1.472 0.607 0.962 
IL-12p70 -1.369 0.489 -1.192 0.455 0.047 0.435 -3.323 0.534 0.285 0.751 
IL-4 -1.979 0.766 -1.945 0.781 0.001 0.941 -2.126 1.042 0.893 0.962 
IFNα -0.457 0.270 -0.41 0.205 0.013 0.419 -4.725 5.527 0.500 0.935 
 
Results of unadjusted univariate logistic regressions of inflammation (IV) on responder versus non-
responder groups (DV) before inpatient treatment. Bold IM names and p values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. MCP1 was not markedly different 
overall between responders and non-responders. All other regression models were adequately fitted 










 lg-mean    SD 
Non-responders 
 lg-mean     SD 
r2 OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.404 0.151 0.426 0.225 0.005 0.517 -7.264 5.353 0.785 0.956 
IL-6 0.037 0.339 0.044 0.312 0.000 0.931 -3.441 2.611 0.949 0.964 
CRP 6.341 0.588 6.610 0.560 0.071 0.430 -3.000 0.496 0.218 0.956 
IL-10 -0.378 0.257 -0.374 0.318 0.000 0.940 -3.728 3.405 0.964 0.964 
IL-8 1.511 0.785 1.634 0.570 0.010 0.770 -2.234 0.817 0.650 0.956 
IL-12 2.156 0.200 2.114 0.247 0.012 2.518 -3.559 5.978 0.620 0.956 
IL-7 1.176 0.268 1.184 0.135 0.000 0.841 -3.857 5.414 0.918 0.964 
IL-15 0.363 0.109 0.327 0.151 0.028 11.016 -4.214 10.861 0.464 0.956 
IL-16 2.362 0.218 2.340 0.197 0.004 1.740 -3.899 5.300 0.772 0.956 
IL-17 0.198 0.270 0.223 0.289 0.003 0.703 -3.936 3.246 0.822 0.959 
MCP1 2.400 0.152 2.394 0.202 0.000 1.202 -5.152 5.479 0.952 0.964 
MCP4 2.197 0.175 2.246 0.293 0.016 0.366 -7.670 3.160 0.631 0.956 
Mip1b 2.218 0.228 2.150 0.213 0.032 4.491 -2.344 7.841 0.450 0.956 
Eotaxin 2.374 0.203 2.277 0.246 0.063 7.944 -1.495 8.384 0.281 0.956 
sICAM1 5.600 0.152 5.617 0.175 0.004 0.499 -5.790 6.119 0.773 0.956 
sVCAM1 5.598 0.143 5.657 0.148 0.056 0.050 -11.078 2.957 0.292 0.956 
SAA 6.575 0.589 6.783 0.456 0.050 0.470 -3.192 0.669 0.292 0.956 
TARC 2.505 0.376 2.582 0.279 0.018 0.475 -3.221 2.637 0.497 0.956 
Tie2 3.677 0.077 3.694 0.095 0.013 0.084 -14.122 8.736 0.606 0.956 
IP-10 2.547 0.141 2.621 0.190 0.067 0.052 -12.794 2.255 0.274 0.956 
IFNγ 0.836 0.262 0.942 0.298 0.067 0.176 -6.420 1.474 0.266 0.956 
Eotaxin3 1.292 0.284 1.236 0.189 0.033 3.851 -1.694 6.035 0.388 0.956 
Mip1a 1.377 0.409 1.380 0.242 0.005 0.689 -3.895 1.827 0.729 0.956 
IL-5 -0.353 0.425 -0.319 0.420 0.005 1.464 -3.620 3.765 0.743 0.956 
TNFβ * -1.145 0.384 -0.975 0.222 0.030 0.363 -3.490 2.005 0.337 0.956 
IL-12p70 -1.136 0.614 -1.042 0.585 0.018 0.666 -3.024 0.789 0.571 0.956 
IL-4 -1.562 0.404 -1.818 0.404 0.115 4.972 -0.358 5.059 0.114 0.956 
IFNα -0.472 0.275 -0.544 0.265 0.024 0.487 -2.097 5.556 0.518 0.956 
 
Results of unadjusted univariate logistic regressions of inflammation (IV) on responder versus non-
responder group (DV) after inpatient treatment.   
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. TNFβ did appear different overall 
between responders and non-responders. All other regression models were adequately fitted according to 






 Table 3.7   Inflammatory changes over time in responders and non-responders 
 
IM 
  Before vs. after treatment Treatment x response interaction 
F p cor. p F p cor. p 
TNFα 0.277 0.603 0.804 2.743 0.109 0.744 
IL-6 0.019 0.893 0.983 0.236 0.631 0.810 
CRP 0.866 0.360 0.775 0.365 0.551 0.810 
IL-10 4.971 0.037 0.308 0.824 0.372 0.744 
IL-8 0.365 0.551 0.802 1.090 0.306 0.744 
IL-12 0.117 0.735 0.936 0.001 0.971 0.971 
IL-7 0.041 0.840 0.983 0.615 0.440 0.800 
IL-15 1.292 0.266 0.700 0.569 0.457 0.800 
IL-16 0.012 0.915 0.983 1.288 0.266 0.744 
IL-17 0.578 0.454 0.802 0.451 0.507 0.810 
MCP1 4.569 0.043 0.308 3.801 0.062 0.744 
MCP4 0.325 0.573 0.802 0.192 0.665 0.810 
Mip1b 0.001 0.977 0.983 1.884 0.181 0.744 
Eotaxin 0.869 0.359 0.775 3.929 0.058 0.744 
sICAM1 4.471 0.048 0.308 0.245 0.624 0.810 
sVCAM1 1.778 0.194 0.679 0.008 0.931 0.966 
SAA 0.464 0.502 0.802 1.604 0.216 0.744 
TARC 0.001 0.978 0.983 0.402 0.532 0.810 
Tie2  0.529 0.473 0.802 1.026 0.320 0.744 
IP-10 1.480 0.234 0.700 0.123 0.729 0.851 
IFNγ 7.357 0.011 0.308 1.362 0.253 0.744 
Eotaxin3 0.000 0.983 0.983 1.690 0.205 0.744 
Mip1a 0.529 0.473 0.208 1.026 0.320 0.744 
IL-5 0.327 0.572 0.802 0.056 0.815 0.913 
TNFβ 4.018 0.055 0.308 0.824 0.372 0.744 
IL-12p70 3.160 0.087 0.356 0.010 0.921 0.966 
IL-4 3.149 0.089 0.356 0.209 0.651 0.810 
IFNα 1.245 0.275 0.700 0.852 0.365 0.744 
 
Results of 2x2 mixed-factorial ANOVA comparing paired IM changes over time (pre- to post-treatment) 
between responders and non-responders. The before vs. after treatment columns describe the main effect 
of cytokine comparison between time points in the full sample and the Treatment x response interaction 
column describes the effect of response status on inflammatory change over time (n = 29). Bold IM names 
and p values indicate significant effects. For mean IM values before and after treatment, refer to Tables 3.3 
and 3.4 (or for responders and non-responders, Tables 3.5 and 3.6). 
F = ANOVA test statistic (degrees of freedom 1, 27), p = uncorrected p, before Simes control for multiple 












TNFα did not differ significantly between patient and control groups, or over time. On admission, 
levels correlated positively with extent of previous treatment-resistance (r = 0.365, p = 0.029), and 
the discharge level of TNFα was higher in patients who had more severe depression in the longer-
term (r = 0.473, p = 0.026).  
 
3.4.4.2 IL-6 
IL-6 levels were slightly higher in the TRD than control group. At baseline, a small elevation was 
indicated only when adjusting for age, gender and BMI before Simes control for multiple 
comparisons (OR = 5.202, p = 0.031, corrected p = 0.058). At the post-treatment measurement 
the group difference was significant before controlling for multiple comparisons in the unadjusted 
regression (OR = 6.764, p = 0.043, corrected p = 0.075); this effect was stronger when adjusting 
for age, gender and BMI (OR = 8.666, p = 0.025, corrected p = 0.044). At this time point those 
with elevated IL-6 were significantly more likely to have a worse long-term outcome as shown by 
independent t-tests comparing ‘good’ and ‘poor’ response (t(20) = 3.054, p = 0.005; see Figure 
3.1) and by correlations with HAM-D score in the long-term (r = 0.509, p = 0.016). IL-6 levels after 
treatment were significantly higher where depression had been more severe before treatment 
(retrospectively): r = 0.557, p = 0.002. At admission but not discharge, IL-6 was correlated to 
number of medications taken (r = 0.367, p = 0.030), age (r = 0.420, p = 0.012) and cognitive 
impairment (r = 0.379, p = 0.023). IL-6 was also higher before treatment in those with physical 
illness (t(34) = 2.407, p = 0.030). Both measurements of IL-6 elicited positive correlations with 
BMI (r = 0.346, p = 0.039 and r = 0.431, p = 0.020 respectively) and prior treatment resistance (r 
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Figure 3.1   Discharge levels of IL-6 and long-term outcome 
 
Log transformed mean values of IL-6 are presented. Error bars represent standard error of the mean (SEM). 
Log values: Good outcome mean = -0.161, SEM = 0.097, n = 11; Poor outcome mean = 0.202, SEM = 0.069, 




CRP was not significantly different between TRD and control subjects. Elevated CRP at discharge 
was associated with concurrent severity of depression (HAM-D score): r = 0.374, p = 0.046, and 
was found to predict a poorer long-term outcome (t(20) = 2.421, p = 0.024; see Figure 3.2). CRP 
was higher in older patients at both time points (r = 0.403, p = 0.015; r = 0.248, p = 0.046). At 
baseline only, positive correlations were found with number of medications taken (r = 0.444, p = 
0.008), and severity of prior treatment-resistance (r = 0.346, p = 0.039). 
 





















p  =  0 .0 2 4
 
Figure 3.2   Discharge levels of CRP and long-term outcome 
 
Log transformed mean values of CRP are presented, with error bars representing standard error of the mean 
(SEM). Log values: Good outcome mean = 6.094, SEM = 0.139, n = 11; Poor outcome mean = 6.615, SEM 




IL-10 increased between pre- and post-treatment measurements (F(1,27) = 4.971, p = 0.037; see 
Figure 3.3). Baseline levels were higher in patients taking more medications (r = 0.384, p = 0.023).  
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Figure 3.3   Inflammatory marker increases during inpatient treatment 
 
Log transformed mean values of IMs over time, with error bars representing standard error of the mean 
(SEM). Note that axes have been cut according to IM levels expressed to depict differences clearly. For all 
IMs, n = 29. Log values: IL-10 pre-treatment mean = -0.497, SEM = 0.057, post-treatment mean = -0.376, 
SEM = 0.052; IFNγ pre-treatment mean = 0.759, SEM = 0.049, post-treatment mean = 0.878, SEM = 0.051; 
MCP1 pre-treatment mean = 2.328, SEM = 0.028, post-treatment mean = 2.397, SEM = 0.032; sICAM1 pre-




Levels of IL-8 were significantly higher in the TRD than control group at both baseline and 
discharge, demonstrated by both unadjusted univariate logistic regressions and when adjusting 
for age, gender and BMI. At pre-treatment the unadjusted regression (OR = 39.095, p = 0.002, 
corrected p = 0.006) was marginally improved by adjustment for these factors (OR = 60.367, p = 
0.002, corrected p = 0.006), and this pattern was similar after treatment between unadjusted (OR 
= 108.174, p = 0.002, corrected p = 0.006) and adjusted (OR = 140.003, p = 0.006, corrected p = 
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0.015). Discharge levels of IL-8 were higher in those with a higher HAM-D score in the longer 
term (r = 0.579, p = 0.005). 
  
3.4.4.6 IL-12 
IL-12 was slightly higher in the TRD patients than controls at baseline: The unadjusted regression 
(OR = 7.749, p = 0.040, corrected p = 0.074) was not improved much when adjusting for age, 
gender and BMI (OR = 9.357, p = 0.044, corrected p = 0.077). At discharge, IL-12 was more 
elevated in patients than controls: the unadjusted regression (OR = 19.871, p = 0.008, corrected 
p = 0.020) was slightly strengthened by adjustment for age, gender and BMI (OR = 32.778, p = 
0.010, corrected p = 0.022). IL-12 was correlated positively at baseline with previous treatment-
resistance (r = 0.361, p = 0.031). TRD patients with more cognitive impairment had somewhat 
higher IL-12 both before (r = 0.382, p = 0.022) and after (r = 0.449, p = 0.014) inpatient treatment. 
 
3.4.4.7 IL-7 
IL-7 did not differ between patient and control groups at baseline or discharge. Levels of this 
cytokine were lower at baseline in subsequent non-responders than responders, but this was not 
significant after control for multiple comparisons (OR = 85.531, p = 0.022, corrected p = 0.616). 
IL-7 at discharge was higher in more cognitively impaired patients (r = 0.453, p = 0.014).  
 
3.4.4.8 IL-15 
Baseline IL-15 was higher in older participants (r = 0.392, p = 0.018) and in those with physical 
health problems (t(34) = 2.065, p = 0.047).  
 
3.4.4.9 IL-16 
IL-16 was higher in the TRD than control group before and after treatment: this was significant at 
pre-treatment in unadjusted (OR = 38.153, p = 0.017, corrected p = 0.037) and adjusted (OR = 
45.366, p = 0.020, corrected p = 0.043) regression analyses, and similarly at post-treatment 
(unadjusted OR = 42.881, p = 0.014, corrected p = 0.028; adjusted: OR = 44.770, p = 0.008, 
corrected p = 0.019). Baseline IL-16 was positively correlated with age (r = 0.515, p = 0.001) and 
number of medications taken (r = 0.531, p = 0.001), as well as being higher in patients with 
physical illness (t(34) = 3.258, p = 0.011). At the discharge measurement, IL-16 was somewhat 
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higher in people with more prior treatment-resistance (r = 0.415, p = 0.025) and cognitive 
impairment (r = 0.439, p = 0.017).  
 
3.4.4.10 IL-17 
All main comparisons of IL-17 were not statistically significant. At pre-treatment, those with higher 
IL-17 had more extensive cognitive impairment (r = 0.433, p = 0.008).  
 
3.4.4.11 MCP1 
MCP1 was slightly lower in TRD than control participants at baseline, but this was not quite 
significant after both adjustment for covariates and Simes multiple comparisons control 
(unadjusted regression: OR = 0.042, p = 0.035, corrected p = 0.070; adjusted OR = 0.024, p = 
0.031, corrected p = 0.058). Levels of MCP1 increased during treatment (F(1,27) = 4.569, p = 
0.043, corrected p = 0.308; see Figure 3.3). At admission MCP1 was higher in male than female 
patients (t(34) = 2.210, p = 0.033) and those taking more medications (r = 0.350, p = 0.040). 
 
3.4.4.12 MCP4 
Levels of MCP4 were elevated in the patient group at both admission (unadjusted OR = 236.996, 
p = 0.001, corrected p = 0.003; adjusted OR = 372.803, p = 0.001, corrected p = 0.003) and 
discharge (unadjusted OR = 1572.173, p = 0.001, corrected p = 0.004; adjusted OR = 3912.782, 
p = 0.001, corrected p = 0.003). Elevated MCP4 levels within TRD patients at baseline predicted 
a poor long-term outcome, both between groups (t(26) = 2.471, p = 0.015) and in correlation with 
long-term depression severity (r = 0.43, p = 0.022). The post-treatment measurement of MCP4 
was positively correlated with age (r = 0.416, p = 0.025). 
 
3.4.4.13 Mip1b 
Mip1b levels were similar between groups at baseline but were elevated in the TRD group at 
discharge: in unadjusted regression (OR = 24.594, p = 0.026, corrected p = 0.049) and when 
adjusting for age, gender and BMI (OR = 42.726, p = 0.014, corrected p = 0.026). Baseline levels 
of this chemokine were higher in patients with a higher MSM score indicating more refractory 





The TRD group had high levels of Eotaxin at both baseline (unadjusted OR = 12108.259, p = 
0.001, corrected p = 0.003; adjusted OR = 31809.731, p = 0.001, corrected p = 0.003), and 
discharge (unadjusted OR = 6043.150, p = 0.002, corrected p = 0.006; adjusted OR = 13151.451, 
p = 0.001, corrected p = 0.003). Baseline levels of Eotaxin were higher in those who subsequently 
underwent more medication changes during treatment (r = 0.425, p = 0.015), and post-treatment 
levels were higher in those more cognitively impaired (r = 0.457, p = 0.013).  
 
3.4.4.15 sICAM1 
TRD inpatients had significantly lower levels of sICAM1 both time points: at baseline in unadjusted 
(OR = 0.003, p = 0.001, corrected p = 0.003) and adjusted (OR = 0.002, p = 0.001, corrected p = 
0.003) regressions; at discharge unadjusted (OR = 0.011, p = 0.001, corrected p = 0.004) and 
adjusted (OR = 0.008, p = 0.001, corrected p = 0.003) regressions. sICAM1 increased during the 
treatment period (F(1,27) = 4.471, p = 0.048, corrected p = 0.308); see Figure 3.3.   
 
3.4.4.16 sVCAM1 
Lower levels of sVCAM1 were identified in TRD individuals than controls consistently: pre-
treatment unadjusted (OR = 0.001, p = 0.001, corrected p = 0.003) and adjusted (OR = 0.0003, 
p = 0.001, corrected p = 0.003) comparisons; post-treatment unadjusted (OR = 0.002, p = 0.001, 
corrected p = 0.004) and adjusted (OR = 0.001, p = 0.001, corrected p = 0.003) regression 
analyses. Before treatment, higher levels of this biomarker were associated with more 
medications taken (r = 0.348, p = 0.04). 
 
3.4.4.17 SAA 
Main comparisons did not yield significant results. Baseline SAA was higher in those taking more 
medications (r = 0.399, p = 0.018) and in older patients (r = 0.388, p = 0.019).   
 
3.4.4.18 TARC 
TARC was elevated in the TRD group compared to controls at both measurements: at admission 
in unadjusted (OR = 9.083, p = 0.011, corrected p = 0.026) and adjusted regressions (OR = 
10.579, p = 0.017, corrected p = 0.040), and at discharge in unadjusted (OR = 27.092, p = 0.011, 
corrected p = 0.026) and adjusted regressions (OR = 33.244, p = 0.014, corrected p = 0.026). 
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Before inpatient treatment, depression severity (HAM-D score) was greater in participants with 
concurrently higher TARC levels (r = 0.375, p = 0.024). 
 
3.4.4.19 Tie2 
Tie2 was significantly higher in patients than controls at pre-treatment (unadjusted OR = 
5352.372, p = 0.006, corrected p = 0.015, adjusted OR = 7958.018, p = 0.002, corrected p = 
0.006) and post-treatment (unadjusted OR = 17454.720, p = 0.001, corrected p = 0.004, adjusted 
OR = 19893.766, p = 0.001, corrected p = 0.003). Positive correlations were identified between 
baseline levels of Tie2 and BMI (r = 0.439, p = 0.007) and number of medications taken with 
discharge levels (r = 0.396, p = 0.037).  
 
3.4.4.20 IP-10 
IP-10 was markedly increased in TRD compared to control participants at both baseline 
(unadjusted OR = 11176.348, p = 0.001, corrected p = 0.003; unadjusted OR = 23474.149, p = 
0.001, corrected p = 0.003) and discharge (unadjusted OR = 7553578.615, p = 0.001, corrected 
p = 0.004; adjusted OR = 13997849.329, p = 0.001, corrected p = 0.003). At discharge, cognitive 
impairment was also greater in TRD patients with higher IP-10 (r = 0.500, p = 0.006).  
 
3.4.4.21 IFNγ 
No difference in IFNγ was found between TRD and control groups. IFNγ levels increased during 
treatment (F(1,27) = 7.357, p = 0.011, corrected p = 0.308); see Figure 3.3. A positive correlation 
was identified between cognitive impairment and IFNγ at baseline (r = 0.512, p = 0.001). 
 
3.4.4.22 Eotaxin-3 
Eotaxin-3 levels were substantially higher in patients than controls: at baseline (unadjusted OR = 
140342.049, p = 0.001, corrected p = 0.003; adjusted OR = 299888.063, p = 0.001, corrected p 
= 0.003) and discharge (unadjusted OR = 292160.454, p = 0.001, corrected p = 0.004; adjusted 
OR = 485738.104, p = 0.001, corrected p = 0.003). Higher Eotaxin-3 was associated with taking 





Mip1a was higher in inpatients than controls, both before (unadjusted OR = 87.215, p = 0.001, 
corrected p = 0.003; adjusted OR = 101.792, p = 0.001, corrected p = 0.003) and after (unadjusted 
OR = 1902.646, p = 0.001, corrected p = 0.004; adjusted OR = 101334.401, p = 0.001, corrected 
p = 0.003) treatment. At discharge Mip1a was positively correlated with depression severity in the 
long-term (r = 0.428, p = 0.047). 
 
3.4.4.24 IL-5 
TRD subjects had significantly higher IL-5 than controls at both admission (unadjusted OR = 
9.848, p = 0.001, corrected p = 0.003; adjusted OR = 12.276, p = 0.001, corrected p = 0.003) and 
discharge (unadjusted OR = 6.338, p = 0.012, corrected p = 0.026; adjusted OR = 14.458, p = 
0.001, corrected p = 0.003). Levels of IL-5 at discharge were higher among those with a higher 
BMI (r = 0.480, p= 0.008). 
 
3.4.4.25 TNFβ 
TNFβ was lower in the TRD patients than controls at baseline (unadjusted OR = 0.201, p = 0.001, 
corrected p = 0.003; adjusted OR = 0.189, p = 0.012, corrected p = 0.031) but not after treatment. 
At discharge, patients with higher TNFβ had a slightly earlier age of onset (r = -0.41, p = 0.027) 
and more retrospective treatment-resistance (r = 0.432, p = 0.019).   
 
3.4.4.26 IL-12p70 
At discharge, levels of IL-12p70 were positively correlated with childhood trauma severity (r = 
0.457, p = 0.032).  
 
3.4.4.27 IL-4 
At discharge only, TRD patients had higher levels of IL-4 than controls (unadjusted OR = 10.306, 
p = 0.001, corrected p = 0.004; adjusted OR = 11.406, p = 0.002, corrected p = 0.006). At 
admission, unipolar patients had slightly higher levels of IL-4 than bipolar patients (t(31) = -2.287, 
p = 0.041). This cytokine also showed a small positive correlation at admission with depression 





At discharge, IFNα levels were positively correlated with HAM-D score retrospectively at 
admission (r = 0.424, p = 0.025) and with an earlier age of depression onset (r = -0.589, p = 
0.001). 
 
 For IMs that were significantly different in main comparisons when corrected for multiple 
comparisons, a heat-map displays relative values between participants at both time points (Figure 
3.4). All of these were significantly different only between TRD patients and controls (higher IL-6, 
IL-8, IL-12, IL-16, MCP4, Mip1a, Mip1b, Eotaxin, Eotaxin-3, TARC, Tie2, IP-10, IL-5, IL-4 and low 





Figure 3.4   Heat-map of significant inflammatory markers between participants 
 
Pre = pre-treatment, post = post-treatment. Each row represents a participant, grouped into TRD responders 
(n = 20), TRD non-responders (n = 16) and healthy controls (n = 36). Those without an IM measurement at 
post-treatment are ordered last in the respective categories, and denoted by a diagonal line. The lowest 
levels across the full sample (N = 72 across both time points) are depicted using green and the highest levels 






























































































































































































 Further Comparisons 
3.4.5.1 IM inter- and intra-correlations 
Many IMs were intra-correlated (between admission and discharge); see Supplementary Table 
3.4. Inter-correlations between different IMs at each time point were frequently highly significant. 
Supplementary Tables 3.5 and 3.6 contain the full inter-correlation IM matrices for pre- and post-
treatment measurements. The acute phase proteins SAA and CRP were most strongly related (r 
= 0.592, p < 0.001). These two markers appeared within a cluster also including IL-6 and IL-16 
which were all strongly inter-connected. IL-6, TNFα and IP-10 appeared to most frequently 
correlate with different biomarkers at the p < 0.01 level. Another cluster mainly comprised of 
chemokines was also apparent, including Eotaxin, MCP4, TARC, IL-7 and Mip1b to a lesser 
extent (though unexpectedly none of these related closely with Eotaxin-3). 
  
 
3.4.5.2 All subsets regression  
IMs entered as potential predictor variables into the all subsets regression algorithm were IL-6, 
TNFα, CRP, IL-15, IL-16, IL-17, IL-10, IL-12, IL-7, IL-8, MCP1, MCP4, Eotaxin, sICAM1, sVCAM1, 
SAA, Mip1b, TARC, Tie2, IP-10, IFNγ and Eotaxin-3). The following additional variables were 
also entered: Age, gender, BMI, cognitive impairment, age of depression onset, treatment-
resistance score, physical illness score, baseline depression severity, number of medications, 
bipolar disorder and lifetime psychosis. Data were pruned to yield potential models with < 4 
predictor variables; for 33 potential predictor variables, a binomial coefficient of n unordered 
outcomes for k < 4 possibilities demonstrated 40,920 possible model combinations (subsets). The 
10 potential models with the smallest BIC information criterion were considered. These are 




Table 3.8   Pre-treatment predictors of post-treatment severity 
 
 




N medications, TARC, IL-7*, IL-15* 0.007 0.363 123.805 116.028 1.761 
2 
N medications, TARC, IL-7* 0.015 0.282 124.414 118.193 1.909 
3 
N medications, TARC, IL-7*, IL-17 0.013 0.335 125.325 117.548 1.962 
4 
TARC, IL-15*, IL-7* 0.009 0.301 125.794 119.46 1.879 
5 
N medications, age, TARC, IL-7* 0.016 0.324 125.849 118.072 1.975 
6 
N medications, TARC, IL-8, IL-7* 0.018 0.321 126.051 118.274 1.841 
7 
N medications, TARC, IL-12*, IL-7* 0.019 0.318 126.194 118.417 2.039 
8 
N medications, Tie2, TARC, IL-7* 0.023 0.307 126.732 118.955 2.005 
9 
N medications, TARC, IL-7*, SAA 0.025 0.303 126.966 119.189 1.868 
10 
N medications, TARC, IL-16, IL-7* 0.025 0.302 126.995 119.219 1.955 
 
Unless indicated, higher units of the predictor variables are associated with higher severity after treatment.  
* = lower levels predict greater depression severity.   
 
 
TARC and number of medications were mostly frequently found in the best models, all of which 
were significant and had an acceptable absence of collinearity, measured by the Durbin-Watson 
statistic. The model containing number of medications, TARC, IL-7 and IL-15 yielded the lowest 
BIC value (123.805) and had the lowest AIC (AIC = 116.028), the highest r2 (r2 = 0.363) and 
lowest p value (p = 0.007) of those considered. Although IL-15 was only present in one other of 
the ten likely ‘best’ sets of predictors, the other three variables were included in almost all of the 
considered models. This was judged to be the most appropriate model.  
 
All predictors except for medication independently contributed to severity after therapy: low levels 
of IL-7 (OR = -0.572, p = 0.002; 95% CI’s -28.049, -6.507) and IL-15 (OR = -0.286, p = 0.018; 
95% CI’s -21.53, -2.301); and high levels of TARC (OR = 0.566, p = 0.006; 95% CI’s 2.001, 
15.846). Number of medications appears to be present as a control for other variables (OR = 









3.5 Discussion   
Inflammation may play an important role in treatment resistance and response in depression. 
Although much evidence has previously linked abnormal levels of inflammatory proteins with the 
presence of depression, there is inconsistency in the literature and it may be that inflammation is 
only dysregulated in some subpopulations of mood disorders. Very few studies have previously 
investigated a range of inflammatory proteins in severely treatment-resistant depressed 
populations, either in comparison with controls or longitudinally with treatment.  
The findings of this study highlight the importance of measuring a spectra of biomarkers and valid 
assessments of treatment response, and suggest that inflammatory responses potentially alter 
with treatment-resistant depression in a sample of TRD inpatients. 
 
 Does an inflammatory state predict short-term treatment response?  
Before inpatient intervention, IL-7 is slightly lower in patients who subsequently do not respond 
to treatment. Serum IL-7 (Lehto et al. 2010) has previously been reported as lower in major 
depression than controls, even when controlling for medication use and demographic factors. 
While Einvik et al. (2012) identified a negative correlation between plasma IL-7 levels and 
depression severity, Hall et al. (2013) have also reported a negative correlation when measuring 
serum IL-7 in men, but the opposite effect for plasma levels in women. It is unclear why serum 
and plasma levels of the same protein would elicit contrasting findings, but we did not replicate 
gender differences in our study, or differences between patients and controls. IL-7 has not been 
compared between non-responders and responders in previous studies, but the existence of 
slightly lower levels in this investigation could potentially represent a disruption to early T-cell 
development, impairing subsequent inflammatory activity and potentially acting as a barrier to 
non-response. In fact, since 5-HT is a modulator of T-cell activity and T-cells express serotonin 
receptors, even a small a reduction in T-cell growth (indicated by reduced IL-7) may diminish 
antidepressants’ serotonin-enhancing mechanisms and limit their clinical benefits. IL-7 appears 
to upregulate both CD4+ and CD8+ cells, but previously high cytotoxic T cells have predicted a 
poorer response to venlafaxine or imipramine (Grosse et al. 2016), which does not support our 
findings. Low IL-7 also strongly predicts subsequent severity as identified in all subsets regression 
alongside low IL-15 and high TARC (see below, Section 3.5.8). Interestingly, the significance of 
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this effect was increased substantially by the presence of medication in the model. All of these 
cytokines are heavily involved in T-cell activity. TARC upregulates a Th2 to Th1 shift, as well as 
regulatory T-cells of which IL-15 is another T-cell growth factor. It is possible that these cytokines 
are key representatives of a T-cell related inflammatory imbalance in refractory depression. TARC 
is elevated in the TRD patients, but neither IL-15 or IL-7 differ significantly between patient and 
control subjects. Of these three markers, only TARC and IL-7 are inter-correlated in this study. 
Short-term response is not predicted by other IMs, and stronger effects are seen for the prediction 
of long-term outcome.  
 
 Does an inflammatory state predict other measures of a poor clinical 
outcome? 
At discharge from the inpatient unit, IL-6 and IL-8 are markedly higher in TRD patients with a 
poorer long-term outcome. For IL-6 this has previously been found (Fornaro et al. 2006); for IL-8 
only non-significant elevations in non-responders have been observed (Eller et al. 2009). We also 
find higher levels of CRP and MCP4 in patients with a poor long-term outcome. While high CRP 
has previously been reported in subsequent non-responders (Uher et al. 2014), this is the first 
evidence that high levels of MCP4 may also be predictive of treatment outcome. MCP1 is related 
to MCP4 (both theoretically and in this study at p < 0.01) and low MCP1 has previously been 
found to predict non-response in a similar population of inpatients with TRD (Carvalho et al. 2013). 
MCP1 is non-significantly lower in responders in this study. Our assessment of IMs in relation to 
long-term outcomes of inpatient treatment has not previously been studied. We find that 
comparing good and poor outcome (i.e. absence and presence of depression) in the longer term 
yields more predictive effects of IMs than conventionally calculated short-term treatment 
response. All of these potential long-term outcome predictors are strong pro-inflammatory 
markers, most with chemoattractant properties, involved in upregulating innate immune 
responses (although many also have roles in adaptive immunity) and are higher in patients with 
a poorer outcome. In line with this, similar IM correlations with severity are observed: in addition 
to IL-8, a number of pro-inflammatory cytokines are higher in those with more severe depression 
in the long-term (MCP4, TNFα, Mip1a); these 4 markers all inter-correlate at p < 0.05 and most 
at p < 0.01.  
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To a similar extent, cross-sectional correlations between depression severity and IMs are 
observed at pre-treatment for TARC and IL-4 and post-treatment for CRP. Higher IL-4 in more 
severely depressed patients may reflect high T-cell activity (as T-cells produce IL-4), especially 
in conjunction with TARC, despite the two markers not being inter-correlated.  
 
No pre-treatment IM levels correlate with post-treatment severity when assessed individually but 
when considered in an all subsets exploratory approach high TARC, low IL-15 and IL-7 predict 
post-treatment severity. Continuous measures of severity (using total HAM-D scores) after 
treatment is an alternative outcome measure, which has been previously explored in some TRD 
studies (e.g. Carvalho et al. 2013). 
 
 Is there an inflammatory state in TRD? 
The present results replicate previous findings of elevated inflammation, in a population of 
treatment-resistant inpatients. 12 out of the 28 IMs are significantly different between TRD and 
control participants at both pre- and post-treatment, remaining so following control for the 
influence of age, gender and BMI. Most of these IMs are elevated in TRD (IL-8, IL-16, MCP4, 
Eotaxin, Eotaxin-3, IP-10, Mip1a, TARC, Tie2 and IL-5). Tie2, TARC and Eotaxin-3 have not 
previously been compared between depressed and non-depressed populations and represent 
new potential targets for this field. IL-16 (Stelzhammer et al. 2014), Eotaxin (Magalhaes et al. 
2014), MCP4 (Diniz et al. 2015), IP-10 (Simon et al. 2008), Mip1a (Merendino et al. 2004) and IL-
5 (Dahl et al. 2014) have all been sparsely and inconsistently elevated in non-TRD depression.  
 
sICAM1 and sVCAM1 are notably lower in this sample of inpatients than controls at both 
assessments (despite some increase in sICAM1 with treatment). This is unexpected, as these 
chemoattractant proteins function as part of a pro-inflammatory response and have in few studies 
been found as elevated in depression (Schaefer et al. 2016; Dimopoulos et al. 2006). A 
speculatory explanation for low CAM levels is that they have penetrated the BBB and are more 
active in the CNS than the periphery; sICAM1 in particular has important functions to recruit 
lymphocytes in neuroinflammation, although sVCAM1’s role in the CNS is less clear-cut 
(Takeshita and Ransohoff 2012). MCP1 can also increase cytokine infiltration into the CNS, and 
is lower at pre-treatment in TRD patients. Our findings could therefore reflect an imbalance 
between peripheral and CNS (which we were not able to examine) inflammation.  
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This is in contrast with the aforementioned IMs elevated in TRD, which include six chemokines 
(MCP4, Mip1a, Eotaxin, Eotaxin-3, IP-10 and IL-8) and markers indicating increased pro-
inflammatory signalling such as Tie2. While IL-8 has previously been identified as elevated in 
depression, this was not significant in a meta-analysis comprising 7 studies (Eyre et al. 2016b). 
Eyre et al. proposed, similar to our speculation above, that IL-8 may be dysregulated in the CNS 
but not in the periphery, as BBB permeability can facilitate IL-8 migration across the BBB and in 
turn the recruitment of other immune molecules to its site. It is possible that circulating IL-8 is 
more elevated in chronic affective disorders, which is supported by our present results (and that 
this chemokine was higher after treatment in those with a poorer outcome in the long-term).  
IL-16 also acts as a chemoattractant for monocytes and T cells, as well as eosinophils whose 
development IL-5 is key for. Elevations of these two cytokines in TRD at both measurements, as 
well as IL-4 at post-treatment, could implicate Th2 inflammation in these samples. The elevated 
IL-4 that we see in TRD compared to control groups is in slight contrast to previous null findings 
in meta-analyses (Dowlati et al. 2010; Liu et al. 2012a). The other inflammatory marker different 
in TRD than non-depressed participants is TNFβ, lower in TRD at baseline only. This cytokine 
has rarely been investigated in depression; further research is required to establish whether it is 
abnormally present in some patients with depression and whether this is a trait or state occurrence 
in mood disorders. The reason for pre-treatment attenuations of TNFβ in TRD is unclear, as this 
biomarker is considered highly pro-inflammatory and closely related to TNFα (at baseline only we 
find TNFα and TNFβ to be inter-correlated). Neither sICAM1, sVCAM1 or TNFβ are associated 
strongly with additional variables measured (i.e. relating to demographic, lifestyle or health), and 
these being attenuated may reflect an inflammatory imbalance in TRD.  
 
None of the a priori markers of interest (TNFα, CRP and IL-6) significantly differ between TRD 
patients and non-depressed controls. IL-6 is tentatively higher in the TRD group after treatment, 
but overall these contrast with previous findings (Haapakoski et al. 2015, Strawbridge et al. 2015) 
and it is likely that age and BMI matching between groups contributes to this result (Howren et al. 
2009, Hiles et al. 2012a). However, in this group of highly treatment-resistant patients there is 
evidence of an inflammatory state characterised by high levels of many cytokines and 
chemokines, and with suppression of a few inflammatory markers. Certainly, the bidirectionality 
of our findings suggests a complex relationship between TRD and immune responses, which is 




 Is inflammation a state or trait phenomenon in TRD? 
Most IMs show comparable differences between TRD and control groups both pre- and post- 
inpatient treatment. Markers that are consistently different between TRD and control participants 
over time (i.e. IL-8, IL-16, MCP4, Mip1a, Eotaxin, Eotaxin-3, Tie2, IP-10, IL-5, sVCAM1 and 
sICAM1) could represent ‘trait’ depression biomarkers. Mostly, these do not show notable 
changes during treatment, but sICAM1 as well as MCP1, IL-10, and IFNγ increase to some 
degree between the pre- and post- inpatient measurements. A rise in inflammatory marker levels 
with treatment may appear unexpected and in contrast with meta-analytic findings (Hannestad et 
al. 2011, Hiles et al. 2012b, Valkanova et al. 2013, Strawbridge et al. 2015) but there are a number 
of potential explanations. IL-10 has been found to decrease slightly alongside short-term 
treatment with a single antidepressant (Hiles et al., 2012b), which could reflect a normalisation if 
elevated in patients before treatment, but this meta-analysis was small and the treatment 
characteristics are distinct in this study. However, as IL-10 actively downregulates pro-
inflammatory responses, this increase may represent a resolution of inflammation alongside 
reduction in depressive symptoms. Both sICAM1 and MCP1 were attenuated in the TRD group 
at pre-treatment and therefore increased levels may be an indicator of reduced imbalance of 
inflammatory activity. IFNγ was not related to other factors measured in this study, except for a 
positive association with cognitive impairment in TRD before treatment and inter-correlations with 
a few other IMs: as expected, IP-10 at both time points and IL-12 (only pre-treatment) as well as 
with IL-15 at both time points. IFNγ and IL-15 are thought to be linked through their influences on 
B-cell responses: Gill et al. (2009) assessed interactions between IL-15 and IFNγ using mice that 
either under- or overproduce IL-15, reporting that a reduction in B-cells in the high-IL-15 mice was 
due to inhibition by IFNγ. Therefore, perhaps the increase in IFNγ reflects an attempt to suppress 
high Th2 activity in patients (as demonstrated for example by high IL-4 and IL-5 in TRD 
participants). 
 
It is possible that the unanimous medicated status of patients at study entry, or the length and 
intensity of the treatment intervention contribute to increases in IM levels. The increased use of 
antipsychotic medication during inpatient treatment may have led to increased adipose tissue 
mass, where adipokines (including MCP1) are released. Recently, in human as well as preclinical 
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studies, a direct effect of both typical and atypical antipsychotics has demonstrated a rise in MCP1 
and IL-8 (Sárvári et al. 2014). BMI is only measured at pre-treatment so weight changes could 
not be examined. Melatonin is thought to have immunosuppressive effects, partly illustrated by 
heightened IL-10. Melatonin levels may also be dysregulated in patients with severe depressive 
illness showing low levels at night time, but not in drug-free depression (Carvalho et al. 2006); as 
it is likely that antidepressants (particularly targeting norepinephrine, such as mirtazapine) 
influence melatonin levels. Additionally, factors that alter with clinical improvements such as sleep 
quality and potentially amount of natural light exposure, may be related to an increase in IL-10 or 
MCP1 levels.   
 
 Does an inflammatory state reflect prior treatment-resistant 
depression?   
Post-treatment IL-6 is higher in patients who were more severely depressed before treatment 
began. To a tentative extent, this is also observed for IFNα. These correlations might reflect a 
generally more severe illness (IFNα is also higher in patients with an earlier age of onset) or pre-
existing treatment-resistance in these patients who had greater symptom severity when admitted 
to the unit. However, treatment-resistance as assessed using the MSM staging tool also 
incorporates duration and number of treatments undertaken for the current episode (Fekadu et 
al. 2009b, 2010). Frequently, small positive correlations with treatment resistance (MSM score) 
are identified with IMs: IL-6 at both time points; TNFα, CRP, IL-12 and Mip1b at pre-treatment 
only and at post-treatment with IL-16 and TNFβ. Most of these markers are higher in TRD than 
control groups, except for TNFβ which appears significantly attenuated in TRD patients. It is 
possible that this cytokine only increases in the most refractory patients. All of these biomarkers 
have pro-inflammatory actions; overall these findings support the theory that TRD could represent 
an ‘inflammatory’ subgroup of depression (Raison et al. 2013a), for whom anti-inflammatory 




 Does inflammation in TRD patients with bipolar and unipolar disorders 
differ?   
One biological difference only is observed between unipolar and bipolar TRD patients in this 
study. To a degree, IL-4 appears lower at baseline in participants with bipolar depression. We 
believe that this is the first study to investigate longitudinal inflammatory changes (or with 
treatment-resistant patients) in bipolar compared to unipolar depression, but advise that this result 
should be interpreted cautiously due to some levels non-detected (imputed), the small size of 
effect  and small number of bipolar cases. The participants categorised as bipolar in this study 
are likely to have more prominent depressive than manic symptoms and more complex affective 
syndromes than is the case with representative samples of bipolar disorder diagnosed patients in 
the community, as the Affective Disorders Unit principally treats treatment-resistant depression. 
However, in contrast to previous studies which have compared IMs between unipolar and bipolar 
groups (e.g. Becking et al. 2015) it is unlikely that undetected bipolar symptoms have been 
misclassified as unipolar TRD in this study, as patient records contained detailed clinical histories 
and they were subject to long periods of longitudinal observation. All patients grouped as bipolar 
TRD had a previous hypomanic or manic episode according to the MINI criteria, although it is 
possible that this definition may have included hypomanic or mixed states that could be 
considered subclinical (Phelps and Ghaemi 2006). 
 
 How is inflammation in TRD influenced by other factors?   
Substantial previous research has linked inflammatory markers with numerous factors (including 
childhood trauma, BMI and age), and this has been postulated as a source of inconsistency and 
heterogeneity of evidence to date (e.g. Hiles et al. 2012b). In this study, treatment-responders do 
not differ from non-responders in any of the additional possible modifying variables. This is 
somewhat unexpected; particularly the Maudsley Staging Method has demonstrated a significant 
ability to predict response in similar, albeit larger samples (e.g. Fekadu et al. 2009b, Wooderson 
et al. 2011). Number of medications taken is, not unexpectedly, highly correlated with treatment-
resistance (MSM score) and is more strongly associated with IMs (particularly CRP and IL-16, 
but also IL-6). Number of changes in medication during treatment, however, only significantly 
relates to high pre-treatment Eotaxin. This might be due to the complexity with which prescription 
decisions are made in contrast with the broad nature of this assessment of treatment changes. 
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Age is also higher in those taking more medication and is positively related to CRP, SAA, IL-6 
and IL-16. As expected, age is higher alongside physical illness. Both age and physical illness 
are higher in those with a later age of depression onset, but age of onset is related only to 
cytokines that had some non-detected levels (IFNα, TNFβ, IL-4). Physical illness severity is also 
more prevalent in patients with a higher BMI, which is particularly associated with high Tie2 and 
IL-5. Cognitive function is not associated with the aging or health-related factors as described 
above, but impairments are greater in the presence of high IL-17, IP-10 and IFNγ, and to a lesser 
extent IL-6, IL-16, IL-12 and Eotaxin. Chronic inflammatory activation can impair cognition through 
a number of neurobiological routes, and is a potential link between affective illnesses and 
cognitive symptoms (Rosenblat et al. 2015, Bauer et al. 2014). Previous evidence also suggests 
a role of physical illness (e.g. Maes et al. 2011a) and demographic factors (e.g. Howren et al. 
2009) in the inflammation-depression relationship. In contrast with the previous literature, neither 
gender (Howren et al. 2009) nor history of childhood trauma (Danese et al. 2011) correlate with 
inflammatory activity to p < 0.01 in this study. The influence of additional factors on the relationship 
between treatment and response in depression is expanded upon in Section 6.1.6. 
  
 Can treatment response be predicted by a combination of 
inflammatory and non-inflammatory markers? 
It was not possible to control for each of the potential modifying factors in examining the 
relationship between IMs and treatment response due to low statistical power. An exploratory all-
subsets regression analysis assessed a combination of 33 potential inflammatory and non-
inflammatory measures, on their ability to predict depression severity at discharge from the 
inpatient unit. Findings suggest that the number of medications taken is an important covariate, 
which when taken into account shows high levels of TARC, and low levels of interleukins IL-7 and 
IL-15 to predict greater severity after treatment. As mentioned above in Section 3.5.1, a lack of 
T-cell homeostasis could provide an explanation for why aberrant TARC, IL-7 and IL-15 might 
interact with the intensity of treatment to result in more severe depression on discharge from the 
inpatient ward. Investigating the contribution of a comprehensive panel of biomarkers to clinical 
states is important in order to understand the whole inflammatory system in context, as well the 
role of individual proteins, within this relationship. This finding also highlights the benefits of 
examining the interaction of clinical factors on inflammation and depression. The number of 
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medications that patients are treated with has traditionally been used to define treatment-resistant 
depression; we suggest that the addition of inflammatory measures could enhance the predictive 
power of this in determining treatment-resistance in depression.   
 
We could not assess the full set of 33 cytokines, as five were excluded due to poor detection of 
levels. All of these (IL-1α, IL-1β, IL-2, IL-13 and GM-CSF) have previously been found to circulate 
at undetectable levels of serum, although articles often do not report this explicitly as a limitation 
(Byrne et al. 2013). Particularly for the T-cell growth factor IL-2, a larger proportion of non-
responders than responders had undetectable levels (especially at pre-treatment) and it is 
plausible that these low levels of IL-2 could reflect part of a T-cell imbalance that interferes with 
psychopharmacological treatment mechanisms in some individuals increasing their risk for 
treatment-resistance.    
 
 Limitations and Strengths 
The exploratory design of this study carries a number of weaknesses regarding the interpretation 
and attribution of its findings. Notably, this includes a small sample size and large number of 
comparisons, as well as incomplete IM follow-up and clinical long-term follow-up data, non-
detected IM data, non-standardisation of treatments received (including medication dose and 
type, length and intensity of inpatient intervention), the fact that TRD and control groups were 
recruited from different sources and the inability to account for additional factors on inflammatory 
activity (such as the influence on factors such as food or other substances consumed). These are 
expanded upon below. 
 
All subsets regression techniques have the tendency to overfit models (Rencher and Pun 1980) 
which was addressed by the use of BIC and AIC alongside r2 values and clinical or scientific 
justification (Sullivan et al. 1989). While a number of statistically significant models were yielded, 
this analysis was conducted as an exploration of the potential for inflammatory and non-
inflammatory data to predict clinical outcomes to inpatient treatment in TRD, and requires 
stringent replication. The small sample size is a clear drawback to obtaining a robust finding in 
this study.  
 
The sample size and number of comparisons undertaken in this investigation render our findings 
vulnerable to false positive and/or false negative (masked) results. While we employed Simes 
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control for multiple comparisons to minimise the risk of type I error, this may have rendered 
potentially important findings non-significant (Rothman et al. 1990; Streiner et al. 2011) in the 
main comparisons. We have reported uncorrected p values of < 0.05 in order to maintain 
consideration of these tentatively significant comparisons. In comparisons where only a few 
markers were significant, Simes correction resulted in no significant results (e.g. changes during 
treatment) deriving partly from the test’s assumption that IVs should be correlated. This biomarker 
array does contain heterogeneity; not all IMs are intercorrelated, but we posit that because a 
number of IMs show small increases with treatment this suggests an overall inflammatory pattern 
that is relatively coherent within this comparison. Not all analyses were subject to Simes control, 
and many of these comparisons have not yet been conducted in depression, or TRD: this was 
carried out as an initial exploratory study, which has yielded promising findings.  
 
Further limitations which must be considered in deriving meaning from these results include the 
lack of ability to control for acute infection or inflammation, especially due to a known physical 
condition. We attempted to account for use of non-steroidal anti-inflammatory drugs, which did 
not appear to alter results, but the possibility of an acute inflammatory state biasing the current 
results is not impossible. Although we log-transformed cytokine variables and bootstrapped 
statistical analyses, reporting 95% confidence intervals, outlier cytokine values may have affected 
findings. This is important to consider when interpreting results. In addition, the different 
recruitment sources that TRD and control groups originated from resulted in separately assayed 
samples across multiple batches. Due to this, the quality of assays and their comparability could 
not be measured. While the assay itself is of high quality, reliability and sensitivity (Dabitao et al. 
2011), factors such as type and length of specimen storage may have induced bias by 
degradation of some biomarkers. To minimise this, thorough attempts were made for 
standardisation of data collection, assessment, and analysis between groups. Before the array 
was run, neither patients’ or controls’ serum samples had been thawed and refrozen, or were 
more than 4 years old. The TRD group samples had, however, been transported from one freezer 
to another (with minimal temperature interference) and had been stored for slightly longer before 
IMs were assayed. Because of this we posit that if either group’s specimens had been susceptible 
to cytokine degradation during between collection and analysis it would have been the TRD 
patients, but the number of proteins elevated in TRD do not specifically suggest this and there is 
not strong evidence indicating degradation over a 4 year period (Zhou et al. 2010). The MSD chip 
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has high sensitivity to detect most markers, but non-detection did occur for over a third of the IM 
panel (for the same cytokines as have been reported previously; Byrne et al. 2013). We may have 
yielded a more sensitive measure of low protein levels in plasma than serum. Non-detected levels 
were imputed using half the detection cut-off (LLOD/2). This is considered acceptable where 
levels are likely to be undetected due to true minimal levels present in sera (Marques-Vidal 2011) 
but this method of imputation does succumb to reduced variance within the sample (as with all 
single imputation methods) and due caution should be paid when interpreting IFNγ and Eotaxin-
3 (<10% non-detected) and Mip1a, IL-5, TNFβ, IL-12p70, IL-4 and IFNα (10-50% non-detected). 
Notwithstanding the promising results identified here, future studies should consider these issues 
when selecting biomarkers, assay and analysis techniques.  
 
The wider array of IMs that we measure is an advantage to this study, especially as it permits a 
more complete picture of inflammatory activity. Consequently, our results indicate that there are 
more inflammatory biomarkers than those often measured in research studies, which may be 
important in understanding the pathophysiology of TRD as well as MDD and other mood 
disorders, and for using biomarkers to improve clinical care. The large number of potential IM-
modifiers measured has also enabled a more complete understanding of how inflammation is 
altered in treatment-resistant depression: health- and aging-related factors appear most important 
for controlling in future studies investigating inflammation in depression. Physical illness severity 
appears related to IMs, as anticipated, but was measured using a cursory summary scale (the 
MCIRS) that is likely to possess high sensitivity but low specificity (Miller et al. 1992); medical 
comorbidity could be comprehensively examined in future hypothesis-driven research. 
 
An additional strength of this study was the use of multiple measures of treatment outcome. 
Research has not yet identified robust and reliable predictors of treatment-outcome, despite many 
previous attempts. As most studies utilise the traditional method of a 50% reduction of severity 
score between baseline and treatment endpoint, we explore additional alternative measures of 
outcome which may provide more reliable or valid indicators of treatment success. Response was 
assessed as traditionally and with the examination of continuous severity scores (both assessed 
at treatment endpoint), but also at a longer-term follow-up 3-12 months after treatment. 
Unfortunately, for pragmatic reasons the follow-up measurement was not at a standardised time 
point (e.g. 12 months after treatment) and did not contain an IM measurement, or the full sample. 
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Despite these limitations, depression at follow-up is found to be more predicted by IMs than at 
either earlier measurement.  
 
 Recommendations for future work 
Future studies should contemplate the benefits of assessing response at a time after treatment 
in evaluating symptoms after any transient ‘treatment-end’ effects have subsided. We recommend 
that measuring response at multiple time points is useful to assess continuity of wellbeing, which 
might be considered a more valid measurement of outcome.  
Our results support existing theories that inflammation is dysregulated in refractory depression, 
but illustrate that factors such as age, physical illness and medication must be accounted for in 
order to obtain meaningful results. This may be particularly important in specifically TRD studies, 
as TRD has been associated with reduced physical health and increased medication intake. 
Future work must establish the long-term relationship between a range of medications and 
inflammatory activity, to establish whether treatments can be optimised using regular 
measurements of IM levels alongside severity of illness.  
 
This study has not been able to determine definitively whether TRD represents an ‘inflammatory 
subgroup’ of depression. In this study, small elevations of many IMs are found in more treatment-
resistant patients, but TRD is only measured within the current episode. A summary score for 
lifetime treatment-resistance (including number as well as duration and severity of episodes, and 
total number of failed and successful treatment trials) may elicit stronger associations. This might 
be a fruitful avenue for future research investigating the stratification of patients with mood 
disorders and predicting future response to treatments. Pathways to improved prospective 
identification of TRD are detailed in Section 6.4.4. It would be useful for future work to directly 
compare IMs in TRD and non-TRD participants, accounting for potentially confounding factors. 
Other than tentatively lower IL-4 in bipolar patients, we do not find inflammatory differences 
between bipolar and unipolar affective disorders; further research using ultrasensitive assays is 
required, in samples with representative groups of bipolar and unipolar depressed participants. 
 
In light of the limitations and novel comparisons examined in this work, we highlight that the 
findings should be judged as exploratory and urge future research to replicate the comparisons 
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reported here in large, well-defined populations measuring a panel of biomarkers and controlling 
for additional potentially mediating factors. 
 
 Clinical implications 
The wider array of inflammatory markers identified in this study as aberrant in TRD could, if 
sufficiently replicated, provide additional putative antidepressant targets for compounds known to 
affect molecules such as tyrosine-kinase2 or chemokines. The potential for existing anti-
inflammatory treatments, such as TNFα-antagonists (Tyring et al. 2006, Raison et al. 2013b, 
Krishnadas et al. 2016) or IL-6 antagonists (Wolfe 2016) are already showing promise for mood 
disorders. We find that inflammation tends to be higher in TRD patients with a poorer long-term 
outcome or more severe depression in the current episode. As previously proposed, those with 
high TRD or high inflammation could characterise subpopulations of depressed patients for whom 
adjunctive anti-inflammatory treatment may be beneficial (Raison et al. 2013b). If an inflammatory 
subtype can be determined and confirmed in future work, this has considerable implications for 
targeting and optimising interventions. It is appears that simultaneously considering inflammatory 
and non-inflammatory measures before treatments may be a pathway towards predicting clinical 
outcomes in MDD or TRD. The clinical potential from this work is discussed further in Section 6.5.  
 
 Contextualisation and concluding findings  
This study is the first longitudinal investigation of treatment-resistant depression that measures 
many of these inflammatory markers. Tie2, TARC, Eotaxin-3, Eotaxin, IP-10, MCP4, IL-16, IL-8, 
Mip1a and IL-5 appear trait-elevated in TRD patients compared to matched controls, while 
sVCAM1 and sICAM1 are consistently attenuated. IL-10 increases with treatment have previously 
been attributed to its role as an anti-inflammatory cytokine (Maes et al. 1997a), whereas sICAM1 
and MCP1 increases brought levels towards the control group average. IFNγ increases may 
indicate an attempt to suppress Th2 inflammation, but in contrast to previous studies, all of the 
TRD group were medicated at baseline, often taking high doses and multiple psychotropic 
combinations which continued and/or increased during the inpatient stay. IL-6 and TNFα are 
higher in the most treatment-resistant patients, both retrospectively and prospectively. Overall 
treatment-resistance is modestly associated with a number of markers (IL-16, IL-12, Mip1b, IL-6, 
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TNFβ, TNFα and CRP). Similarly, TNFα, IL-6, CRP and TARC are modestly predictive of future 
poor outcomes. In contrast, low levels of regulatory cytokines IL-7 and IL-15 predict short-term 
non-response. Particularly for IL-6 and CRP, non-significant group differences between TRD and 
controls are likely partly attributable to the matched control design (especially age) and factors 
such as medication; although medication use was not assessed in controls, this group are of fairly 
high age and recruited from the community, and many are likely to be taking statins or other 
commonly-prescribed medications. On the other hand, many IMs were stably elevated in TRD 
than control groups but did not associate with clinical factors within the patient group (including 
IP-10, Tie2, IL-5, Eotaxin, Eotaxin-3). 
 
Our findings potentially illustrate a drawback to assessing response at treatment-endpoint in 
inpatient studies, as most significant effects were with long-term rather than short-term outcomes, 
even with the reduced sample size at follow-up. Longer term outcome is also probably of more 
importance and relevance to patients. For those IMs that were elevated in patients with a poorer 
treatment outcome, it is possible that a failure to reduce levels after treatment could occur in TRD 
patients who do not maintain wellbeing in the months following treatment (particularly IL-8 and IL-
6). Shorter-term increases in inflammatory markers might occur as a response to treatment effects 
(such as medication, behavioural or physical activation) associated with improvement, or the 
experience of stress associated with the inpatient environment or the prospect of discharge. 
These increases could precede a longer-term gradual decline in inflammation alongside 
maintained recovery. The lack of follow-up inflammatory measurement did not permit an 
exploration of this theory, which is expanded on in Section 6.2.2. 
 
The attribution of longitudinal changes observed in inflammatory activity could be informed using 
non-pharmacological treatment studies in people with depression. We address this in the 
following Chapter (Study 3). This would enable greater understanding of inflammatory 
mechanisms over the course of depressive disorders. This could enable a great improvement in 
optimising care for many patients.  
  




 An investigation of inflammation as a 
predictor of response to psychological therapy in 
patients with depression (Study 3) 
 
 
4.1 Abstract   
Inflammation has been linked with treatment-response in depression but has rarely compared 
symptom subtypes or been assessed longitudinally alongside psychological therapy. This study 
investigated the relationships between inflammation, depressive subtypes and clinical outcomes 
in response to therapy. 
Patients with depression (N=96) were assessed before and after undertaking a course of 
psychological therapy in secondary care services. At both assessments, IMs were analysed from 
serum alongside depressive symptoms and additional factors (demographic, clinical, social and 
functional). Therapy outcomes (treatment-response and severity at endpoint) and symptom-
subtypes (somatic vs. cognitive subtype and bipolar vs. unipolar depression) were compared with 
inflammatory markers. IM changes during the therapy period were also assessed.   
49% of participants responded to treatment. Pre-treatment depression severity and quality of life 
were poorer in participants with more severe depression after therapy. High levels of TNFα and 
low IFNγ were also strongly predictive of post-treatment severity. As well as TNFα, elevated IL-6 
and sICAM1 significantly predicted non-response to therapy. CRP and TARC were highly 
associated with a poor response after therapy. Participants with more somatic than cognitive 
symptoms had higher IL-6, sICAM1 and Mip1b. In the somatic subgroup only, IL-6 and SAA 
showed decreases with treatment. IL-7, IL-8 and IL-15 increased markedly with treatment, 
regardless of participant subgroup.  
This is the first study to have assessed a wide range of inflammatory proteins and psychosocial 
measures as potential predictors of response to psychological treatment for depression. Results 
suggest that inflammation is associated with increased disability and provide novel evidence that 
IMs in conjunction with self-report information can predict response to psychological therapy. 
Further work may enhance the ability to predict treatment-response by assessing distinct, 





4.2 Introduction       
It has been proposed that the inflammatory response plays a role in the treatment of depressive 
disorders (e.g. Haroon et al. 2012) and with clinical response (Strawbridge et al. 2015). Indeed, 
antidepressant and other psychotropic medications appear to affect inflammatory activity 
(Janssen et al. 2010). These effects vary between medications and across studies (see Section 
1.4.4) in a difficult-to-model manner, although a high proportion of longitudinal IM studies have 
measured baseline inflammation in unmedicated participants (or following a wash-out period) and 
most are treated with antidepressants during a treatment period (Strawbridge et al. 2015). At 
present it is therefore challenging to detangle the effects of pharmacology and clinical 
improvements in understanding longitudinal inflammatory alterations in depression.   
  
The existence of non-biological interventions for mood disorders can facilitate an observation of 
inflammatory changes during treatment that are not purely attributable to biological treatment 
effects. However, this opportunity has rarely been taken advantage of in assessing response to 
treatments. Harley et al. (2010) pooled two studies whose methodology was almost identical: one 
an antidepressant RCT and one a psychological intervention RCT for MDD. Elevated CRP 
predicted greater non-response to interpersonal psychotherapy or CBT, but a good response to 
nortriptyline or fluoxetine. The above studies did not examine the longitudinal effects of these 
treatments on inflammatory activity, but their findings might indicate psychological or psychotropic 
treatment categorisation as a potential candidate on which to stratify interventions using 
inflammatory markers if sufficiently replicated.  
 
As a whole, the evidence suggests that inflammation is not abnormally present in all people 
suffering with depression but appears in a proportion of the depressed population. As detailed in 
Section 1.6.1, most evidence of subgroups in depression has focused on atypical and melancholic 
subtypes. Both atypical (Lamers et al. 2013) and melancholic (Karlovic et al. 2012) depression 
have been separately identified with elevated markers in comparison to the other, but a lack of 
IM differences between melancholic and non-melancholic depression has also been reported 




A wide array of other depressive symptoms that are not accounted for by currently-defined 
subtypes have been associated with increased inflammation (e.g. Capuron 2008), representing 
an extensive range of symptom profiles. Specifically, an early study to suggest an inflammatory 
subtype delineation reported IL-1β to be increased in dysthymia or longer-lasting depression, and 
purported that cytokine elevations might occur in depression with neurovegetative features 
(Anisman et al. 1999). Another investigation found fatigue to be associated with high levels of 
neurological G-CSF, IL-10 and IFNγ in people with non-specific neurological symptoms without 
depression, but not in individuals with depression (Hestad et al. 2016).  
 
The conception of a depressive ‘somatic-subtype’ could reflect patients who have an aberrant 
inflammatory profile, given the similarities with sickness behaviour (Maes et al. 2012a) as well as 
the inflammatory increases that have been established in metabolic disorders (Evans et al. 2005) 
and purported in somatic disorders (e.g. Strawbridge et al. 2016b). Penninx et al. (2013) have 
explicitly proposed that somatic symptoms of depression might co-occur with an inflammatory 
state. Einvik et al. (2012) do not necessarily support this. The authors split the Beck Depression 
Inventory (BDI) measure into somatic (disruptions to sleep, fatigue, appetite, weight, somatic 
preoccupation, loss of libido and ability to work) and psychological items (describing feelings of 
failure, guilt, self-hate, suicidality, irritability, indecisiveness and body image cognitive distortions) 
following validation of these as distinct groups in a factor analysis (Schotte et al. 1997). They 
identified many non-significant findings, and some overall negative correlations with severity; 
specifically, a higher somatic score was found with low levels of TNFα, IFNγ and IL-7 and 
psychological score with low Mip1b and only IL-4 to differ significantly between these (with a 
positive relationship arising only with psychological symptoms). Except for slightly lower IL-7, 
Einvik et al.  (2012) identified no differences between MDD and control IM levels, though the study 
was a community cohort and some controls were taking antidepressant medications, suggesting 
a potentially undetected remitted mood disorder. The distinction between somatic and cognitive 
symptoms in this study did not contain low mood or anhedonia which are core symptoms of 
depression, or psychomotor symptoms; additionally somatic preoccupation was categorised as 
somatic but may represent more of a cognitive than somatic phenomenon.  
 
In contrast, Duivis et al. (2013) identified heightened CRP, IL-6 and TNFα in correlation with high 
somatic symptom severity but not cognitive severity of depression, when demographics (age, 
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gender, years of education), health (diabetes or cardiovascular disease or physical medication 
use) and antidepressant use, but not lifestyle (smoking and alcohol consumption, BMI and 
physical activity) were controlled for. Cognitive and somatic symptoms of anxiety were also 
measured and showed similar but slightly weaker effects. Somatic symptoms were scores from 
items on the IDS depression scale pertaining to difficulties with sleep, fatigue, appetite or 
psychomotor retardation/agitation, while cognitive symptoms were those relating to low mood, 
anhedonia, guilt, concentration or suicidality. 
 
No studies have yet dichotomised participants into ‘somatic’ or ‘cognitive’ (or similar) subgroups 
when measuring IMs, and these symptom subscales have not been assessed alongside 
treatment or treatment-response. However, if a somatic subgroup is reliably shown to differ from 
other individuals with depression in terms of inflammation, it may provide indications for treatment 
stratification to improve clinical outcomes. Depressed patients with a bipolar disorder may be 
more likely to have metabolic or neurovegetative symptoms (Łojko et al. 2015), and as discussed 
in Section 1.6.3 the presence of a bipolar disorder might alter inflammatory associations in 
depression.  
 
Major psychiatric comorbidity is often an exclusion criteria of studies in this field, and distinct 
psychiatric disorders have been identified alongside higher IM levels; for example, eating 
disorders (Ahrén-Moonga et al. 2010), or anxiety (von Känel et al. 2009) where inflammation may 
be elevated independently of depressive symptoms. Concurrent anxiety, or other psychiatric 
comorbidities, may be associated with an increased risk for non-response to treatments 
(Wooderson et al. 2011), but the nature of the relationship between depression, other psychiatric 
symptoms, inflammation and treatment-response is not understood. The presence of personality 
disorder is rarely assessed and has not been controlled for in almost all investigations of IMs and 
depression. However, elevated inflammation has been reported in individuals with higher trait 
hostility (Stewart et al. 2008) or psychoticism, as well as with low extraversion / high introversion 
(Millar et al. 2013); these traits may occur alongside an increased susceptibility to psychiatric 
illness.   
 
Use of naturalistic designs can facilitate the recruitment of larger samples due to inclusivity and 
the ability to assess biomarkers in participants who are both medicated and unmedicated during 
psychotherapy. Inflammation is altered by many factors in addition to medication; age, gender, 
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BMI, physical illness (Howren et al. 2009; Hiles et al. 2012b) and childhood trauma (Danese et 
al. 2008) have all been emphasised as important. However, there are many further factors that 
are likely to influence IM levels and may relate with responsiveness to treatment, such as 
everyday functioning. In addition to the measurement of prior treatment-resistance (Raison et al. 
2013a), those of substance use, recent life stressors and functional impairments are rarely 
measured or reported in the research literature.  
  
This exploratory study aimed to improve understanding of the relationships between subgroups 
of people with depression and their outcome to psychological therapy with a large panel of IMs, 
measured before and after treatment. The study addressed a number of as-yet unexamined 
constructs: the effect of non-pharmacological therapies on a large array of inflammatory markers 
and clinical outcome measures, with categorisation of patients based on a greater severity of 
somatic or cognitive / emotional symptoms of depression, and while also assessing potentially 
modifying factors (such as psychiatric comorbidity, treatment-resistance, early and recent life-
stress, health and functioning).  
 
 Hypotheses  
In response to the accumulated literature, the following null hypotheses were proposed for 
measurements before treatment, after treatment, and in changes between time points: 
Main null hypotheses: 
1) Pre-treatment levels of inflammatory markers will not differ between depressed patients 
who subsequently do, and do not, respond to psychological treatment; 
2) Post-treatment IM levels will not differ between responders and non-responders  
3) IM levels will not change between pre- and post-treatment measurements 
Exploratory null hypotheses: 
4) There will not be inflammatory differences between participants with prominently somatic 
or cognitive symptom presentations; 
5) Use of psychotropic medication concomitant with psychological therapy will not alter 
inflammatory changes occurring alongside treatment; 
6) IM levels will not show significant differences between bipolar and unipolar depression; 
7) Inflammation will not correlate with depression severity; 
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8) Anxiety severity will not be related to IM levels; 
9) Additional factors will not significantly associate with treatment-response and/or 
inflammation. Additional factors inspected are: Age, gender, BMI, medication (any, or 
specifically psychotropic), physical illness severity, traumatic experiences in childhood, 
prior treatment resistance (summary score, age of onset), personality disorder traits, 
health-related quality of life impairment, subjective health rating, recent life stressors, 
substance use, occupational functioning, and number of psychiatric comorbidities;  
10) Inflammatory markers will not be related to one another. 
It is anticipated that our null hypotheses will be rejected for some but not all biomarkers. As 
in Chapter 3, the a priori markers expected to demonstrate significant associations with 
treatment-response are TNFα, CRP and IL-6. Other markers that might be expected to 
demonstrate similar patterns to these cytokines particularly include pro-inflammatory 
cytokines, acute phase proteins and chemokines.  
 
4.3 Methods  
 Design  
This study was a longitudinal, naturalistic treatment investigation of individuals with depression 
who undertook psychological therapy in secondary care. The majority of the sample completed 
treatment in the NHS Improving Access to Psychological Therapy (IAPT) NHS service, Southwark 
Borough (n=87; n=8 other London IAPT services; n=1 private CBT course). The two study time 
points were before treatment (when participants had been assessed by the IAPT service and 
referred for psychological therapy, but not yet started treatment) and after treatment (2-6 weeks 
following completion of psychological therapy without plans to start new therapy). Ethical approval 
was obtained by Camberwell & St Giles NHS Research Ethics Committee (reference 322/03) and 
Bromley NHS Research Ethics Committee (reference 13/LO/1347). 
 
 Participants 
Participants were identified following a referral to IAPT services if they had consented to be 
contacted (as part of the Consent for Contact (C4C) scheme permitting approved studies to 
contact patients who have opted-in). Some participants (n=9) who were also awaiting a 
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psychological therapy were recruited by responding to community advertisements. Data collection 
methods were the same for those recruited by community advertisement. Potential participants 
were invited to participate after considering study information and informed consent was provided 
prior to commencing the baseline research assessment. For further details of recruitment 
procedures, see Grant et al. (2014).  
 
Participants were included in the study if their scores exceeded standardised cut-offs (>10) on 
the PHQ9, indicating current depression, and if they had been referred for a course of 
psychological therapy. While initially 99 participants were included, 3 did not undertake any 
treatment (no sessions attended n=2, referred to non-psychological service n=1), leaving a final 
sample of 96 participants who had completed therapy. Treatment completion was defined as 
attendance at >4 therapy sessions.  
 
All participants completed clinical outcome data before and after therapy. IM data were missing 
for 46 participants (17 were uncontactable, 28 were unavailable to attend for blood collection 
within study timeframes, 1 had developed a needle phobia). For these participants, PHQ9 and 
GAD7 scores were available from the final therapy session and were used as severity outcome 
measures. Therefore, 50 participants provided both IM and psychological data at both 
measurement time points.   
 
 Measures  
Treatment-outcome measures: 
The PHQ9 (Kroenke and Spitzer 2002) assessed the severity of depressive symptoms at both 
pre- and post- treatment measurements. PHQ9 scores at the post-therapy assessment were used 
to calculate treatment outcomes: treatment-response (achievement of a 50% reduction in severity 
score between pre- and post-treatment or a score of <10 after treatment, indicating remission) 
and severity after therapy (represented by total PHQ9 score). 
 
Measures of depression subtypes:  
The PHQ9 assessed impairments in the 9 symptom domains of DSM-IV-defined depression. 
Using the methods reported by Duivis et al. (2013), symptom domains were categorised as 
‘somatic’ (fatigue and disturbances to sleep, appetite and psychomotor function) or ‘cognitive’ 
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(comprising the more psychological symptoms of depressed mood, anhedonia, guilt, 
concentration difficulties and suicidal ideation). Severity scores for both ‘somatic’ and ‘cognitive’ 
subscales were calculated. Participants with a higher somatic than cognitive score were 
considered as having a somatic-type depression; a greater proportion of the total PHQ9 score is 
comprised of cognitive symptoms and participants with equal scores for each were categorised 
as somatic for this reason.    
The MINI interview (Sheehan et al. 1998) was conducted at baseline from which presence or 
absence of a bipolar disorder was calculated (i.e. by meeting criteria for a history of hypomania 
or mania). In cases of missing data (n = 5), the Hypomanic Checklist (HCL-16) had been 
completed by a subset of participants and was used instead, defined by a cut-off score of >8 
(Forty et al. 2010).  
 
Additional exploratory outcomes:  
The GAD7 (Spitzer et al. 2006) measured anxiety severity at both pre- and post-therapy 
assessments. The remaining measures were completed at the pre-treatment assessment only.  
Factors relating to retrospective treatment resistance comprised overall resistance of the current 
episode examined using the MSM (Fekadu et al. 2009b; see also Section 3.3.3), where higher 
scores indicate greater TRD (score range 3-17). Age of depression onset and number of 
comorbidities additional to depression were assessed using relevant items from the MINI 
(Sheehan et al. 1998).  
Age, gender and BMI were measured as the most likely mediating variables on inflammation.  
Health factors included: physical illness severity as a total score on the MCIRS measure (Miller 
et al. 1992) with higher scores indicating greater severity (see also Section 3.3.3), and a 
subjective rating of momentary health was measured as part of the EQ5D questionnaire: this uses 
a visual scale from 0-100 (where 100 represents best health imaginable and 0 as worst health 
imaginable). 
Disability or functional measures were obtained using the EQ5D questionnaire of health-related 
quality of life (Dolan 2000), which provides a score indicating wellbeing in terms of mobility, self-
care, daily activities, pain or fatigue and mood, where a higher score (range 5-15) indicates poorer 
quality of life. Occupational functioning was indicated by whether people were not working or 
working (either part-time or full-time, including students). 
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Lifestyle factors included substance use (quantity of any substances, as defined by the MINI, 
consumed over the preceding month), alcohol use (average number of units per week) and 
smoking (average number of cigarettes smoked per day). Each of these was subsequently 
converted into dichotomous variables to avoid non-normal data distributions (as was indicated by 
skewness and kurtosis values).  
The MINI also was used to ascertain the age of depression onset and total number of psychiatric 
comorbidities (excluding mood disorder sections). 
The Standardised Assessment of Personality–Abbreviated Scale (SAPAS) measured traits of 
personality disorder (Moran et al. 2003). The SAPAS is scored from 0-8, with 8 representing high 
personality disorder traits.    
In addition, medication use (both psychotropic and non-psychotropic), as well as therapy 
intervention characteristics (the type and duration of treatment, and number of therapy sessions) 
were recorded.   
Additional psychological factors assessed included the experience of early-life trauma using the 
CTQ (Bernstein et al. 1994), with higher scores indicating more trauma (see also Section 3.3.3), 
and of recent-life stressors using the Holmes & Rahe Life Stress Inventory (HR-LSI). The HR-LSI 
measures stressful events over the previous year (Holmes and Rahe 1967) and was assessed at 
the post-treatment assessment to ensure the period of time measured included the therapy 
duration and both study assessments.  
 
Inflammatory Measures:  
Biological sample collection and storage was facilitated by National Institute of Health Research 
(NIHR) BioResource for Mental Health (Maudsley). Blood was collected to measure inflammation 
from serum (1 x 5ml tube). Following complete clotting, tubes were centrifuged and serum 
extracted, transferred into cryovials and frozen at -80°C. Serum concentrations of biomarkers 
were then assayed using the same methods as in Chapter 3, on the ultra-high sensitivity Meso 
Scale Discovery 40-Plex kit (see Section 3.3.3). The panel of biomarkers was identical to Chapter 
3, except for IFNα, which was not measured in this study due to unavailability of assay. Thus, the 
32 IMs examined were: CRP, IFNγ, IL-10, IL-12, IL-12p70, IL-13, IL-15, IL-16, IL-17, IL-1α, IL-1β, 
IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), TNFα, TNFβ, Eotaxin (CCL11), Eotaxin-3 (CCL26), GM-
CSF, IP-10 (CXCL10), MCP1 (CCL2), MCP4 (CCL13), Mip1a (CCL3), Mip1b (CCL4), serum 
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amyloid A (SAA), sICAM1 (sCD54), sVCAM1 (sCD106), TARC (CCL17) and Tie2. Unless 
reported otherwise, biomarker levels are expressed as picograms per millilitre (pg/ml). 
 
 Data Analysis 
Inflammatory markers and clinical variables were measured before and after psychological 
therapy.  
 
Data Cleaning:  
Initially, raw IM data were inspected and coefficients of determination (r2) of standard curves 
calculated. Data cleaning was undertaken using the same methods as in Chapter 3: IMs with < 
50% values not detected at either time point were included. Non-detected IM data were imputed 
using LLOD/2 (Croghan & Egeghy 2003, see Section 3.3.4). IM values were transformed (log 
base 10) prior to parametric test analysis. Normality of data distribution was assessed for all 
variables by examining skewness and kurtosis values, frequency distribution (histogram plots), 
stem and leaf plots, P-P (probability-probability) plots, Q-Q (quantile-quantile) plots and box plots, 
and the Kolmogorov-Smirnov test. Analyses included a bootstrap of 1000 resamples, in order to 
minimise effects of slightly non-normally distributed data (Sufahani & Ahmad 2012).  
 
Main comparisons: 
The main comparisons focused on inflammatory associations with treatment outcomes and over 
time, in accordance with hypotheses. For all IMs analysed, the following comparisons were 
conducted:   
a) Whether IM levels at pre-treatment can predict subsequent response to psychological therapy 
(hypothesis 1) was assessed using logistic regressions, with response as the outcome (DV) 
variable and IM as the predictor (IV) variable. Both univariate regressions, unadjusted for 
other factors, and multivariate regressions adjusting for age, gender and BMI were 
conducted.   
b) Using the same tests as above, post-treatment IM measurements were compared between 
responders and non-responders (hypothesis 2).  
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c) Inflammatory changes with psychological therapy, between pre- and post-treatment 
assessments, were measured using a 2x2 mixed-factorial ANOVA analysis between 
responders and non-responders over time (in accordance with hypothesis 3).  
All of the main analyses employed a Simes control for multiple comparisons, as in Chapter 3. 
 
Exploratory comparisons: 
d) Differences in inflammation between participants with a primarily somatic vs. cognitive 
depression subtype were explored by conducting independent-samples t-tests at each time 
point of IM (IV) between subtype group (DV). Additionally, IM changes over time between 
these subgroups is assessed using a 2x2 mixed-factorial ANOVA test; as in main comparison 
c), but between somatic and cognitive subtypes. This addresses hypothesis 4.   
e) In order to determine whether inflammatory changes occur in participants only receiving 
psychological treatment, in comparison with both psychological and pharmacological 
treatment for depression, a third 2x2 ANOVA was carried out to observe changes over time 
between participants taking psychiatric medication and unmedicated patients (addressing 
hypothesis 5). Independent-samples t-tests were conducted to assess IM levels at each time 
point in medicated versus unmedicated participants.  
f) Bipolar and unipolar depressed participants were compared in terms of inflammation before 
and after treatment, using independent-samples t-tests as above, and over time using a 2x2 
ANOVA as described above for other between-subjects variables. The comparison of bipolar 
and unipolar depression addresses hypothesis 6.  
g) Correlations assessed continuous relationships between IM levels and depression severity 
(total PHQ9 scores) at both pre- and post- treatment (hypothesis 7). Separate somatic 
somatic severity (sum of somatic items on the PHQ9) and cognitive severity (sum of cognitive 
items) were also considered in comparison with IMs. All correlational (continuous) analyses 
utilised Pearson’s coefficients. 
h) Correlations examined relationships between anxiety severity (total GAD7 score) and IM 
levels at both time points (hypothesis 8).  
i) Continuous associations between IM levels and additional pre-treatment factors (potential 
modifying factors) were assessed, to address hypothesis 9. These included age, BMI, 
physical illness severity (MCIRS score), childhood trauma severity (CTQ score), extent of 
treatment-resistance (MSM score), age of depression onset, number of psychiatric 
125 
 
comorbidities (sum of current diagnoses met on the MINI, excluding mood disorder sections), 
life stress severity (HR-LSI score), extent of personality disorder traits (SAPAS score), health-
related quality of life (EQ5D score) and subjective health rating (score 0 – 100). Gender, 
occupational functioning, smoking, alcohol and substance consumption, medication status 
(any regular medication) and psychotropic medication status were dichotomous variables for 
which IMs were compared between groups using independent samples t-tests.  
j) The relationships between each IM were inspected using correlations at both pre-treatment 
and post-treatment (inter-IM correlations). For each biomarker, the relationship between 
levels over time (intra-IM correlation) was also examined.  
 
An all subsets regression approach (Lawless and Singhal 1987) was undertaken to explore the 
optimal set of variables, measured before treatment, that can be used to predict depression 
severity after treatment. The same approach was taken as in Study 2 (Chapter 3). The 10 models 
with lowest BIC values were considered, and the optimal model was selected based on BIC, AIC 
and r2 values, and scientific justification, alongside the Durbin-Watson collinearity statistic.      
 
 
4.4 Results  
 Sample characteristics 
Participants had moderately severe depression at baseline (according to PHQ9 score categories; 
mean score = 18.4, SD = 4.4). All 96 participants undertook psychological treatment (averaging 
12 sessions over 7 months), of which 47 participants (49%) met criteria for treatment-response 
and 49 (51%) were non-responders. See Table 4.1 for characteristics of the responder and non-
responder subsamples. Non-responders had more severe depression and anxiety symptoms and 
a poorer health-related quality of life at all measurement time points. They also had more 




Table 4.1   Outpatient participant characteristics 
 
 
Full sample  
N = 96 
Responders  
n = 47 
Non-responders 




n female (%) 68 (72%)  36 (77%)  32 (65%)  
 
Age  
Mean age (range) 37.7 (18-77)  35.5 (19-71)  39.8 (18-77)  
 
BMI 
Mean BMI (range) 25.8 (16-47) a  25.2 (16-47) 26.1 (18-45)  
 
Symptom subtype 
n somatic (%) 26 (33%) b  12 (31%) 14 (36%) 
 
Bipolar status 
n bipolar spectrum (%) 30 (31%)          15 (32%)  15 (31%)  
 
Childhood trauma severity 
Mean CTQ score (range) 52.2 (28-114) c 52 (28-114)  52.5 (28-102)  
 
Physical illness 
Mean MCIRS score (range) 16.4 (13-28) d 16.3 (13-28)  16.8 (13-25)  
 
Medication (any)   
n medicated (%) 72 (75%)           32 (68%)  40 (82%)  
 
Psychiatric medication   
n medicated (%) 45 (47%)           18 (38%)  27 (55%)  
 
Treatment-resistance 
Mean MSM score (range) 5.82 (3-10)        5.82 (3.5-9)  5.82 (3-10)  
 
Age of onset (mood disorder) 
Mean age (range) 17.5 (4-48) e 17.4 (6-44) 17.7 (4-48) 
 
Pre-treatment depression severity 
Mean PHQ9 score (range) 18.4 (10-27)      17.4 (10-25)  19.4 (10-27)  
 
0.022 
Post-treatment depression severity 
Mean PHQ9 score (range) 10.9 (0-27)        5 (0-21)   16.5 (10-27)  
 
<0.001 
Pre-treatment anxiety severity 
Mean GAD7 score (range) 14.8 (3-21)        14 (5-20)           15.7 (3-21)       
  
Post-treatment anxiety severity 
Mean GAD7 score (range) 9.3 (0-21)          4.9 (0-17)          13.5 (4-21)       
 
<0.001 
Number of therapy sessions   
Mean number (range) 11.9 (4-35) f 10.8 (4-32)        13.2 (4-35)       
  
Number of psychiatric comorbidities 
Mean number (range)  3.2 (0-7)           2.6 (0-7)            3.6 (0-7)           
 
0.015 
Recent life stress   
Mean HR-LSI score (range) 185.9 (13-422) g 169.6 (13-325) 226.7 (36-422) 
 
Personality disorder traits   
Mean SAPAS score (range) 3.5 (0-8) h 3.3 (0-8)           3.9 (0-7)           
 
Quality of life impairment 
Mean EQ5D score (range) 7.7 (5-12) i 7.3 (5-10)         8.2 (5-12)         
 
0.011 
Subjective health rating  




n regular smokers (%)  13 (25%) j 9 (27%)            4 (22%)  
 
Alcohol consumption 
n regular alcohol users (%) 36 (39%) a 21 (46%)          15 (32%)          
 
Substance use 
n substance users (%) 20 (21%)          14 (30%)          6 (13%)            
  
Occupational function 





* Non-significant unless stated 
a n = 93 (46 responders, 47 non-responders) 
b n = 78 (39 responders, 39 non-responders) 
c n = 91 (45 responders, 46 non-responders) 
d n = 89 (45 responders, 44 non-responders) 
e n = 80 (40 responders, 40 non-responders) 
 
f n = 95 (47 responders, 48 non-responders) 
g n = 51 (32 responders, 19 non-responders) 
h n = 92 (44 responders, 48 non-responders) 
i n = 91 (44 responders, 47 non-responders) 
j n = 51 (33 responders, 18 non-responders) 
k n = 95 (46 responders, 49 non-responders) 
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 Treatment characteristics 
At baseline, 75% of the sample were taking at least one medication. None were taking NSAID 
medications. 47% were taking antidepressant medication (38% of subsequent responders, 55% 
non-responders). After treatment these rates were similar (42% responders, 68% non-
responders, of n = 52); more responders than non-responders were followed-up after treatment 
and of these more non-responders were taking psychotropic medication. Most medicated 
participants were treated with monotherapy. Antidepressant treatment is considered using the 
same categories as in Chapter 3 (see 3.4.2) and is detailed in Table 4.2 below. Over time, 6 
participants (12%) underwent some changes in medication.  
57 subjects had CBT-based therapy, 26 had counselling, 3 had a short-term dynamic-focused 
psychotherapy and 10 participants had more than one type. There were more non-responders in 
the latter group, which likely reflects more extensive treatment provision to treatment-resistant 
patients. Whilst we defined attendance at a minimum of 4 sessions as an adequate treatment 
trial, only 4 participants had less than 6 therapy sessions (1 responder, 3 non-responders).  
 





Changes over treatment R 
n = 47 
NR 
n = 49 
R 
n = 33 
NR 
n = 19 
Unmedicated   29 22 19 6 
NR: 1 started escitalopram, 1 started venlafaxine.  

















































































NR: 1 added lamotrigine & nortriptyline to mirtazapine 













R = responder, NR = non-responder. SSRI = Selective Serotonin Reuptake Inhibitor, SNRI = Serotonin-
Norepinephrine Reuptake Inhibitor, NaSSA = noradrenergic and specific serotonergic antidepressant. TCA 
= Tricyclic antidepressant.  
44 participants did not have post-treatment data. Of 52 participants followed up, 1 non-responder kept 
taking mirtazapine adding lamotrigine and nortriptyline, 1 non-responder switched from fluoxetine to 
sertraline; 1 responder stopped taking mirtazapine; of those unmedicated before therapy 1 responder 
started taking concomitant sertraline and lamotrigine, 2 started monotherapy (escitalopram, venlafaxine). 
a  1 responder after treatment taking sertraline and lamotrigine concomitantly. 
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b  1 non-responder taking lamotrigine, nortriptyline and mirtazapine concomitantly. 
 
 Inflammatory marker characteristics 
All IMs appeared accurately determined (all standard curves with r2 > 0.99). Of the 32 markers, 
TNFβ and Eotaxin-3 had <10% undetected levels which were subjected to imputation and should 
be interpreted with due caution. 9 biomarkers all had > 50% values not detected (IL-12p70, IL-
13, GM-CSF, IL-4, IL-2, IL-1α, IL-1β, Mip1a and IL-5) and were excluded from analyses. Thus, 
23 IMs are examined in this study. See Supplementary Table 4.1 for non-detection rates and 
imputation methods of IM data. There were no striking differences in whether responder or non-
responder participants’ IM levels were undetected. Slightly more responders had undetected 
levels of TNFβ and Eotaxin-3 (as well as IL-13, GM-CSF, IL-4 and Mip1a although most of these 
values were not detected), while for IL-12p70 and IL-2 slightly more non-responders had non-
detected levels.  
Following transformation, all IMs met criteria for normal distribution and all continuous non-
biological variables were also normally distributed.  
 
 Main comparisons 
As in Chapter 3, results for each IM are detailed below Tables 4.3, 4.4 and 4.5, which display the 
main comparisons.  
Before control for multiple comparisons, elevated IL-6, TNFα and sICAM1, and attenuated IFNγ, 
at baseline predicted non-response (Table 4.3), and after treatment elevated IL-6, CRP, MCP4, 
sICAM1 and TARC were higher in non-responders (Table 4.4). However, these significant 
findings did not survive Simes correction for multiple comparisons. Age, gender and BMI did not 
affect these comparisons (results displayed in Supplementary Table 4.2 and 4.3) although TARC 
elevations in non-responders after treatment remained significant after Simes multiple correction 
when adjusted for age, gender and BMI. During treatment, a number of cytokines showed 
increases (between pre- and post-treatment assessments): IL-8 and IL-15 increases remained 
significant after Simes correction, while IL-7 and IL-17 were significant only before control for 









  lg-mean    SD 
Non-responder 
  lg-mean     SD 
r2 OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.289 0.108 0.348 0.111 0.090 0.007 -9.686 -1.006 0.016 0.138 
IL-6 -0.318 0.286 -0.170 0.276 0.088 0.149 -3.496 -0.453 0.011 0.138 
CRP 6.201 0.539 6.388 0.557 0.039 0.531 -1.418 0.145 0.091 0.419 
IL-10 -0.732 0.407 -0.675 0.304 0.009 0.629 -1.786 0.783 0.417 0.779 
IL-8 0.951 0.182 0.979 0.165 0.009 0.393 -3.430 1.681 0.440 0.779 
IL-12 1.307 0.163 1.305 0.181 0.000 0.992 -1.940 1.773 0.991 0.991 
IL-7 1.967 0.222 1.968 0.278 0.000 1.080 -2.171 2.780 0.954 0.991 
IL-15 0.447 0.105 0.439 0.127 0.002 1.896 -3.022 4.221 0.728 0.887 
IL-16 2.325 0.177 2.329 0.162 0.000 0.871 -2.823 2.524 0.915 0.991 
IL-17 0.256 0.390 0.199 0.303 0.009 1.626 -0.799 1.811 0.409 0.779 
MCP1 2.457 0.152 2.470 0.172 0.002 0.611 -3.312 1.886 0.733 0.887 
MCP4 2.170 0.189 2.182 0.226 0.001 0.754 -2.467 1.757 0.783 0.901 
Mip1b 2.089 0.193 2.145 0.179 0.031 0.188 -4.530 0.563 0.174 0.572 
Eotaxin 2.296 0.208 2.326 0.223 0.007 0.517 -2.944 1.393 0.485 0.783 
sICAM1 6.481 0.415 6.546 0.353 0.072 0.010 -9.293 -0.557 0.018 0.138 
sVCAM1 5.668 0.097 5.717 0.111 0.004 0.278 -6.311 3.308 0.577 0.783 
SAA 5.775 0.097 5.785 0.085 0.010 0.639 -1.527 0.735 0.425 0.779 
TARC 2.472 0.226 2.526 0.297 0.014 0.453 -2.512 0.733 0.304 0.779 
Tie2 3.625 0.192 3.703 0.176 0.061 0.076 -6.965 -0.134 0.140 0.537 
IP-10 2.326 0.154 2.368 0.241 0.015 0.348 -4.120 0.870 0.382 0.779 
IFNγ 0.707 0.285 0.592 0.249 0.060 5.205 0.102 3.755 0.042 0.242 
Eotaxin3 0.742 0.491 0.795 0.442 0.004 0.781 -1.184 0.725 0.579 0.783 
TNFβ -0.725 0.541 -0.663 0.428 0.006 0.765 -1.255 0.576 0.553 0.783 
 
Results of unadjusted univariate logistic regressions of inflammation (IV) on responder versus non-
responder group (DV) before psychological treatment. Bold IM names and p values indicate significant 
effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.  










lg-mean    SD 
Non-responder 
lg-mean     SD 
r2 OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.303 0.108 0.338 0.123 0.030 0.064 -10.210 2.810 0.310 0.466  
IL-6 -0.298 0.298 -0.079 0.299 0.165 0.062 -7.081 -0.682 0.027 0.157 
CRP 6.172 0.506 6.599 0.568 0.182 0.216 -3.308 -0.446 0.006 0.067 
IL-10 -0.652 0.289 -0.567 0.259 0.030 0.313 -3.415 1.191 0.239  0.466 
IL-8* 1.012 0.130 1.081 0.175 0.068 0.038 -10.259 0.846 0.148  0.369 
IL-12 1.359 0.144 1.415 0.180 0.007 1.974 -3.401 3.312 0.609  0.643 
IL-7 1.970 0.200 1.937 0.264 0.041 0.094 -7.587 1.901 0.257  0.466 
IL-15 0.481 0.115 0.530 0.105 0.061 0.016 -11.896 1.615 0.150  0.369 
IL-16 2.300 0.147 2.334 0.163 0.015 0.225 -6.226 3.171 0.504  0.592 
IL-17 0.309 0.347 0.288 0.279 0.001 1.232 -1.760 2.338 0.817  0.831 
MCP1 2.467 0.168 2.549 0.218 0.063 0.072 -10.644 1.082 0.285  0.466 
MCP4 2.142 0.151 2.272 0.220 0.152 0.016 -10.689 -0.680 0.025  0.157 
Mip1b 2.115 0.159 2.117 0.135 0.000 0.924 -4.747 4.327 0.962  0.962 
Eotaxin 2.317 0.213 2.359 0.254 0.011 0.432 -4.118 1.907 0.553  0.604 
sICAM1 6.413 0.468 6.646 0.332 0.134 0.002 -14.894 -0.371 0.037 0.159  
sVCAM1 5.684 0.100 5.758 0.124 0.060 0.011 -15.061 2.040 0.247  0.466 
SAA 5.782 0.092 5.825 0.114 0.091 0.264 -4.406 0.067 0.112 0.323  
TARC* 2.451 0.266 2.720 0.336 0.236 0.030 -6.469 -1.723 0.003  0.067 
Tie2 3.607 0.223 3.682 0.231 0.037 0.185 -8.260 1.213 0.370  0.466 
IP-10 2.332 0.151 2.383 0.191 0.030 0.153 -7.253 2.033 0.348  0.466 
IFNγ 0.701 0.316 0.538 0.320 0.084 5.743 -0.338 4.334 0.079  0.271 
Eotaxin3 0.743 0.496 0.916 0.404 0.051 0.343 -4.240 0.590 0.290  0.466 
TNFβ* -0.664 0.469 -0.578 0.388 0.013 0.621 -2.251 1.013 0.509  0.592 
 
Results of unadjusted univariate logistic regressions of inflammation (IV) on responder versus non-
responder group (DV) after psychological treatment. Bold IM names and p values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. When adjusting for age, gender 
and BMI each regression model fit was satisfactory. All other regression models were adequately fitted 









Before vs. after treatment Treatment x response interaction 
F p cor. p F p cor. p 
TNFα 0.023 0.880 0.950 0.015 0.902 0.909 
IL-6 0.004 0.950 0.950 0.032 0.859 0.909 
CRP 0.022 0.883 0.950 0.068 0.795 0.909 
IL-10 3.164 0.082 0.236 2.167 0.147 0.676 
IL-8 14.600 0.0009 0.021 2.352 0.132 0.676 
IL-12 0.842 0.363 0.816 0.542 0.465 0.901 
IL-7 7.181 0.010 0.077 0.188 0.666 0.901 
IL-15 9.826 0.003 0.035 0.345 0.560 0.901 
IL-16 0.328 0.511 0.840 2.301 0.136 0.676 
IL-17 5.049 0.027 0.167 3.058 0.087 0.676 
MCP1 3.322 0.075 0.236 1.455 0.234 0.769 
MCP4 0.110 0.742 0.948 0.074 0.787 0.909 
Mip1b 0.557 0.459 0.816 0.013 0.909 0.909 
Eotaxin 0.170 0.682 0.948 0.287 0.595 0.901 
sICAM1 0.173 0.680 0.948 0.015 0.903 0.909 
sVCAM1 2.850 0.098 0.250 2.628 0.112 0.676 
SAA 0.688 0.411 0.816 0.349 0.558 0.901 
TARC 0.553 0.461 0.816 0.333 0.567 0.901 
Tie2  0.008 0.928 0.950 0.851 0.361 0.901 
IP-10 0.076 0.784 0.949 0.224 0.638 0.901 
IFNγ 3.440 0.070 0.236 0.301 0.586 0.901 
Eotaxin3 0.142 0.708 0.948 0.019 0.892 0.909 
TNFβ 3.403 0.071 0.236 1.532 0.222 0.769 
 
Results of 2x2 mixed-factorial ANOVA comparing IM changes over time (pre- to post-treatment) between 
responders and non-responders. The before vs. after treatment columns describe the main effect of cytokine 
comparison between time points in the full sample and the Treatment x response interaction column 
describes the effect of response status on inflammatory change over time (n = 51). Bold IM names and p 
values indicate significant effects.  
F = ANOVA test statistic (degrees of freedom 1, 48), p = uncorrected p, before Simes control for multiple 








Elevated TNFα at baseline predicted subsequent non-response to treatment, significant only 
before control for multiple comparisons in both the univariate (unadjusted) logistic regression (OR 
= 0.007, p = 0.016, corrected p = 0.138) and when adjusting for age, gender and BMI (OR = 
0.006, p = 0.026, corrected p = 0.268). See Figure 4.1 for a depiction of TNFα elevations in non-
responders compared to responders before and after treatment (non-significant at the latter time 
point). Pre-treatment TNFα was correlated positively with depression severity cross-sectionally at 
pre-therapy (r = 0.275, p = 0.007) and prospectively at post-therapy (r = 0.286, p = 0.005). Before 
treatment, these correlations appear stronger with somatic (r = 0.354, p = 0.001) than cognitive 
(p = 0.053) symptoms. TNFα was also positively correlated with anxiety severity at pre- (r = 0.282, 
p = 0.006) and post-treatment (r = 0.254, p = 0.012). At baseline, significant positive correlations 
were identified between TNFα levels and number of comorbid psychiatric diagnoses (r = 0.219, p 
= 0.032), age (r = 0.26, p = 0.011), health-related quality of life (r = 0.402, p < 0.001), physical 
illness (r = 0.214, p = 0.044) and elevations were also found in those not employed (t(92) = -3.76, 
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Figure 4.1   TNFα levels between responders and non-responders   
 
Log transformed mean values of TNFα are presented. Error bars represent standard error of the mean 
(SEM). Log values for pre-treatment: Non-responder mean = 0.348, SEM = 0.016, n = 49; Responder mean 
= 0.289, SEM = 0.016, n = 47. After treatment non-responder mean = 0.338, SEM = 0.029, n = 18; 






Elevated IL-6 at baseline predicted non-response before controlling for multiple comparisons, 
both in the unadjusted regression (OR = 0.149, p = 0.011, corrected p = 0.138) and adjusting for 
age, gender and BMI (OR = 0.154, p = 0.035, corrected p = 0.268); see Figure 4.2. After treatment 
IL-6 was similarly higher in non-responders in the unadjusted univariate regression (OR = 0.062, 
p = 0.027, corrected p = 0.157) but the association was less strong when adjusting for age, gender 
and BMI (OR = 0.057, p = 0.052, corrected p = 0.239).  
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Figure 4.2   IL-6 between responders and non-responders 
 
Log transformed mean values of IL-6 presented; for clarity, a value of 1 has been added to IM data in the 
graph. Error bars show standard error of the mean (SEM). Log values for pre-treatment: Non-responder 
mean = -0.170, SEM = 0.040, n = 49; Responder mean = -0.318, SEM = 0.042, n = 47. After treatment: Non-
responder mean = -0.079, SEM = 0.070, n = 18; Responder mean = -0.298, SEM = 0.053, n = 32. 
 
 
Pre-treatment levels of IL-6 were positively correlated with severity after therapy (r = 0.280, p = 
0.006). Somatic symptom score was positively correlated with IL-6 before (r = 0.261, p = 0.021) 
and after (r = 0.342, p = 0.028) treatment, while cognitive-score severity was not correlated at 
either time point. Over time, the somatic group showed decreases in IL-6 while predominantly 
cognitive-symptom subtype individuals had increases in IL-6 (interaction F(1,38) = 6.329, p = 
0.016); see Figure 4.3. Baseline levels of IL-6 were additionally higher with greater physical illness 
(r = 0.281, p = 0.008) and in participants who were not currently working (t(91) = -2.448, p = 
0.017). At both pre- and post-therapy, positive correlations were found with IL-6 and age (r = 
0.369, p = 0.001; r = 0.526, p < 0.001) and health-related quality of life impairment (r = 0.359, p 













Figure 4.3   IL-6 change with therapy in somatic versus cognitive symptom subtype 
 
Log transformed mean IL-6 values over time (error bars show SEM); interaction with symptom subtype. For 
clarity of the Figure, a value of 1 has been added to IM data in the graph. Log values for participants with a 
somatic subtype (n=16): pre-treatment mean = -0.17, SEM = 0.08, post-treatment mean = -0.27, SEM = 
0.083. Participants with a cognitive subtype (n = 24): pre-treatment mean = -0.275, SEM = 0.066, post-




After treatment, CRP was higher in non-responders. Both unadjusted and adjusted regression 
analyses were significant only prior to control for multiple comparisons: unadjusted OR = 0.216, 
p = 0.006, corrected p = 0.067; adjusted OR = 0.234, p = 0.023, corrected p = 0.199 (see Figure 
4.4). CRP after treatment was also higher in more severely depressed participants (r = 0.314, p 
= 0.030). At baseline, CRP was positively correlated with childhood trauma severity (r = 0.217, p 
= 0.038). Both measurements were related positively to age (pre-treatment r = 0.245, p = 0.016; 
post-treatment r = 0.428, p = 0.002) and to health-related quality of life impairment (r = 0.333, p 
= 0.001; r = 0.320, p = 0.027).   




















l) S o m a t ic
C o g n itiv e
135 
 






















N o n -re s p o n d e rs
R e s p o n d e rs
p  =  0 .0 0 6
 
Figure 4.4   CRP levels in responders and non-responders   
 
Log transformed mean values and error bars (SEM) presented. Log values pre-treatment: Non-responder 
mean = 6.388, SEM = 0.080, n = 49; Responder mean = 6.201, SEM = 0.079, n = 47. Post-treatment: 




Participants taking psychotropic medication at baseline had small reductions in IL-10 while the 
levels of unmedicated participants increased (F(1,48) = 5.193, p = 0.027; see Figure 4.5). No 
other comparisons for IL-10 yielded significant results. 
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Figure 4.5   IL-10 changes with treatment; interaction with psychotropic medication  
 
Log transformed mean IL-10 values over time (error bars show SEM); interaction with psychotropic 
medication use. For clarity of the Figure, a value of 1 has been added to IM data in the graph. Log values 
for unmedicated participants (n=26): pre-treatment mean = -0.668, SEM = 0.053, post-treatment mean = -
0.581, SEM = 0.055. Medicated participants (n = 24): pre-treatment mean = -0.643, SEM = 0.055, post-







IL-8 levels increased alongside treatment (F(1,48) = 14.600, p < 0.001, corrected p = 0.021); see 
Figure 4.6. Pre-treatment IL-8 was higher alongside more severe physical illness (r = 0.295, p = 
0.005), poorer health-related quality of life (r = 0.332, p = 0.001), unemployment (t(92) = -2.437, 
p = 0.013) and older age (r = 0.304, p = 0.003). People who smoked had higher levels of IL-8 
before treatment (t(50) = 2.268, p = 0.011). After therapy, IL-8 positively correlated with number 
of psychiatric comorbidities (r = 0.312, p = 0.027). 
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Figure 4.6   IM increases with psychological therapy 
 
Log transformed mean values and error bars (SEM) are presented. Note that axes have been cut according 
to IM levels expressed to depict differences clearly. For all IMs, n = 50. Log values, IL-8: Pre-treatment mean 
= 0.96, SEM = 0.025, Post-treatment mean = 1.037, SEM = 0.021. IL-15: Pre-treatment mean = 0.454, SEM 
= 0.015, Post-treatment mean = 0.499, SEM = 0.016. IL-7: Pre-treatment mean = 1.317, SEM = 0.024, Post-
treatment mean = 1.379, SEM = 0.022. IL-17: Pre-treatment mean = 0.206, SEM = 0.056, Post-treatment 






After treatment, negative correlations were identified between IL-12 and number of psychiatric 
comorbidities (r = -0.284, p = 0.046) and severity of somatic depressive symptoms at baseline (r 
= -0.355, p = 0.024). Participants who smoked had lower levels of IL-12 at the pre-treatment (t(50) 
= -2.8, p = 0.025) and post-treatment (t(48) = -2.917, p = 0.028) measurement.   
 
4.4.4.7 IL-7 
Participants with a somatic subtype had higher IL-7 before therapy (t(76) = 2.38, p = 0.021). At 
this time point IL-7 was negatively correlated slightly with concurrent depression severity (r = -
0.208, p = 0.042). IL-7 increased alongside treatment (F(1,48) = 7.181, p = 0.010, corrected p = 
0.077; see Figure 4.6).  After treatment, participants who smoked had lower IL-7 (t(48) = -2.33, p 
= 0.036).   
 
4.4.4.8 IL-15 
IL-15 increased significantly during the treatment period (F(1,48) = 9.826, p = 0.003, corrected p 
= 0.035); see Figure 4.6. IL-15 correlated significantly with physical illness severity at baseline (r 
= 0.408, p = 0.004). Post-treatment IL-15 levels were higher alongside more severe childhood 
trauma (r = 0.391, p = 0.005), older age (r = 0.464, p = 0.001), and unemployment (t(48) = -2.042, 
p = 0.036).  
 
4.4.4.9 IL-16 
At baseline, anxiety was more severe in those with high IL-16 (r = 0.357, p = 0.012) but 
correlations with depression severity were not significant. Childhood trauma was associated with 
elevations in IL-16, both at baseline (r = 0.279, p = 0.007) and follow-up (r = 0.390, p = 0.006). 
Both recent life stress (r = 0.291, p = 0.043) and substance use (t(48) = 1.915, p = 0.022) were 
slightly higher in participants with elevated IL-16 after treatment.   
 
4.4.4.10 IL-17 
IL-17 showed slight increases with therapy (F(1,48) = 5.049, p = 0.027, corrected p = 0.167, see 
Figure 4.6). At pre-treatment, IL-17 levels were higher in participants not taking any regular 





Levels of MCP1 at baseline were correlated significantly with health-related quality of life 
impairments (r = 0.299, p = 0.004) and physical illness severity (r = 0.299, p = 0.004). At both 
time points, MCP1 correlated positively with age (r = 0.359, p < 0.001; r = 0.363, p = 0.01).  
 
4.4.4.12 MCP4 
Following treatment, non-responders had higher levels of MCP4 than responders: unadjusted 
regression (OR = 0.016, p = 0.025, corrected p = 0.157); regression adjusting for age, gender 
and BMI (OR = 0.014, p = 0.038, corrected p = 0.219). Before therapy, MCP4 was higher in 
medicated participants (t(94) = 1.966, p = 0.022). After therapy MCP4 was highly correlated with 
in quality of life impairment (r = 0.488, p < 0.001) and was higher in participants who did not drink 
alcohol (t(48) = -2.707, p = 0.008). Both before and after treatment, positive correlations were 
identified with physical illness severity (r = 0.212, p = 0.046; r = 0.286, p = 0.047) and with age (r 
= 0.267, p = 0.009; r = 0.311, p = 0.028).  
 
4.4.4.13 Mip1b 
Before therapy, Mip1b correlated positively with concurrent depression severity (r = 0.25, p = 
0.014) and anxiety severity (r = 0.257, p = 0.012). These associations were found specifically for 
somatic items (r = 0.288, p = 0.011) and not cognitive items (p = 0.083) of the PHQ9. Participants 
who did not drink alcohol had somewhat higher levels of Mip1b at pre-therapy (t(91) = -2.451, p 
= 0.018) and post-therapy (t(48) = -2.157, p = 0.035) measurements. 
 
4.4.4.14 Eotaxin 
Eotaxin and age were correlated at both time points (r = 0.312, p = 0.002; r = 0.283, p = 0.046). 
At baseline high Eotaxin was also found alongside a poor quality of life (r = 0.251, p = 0.016). At 
the post-therapy assessment, positive correlations were identified with childhood trauma history 




sICAM1 was slightly higher in non-responders than responders at both time points. At baseline, 
in unadjusted regression (OR = 0.010, p = 0.018, corrected p = 0.138) and adjusted regression 
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(OR = 0.013, p = 0.034, corrected p = 0.268), and after therapy in unadjusted (OR = 0.002, p = 
0.037, corrected p = 0.159) but less so in adjusted (OR = 0.003, p = 0.070, corrected p = 0.268) 
regressions. Baseline levels of sICAM1 significantly and positively correlated with severity scores 
at both time points for depression (r = 0.276, p = 0.007; r = 0.287, p = 0.005) and anxiety (r = 
0.295, p < 0.001; r = 0.32, p < 0.001), but post-treatment levels were not correlated with severity. 
At both time points, sICAM1 was related to the somatic but not cognitive scores from the baseline 
PHQ9 (somatic correlations; r = 0.268, p = 0.018; r = 0.323, p = 0.042; cognitive correlations both 
p > 0.05). Levels of this biomarker were correlated at both time points positively with age (r = 
0.298, p = 0.003; r = 0.501, p < 0.001) and physical illness score (r = 0.379, p = 0.008; r = 0.439, 
p = 0.002), and were higher in participants who did not work (t(93) = -2.833, p = 0.007; t(48) = -
2.207, p = 0.031). At baseline only, positive correlations were present with quality of life 
impairments (r = 0.388, p < 0.001) and childhood trauma experience (r = 0.266, p = 0.011).  
 
4.4.4.16 sVCAM1 
sVCAM1 increased during therapy in unipolar but decreased in bipolar participants (F(1,48) = 
5.006, p = 0.030). Alcohol consumers had lower levels of sVCAM1 before therapy (t(91) = -2.283, 
p = 0.025).  
 
4.4.4.17 SAA 
Patients with a predominantly somatic subtype showed decreases during treatment in contrast 
with small increases in the cognitive subgroup (interaction F(1,38) = 4.881, p = 0.033). Baseline 
SAA was positively correlated with childhood trauma history (r = 0.383, p < 0.001) and personality 
disorder traits (r = 0.213, p = 0.042). After therapy, positive correlations were identified with age 
(r = 0.366, p = 0.009) and physical illness severity (r = 0.302, p = 0.035).   
 
4.4.4.18 TARC 
Non-responders had high levels of TARC after completing treatment. This effect was significant 
after Simes control for multiple comparisons in the multivariate regression adjusting for age, 
gender and BMI (OR = 0.039, p = 0.001, corrected p = 0.023) but not univariate unadjusted 
regression (OR = 0.030, p = 0.003, corrected p = 0.067); see Figure 4.7. Likewise, higher levels 
of TARC were found in those with greater depression severity after treatment (r = 0.346, p = 
0.014). At both assessments TARC was correlated with physical illness (r = 0.241, p = 0.023; r = 
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0.306, p = 0.033), and anxiety severity (r = 0.209, p = 0.041; r = 0.326, p = 0.021). Prior to 
treatment, patients taking psychotropic medication had higher levels of TARC (t(94) = 2.282, p = 
0.029), as did those with more treatment-resistant depression (r = 0.208, p = 0.042), childhood 
trauma (r = 0.285, p = 0.006), traits of personality disorder (r = 0.335, p = 0.030) and a poorer 
health-related quality of life (r = 0.401, p = 0.005).   
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Figure 4.7   TARC levels in responders and non-responders 
 
Log transformed mean values and error bars (SEM) presented. Log values before treatment: Non-responder 
mean = 2.526, SEM = 0.042, n = 49; Responder mean = 2.472, SEM = 0.033, n = 47 (p = 0.316). After therapy: 




Subjects with a bipolar diathesis had decreases in Tie2 after treatment while unipolar participants 
had small increases (interaction F(1,48) = 5.089, p = 0.029). Health-related quality of life was 
poorer in those with high Tie2 at baseline (r = 0.218, p = 0.038). 
 
4.4.4.20 IP-10 
Before therapy, IP-10 was higher in patients with a poor quality of life (r = 0.241, p = 0.021), non-
smokers (t(50) = -2.278, p = 0.003) and those not working (t(93) = -2.557, p = 0.005). At both time 
points, IP-10 was higher in older subjects (r = 0.238, p = 0.02; r = 0.327, p = 0.020). After therapy, 





Subsequent non-responders had lower IFNγ before therapy than responders, significant only prior 
to control for multiple comparisons in unadjusted (OR = 5.205, p = 0.042, corrected p = 0.242) 
and adjusted (OR = 5.664, p = 0.049, corrected p = 0.282) regression analyses. After treatment, 
IFNγ was lower in non-responders only when adjusting for age, gender and BMI, although these 
factors did not significantly affect the association (IFNγ OR = 9.331, p = 0.026, corrected p = 
0.199). Pre-therapy IFNγ correlated negatively with subsequent depression severity (r = -0.240, 
p = 0.019) and after therapy IFNγ levels correlated with concurrent depression severity (r = -
0.327, p = 0.020). The same finding occurred for anxiety severity (r = -0.289, p = 0.004; r = -0.393, 
p = 0.005 respectively). Both early life (r = -0.273, p = 0.009) and current life stress (r = -0.369, p 
= 0.008) were negatively correlated with IFNγ at baseline. After treatment IFNγ was lower in the 
presence of more psychiatric comorbidities (r = -0.384, p = 0.006) and personality disorder traits 
(r = -0.312, p = 0.044). 
  
4.4.4.22 Eotaxin-3 
Eotaxin-3 levels were found to be higher before treatment in people who were more treatment-
resistant (r = 0.222, p = 0.03) and who had a poorer quality of life (r = 0.223, p = 0.033).   
 
4.4.4.23 TNFβ 
TNFβ did not demonstrate any significant effects between groups or over time.   
 
In main comparisons, the only IMs that were significant when corrected for multiple comparisons 
were the increases in IL-8 and IL-15 during the therapy time period (between pre- and post-
therapy measurements), and the heightened TARC in non-responders after treatment. A heat-































       
 
-  continues in next column 
 
Figure 4.8   Heat-map of IL-8, IL-15 and TARC levels 
 
Pre = pre-treatment, post = post-treatment. Each row represents a participant, grouped into TRD responders, 
TRD non-responders and healthy controls. Those without an IM measurement at post-treatment are ordered 
last in the respective categories, and denoted by a diagonal line. Low levels are depicted using green; high 
levels with red.  
 






































































































            
                         
                         
                         
                         
                         
                         
                         
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                        
                         
                         
                         
                         
                         
                         
                         
                         
                         
                        
                        
                        
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                       
                        
                    




 Further Comparisons 
 
4.4.5.1 IM intra- and inter-correlations  
Most IMs demonstrated high intra-correlations over time (see Supplementary Table 4.4), and 
many were highly inter-correlated with one another. See Supplementary Tables 4.5 and 4.6 for a 
full matrix of inter-correlations between markers at each time point. Two chemokines, MCP1 and 
Eotaxin were the most closely related (r = 0.615, p < 0.001), and appeared to form a cluster with 
primarily other chemokines (Eotaxin-3, TARC, IP-10, MCP4 and intercellular adhesion molecules 
sICAM1 and sVCAM1). IL-6, CRP and SAA seem to form a separate cluster. 
 
4.4.5.2 All subsets regression analyses 
Using the a priori criteria, the all subsets regression analyses included all data with less than 
<10% missing. Thus, all 23 IMs were considered, as well as the following 17 non-IM variables 
measured at baseline: Age, gender, BMI, treatment-resistance (MSM), depression severity (total 
PHQ9 score), anxiety severity (GAD7 total score), number of therapy sessions, physical illness 
severity (MCIRS score), childhood trauma (CTQ score), health-related quality of life (EQ5D 
score), occupational status, bipolar subtype, psychotropic medication status, number of 
comorbidities, alcohol use, substance use and subjective health score. A total of 40 potential 
predictor variables would have run an unwieldy ~90,000 models, even maintaining a maximum k 
of four predictors per model. Therefore inflammatory (n = 23) and non-inflammatory (n = 17) 
factors were examined in separate all subsets analyses, yielding a total of 8855 and 2380 models 






Table 4.6   Pre-treatment inflammatory predictors of post-treatment severity 
   
 
 
Predictor variables in each model p r2  BIC  AIC 
 Durbin-
Watson 
1 IFNγ*, TNFα 0.000278 0.16143 366.21 373.9029 1.841373 
2 IFNγ*, TNFα, sICAM1 0.000464 0.17586 366.544 376.8009 1.885914 
3 IFNγ*, TNFα, sVCAM1 0.000473 0.175496 366.586 376.8433 1.834312 
4 IFNγ*, TNFα, IL-6 0.000651 0.169467 367.285 377.5427 1.869834 
5 IFNγ*, TNFα, IL-7*  0.000656 0.169327 367.302 377.5589 1.826862 
6 IFNγ*, TNFα, MCP4 0.000663 0.169128 367.325 377.5819 1.821666 
7 IFNγ*, TNFα, IL-17  0.000768 0.166328 367.648 377.9049 1.855057 
8 IFNγ*, TNFα, Tie2 0.000771 0.166256 367.656 377.9131 1.867566 
9 IFNγ*, sICAM1 0.00196 0.125478 370.24 377.9329 1.916061 
10 slCAM1 0.00462 0.082239 372.873 378.0015 1.930101 
 
Unless indicated, higher units of the predictor variables are associated with higher severity after treatment.  
* = lower levels predict greater depression severity.   
 
 
 Table 4.7   Pre-treatment non-biological predictors of post-treatment severity 
 
 
Predictor variables in each model p  r2  BIC  AIC 
 Durbin-
Watson 
1 PHQ9, MCIRS, EQ5D, alcohol use* 0.00000175 0.338 298.974 311.008 1.890 
2 GAD7, MCIRS, EQ5D, alcohol use* 0.00000353 0.325 300.548 312.581 1.980 
3 N-therapy, MCIRS, EQ5D, alcohol use* 0.0000194 0.296 301.373 313.345 1.911 
4 PHQ9, MCIRS, EQ5D, substance use* 0.000000129 0.376 302.741 314.895 1.855 
5 PHQ9, N-therapy, MCIRS, EQ5D 0.000000546 0.355 302.905 314.999 1.799 
6 MCIRS, SAPAS, EQ5D, alcohol use* 0.000102 0.263 304.064 316.036 2.028 
7 PHQ9, MCIRS, EQ5D, SAPAS 0.00000142 0.338 303.966 316.060 1.797 
8 PHQ9, MCIRS, subjective health*, alcohol use* 0.0000192 0.293 304.361 316.394 1.965 
9 MCIRS, EQ5D, alcohol use*   0.0000412 0.254 306.846 316.473 2.000 
10  PHQ9, MCIRS, EQ5D 0.000000571 0.327 307.139 316.863 1.793 
 
Unless indicated, higher units of the predictor variables are associated with higher severity after treatment.  
* = lower levels predict greater depression severity.   
PHQ9 = depression severity score, MCIRS = physical illness severity score, EQ5D = measure of health-
related quality of life impairment, GAD7 = anxiety severity score, N-therapy = number of therapy sessions, 






The non-inflammatory model yielded the strongest predictors of depression outcome. 
Surprisingly, alcohol and substance use were positive predictors of low depression severity which 
is not in accordance with previous literature. However, there may be confounding as especially 
alcohol consumption was associated with less severe physical illness and thus may not represent 
an independent factor. The second-highest r2 value and p value (r2 = 0.355; p = 0.000000546) 
did not contain alcohol or substance non-use but depression severity, number of therapy 
sessions, physical illness severity and health-related quality of life. The BIC value was not much 
larger for this model and there was an acceptable absence of collinearity (demonstrated by the 
Durbin-Watson statistic) indicated. Physical illness did not independently predict post-treatment 
depression severity (OR = -0.058, p = 0.59) but served as a control for other factors; more therapy 
sessions received during therapy also only trended towards significance (OR = 0.173, p = 0.065) 
but both high depression severity before treatment (OR = 0.359, p = 0.001; 95% CI’s -0.262, 
0.926) and impairments in quality of life (OR = 0.308, p = 0.009, 95% CI’s 0.32, 2.224) were highly 
predictive of more severe depression after treatment. 
 
In the IM-only examination, many models were statistically significant, albeit less strongly than for 
non-biological variables. The combination of low IFNγ and high TNFα were consistently identified 
alongside each other in the best models. Indeed the model including both of these and no other 
predictors had the lowest BIC and p values (p = 0.000278), and comparable Durbin-Watson 
collinearity and AIC values. Both high TNFα (OR = 0.325, p = 0.001, 95% CI’s 8.552, 32.675) and 
low IFNγ (OR = -0.285, p = 0.004, 95% CI’s -12.526, -2.501) contributed significantly to severity. 
 
When these four non-IM and two-IM variables were all entered together into a final regression, a 
more significant finding was identified, as anticipated: r2 = 0.412, p = 0.000000242. In this model, 
depression severity (OR = 0.345, p = 0.001, 95%’s 0.243, 0.896) and to a lesser extent quality of 
life (OR = 0.221, p = 0.048, 95% CI’s 0.009, 1.869) remained independent predictors of outcome. 
IFNγ also contributed to a potentially significant extent (OR = -0.224, p = 0.015, 95%’s -10.822, -
1.107). However TNFα was no longer significant (p = 0.096). When accounting for these factors, 
a higher number of therapy sessions tentatively contributed to post-therapy severity (OR = 0.189, 
p = 0.041, 95%’s 0.015, 0.516). As expected, physical illness was not an independent contributor 





4.5 Discussion  
These findings provide an insight into inflammatory changes that can occur alongside non-
pharmacological treatment, even in the absence of clinical recovery from depression. Results 
help to clarify some of the inflammatory associations with depression over time and with response 
to treatment, incorporating indications into the activity of a range of inflammatory markers across 
subtypes of depressed individuals undergoing psychological treatment. The therapy response 
rate of 49% is comparable to those previously reported for IAPT psychological therapy services 
(Gyani et al. 2011). Treatment non-responders had poorer ratings of depression, health-relating 
quality of life, occupational function and more psychiatric comorbidities before starting treatment. 
This is generally in line with previous literature (e.g. Bennabi et al. 2015).  
 
 Inflammatory relationships with treatment response 
At baseline, 4 out of 23 biomarkers are significantly different between subsequent responders 
and non-responders at p < 0.05. Marked elevations are observed for TNFα and IL-6 in non-
responders (less significantly for sICAM1 and attenuated IFNγ). Both TNFα and IL-6 have 
previously been reported as higher in acute than remitted depressed states (O’Brien et al. 2007) 
or to predict non-response to antidepressant treatment (Lanquillon et al. 2000, Yoshimura et al. 
2013). Both of these cytokines are highly related functionally in their important involvement in 
early acute inflammation initiating expression of additional proteins and are inter-related at p < 
0.01 in this study. We also find them to be correlated with quality of life which is strongly related 
to response in this study. IL-6 and TNFα have both been identified at a meta-analytic level 
(Strawbridge et al. 2015) to be potentially useful biomarkers of non-response in depression. 
sICAM1 has not been examined for its potential to predict response to treatments for depression 
but interplays with IL-6 and TNFα: Kurokouchi et al. (1998) demonstrated that treatment with 
TNFα clearly and comparably enhances IL-6 and ICAM1 RNA in a dose-response fashion. The 
authors indicate this effect as occurring through NFkB activation, but in an inflammatory response 
cell adhesion molecules also interact less directly with these cytokines through their function 




After therapy, TNFα is not associated with treatment response, while IL-6 and sICAM1 are higher 
in non-responders. The other main biomarker considered a priori to be involved with clinical 
outcomes, CRP, is highly correlated with these two IMs and is associated with treatment response 
after psychological treatment. CRP is also elevated in those with a poor quality of life prior to 
treatment. CRP has previously been found to correlate with depression severity after treatment, 
which is supportive of our findings (Chang et al. 2012). This is the first study to identify TARC and 
MCP4 as higher in non-responders after treatment.   
In general our results suggest a pro-inflammatory state in non-responders characterised by the 
presence of high levels of prominent Th1 cytokines TNFα and IL-6 as well as CRP signalling an 
early immune response, in combination with the related cell-adhesion molecule sICAM1 and 
chemokines MCP4 and TARC, which work together with CAMs on the endothelial surface. The 
finding of low IFNγ prior to therapy in non-responders indicates some Th1 inflammatory imbalance 
in these patients. IFNγ is principally produced by natural killer cells (as well as activated T-cells); 
decreased natural killer cell activity has been reported in depression previously and may not alter 
with treatment (Schleifer et al. 1999). Schleifer et al. further reported a lack of consistent 
relationship between lymphocyte expression and natural killer cell activity. Perhaps low natural 
killer cell activity could contribute to low IFNγ and lead to inflammatory system imbalance.   
 
 Relationships between inflammation and depression severity 
Similar IMs are associated with severity to those found in the comparisons discussed above: both 
pre- and post-therapy PHQ9 scores are correlated with high pre-treatment levels of sICAM1, IL-
6 and TNFα. Other than IL-6, inflammatory associations with prior depression severity are not 
significant. Overall severity of treatment-resistance is only modestly related to TARC and Eotaxin-
3 levels at pre-treatment, which are higher in more TRD patients. Anxiety and depression severity 
appear comparably related to IM levels. IL-16 and IFNγ appear more strongly related to anxiety 
than depression severity in this study, while TARC appears more closely associated with 
depressive symptoms.  
 
The all subsets regression analyses focused on depression severity after treatment as an 
outcome measure. A substantial proportion of the variance in therapy outcome can be predicted 
by both psychological (in particular, poorer levels of health-related quality of life and high pre-
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treatment depression severity) and inflammatory (low IFNγ and high TNFα) variables. While this 
finding is strongly significant, many other potential models demonstrated similar extents of 
outcome prediction. The selected model was chosen in favour of those where alcohol or 
substance users had lower severity after treatment. It is unclear why these factors may predict a 
better outcome after psychological therapy. Depression and anxiety (at both assessments), and 
physical illness severity are greater in non-users of alcohol. It is therefore possible that some 
participants do not drink alcohol due to current illness and this may have confounded the effect 
between inflammation and treatment response. In general, the level of alcohol consumption in 
this study was fairly low, and small- to –moderate alcohol intake has been linked with improved 
health outcomes in general (Rimm et al. 1999).   
 
 Longitudinal changes in IM levels alongside psychological therapy 
IL-8 and IL-15 in particular demonstrate significant increases alongside treatment, while IL-17 and 
IL-7 show a small increase. Neither medication use nor clinical factors affect these occurrences 
significantly, suggesting that indeed the process of psychological therapy influences inflammatory 
activity. It is not possible to confirm that whether these changes are a result of lifestyle changes, 
activity levels, or other factors including the possibility that small reductions of depressive 
symptoms may have affected inflammation even in those not improving sufficiently to be 
categorised as responders. As a known pro-inflammatory chemokine, a rise in IL-8 levels is 
somewhat in contrast with other findings suggesting that heightened inflammation is associated 
with poor clinical state, but appears to reduce leukocyte binding to endothelial cells which is not 
conducive to pro-inflammatory responses (Qazi et al. 2011). The release of IL-8 is aided by IL-17 
in endothelial cells and by both IL-15 and IL-7 in monocytes (Qazi et al. 2011). However, in this 
study the four cytokines are not inter-correlated. Increases in IL-15 and IL-7 might indicate an 
expansion in T-cell growth, which may equate with increases in monoamine activity, even in 
individuals with minor reductions in depression severity. The anti-inflammatory cytokine IL-10 was 
the only IM whose changes over time differed between patients with and without psychotropic 
medication use. This marker showed an increase only in participants not taking medication. Some 
antidepressants can suppress IL-10 levels, with evidence including duloxetine (Fornaro et al. 
2013) and a range of SSRI’s with long-term use (Hernandez et al. 2008). It is possible that the 
suppressive effects of monoamine reuptake inhibitors are masked by additional 
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neurotransmission-enhancing effects of psychological therapy, potentially including melatonin as 
well as serotonin and norepinephrine.   
 
 Inflammatory modification by additional variables 
Aside from its interactive effect with psychotherapy on IL-10, psychotropic medication use is not 
associated with inflammation. Partly, this may be explained by the variety of different treatments 
taken (mostly comprised of SSRI’s but also including SNRI’s, mood stabilisers and antipsychotics) 
and that medication regimes appear largely stable over time. MCP4, TARC and IL-17 are higher 
in users of medication more generally, as found in Study 2, but these findings are not consistent 
between time points. As anticipated, age and physical illness are associated with IM levels. 
Factors that may indicate general disability or low wellbeing include poor health-related quality of 
life ratings or unemployment. These have rarely been measured in comparison with inflammatory 
markers but likely relate closely to other variables such as age and physical illness. Similar IM 
associations are found with age, illness, occupational status and health-related quality of life. 
Frequently, correlations with inflammation are stronger with quality of life than these other factors. 
This supports a previous study which indicated that high CRP predicts poorer emotional and 
social quality of life in a community study of older adults, and promotes the importance of 
modelling biological and psychological factors together (Nowakowski 2014). The influence of 
additional factors on inflammation is discussed further in Section 6.1.6. 
 
 Inflammatory relationships between symptom subtypes 
IL-7 is tentatively higher in participants with a primarily somatic subtype at baseline. Many IMs 
correlate with the somatic subscale but not cognitive subscale from the PHQ9 (positively with IL-
6, Mip1b, sICAM1, and negatively IL-12), but only with TNFα at the p < 0.01 level. To a modest 
extent, IL-6 and SAA decrease with psychological therapy in somatic-subtype but not cognitive-
subtype depression. Taken together, we theorise that these results indicate a stronger 
relationship between inflammation and somatic than cognitive or emotional presentations of 
depression, which supports Duivis et al. (2014)’s previous findings. This effect may be more 
pronounced than either the current study or previous studies have observed, due to the cursory 
measurement used to define a somatic subtype. Further investigation is warranted to establish 
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whether the few significant findings identified here signify meaningful differences between 
patients with predominantly somatic or non-somatic symptoms. The severity of specific symptoms 
mirroring sickness behaviour (which are slightly distinct from those considered here) may provide 
another target for an inflammatory symptom subtype.   
 
 Inflammatory relationships between diagnostic subtypes 
Bipolar depression is associated with reductions in Tie2 and sVCAM1 over time while these 
remain high in unipolar participants. These markers have not been examined between these 
groups before, but could represent subtly different mechanisms between these mood disorders 
in terms of inflammatory signalling or small differences driven by possible activity or mood lability, 
or medication differences, although these were not detected using the method employed. True 
effects may also have been masked due to reduced sample size at post-treatment. Approximately 
one third of participants met criteria for a bipolar disorder, which accords with previous reports 
(Manning et al. 1997) though most participants were assessed using the MINI interview and where 
data were missing the HCL-16 checklist was used. Particularly the HCL has been criticised for 
over-indicating bipolar disorders (Phelps and Ghaemi 2006). This means that some of the 
participants classified as bipolar in this study may actually have experienced subclinical bipolar-
spectrum symptoms. Furthermore, this sample may not represent the full spectrum of bipolar 
disorder: most met criteria for hypomania but not mania, and were not treated a mood stabiliser. 
These are key areas to be addressed in future, hypothesis-driven research.  
 
 Strengths and Limitations 
As in Chapter 3, this study is limited by low statistical power arising from small numbers and 
particularly the reduced follow-up sample, in conjunction with the number of comparisons, IMs 
with non-detected levels (that were imputed), the inability to account for all potential contributing 
factors to IM levels (including those of food or drink consumed and time of blood collection) and 
non-standardisation of psychological therapy and adjunctive treatments. Additionally clinical 
characteristics such as number of episodes, and treatment characteristics such as type and 
duration of therapy were not analysed statistically and may have affected results. The limitations 




This is the first study to comprehensively assess the combination of proteomic inflammatory 
biomarkers and psychological factors in predicting response to psychological therapy for 
depression. Research exploring homogenous subtypes, particularly those relating to 
inflammatory biomarkers, are scarce. A potential ‘somatic’ symptom subtype is addressed in the 
present study. Measurement criteria used to determine subtype categorisation are 
unstandardised and may not accurately reflect those participants experiencing a somatic-type 
mood disorder. A measure of atypical depression would have enabled an assessment of this 
subtype, posited to be importantly related to inflammation (Lamers et al. 2016). The 
characterisation of bipolar depression and non-detection of certain biomarkers are detailed 
further, alongside further considerations when interpreting findings, in Section 6.3 as well as 
previously in Section 3.5.9. Unlike Study 2, all serum specimens were assayed in the same run 
and were randomised in terms of plate locations (but ensuring a stratification of pre- versus post-
treatment samples per plate) Samples had been stored for less than 3 years after collection by 
time of assay. Despite this, a higher number of IMs were excluded from analyses in this chapter 
than in Chapter 3, due to high non-detection. This reduced the scope with which we were able to 
assess inflammatory activity in these patients. 
 
Pertinent also to subtype categorisation, we assess symptoms of depression (using the PHQ9) 
but not MDD diagnosis. Diagnostic accuracy of MDD has previously been suggested as important 
when assessing inflammatory abnormalities in depression (Hiles et al. 2012b), and it is possible 
that some of the participants would not have met criteria for MDD diagnosis. However, the PHQ9 
indicated clinically significant symptoms of depression in all participants, and this measure is 
feasible for assessing severity, symptom subtypes and administering longitudinally. This scale 
has indeed outperformed other widely-used measures at discriminating between treatment-
response (Kounali et al. 2016). The self-report nature of rating scales used to determine 
depression, and additional measures in this study, entails an element of participant subjectivity. 
However, the use of these measures are advantageous for practicality and utility purposes when 
considering the applicability of findings in clinical practice, with many taking <5 minutes to 
complete.  
 
At the post-therapy measurement, IM data were not provided by a greater proportion of non-
responders than responders and clearer effects may have been observed if follow-up data were 
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complete. Despite this, differences in inflammation can be found based on outcome to 
psychological therapy. This study has assessed two outcome measures: treatment response and 
overall severity of depression after therapy, but additional outcome definitions may have elicited 
stronger findings still. For example, remission from depression is often cited as the principal 
clinical aim in treating patients.  
 
 Future recommendations  
A need for psychoneuroimmunological research to shift focus towards translational applications 
has been recently reported widely. While further investigation into the inflammation-response link 
in depression is warranted, it is proposed that another primary focus should be the identification 
of potential subtypes that may include an ‘inflammatory’ component in depression. Somatic 
subtyping, if measured in a specific fashion, may correspond with inflammatory markers. Further 
elucidation of factors such as bipolarity is also important. Our findings suggest that a combination 
of high TNFα, low IFNγ, depression severity and poor quality of life (in conjunction with treatment 
intensity and poor physical health) can explain approximately 40% of the variability of depression 
severity after psychological therapy. This requires rigorous validation, and control for further 
factors which will likely increase the predictability of subsequent treatment response.  
 
 Clinical implications 
If individuals can be prospectively identified as potential non-responders, enhanced care and 
monitoring could be provided to these patients, to increase the probability of achieving remission. 
Particularly high levels of IMs or somatic symptoms may indicate stratification to more appropriate 
treatments (for instance a short-term course of an anti-inflammatory medication concomitant with 
a ‘stepped-up’ psychotherapy programme). If an inflammatory subtype exists, it also has the 
potential for more accurate diagnosis and individualised antidepressant selection (see Section 
6.5). 
 
 Summary and conclusions  
This study has demonstrated elevated inflammatory biomarkers in people with depression who 
are non-responsive to treatment. A poor outcome following psychological therapy is predicted 
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prospectively by elevated IL-6, sICAM1 and TNFα, and attenuated IFNγ as well as non-biological 
measures (severe depression and poor quality of life, and potentially abstinence from alcohol, 
poor health, unemployment and having a psychiatric comorbidity). After treatment, in addition to 
IL-6 and sICAM1, CRP, TARC and MCP4 were higher cross-sectionally in therapy non-
responders. IL-6, TNFα, IL-7 and SAA appear particularly associated with somatic symptoms in 
depression. IL-7, IL-17, IL-8 and IL-15 show overall increases alongside therapy, while IL-10 
increases only in unmedicated participants. People with bipolar depression may demonstrate 
greater reductions in Tie2 and sVCAM1 with therapy.   
 
The most substantial finding suggests that high pre-treatment depression severity and TNFα in 
conjunction with low IFNγ and quality of life predict post-treatment severity, when controlling for 
physical illness and the number of sessions provided in therapy. These findings have the potential 
to improve treatment selection and outcomes for people with depression, if our predictive model 
of response is optimised and validated. Further improvements may be seen if an ‘inflammatory 
subtype’ of depression is discovered. Finally, these findings accord with the growing consensus 
that TNFα, IL-6 and CRP are important biomarkers with translational potential in mood disorders, 







  A supplemental cross-study comparison of 





Few studies have thus far compared inflammatory protein levels between treatment-resistant 
depression, major depression and healthy controls, particularly when measured longitudinally. In 
this chapter, we compare IM levels between the participants in studies 2 and 3 (Chapter 3 and 
4), both before and after treatment.   
Results showed that TRD inpatients had higher levels of IL-8 and IP-10 at both time points than 
both depressed outpatients and non-depressed controls. A number of IMs were higher in both 
patient groups than controls, including IL-16, MCP4, Eotaxin, TARC and Tie2. Outpatients had 
higher levels of IL-7 and IL-15 than either TRD inpatients or controls, while inpatients had lower 
levels of sICAM1 and sVCAM1 than both other groups. When comparing patients’ inflammatory 
levels with treatment response, pre-treatment TNFα, IL-6, CRP and sICAM1 were higher in those 
subsequently not responding to treatment, while after treatment non-responders had higher 
MCP4, SAA, CRP and TARC. Over time, levels of MCP1, IL-10, IL-15, sICAM1 and sVCAM1 
increased. Neither of the comparisons with response or time appeared significantly different 
between inpatient and outpatient study participants.  
These findings are supportive of an overall inflammatory state in depression. The presence of 
some high regulatory and anti-inflammatory cytokines suggest an imbalance of the inflammatory 
system in patients but age, lifestyle and clinical factors are likely to have contributed meaningfully 






Inflammatory markers have often (Haapakoski et al. 2015) but not always (Einvik et al. 2012) 
been reported as elevated in depression, and it has been proposed that TRD is associated with 
more pronounced inflammatory activity (Raison et al. 2013a).  
Due to the heterogeneity of depression, it is useful not only to conduct studies of subgroups such 
as TRD or inflammatory changes with psychological treatment, but also to compare these. We 
were not able to recruit a matched, non-depressed control group in Study 3. In this chapter we 
seek to compare inflammation between the sample of depressed outpatients (Study 3), and both 
non-depressed controls (matched with TRD inpatients) and inpatients from Study 2. In both 
patient groups, we also analyse inflammatory changes with treatment response and different 
treatment modalities that patients undertook (multidisciplinary inpatient treatment versus 
psychological outpatient therapy). It was anticipated that inflammation would be more elevated in 
treatment-resistant inpatients who were taking multiple medications at both measurements. Less 
treatment-resistant outpatients would be expected to have lower inflammation than a TRD 
inpatient sample and higher inflammation than non-depressed controls. However, the patients in 
Study 3 are younger, had lower BMI and medication consumption than the participants in Study 
2; as the controls were age- and BMI-matched with inpatients, the non-depressed group are older 
with a higher BMI than outpatients. Therefore, in this Chapter it was expected that adjustment for 
age and BMI would demonstrate elevated IM levels in outpatients compared to controls. It was 
also considered that a different pattern of IM change may occur between patients undertaking 
pharmacological, multidisciplinary treatment and those having (mainly) non-pharmacological, 
psychological therapy.  
 
 
5.3 Methods  
We undertook an exploratory analysis of IM levels between all participants from Studies 2 and 3 
(Chapters 3 and 4) at pre- and post-treatment: N = 247. This is intended as a cursory comparison; 
for further detail regarding participant and inflammatory marker characteristics, see respectively 
Chapters 3 and 4.   
 
In this cross-study exploration, IM data were pooled from TRD inpatients at pre-treatment (n = 
36) and post-treatment (n = 29), depressed outpatients at pre-therapy (n = 96) and post-therapy 
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(n = 50), and non-depressed controls (n = 36) at one time point only. All fully detected IMs across 
studies were assessed (n = 20).  
 
The data cleaning methodologies are detailed in Chapter 3 and 4; similarly here a bootstrap of 
1000 resamples was applied to analyses.  
Firstly, a multinomial logistic regression was used to compare inflammation between controls, 
inpatients and outpatients, adjusting for age, gender and BMI. Because the inpatients and controls 
were directly compared in Study 2, the outpatient depressed group was included as the reference 
category; only outpatient versus control and outpatient versus inpatient comparisons are reported 
in tables. This multinomial regression was conducted with both patients’ pre- and post-treatment 
measurements. Only the regression results adjusting for age, gender and BMI are focused on 
(unadjusted regression analyses are not corrected for multiple comparisons), although 
unadjusted analyses are also reported in text where unadjusted p < 0.05 but adjusted p > 0.05), 
since age in particular was so much higher in Study 2 than Study 3 and this is likely to have led 
to increased IM levels.  
Secondly, a logistic regression assessed whether treatment response (DV) was predicted by 
inflammation (IV) and whether this differed between studies (covariate), both testing pre-
treatment and post-treatment IM levels. 
Finally, we conducted a 2x2x2 mixed model repeated-measures ANOVA with two independent 
variables: group (inpatient versus outpatient) and response to treatment (responder versus non-
responder), to examine inflammatory changes over time between participants across studies, and 
treatment interventions.  
A Simes control for multiple comparisons was employed in order to reduce the likelihood of type 
I error, as in previous chapters. 
 
 
5.4 Results   
The age of outpatients (M = 37.59, SD = 12.64) was significantly higher than controls (M = 54.53, 
SD = 13.59) and inpatients (M = 54.56, SD = 14.31). Independent-samples t-tests confirmed this 
(outpatients versus controls: t(130) = 6.714, p < 0.001; outpatients versus inpatients: t(13) = 
6.619, p < 0.001). The proportion of male and female participants did not differ between studies. 
BMI was slightly higher in inpatients (M = 28.22, SD = 5.75) than outpatients (M = 25.92, SD = 
157 
 
6.63); t(127) = 1.834, p = 0.069. Controls (M = 28.17, SD = 6.63) demonstrated a comparable 
increase in BMI compared to outpatients; t(127) = 1.867, p = 0.064.  
Overall, 51% of patients responded to treatment (66 responders; 63 non-responders). These two 
groups did not differ in age, gender or BMI (all p > 0.05).  
 
As in previous chapters, the current findings are summarised and set out in Tables before the 
detailed results are discussed for each biomarker below. 
 
Results of the multinomial regressions between participant groups are displayed in Table 5.1 (pre-
treatment levels) and Table 5.2 (post-treatment levels). The tables detail the reference category 
of the dependent variable as outpatients (Study 3), in comparison with both controls and with 
inpatients (inpatients versus controls is focused on in Study 2, Chapter 3). Before treatment, 9 
IMs differed between outpatients and controls (all higher in outpatients; IL-8, IL-16, IL-7, IL-15, 
MCP1, MCP4, Eotaxin, TARC and IP-10). At this time point, outpatients additionally had higher 
levels of IL-7, IL-15, MCP1, Eotaxin, sICAM1 and sVCAM1, and lower IL-10, IL-8, IL-12 and IP-
10 than inpatients. After treatment, the only variations in findings were that IL-16 was no longer 
significantly higher in outpatients than controls but IL-17 now was, while Eotaxin was no longer 
higher in outpatient than inpatient participants. Results of the logistic regressions examining 
inflammation as a predictor of treatment response between studies are displayed in Table 5.3 
(pre- and post-treatment inflammation). This finds elevated TNFα, IL-6, CRP and sICAM1 at 
baseline to predict poorer subsequent treatment response. After treatment, CRP, MCP4, SAA 
and TARC are elevated in association with non-response. However the only effect to survive 
Simes control for multiple comparisons was the latter (high TARC in non-responders to 
psychological therapy). Table 5.4 outlines IM changes alongside treatment in relation to treatment 
response between studies (multi-factorial ANOVA analyses). Regardless of response or study 
(inpatient versus outpatient), levels of IL-10, IL-15, MCP1, sICAM1 and sVCAM1 increased during 
the treatment period. These effects were not strong or frequent enough to remain significant after 
Simes control for multiple comparisons. 
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lg-mean   SD   
 
Inpatients 
lg-mean    SD   
 
Controls 
lg-mean    SD   
 Outpatients vs. Controls  Outpatients vs. Inpatients 
r2 OR 
95% CI 
Lower  Upper   
p cor. p OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.319 0.113 0.370 0.188 0.376 0.163 0.372 6.300 -2.025 4.703 0.223 0.343 4.796 -2.613 5.105 0.433 0.541 
IL-6 -0.266 0.357 0.016 0.400 -0.140 0.315 0.386 0.509 -2.497 0.810 0.397 0.461 2.915 -0.818 3.129 0.252 0.360 
CRP 6.296 0.553 6.415 0.697 6.570 0.568 0.372 0.996 -0.781 0.827 0.991 0.991 0.622 -1.379 0.326 0.235 0.360 
IL-10 -0.703 0.358 -0.498 0.300 -0.641 0.408 0.421 3.189 -0.350 3.078 0.128 0.218 14.648 1.216 5.555 0.003 0.007 
*IL-8 0.965 0.173 1.348 0.592 0.935 0.176 0.505 0.039 -6.952 -0.996 0.012 0.030 13.635 0.920 5.552 0.006 0.012 
IL-12 1.306 0.171 2.110 0.249 2.001 0.222 0.398 1.875 -1.016 2.364 0.432 0.480 12.665 0.755 4.990 0.002 0.006 
IL-7 1.967 0.251 1.142 0.183 1.165 0.222 0.448 0.010 -8.529 -1.863 0.002 0.006 0.006 -8.706 -2.915 0.001 0.004 
IL-15 0.443 0.116 0.341 0.135 0.319 0.093 0.543 0.014 -0.021 -0.010 0.001 0.004 0.008 -0.019 -0.007 0.001 0.004 
*IL-16 2.327 0.168 2.352 0.219 2.228 0.168 0.417 0.016 -8.661 -1.037 0.014 0.031 0.694 -3.146 2.293 0.785 0.872 
IL-17 0.227 0.348 0.157 0.348 0.157 0.402 0.369 0.535 -2.071 0.591 0.300 0.376 0.535 -1.916 0.593 0.311 0.415 
MCP1 2.464 0.162 2.313 0.159 2.406 0.188 0.535 0.017 -1.180 -0.311 0.002 0.006 0.050 -0.159 -0.071 0.001 0.004 
*MCP4 2.176 0.208 2.135 0.252 1.800 0.222 0.604 0.029 -1.292 -0.624 0.001 0.004 0.202 -4.027 0.719 0.115 0.209 
Mip1b 2.118 0.187 2.129 0.298 2.083 0.153 0.368 0.542 -3.265 1.558 0.544 0.573 1.760 -2.681 3.485 0.738 0.872 
*Eotaxin 2.312 0.215 2.252 0.166 1.969 0.179 0.682 0.007 -0.259 -0.114 0.001 0.004 0.017 -8.007 -1.638 0.003 0.007 
*sICAM1 5.693 0.107 5.577 0.134 5.824 0.267 0.523 7.191 -1.893 5.923 0.263 0.376 0.001 -12.767 -4.975 0.001 0.004 
*sVCAM1 5.780 0.091 5.602 0.128 5.905 0.289 0.589 14.213 -1.084 6.502 0.131 0.218 0.002 -18.649 -7.066 0.001 0.004 
SAA 6.514 0.384 6.671 0.719 6.826 0.516 0.372 1.647 -0.495 1.620 0.301 0.376 0.958 -1.195 0.978 0.932 0.932 
*TARC 2.500 0.265 2.464 0.336 2.282 0.237 0.459 0.020 -6.510 -2.486 0.001 0.004 0.247 -3.680 0.718 0.157 0.262 
*Tie2 3.665 0.187 3.666 0.080 3.577 0.123 0.411 0.016 -10.657 -1.231 0.028 0.056 1.410 -3.600 4.110 0.843 0.887 
*IP-10 2.347 0.203 2.533 0.206 2.200 0.166 0.568 0.006 -9.447 -3.234 0.001 0.004 94.135 2.080 8.664 0.002 0.006 
 
Results of multinomial regression (reference category, outpatients) of inflammation (IV) in Outpatient versus Control and Outpatient versus Inpatient groups (DV) before patients 
underwent treatment. Bold IM names and p values indicate significant effects. Age also contributed significantly to all models (all < 0.01); neither gender or BMI contributed significantly 
to any model. 
* significantly different between inpatients and controls at corrected p < 0.05 when adjusted for age, gender and BMI. All higher in inpatients than controls except lower sICAM1 and 
sVCAM1. 
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence 
intervals, p = uncorrected p, before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.   
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lg-mean   SD   
 
Inpatients 
lg-mean    SD   
 
Controls 
lg-mean    SD   
 Outpatients vs. Controls  Outpatients vs. Inpatients 
r2 OR 
95% CI 
Lower  Upper   
p cor. p OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.315 0.114 0.413 0.182 0.376 0.163 0.367 8.904 -1.556 6.038 0.194 0.323 39.746 -0.050 8.051 0.042 0.084 
*IL-6 -0.219 0.314 0.040 0.323 -0.140 0.315 0.380 0.433 -2.645 0.904 0.310 0.413 4.570 -0.735 4.468 0.183 0.273 
CRP 6.326 0.563 6.452 0.582 6.570 0.568 0.347 0.996 -1.076 1.040 0.991 0.991 0.642 -1.772 0.557 0.401 0.471 
IL-10 -0.621 0.279 -0.376 0.278 -0.641 0.408 0.457 2.370 -1.252 2.974 0.364 0.455 54.080 1.805 9.618 0.006 0.013 
*IL-8 1.037 0.149 1.562 0.695 0.935 0.176 0.601 0.014 -9.289 -1.478 0.014 0.035 26.607 1.502 6.765 0.003 0.009 
*IL-12 1.379 0.159 2.139 0.217 2.001 0.222 0.408 1.751 -1.974 3.255 0.607 0.674 52.247 1.113 7.717 0.004 0.010 
IL-7 1.958 0.223 1.179 0.219 1.165 0.222 0.530 0.000 -13.798 -5.732 0.001 0.003 0.000 -13.173 -5.519 0.001 0.004 
IL-15 0.499 0.113 0.348 0.127 0.319 0.093 0.670 0.002 -0.054 -0.019 0.001 0.003 0.029 -0.054 -0.016 0.001 0.004 
*IL-16 2.312 0.152 2.353 0.206 2.228 0.168 0.401 0.027 -8.445 0.048 0.054 0.108 1.778 -2.741 3.874 0.703 0.740 
IL-17 0.302 0.321 0.208 0.274 0.157 0.402 0.379 0.149 -4.265 -0.321 0.021 0.047 0.219 -3.434 0.085 0.047 0.086 
MCP1 2.496 0.189 2.397 0.171 2.406 0.188 0.472 0.002 -12.404 -3.891 0.001 0.003 0.001 -13.108 -3.982 0.001 0.004 
*MCP4 2.189 0.188 2.217 0.228 1.800 0.222 0.693 0.003 -2.046 -0.745 0.001 0.003 0.237 -6.711 2.415 0.424 0.471 
*Mip1b 2.116 0.150 2.190 0.221 2.083 0.153 0.383 0.150 -5.463 1.490 0.213 0.328 8.108 -1.397 6.163 0.191 0.273 
*Eotaxin 2.332 0.227 2.334 0.223 1.969 0.179 0.704 0.006 -0.219 -0.973 0.001 0.003 0.126 -5.771 1.132 0.145 0.242 
*sICAM1 5.711 0.114 5.607 0.159 5.824 0.267 0.480 2.098 -3.722 4.256 0.664 0.699 0.002 -12.192 -2.750 0.001 0.004 
*sVCAM1 5.797 0.101 5.623 0.145 5.905 0.289 0.552 3.964 -2.577 4.832 0.439 0.517 0.003 -15.972 -5.196 0.001 0.004 
SAA 6.497 0.435 6.661 0.539 6.826 0.516 0.357 2.051 -0.698 2.295 0.309 0.413 0.967 -1.641 1.408 0.952 0.952 
*TARC 2.548 0.318 2.537 0.336 2.282 0.237 0.507 0.007 -9.046 -3.238 0.001 0.003 0.224 -4.788 1.101 0.228 0.304 
*Tie2 3.634 0.227 3.684 0.084 3.577 0.123 0.398 0.050 -8.489 -0.018 0.125 0.227 8.674 -1.901 6.493 0.271 0.339 
*IP-10 2.350 0.166 2.578 0.164 2.200 0.166 0.665 0.001 -16.438 -4.516 0.001 0.003 845.100 3.045 13.604 0.002 0.007 
 
Results of multinomial regression (reference category, outpatients) of inflammation (IV) in Outpatient versus Control and Outpatient versus Inpatient groups (DV) after patients underwent 
treatment. Bold IM names and p values indicate significant effects. Age also contributed significantly to all models (all < 0.01); neither gender or BMI contributed significantly to any 
model. 
* significantly different between inpatients and controls at corrected p < 0.05 when adjusted for age, gender and BMI. All higher in inpatients than controls except lower sICAM1 and 
sVCAM1. 
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence 









Pre-treatment   Post-treatment  
r2 OR 
95% CI 
Lower  Upper   
p cor. p r2 OR 
95% CI 
Lower  Upper   
p cor. p 
TNFα 0.095 0.014 -7.760 -1.469 0.007 0.090 0.018 0.226 -5.708 2.312 0.414 0.637 
IL-6 0.049 0.304 -2.586 -0.173 0.037 0.240 0.068 0.214 -4.085 0.132 0.091 0.286 
CRP 0.043 0.555 -1.271 -0.042 0.048 0.240 0.137 0.288 -2.387 -0.396 0.008 0.080 
IL-10 0.019 0.530 -1.843 0.408 0.211 0.510 0.016 0.481 -2.576 0.958 0.376 0.627 
IL-8 0.023 0.483 -2.025 0.386 0.157 0.510 0.017 0.623 -2.624 0.518 0.487 0.649 
IL-12 0.005 1.074 -1.563 1.518 0.921 0.921 0.013 2.154 -2.205 2.775 0.461 0.649 
IL-7 0.019 3.337 -0.778 3.569 0.255 0.510 0.018 0.301 -4.451 1.564 0.343 0.624 
IL-15 0.018 5.457 -1.179 4.742 0.247 0.510 0.010 0.292 -6.389 2.982 0.563 0.662 
IL-16 0.005 0.833 -2.274 1.969 0.853 0.898 0.005 0.666 -3.669 2.272 0.767 0.852 
IL-17 0.010 1.462 -0.670 1.404 0.463 0.625 0.004 1.038 -1.347 1.685 0.953 0.953 
MCP1 0.010 0.466 -3.219 1.620 0.500 0.625 0.028 0.207 -5.848 1.109 0.339 0.624 
MCP4 0.005 0.814 -2.081 1.261 0.798 0.887 0.082 0.073 -6.324 -0.005 0.046 0.245 
Mip1b 0.011 0.531 -2.740 1.037 0.488 0.625 0.010 2.224 -1.747 3.905 0.538 0.662 
Eotaxin 0.005 0.781 -2.169 1.434 0.756 0.887 0.005 1.240 -2.503 2.769 0.844 0.888 
sICAM1 0.077 0.013 -7.750 -1.333 0.009 0.090 0.055 0.044 -8.058 0.740 0.100 0.286 
sVCAM1 0.021 0.106 -5.973 0.921 0.194 0.510 0.060 0.025 -8.935 0.383 0.080 0.286 
SAA 0.010 0.775 -1.054 0.454 0.498 0.625 0.075 0.351 -2.728 -0.140 0.049 0.245 
TARC 0.012 0.583 -1.921 0.754 0.359 0.625 0.127 0.110 -4.033 -0.872 0.001 0.020 
Tie2 0.033 0.151 -5.527 0.468 0.194 0.510 0.032 0.171 -7.393 0.840 0.303 0.624 
IP-10 0.012 0.482 -2.904 0.976 0.429 0.625 0.045 0.105 -6.100 0.785 0.159 0.398 
 
Results of logistic regressions of inflammation (IV) on responder versus non-responder group (DV) before 
and after treatments. Bold IM names and p values indicate significant effects. These were adjusted for study 
group (inpatients versus outpatients), which did not affect any IM effects. 
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 






Table 5.4   IM changes over time in responders and non-responders 
 
IM 
Before versus after 
treatment 
Treatment x response 
interaction 
Treatment x study 
interaction 
 F p cor. p F p cor. p F p cor. p 
TNFα 0.266 0.608 0.793  3.511 0.065  0.644 0.413 0.522  0.947 
IL-6 0.017 0.897  0.897 0.513 0.476  0.793 0.024 0.877  0.974 
CRP 0.491 0.486 0.697 0.128 0.722 0.849 0.766 0.384  0.947 
IL-10 8.667 0.004 0.053 0.055 0.815 0.906 1.560 0.215  0.937 
IL-8 2.261 0.137 0.343 1.066 0.305 0.700 0.001 0.974  0.974 
IL-12 0.685 0.410 0.697 .212 0.646 0.849 0.058 0.811  0.954 
IL-7 2.637 0.109 0.311 0.947 0.334 0.700 1.535 0.219  0.937 
IL-15 8.022 0.006 0.053 0.882 0.351 0.700 1.249 0.267  0.937 
IL-16 0.228 0.634 0.793 0.009 0.926 0.975 0.085 0.771  0.954 
IL-17 3.807 0.055 0.183 2.526 0.116 0.644 0.370 0.545  0.947 
MCP1 7.357 0.008 0.053 1.202 0.277 0.700 0.466 0.497  0.947 
MCP4 0.592 0.444 0.697 0.142 0.708 0.849 0.249 0.619  0.952 
Mip1b 0.046 0.831 0.891 2.519 0.117 0.644 0.080 0.778  0.954 
Eotaxin 1.100 0.298 0.662 2.005 0.161 0.644 0.329 0.568  0.947 
sICAM1 4.875 0.030 0.150 0.318 0.574 0.849 3.256 0.075  0.937 
sVCAM1 4.445 0.038 0.152 1.095 0.299 0.700 0.006 0.938  0.974 
SAA 0.038 0.846 0.891 0.764 0.385 0.700 1.180 0.281  0.937 
TARC 0.133 0.717 0.844 .174 0.678 0.849 0.092 0.762  0.954 
Tie2  0.486 0.488 0.697 2.021 0.159 0.644 0.352 0.555  0.947 
IP-10 0.756 0.387 0.697 0.000 0.986 0.986 1.423 0.237  0.937 
 
Results of 2x2x2 mixed-factorial ANOVA comparing IM changes over time (pre- to post-treatment) between 
responders and non-responders, and between Study 2 and 3. The before vs. after treatment column 
describes the main effect of IM over time points; the Treatment x response interaction column describes the 
effect of response status on inflammatory change over time; Treatment x study interaction column describes 
the effect of study group on inflammatory change (n = 79). Bold IM names and p values indicate significant 
effects.  
F = ANOVA test statistic (degrees of freedom 1, 75), p = uncorrected p, before Simes control for multiple 




 TNFα  
Prior to adjustment for age, gender and BMI, TNFα was lower in outpatients than controls before 
(OR = 16.601, p = 0.044) and after (OR = 21.721, p = 0.039) treatment. However, these effects 
did not survive adjustment for age, gender and BMI or Simes cor. After treatment, TNFα was also 
lower in outpatients than inpatients in unadjusted regression (OR = 91.102, p = 0.004), but not 
when adjusting for age, gender and BMI when Simes multiple comparisons control was applied 
(OR = 39.746, p = 0.042, corrected p = 0.084). Elevated pre-treatment TNFα was predictive of 
treatment non-response when adjusting for study group (OR = 0.014, p = 0.007), although it did 
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Figure 5.1   TNFα in responder and non-responder patients 
 
Log transformed mean values of TNFα are presented, significantly higher in non-responder than responder 
participants before treatment (p = 0.007), not different between studies, or after treatment. Error bars represent 
standard error of the mean (SEM). Log values for pre-treatment: Inpatient non-responder mean = 0.427, SEM = 
0.067, n = 16; Inpatient responder mean = 0.325, SEM = 0.041, n = 20; Outpatient non-responder mean = 0.348, 
SEM = 0.016, n = 49; Outpatient responder mean = 0.289, SEM = 0.016, n = 47. After treatment Inpatient non-
responder mean = 0.426, SEM = 0.065, n = 12; Inpatient responder mean = 0.404, SEM = 0.037, n = 17; Outpatient 




IL-6 was significantly higher in TRD inpatients than outpatients before adjustment for age, gender 
and BMI at pre-treatment (OR = 12.872, p = 0.001) and post-treatment (OR = 18.543, p = 0.001). 
These were not significant in the adjusted analyses (see Tables 5.1 and 5.2). At post-treatment, 
IL-6 was somewhat higher in inpatients than controls (see Chapter 3). While not significant after 
controlling for multiple comparisons, higher IL-6 before treatment predicted non-response (OR = 
0.304, p = 0.037, corrected p = 0.240), when adjusting for inpatient versus outpatient group; see 
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 Figure 5.2   IL-6 levels in responder and non-responder patients 
 
Log transformed mean values of IL-6 are presented, significantly higher in non-responder than responder 
participants before treatment (p = 0.037), not different between studies, or after treatment. Error bars 
represent standard error of the mean (SEM). Note that a value of 1 has been added to IM data in the graph 
for clarity. Log values for pre-treatment: Inpatient non-responder mean = 0.035, SEM = 0.128, n = 16; 
Inpatient responder mean = 0.000, SEM = 0.093, n = 20; Outpatient non-responder mean = -0.170, SEM = 
0.040, n = 49; Outpatient responder mean = -0.318, SEM = 0.042, n = 47. After treatment Inpatient non-
responder mean = 0.044, SEM = 0.090, n = 12; Inpatient responder mean = 0.037, SEM = 0.082, n = 17; 
Outpatient non-responder mean = -0.079, SEM = 0.070, n = 18; Outpatient responder mean = -0.298, SEM 




Before adjustment for age, gender and BMI, outpatients had significantly lower CRP than controls 
before therapy (OR = 2.211, p = 0.016), but not after adjusting for these factors. High CRP at pre-
treatment slightly predicted non-response (OR = 0.555, p = 0.048, corrected p = 0.240); the 
association between CRP and response was stronger at post-treatment (OR = 0.288, p = 0.008, 
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 Figure 5.3   CRP levels in responder and non-responder patients 
  
Log transformed mean values of CRP are presented, significantly higher in non-responder than responder 
participants before treatment (p = 0.048) and after treatment (p = 0.008), not different between studies. Error bars 
represent standard error of the mean (SEM). Note that axes have been cut according to IM levels expressed to depict 
differences clearly. Log values for pre-treatment: Inpatient non-responder mean = 6.548, SEM = 0.201, n = 16; 
Inpatient responder mean = 6.309, SEM = 0.162, n = 20; Outpatient non-responder mean = 6.388, SEM = 0.008, n 
= 49; Outpatient responder mean = 6.201, SEM = 0.079, n = 47. After treatment Inpatient non-responder mean = 
6.610, SEM = 0.162, n = 12; Inpatient responder mean = 6.341, SEM = 0.143, n = 17; Outpatient non-responder 
mean = 6.599, SEM = 0.134, n = 18; Outpatient responder mean = 6.172, SEM = 0.089, n = 32. 
 
 
  IL-10 
Pre-treatment IL-10 was higher in inpatients than outpatients (OR = 14.648, p = 0.003, corrected 
p = 0.007) and post-treatment findings were comparable (OR = 54.080, p = 0.006, corrected p = 
0.013). IL-10 was also higher in inpatients than controls after treatment (Chapter 3). See Figure 
5.4 for IL-10 levels across participant groups and time points. The mixed-model ANOVA 
demonstrated an increase in IL-10 over time, although this was not significant after control for 
multiple comparisons (F(1,75) = 8.667, p = 0.004, corrected p = 0.053). This increase did not 
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Figure 5.4   IL-10 levels in all participants before and after treatment 
 
Log transformed mean values of IL-10 are presented, higher in inpatients than outpatients or controls. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 
the mean (SEM). Note that a value of 1 has been added to IM data in the graph for clarity. Log values for IL-




Marked elevations were observed in TRD inpatients than outpatients at pre-treatment (OR = 
13.635, p = 0.006, corrected p = 0.012) and post-treatment (OR = 26.607, p = 0.003, corrected p 
= 0.009). IL-8 was higher in outpatients than controls also before (OR = 0.039, p = 0.012, 
corrected p = 0.030) and after (OR = 0.014, p = 0.014, corrected p = 0.035) treatment. The even 
stronger inpatient elevations of IL-8 compared to controls are detailed in Chapter 3, and see also 
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Figure 5.5   IL-8 levels in all participants before and after treatment  
 
Log transformed mean values of IL-8 are presented, higher in inpatients than outpatients or controls. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 




  IL-12 
Pre-treatment IL-12 levels in the TRD inpatients were higher than outpatients (OR = 12.665, p = 
0.002, corrected p = 0.006), and these effects were similar after treatment (OR = 52.247, p = 
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Figure 5.6   IL-12 levels in all participants before and after treatment 
 
Log transformed mean values of IL-12 are presented, higher in inpatients than outpatients or controls. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 




IL-7 was higher in outpatients than other participants: in comparison with controls at pre-treatment 
(OR = 0.010, p = 0.002, corrected p = 0.006) and post-treatment (OR = 0.0002, p = 0.001, 
corrected p = 0.003), and compared to inpatients also before (OR = 0.006, p = 0.001, corrected 
p = 0.004) and after (OR = 0.0002, p = 0.001, corrected p = 0.004) treatment. See Figure 5.7 for 
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 Figure 5.7   IL-7 levels before and after treatment in all participants 
 
Log transformed mean values of IL-7 are presented, higher in outpatients than inpatients or controls. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 




Both before and after therapy outpatients had higher levels of IL-15 than other groups. Before 
treatment IL-15 was higher in outpatients than controls (OR = 0.014, p = 0.001, corrected p = 
0.004) and elevations in outpatients compared to inpatients were similarly significant (OR = 0.008, 
p = 0.001, corrected p = 0.004). After treatment, outpatients had comparably higher IL-15 than 
controls (OR = 0.002, p = 0.001, corrected p = 0.003) and inpatients (OR = 0.029, p = 0.001, 
corrected p = 0.004); see Figure 5.8. During treatment, an overall increase was found in IL-15 
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  Figure 5.8   IL-15 levels before and after treatment in all participants 
 
Log transformed mean values of IL-15 are presented, higher in outpatients than inpatients or controls. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 





Inpatients had higher IL-16 than controls at both time points (see Chapter 3) but inpatient and 
outpatient levels of this cytokine did not differ from one another. Outpatients also had higher IL-
16 than controls, both before treatment (OR = 0.016, p = 0.014, corrected p = 0.031) and to a 
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Figure 5.9   IL-16 levels before and after treatment in all participants 
 
Log transformed mean values of IL-16 are presented, higher in inpatients than outpatients or controls. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 
the mean (SEM). Note that axes have been cut according to IM levels expressed to depict differences clearly. 




Only when adjusting for age, gender and BMI, post-treatment IL-17 was elevated in outpatients 
compared to controls (OR = 0.149, p = 0.021, corrected p = 0.047) and to some extent in 
outpatients compared to inpatients (OR = 0.219, p = 0.047, corrected p = 0.086). 
 
 MCP1 
As detailed in Chapter 3, inpatients had lower MCP1 before treatment than controls. Inpatients’ 
MCP1 was also lower than outpatient levels at pre-treatment (OR = 0.050, p = 0.001, corrected p 
= 0.004) and outpatients had higher MCP1 than controls (OR = 0.017, p = 0.002, corrected p = 
0.006). At post-treatment, outpatients also had higher MCP1 than both inpatients (OR = 0.001, p 
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= 0.001, corrected p = 0.004) and controls (OR = 0.002, p = 0.001, corrected p = 0.003). MCP1 
increased during treatment, across inpatients and outpatient samples (F(1,75) = 7.357, p = 0.008, 
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Figure 5.10   MCP1 levels before and after treatment in all participants 
 
Log transformed mean values of MCP1 are presented, lower in inpatients and higher in outpatients than 
controls. Time 1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent 
standard error of the mean (SEM). Note that axes have been cut according to IM levels expressed to depict 




Inpatient (see Chapter 3) and outpatient levels both were significantly and consistently higher 
than controls; for outpatients at pre-treatment (OR = 0.029, p = 0.001, corrected p = 0.004) and 
post-treatment (OR = 0.003, p = 0.001, corrected p = 0.003). Inpatient and outpatient levels did 
not significantly differ (Figure 5.11). Non-responders had higher MCP4 after treatment, which was 
not affected by inpatient versus outpatient study, but was not statistically significant after control 
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 Figure 5.11   MCP4 levels before and after treatment in all participants 
 
Log transformed mean values of MCP4 are presented, lower in controls than inpatients or outpatients. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 
the mean (SEM). Note that axes have been cut according to IM levels expressed to depict differences clearly. 




No comparisons yielded significant results.  
 
 Eotaxin 
Depressed participants consistently and significantly had higher levels of Eotaxin than non-
depressed controls. See Chapter 3 for inpatient versus control comparisons. Outpatients had 
higher levels of Eotaxin than controls before treatment (OR = 0.007, p = 0.001, corrected p = 
0.004) and after treatment (OR = 0.006, p = 0.001, corrected p = 0.003). Outpatients also had 
higher levels than inpatients before treatment, only when adjusting for age, gender and BMI (OR 
= 0.017, p = 0.003, corrected p = 0.007) but after treatment Eotaxin did not differ between 
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 Figure 5.12   Eotaxin levels before and after treatment in all participants 
 
Log transformed mean values of Eotaxin are presented, lower in controls than inpatients or outpatients. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 
the mean (SEM). Note that axes have been cut according to IM levels expressed to depict differences clearly. 




As displayed in Figure 5.13, at both time points TRD patients had the lowest levels and controls 
the highest levels of sICAM1. Attenuations in inpatients compared to controls (see Chapter 3) and 
outpatients were large. Outpatients had higher sICAM1 than inpatients before (OR = 0.001, p = 
0.001, corrected p = 0.004) and after treatment (OR = 0.002, p = 0.001, corrected p = 0.004). 
Controls had significantly higher sICAM1 than outpatients only in unadjusted regressions (pre-
treatment OR = 77.511, p = 0.003; post-treatment OR = 18.499, p = 0.013). High baseline sICAM1 
predicted subsequent non-response: OR = 0.013, p = 0.009, corrected p = 0.090. Across both 
studies, sICAM1 was found to increase alongside treatment (F(1,75) = 4.875, p = 0.030, corrected 
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 Figure 5.13   sICAM1 levels before and after treatment in all participants 
  
Log transformed mean values of sICAM1 are presented, higher in controls than outpatients or inpatients (the 
latter particularly low). Time 1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars 
represent standard error of the mean (SEM). Note that axes have been cut according to IM levels expressed 




Findings for sVCAM1 are highly similar to sICAM1 (see Figure 5.14). Before starting treatment, 
outpatients had higher sVCAM1 than inpatients (OR = 0.002, p = 0.001, corrected p = 0.004) and 
this remained after treatment (OR = 0.003, p = 0.001, corrected p = 0.004). Outpatient levels were 
lower than controls’, only significant in unadjusted regression (pre-treatment OR = 58.828, p = 
0.002; post-treatment OR = 15.191, p = 0.018). The mixed model ANOVA found that sVCAM1 
increased over time, regardless of study or treatment response (F(1,75) = 4.445, p = 0.038, 
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  Figure 5.14   sVCAM1 levels before and after treatment in all participants 
 
Log transformed mean values of sVCAM1 are presented, higher in controls than outpatients or inpatients (the latter 
particularly low). Time 1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent 
standard error of the mean (SEM). Note that axes have been cut according to IM levels expressed to depict 







Non-depressed controls had significantly higher levels of SAA than outpatients, that did not 
survive adjustment for age, gender and BMI, at both pre-therapy (unadjusted OR = 3.284, p = 
0.002) and post-therapy (unadjusted OR = 4.035, p = 0.007). SAA levels were slightly higher in 
non-responders after treatment (OR = 0.351, p = 0.049, corrected p = 0.245).   
  
 TARC 
TARC was higher in both depressed than control groups at both time points (Figure 5.15). See 
Chapter 3 for inpatient versus control statistics. The elevation of TARC in outpatients compared 
to controls was similar before therapy (OR = 0.02, p = 0.001, corrected p = 0.004) and afterwards 
(OR = 0.007, p = 0.001, corrected p = 0.003). Across inpatient and outpatient studies, non-
responders had higher levels of TARC after treatment (OR = 0.110, p = 0.001, corrected p = 
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Figure 5.15   TARC levels before and after treatment in all participants 
 
Log transformed mean values of TARC are presented, lower in controls than outpatients or inpatients. Time 
1 = pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of 
the mean (SEM). Note that axes have been cut according to IM levels expressed to depict differences clearly. 
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 Figure 5.16   TARC levels in responder and non-responder patients 
 
Log transformed mean values of TARC are presented, significantly higher in non-responder than responder 
participants only after treatment (p = 0.001), not different between studies. Error bars represent standard 
error of the mean (SEM). Note that axes have been cut according to IM levels expressed to depict differences 
clearly. Log values for pre-treatment: Inpatient non-responder mean = 2.471, SEM = 0.063, n = 16; Inpatient 
responder mean = 2.459, SEM = 0.056, n = 20; Outpatient non-responder mean = 2.526, SEM = 0.042, n = 
49; Outpatient responder mean = 2.472, SEM = 0.033, n = 47. After treatment Inpatient non-responder mean 
= 2.582, SEM = 0.072, n = 12; Inpatient responder mean = 2.505, SEM = 0.036, n = 17; Outpatient non-




Inpatients had higher levels of Tie2 than controls at both time points (Chapter 3). Outpatients had 
higher levels than controls, only before treatment (OR = 0.016, p = 0.028, corrected p = 0.056); 
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Figure 5.17   Tie2 levels before and after treatment in all participants  
 
Log transformed mean values of Tie2 are presented, lower in controls than outpatients or inpatients. Time 1 
= pre-treatment or control measurement; Time 2 = post-treatment. Error bars represent standard error of the 
mean (SEM). Note that axes have been cut according to IM levels expressed to depict differences clearly. 






IP-10 was elevated in both depressed groups compared to controls (see Chapter 3 for 
comparisons between inpatients and controls and Figure 5.18 for group differences depicted). 
Before treatment, outpatients had higher levels than controls (OR = 0.006, p = 0.001, corrected p 
= 0.004) and inpatients had higher levels still compared to outpatients (OR = 94.135, p = 0.002, 
corrected p = 0.006). After treatment, outpatient levels remained higher than controls (OR = 0.001, 
p = 0.001, corrected p = 0.003) and lower than inpatients (OR = 845.100, p = 0.002, corrected p 
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 Figure 5.18   IP-10 levels before and after treatment in all participants 
 
Log transformed mean values of IP-10 are presented, lower in controls than outpatients or inpatients 
(particularly high in inpatients). Time 1 = pre-treatment or control measurement; Time 2 = post-treatment. 
Error bars represent standard error of the mean (SEM). Note that axes have been cut according to IM levels 







Out of 20 inflammatory markers measured, we find that ten are higher in outpatients than non-
depressed controls (at least one measurement time point), when adjusting for covariates. Twelve 
IMs differ between outpatients and inpatients, with five higher in Chapter 3 inpatients (IL-8, IL-10, 
IL-12, IP-10, IL-16) and seven higher in Chapter 4 outpatients than inpatients (IL-7, IL-15, MCP1, 
sICAM1, sVCAM1, Eotaxin and TARC). Three markers not significant in these comparisons are 
yielded as significant predictors of treatment response; high pre-treatment IL-6, TNFα and CRP 
(in addition to sICAM1) are all found in subsequent non-responders. TARC and CRP, and to a 
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lesser extent SAA and MCP4, are all higher after treatment in non-responders. This appears after 
an increase in IL-15, IL-10, MCP1, sVCAM1 and sICAM1 during treatment. It is of note that 
inpatient versus outpatient study does not affect the inflammatory predictors of response (either 
prospective or cross-sectional associations), and that study does not interact with changes over 
time. This is despite clear differences between inpatient and outpatient populations studied, 
particularly regarding their treatments undertaken. It was unfortunate that we could not account 
for medication use or physical health status in these cross-study comparisons. For controls, there 
were available limited notes regarding their physical health indicating that many experienced 
physical conditions and were taking medication. However, the available data were not sufficient 
to include these factors in the present analyses.  
 
Although these findings are expanded upon below in Chapter 6, in the context of all findings 
observed in this thesis and the pre-existing literature, it is important to note that the analyses 
conducted here in Chapter 5 compare completely separate studies, including different participant 
characteristics that could not all be accounted for. There was not an overwhelming preponderance 
of inflammatory elevations in one study compared to the other, which could indicate some 
credibility to the comparisons undertaken. Similar cytokines were poorly detected in both studies, 
although more non-detected values were yielded from Study 3 than Study 2. Due to the reduced 
validity of combining imputed undetected IM data across both studies, in addition to the 
aforementioned limitation of comparing between separate studies, it was considered insufficiently 
informative to also examine inflammatory markers that were undetected in this cross-study 
comparison. However, this does exclude some potentially important markers including those with 
promise reported separately in previous chapters, such as Eotaxin-3 and IFNγ.  
 
The following chapter considers the above points further, gathering together the complete findings 
from Studies 1 to 3 along with the limitations and strengths of these studies, the implications of 





This project aimed to evaluate and utilise the current evidence that has accumulated associating 
depression and inflammation, such that this path of research can progress into translational uses 
to improve clinical outcomes in depressive illnesses. Firstly, the meta-analysis (Chapter 2) 
incorporated existing evidence of proteomic inflammatory biomarkers in association with 
treatment response. Findings were highly heterogeneous and few studies investigated 
depression that was treatment-resistant or was systematically treated with psychological therapy. 
These domains were addressed in Chapters 3 and 4 (Studies 2 and 3) which addressed 
heterogeneity through the measurement of potential modifiers of inflammation and response. 
Finally, an exploratory comparison of group data between Studies 2 and 3 was undertaken (see 
Chapter 5).  
 
The most robust and interesting findings from this series of studies pertain to the consistent link 
between treatment response and the most commonly used inflammatory markers; IL-6, TNFα 
and CRP. Additionally, findings in this thesis characterise novel inflammatory biomarkers that 
appear elevated in both depressed groups than non-depressed controls; TARC, Tie2 and 
Eotaxin-3).   
 
 
6.1 Interpretation of findings 
 Inflammatory aberrations in depressed versus control samples 
Most of the inflammatory markers studied are different between the three populations recruited in 
the latter two studies, generally higher in depressed than control groups. These findings will be 
interpreted by biomarker type.  
 
  
6.1.1.1 Pro-inflammatory cytokines  
Meta-analyses have reliably found IL-6 to be higher in depression (Haapakoski et al. 2015), 
replicated in Study 1 and Study 2 inpatients who have slightly elevated levels compared to 
matched controls and non-matched depressed outpatients. Hiles et al. (2012a) have suggested 
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that IL-6 is modified by the recruitment of patients from hospital settings in MDD studies, which 
may relate to the increased levels of IL-6 in TRD patients, in contrast with similar markers such 
as TNFα. TNFα has often been reported as higher in depression, including in Study 1 meta-
analysis, but is non-significantly higher in inpatients than outpatients and controls when 
accounting for the effects of age.  
Many IMs are higher in inpatients than other groups, including IL-12 whose elevations in TRD are 
more pronounced when compared to outpatients than controls, and is modestly correlated with 
treatment-resistance in Chapter 3. These results generally align with previous reports of IL-12 
(Lee and Kim 2006, Sutcigil et al. 2007) although the role of treatment-resistance in this 
relationship is not established. IL-12 and IL-16 both have effects on CD4 T-cells and demonstrate 
similar elevations in inpatients, although IL-16 is similarly elevated in outpatients and inpatients 
than controls. IFNγ, expected to be associated with IL-12 in particular, is only minimally higher in 
TRD patients than controls. In past research, IFNγ has been indicated as elevated (Simon et al. 
2008, Gabbay et al. 2009, Dahl et al. 2014), similar (Marques-Deak et al. 2007, Einvik et al. 2012) 
or attenuated (Kim et al. 2008, Kiecolt-Glaser et al. 2011) in depression. Mendlovic et al. (1999) 
suggest that suicidal ideation may influence cytokine levels, with non-suicidal depression 
presenting with lower IFNγ than healthy controls. We did not measure suicidality as a single 
construct, only as a contributor to overall depression severity. Outpatients’ IFNγ levels were not 
compared with controls, but negative correlations with depression severity are observed in Study 
3 at both time points. Unlike IL-12 but like IFNγ, IL-12p70 does not appear significantly associated 
with depression status, possibly due to masked effects by imputation as a result of poor detection. 
This is also possible for IFNα.  
 
TNFβ suffered from some undetected datapoints but is found to be is attenuated in inpatient 
depressed participants in spite of being undetected in a larger number of controls than patients. 
This is potentially a state-alteration effect as no differences were found after treatment between 
TRD and control groups (when TNFβ was undetected less frequently), or it might be attributed to 
the inability to account for some of the true protein levels. Rates of non-detected TNFβ are greater 
in Study 2 (particularly non-depressed controls) than Study 3 outpatients (~15% as opposed to 
~8%), but mean TNFβ level appears higher in outpatients than other groups. One study has 
reported TNFβ levels as higher in major depression as measured post-mortem (Shelton et al. 
2011) but this study measured gene expression only in frontal cortex tissue and there are few 
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reports to compare these findings with. The other pro-inflammatory, but non-imputed, marker that 
is slightly higher in outpatients than either controls or inpatients is IL-17 and this is strongly 
correlated with TNFβ at pre-, but not post-treatment in both Study 2 and 3. These two markers 
are both produced by a variety of T-cells. One study has shown heightened IL-17 levels in patients 
(Chen et al. 2011) and another indicates that IL-17 might be a better marker of anxiety (Liu et al. 
2012b). The role of this cytokine in depression is as yet unknown, but it does not yield significant 
associations with any clinical or demographic variables in the current studies, and the reason for 
its elevated levels in outpatients are unclear.    
 
6.1.1.2 Chemokines  
IL-8 appears the most strongly elevated pro-inflammatory cytokine across studies, with inpatients 
possessing clearly the highest levels. While elevated IL-8 in depression has been noted 
previously (e.g. Mikova et al. 2001, Song et al. 2009, Eller et al. 2009) these findings have not 
survived meta-analyses (Eyre et al. 2016b). It has been hypothesised that IL-8 may be elevated 
in CNS but not peripheral depression; and we suggest that IL-8 could be related to an 
accumulative effect of depressive episodes as this chemokine not only is significantly higher in 
outpatients than controls and inpatients than outpatients, but also correlates with subsequent 
severity at long-term follow-up. 
IP-10 (CXCL10) functions similarly to IL-8 but is stimulated by IFNγ and attracts T-cells. The same 
pattern of results is found as with IL-8, in that TRD inpatients had markedly higher levels than 
outpatients who had elevated levels compared to controls. IP-10 has been compared between 
depression and control groups sporadically: in one study, this chemokine was non-significantly 
higher in depressed than non-depressed subjects (Simon et al. 2008) while Wong et al. (2008) 
reported significantly higher IP-10 in MDD which lowered with antidepressants. Together these 
findings implicate IP-10 and IL-8 as potential markers of more established depression or that 
which does not respond to treatments.  
Simon et al. (2008) identified further chemokine elevations in depression, which are replicated in 
the present findings including Eotaxin/CCL11 and Mip1a/CCL3; these have rarely been 
investigated in mood disorders. Similarly, we replicate sparse reports of elevated MCP4 (CCL13) 
in both depressed groups (Diniz et al. 2015). TARC (CCL17) has been reported as persistently 
reduced in suicide attempters, most of whom were not depressed (Janelidze et al. 2011) and 
Eotaxin-3 (CCL26) has shown elevated mRNA expression in euthymic bipolar disorder (Herberth 
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et al. 2011). Neither of these markers have yet been assessed in MDD or TRD populations. The 
CCL chemokines mentioned above all appear higher in both depressed than control groups, 
suggesting an increase in the expression of both innate and adaptive immune cells in depressive 
disorders. In contrast, Mip1b (CCL4) is only higher in inpatient than control groups. Mip1b is also 
correlated with treatment resistance in Study 2, and may be a protein which becomes 
overproduced only in refractory mood disorders.  
The only chemokine found to be strongly attenuated in depression is MCP1. Inpatients 
demonstrate lower levels of MCP1 than controls, and outpatients’ levels are higher than both 
Study 2 groups. Most previous research has identified high MCP1 in depression (Simon et al. 
2008, Sutcigil et al. 2007), but comparable levels (Einvik et al. 2012) and lower levels (Lehto et 
al. 2010) in depressed patients have also been reported. Low MCP1 has, in an investigation 
similar to Chapter 3, predicted non-response to inpatient treatment (Carvalho et al. 2013). 
Considering the functional closeness of MCP1 with MCP4 (and other CCL chemokines), this 
difference could be an important inflammatory marker in depression. It might be speculated that 
in some individuals with persistent depressive illnesses, MCP4 or other chemokine release is 
heightened as a compensatory effect of low MCP1.  
 
6.1.1.3 Acute phase proteins  
Supportive of previous meta-analyses (Howren et al. 2009, Dowlati et al. 2010), Study 1 (Chapter 
2) identifies elevated CRP (in addition to related pro-inflammatory cytokines TNFα and IL-6, and 
a composite of pro-inflammatory markers) in depression compared to controls. Studies 2 and 3 
indicate no differences between CRP and participant group status, though CRP is non-
significantly lower in outpatients and is positively correlated with age in both studies. It is likely 
that our selection of a control group derived from a large population sample (Hatch et al. 2011) or 
the matching of groups by age, gender and BMI contributes to reduced significance observed for 
biomarkers that are clearly associated with aging-related factors: age, physical illness severity 
and medication are frequently correlated with CRP, as well as IL-6 and TNFα across studies. The 
importance of these factors has been highlighted by Howren et al. (2009) and is expanded upon 
in Section 6.2.5. Throughout studies, SAA levels have unsurprisingly been correlated highly with 
CRP (as well as sICAM1 and IL-6), and results show the same pattern. SAA has rarely been 
examined in mood disorders, but in coronary syndromes might be a more sensitive predictor of 
outcome than CRP which is the current gold standard (Kosuge et al. 2007). Accordingly, Kling et 
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al. (2007) posit that SAA may be more strongly associated with depressive states than CRP, 
which is supported by our finding that SAA remains high in non-responders after psychological 
therapy.   
 
6.1.1.4 Pro-inflammatory signalling proteins  
Tie2 (tyrosine kinase-2) interacts with cytokines through, for instance, erythrocyte regulation 
(Silvennoinen et al. 1997) and antidepressants have uncertain effects on tyrosine activity (Porter 
et al. 2005). Tie2 has not previously been examined specifically in MDD, but in these studies 
emerges as higher in depressed than control groups, with inpatients possessing the highest 
levels. Interestingly, Tie2 is not inter-correlated with other IMs in Study 2; in Study 3, positive 
correlations are identified with a range of markers (IL-15, MCP1, MCP4, Eotaxin and sICAM1), 
many of which also function in facilitating transfer of inflammatory molecules across endothelial 
walls. Despite sharing signalling interactions with Tie2 and their supposed stimulation by TNFα 
(Hughes et al. 2000) as well as stress-induced GR increases (Haroon et al. 2012), other 
immunoglobulins sICAM1 and sVCAM1 appear attenuated in both depressed groups studied in 
this thesis. Previous findings have suggested high CAMs in mood disorders (Motivala et al. 2005, 
Parissis et al. 2009). While these two proteins are highly inter-related, they associate differentially 
with other variables between Chapters 3 and 4: neither are significantly related to potential 
modifying factors in the inpatient study and in outpatients, only sICAM1 significantly associates 
with many aging or illness-related factors. sICAM1 also more strongly correlates with other 
markers in the outpatient study than inpatients or than sVCAM1 (including CRP, SAA, TNFα, 
MCP1 and MCP4 which often are higher in older, more physically ill participants with a poorer 
quality of life). sICAM1 and sVCAM1 seem to act similarly to other pro-inflammatory proteins and 
yet are lower in depressed than non-depressed groups. As mentioned in Section 3.5.3), it is 
possible that these markers are instead highly active in the brain, but further research is required 
to address this uncertainty.  
  
6.1.1.5 Regulatory or anti-inflammatory cytokines   
In line with sparse previous findings (Simon et al. 2008), IL-15 and IL-7 appear elevated in 
outpatients compared to non-depressed controls when indirectly compared. However, inpatient 
levels appear comparable with controls. The two cytokines do not inter-correlate in either study, 
but in inpatients low levels of both independently predict depression severity after treatment (for 
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IL-15, only when accounting for TARC and IL-7 levels) and in outpatients both increase alongside 
a psychological treatment program. It is plausible that the overproduction of T-cells occurs in 
depressive episodes that are not treated with medication (such as in Study 3), but that in the 
longer-term T-cell development might be downregulated, in chronic mood disorders.    
IL-10 is a prominent cytokine- and inflammation-inhibitor but the literature contains similar 
inconsistent findings: differences between depressed and control groups have shown levels that 
were similar (Fornaro et al. 2013), reduced (Dhabhar et al. 2009) or elevated (Carvalho et al. 
2013) in depression. The latter study investigated medicated TRD inpatients, while Dhabhar et 
al. (2009) studied unmedicated patients. If psychotropic medication facilitates IL-10 increase this 
provides an explanation for the higher IL-10 found in TRD inpatients than other groups in this 
thesis, especially following more intensive treatment during admission, in conjunction with positive 
correlations identified between number of medications and IL-10 level. On the contrary, only 
unmedicated patients in Study 3 showed a rise in IL-10 (while for those taking antidepressants 
IL-10 reduced slightly). It is plausible that medications within specific pharmacological classes, at 
specific dosages or the duration of use might influence IL-10 levels more than the presence of 
depression. IL-10 differences across participant groups appear similar to those of the pro-
inflammatory cytokine IL-12. IL-10 is known to mediate the suppression of IL-12; a shared 
overexpression of these two cytokines in inpatients could indicate an unsuccessful attempt to 
suppress inflammatory activity in refractory depression. 
 
 Inflammation and subsequent treatment-response 
In both Studies 2 and 3, elevated TNFα and IL-6 predict subsequent non-response to treatment: 
in TRD inpatients, post-treatment levels predict long-term depression severity and in outpatients 
pre-treatment levels predict post-therapy severity and/or response. When combined in Chapter 
5, IL-6, TNFα and CRP all predicted subsequent treatment response, as hypothesised. In Study 
1 meta-analyses, the higher-powered composite panel of inflammatory markers is comprised 
mostly of these three markers and tentatively suggests higher inflammation in subsequent non-
responders. Meta-regression in Study 1 suggested that this finding is more pronounced in 
outpatient than inpatient studies, which somewhat aligns with the larger number of effects 
observed in Chapter 4 than Chapter 3. The reason for this phenomenon is not clear but might be 
explained by more standardised treatment provision, or less complex cases of depression in 
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outpatient than inpatient investigations. When considered in Chapter 5, high MCP4 and sICAM1 
also significantly predicted treatment response. Furthermore, post-treatment levels of IL-6, TNFα, 
CRP and MCP4 in Study 2 are all associated with long-term poor outcomes. It is highly 
encouraging that the same biomarkers appear to predict response across studies in this work. 
Results are contextualised below by the different measurements of clinical outcome utilised. 
 
6.1.2.1 Inflammatory markers predictive of treatment-response 
Low IL-7 in Study 2 is predictive of subsequent non-response to inpatient treatment (see also 
Section 3.5.1). In the outpatient study, treatment non-responders have significantly higher pre-
treatment TNFα (aligning with Chapter 2 findings and those of O’Brien et al. 2007) and IL-6 
(reported by Lanquillon et al. 2000 and Yoshimura et al. 2013), as well as sICAM1 and Tie2 (which 
have not been previously studied) and low levels of IFNγ in non-responders. In previous reports, 
IFNγ was not expressed differently in subsequent responders and non-responders (Landmann et 
al. 1997, Song et al. 2009). In support of our findings, recent reports suggest that non-response 
can be predicted by heightened expression of TNFα and Mip1b genes (Powell et al. 2013), IL-1β 
mRNA expression (Cattaneo et al. 2016) and by IL-1β and IL-6 SNPs (Bufalino et al. 2013).  
Although pre-treatment CRP did not strongly predict response at post-treatment in either study, 
when combined in Chapter 5 high levels of this protein are predictive of non-response. Previous 
investigations have shown differential prediction of response to specific treatments based on 
baseline CRP: in Harley et al. (2010) baseline elevations predicted a poor response to 
psychological therapy (CBT or interpersonal psychotherapy) but a good response to nortriptyline 
or fluoxetine; Uher et al. (2014) replicated this finding for nortriptyline and found the opposite 
effect for fluoxetine response. Conversely, Chang et al. (2012) found higher CRP in early 
responders to fluoxetine or venlafaxine. Our findings support the role of medication in CRP 
production, as inpatients taking more medications had higher levels of this protein. However, 
inflammatory interactions with distinct treatments are unclear for all IMs and could not be 
assessed in the naturalistic treatment designs of the present studies. It is possible that effectively 
controlling for treatment, as well as health and lifestyle effects may enhance the utility of CRP, IL-
6 and TNFα as prospective markers of treatment success. This finding heavily implicates 
macrophage-derived cytokine and subsequent acute phase activity in patients which may interact 
with the ability to achieve treatment response. This also could explain the involvement of 




6.1.2.2 Inflammatory predictions of post-treatment severity  
As expected, predictors of post-treatment severity are similar between Study 2 and 3. In both 
studies, high IL-6 and TNFα are associated with subsequent depression severity; in Study 3, 
sICAM1 is also significant and in all subsets regression analyses high TNFα alongside low IFNγ 
strongly predicts severity of depression after therapy. In Study 2, baseline inflammatory levels do 
not significantly predict depression at discharge from the inpatient service when measured 
individually, but when accounting for medication low levels of IL-7 and IL-15, and high levels of 
TARC predict post-treatment severity. Although significant, this is an exploratory model which 
requires validation, particularly as the role of TARC, IL-7 and IL-15 in mood disorders are largely 
not understood. We suggest, however, that psychotropic medication may partially exert its effects 
by interacting with T-cells in modifying neurotransmission, and thus individuals with low T-cell 
growth proteins might derive a reduced antidepressant benefit from an intensive multidisciplinary 
intervention (see also Section 3.5.1). It is possible that prior use of antidepressants had resulted 
in low T-cell counts, although this hypothesis is not supported by findings from a systematic review 
(Eyre et al. 2016a).  
Furthermore, depression severity in the longer-term (3-12 months after discharge) in Study 2 is 
foreseen by substantially higher IL-8, and modestly higher MCP4, TNFα, IL-6, Mip1a and IL-1β. 
Long-term outcome is rarely investigated in treatment studies where inflammation is measured, 
yet abnormal inflammatory activity has been indicated to precede poorer outcomes in the context 
of medical comorbidities such as IBS, stroke and HIV (Maes et al. 2011a). Assessment of specific 
illnesses may have helped to elucidate whether physical illnesses have affected the relationship 
between inflammation and subsequent indices of severity. 
Previous reports have infrequently measured IM associations with prospective depression 
severity, or have identified non-significant relationships for a range of cytokines (Fornaro et al. 
2013, and Carvalho et al. 2013 with the exception of negatively correlated MCP1). Null findings 
have been reported for all of the most studied inflammatory markers: TNFα (Lanquillon et al. 
2000), CRP (O’Brien et al. 2006) and IL-6 (Himmerich et al. 2010). Of the above, Lanquillon et al. 
(2000) did find a positive correlation between MADRS score and IL-6 but no correlations with 
HAM-D score, similar to non-significant effects on this measure by O’Brien et al. (2006), while 
Himmerich et al. (2010) found increased T-cell expression (CD4 and CD25) in those with more 
severe depression. These were all cross-sectional comparisons. We can conclude that different 
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measures of symptom severity and biomarkers measured may influence correlations between 
inflammation and severity (see also below).  
 
 Concurrent inflammation and clinical state  
Following treatment, high CRP levels associate with greater severity in both Studies 2 and 3. This 
supports some previous findings (e.g. Chang et al. 2012; but not Lanquillon et al. 2000). In the 
outpatient study, pre-treatment levels of TNFα and sICAM1 and post-treatment IL-6 are higher in 
the presence of concurrent severity. These results concur with some reports of post-treatment 
TNFα (Song et al. 2009) or IL-6 (Fornaro et al. 2011) elevations in non-responders, but not in 
other comparisons of severity or outcome for these biomarkers (Yoshimura et al. 2009, Mikova et 
al. 2001, Eller et al. 2009, Landmann et al.1997, Himmerich et al. 2006, Eller et al. 2008). Our 
studies identify a number of associations between depression severity and IMs that have not been 
examined before. Study 2 (Chapter 3) finds higher TARC alongside more severe TRD depression 
at pre-treatment, and in Study 3 (Chapter 4) at post-therapy. The outpatient study yields additional 
IM correlations with severity. The more frequent associations seen in the outpatient than inpatient 
study may be due to reduced heterogeneity (for example of medication number and changes 
during treatment), the larger sample size, or treatment setting. The measure used to assess 
severity, as well as the time of measurement is likely to be important. The PHQ-9 (used in Study 
3) is a self-report measure, but one that allocates equal score allocations to each DSM depressive 
symptom. On the other hand, the HAM-D (used in Study 2) apportions a greater proportion of 
possible scores to sleep symptoms, while also not adequately assessing hypersomnia or 
weight/appetite increase which are associated with the atypical subtype. These are factors 
thought to be related to increased inflammation (Lamers et al. 2013) that may have been under-
detected in Study 2.  
 
 Inflammatory alterations with treatment for depression   
Chapter 2 meta-analytic findings imply that TNFα is persistently elevated following antidepressant 
intervention in non-responders, but reduces with treatment in patients whose depression 
improves. While longitudinal changes in TNFα, CRP or IL-6 are not found overall in Chapters 3 
and 4, elevations are observed for these three proteins in non-responders before and after 
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treatment. Our findings align with the notion that especially TNFα levels could reflect poor 
longitudinal outcomes in depression. By extension, an inability to suppress TNFα production could 
potentially be a physiological barrier to clinical improvement.  
IL-6 was anticipated to decrease with treatment after Study 1 demonstrated significant reductions 
of IL-6 with antidepressants at a meta-analytic level and Study 3 suggests that a subgroup of 
patients with somatic symptoms might show decreases in IL-6 with psychological treatment. CRP 
was expected to interact with medication use, as observed in Study 1. Importantly, most studies 
included in meta-analyses examine unmedicated participants at the baseline measurement, and 
all but one included studies are pharmacological treatment trials. It is possible that antidepressant 
medications alter inflammatory activity initially, but that some stabilisation is achieved over time. 
This might help to explain null findings seen for many biomarkers in the current data.  
 
6.1.4.1 Inflammatory increases alongside treatment   
In contrast to hypotheses, IMs frequently increase alongside treatment. Many of these increases 
may be explained as promoting improved inflammatory system balance. With intensive inpatient 
intervention these comprise IMs which are anti-inflammatory in nature (IL-10), or lower in patients 
before treatment (MCP1 and sICAM1). To a greater extent, psychological therapy appears to 
upregulate cytokines with regulatory functions (IL-8, IL-15 and IL-7), without an apparent influence 
of pharmacotherapy in outpatients only, although these markers appear already elevated in 
outpatients compared to other participant groups. IL-7, IL-15, MCP1 and sICAM1 have been not 
reported longitudinally with treatment for depression prior to these studies. However, low MCP1 
has been reported to predict subsequent non-response in TRD (Carvalho et al. 2013). Increases 
with treatment have previously been reported for IL-8 irrespective of response (Eller et al. 2009) 
and IFNγ in examinations where all patients responded to antidepressants (Hernandez et al. 
2008; Marquez-Deak et al. 2007).   
Hernandez et al. (2008) found IL-10 reductions over 12 months of treatment (Hernandez et al. 
2008) but a lack of IL-10 change has been found in other longitudinal treatment studies for 
depression (Kubera et al. 2000, Song et al. 2009) or mania (Su et al. 2002). Where longitudinal 
change in IL-10 is affected by psychotropic medication use (Study 3) we find increases occurring 
in unmedicated participants but small decreases in medicated subjects. Medication could not be 
accounted for in repeated-measures assessments of IL-10 in Study 2, but both IL-10 and 
medication consumption during treatment show increases and correlations are identified between 
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total medication number and IL-10 level. Chapter 5 results emphasise a rise in IL-15, IL-10, MCP1 
and sICAM1 across studies; in addition sVCAM1 appears to increase when accounting for both 
studies together. Each of these markers are involved with T-cell activity, and either have 
regulatory inflammatory functions or are attenuated in patients compared with controls before 
treatment. Therefore, these findings potentially indicate a move towards immune equilibrium, 
which may be primarily regulated by one or more types of T-cells. Grosse et al. (2016) suggest 
that an increase in Treg cells can occur alongside antidepressant treatment (and high CD8 T-
cells may predict a poor treatment outcome), which does not necessarily implicate an increase in 
Th1 and Th2 growth factors.  
  
6.1.4.2 Inflammatory alterations attributed to clinical outcome   
Meta-analyses suggest that TNFα specifically might reduce alongside treatment only in 
responders, but few interactions between IM change and depression outcomes reach significance 
in our subsequent studies. Yoshimura et al. have previously reported IL-6 reductions with 
antidepressants that were smaller for subjects with more severe depression after treatment 
(Yoshimura et al. 2009); our findings suggest that IL-6 change may occur more in relation to the 
experience of somatic symptoms of depression. The fact that symptom severity and biomarker 
levels do correlate positively, particularly in outpatients undertaking psychological treatment, 
suggests that inflammatory activity is at least partly state-related to depressive illness. Markers 
such as IL-8, IL-10 or IL-6 could demonstrate more reliable effects if changes over time are 
controlled for by other variables (e.g. medication or symptom subtype) or if measured at specific 
time points. For instance, Fornaro et al. (2013) reported IL-10 reductions in early non-responders 
only, who were taking duloxetine. IL-10 is produced in T-cells as well as macrophages, and is 
upregulated by melatonin; perhaps antidepressant (particularly norepinephrine targeting) drugs 
do not increase melatonin or sleep quality in some individuals, reducing their likelihood of 
response. Potentially an inability to maintain IL-10 levels might hinder mood improvements in a 
subset of patients. 
   
6.1.4.3 Inflammatory alterations attributed to patient subgroup   
Study 3 (Chapter 4) demonstrates interactions of sVCAM1 and Tie2 over time between bipolar 
and unipolar depressed patients. During therapy, reductions in levels are observed in participants 
who met criteria on the MINI interview for hypomanic or manic in addition to depressive episodes. 
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Longitudinal studies of bipolar depression have rarely assessed inflammatory changes in 
association with clinical outcome. Bai et al. (2014) posited that inflammation is decreased in 
bipolar depression but increases in both euthymic and manic phases. Our findings do not support 
this, which may be attributable to the populations of bipolar disorder studied (see Section 6.3.2). 
Previously, some longitudinal investigations of bipolar disorder have reported reductions in IL-4 
and IFNγ (Kim et al. 2004), sIL-2R (Tsai et al. 2001) and IL-1RA but not CRP which remained 
elevated (Tsai et al. 2014) upon achievement of euthymia from mood episodes. 
 
Study 3 provides preliminary evidence that people predominantly experiencing somatic symptoms 
of depression might show more pronounced reductions of IL-6 and SAA levels with psychological 
treatment. SAA and IL-6 are highly inter-related in this study and this may represent a shared 
effect. These findings are the first to examine interactions between somatic subtype and 
inflammatory changes during psychological treatment. It is possible that individuals with somatic 
depression have more sensitive or fluctuating inflammatory response systems, or that specifically 
change in somatic symptoms is what affects inflammatory levels. Further understanding of this 
relationship might explain contrasting results of inflammatory alterations over time in depression, 
such as is observed between longitudinal IM changes in the current studies and those from meta-
analyses (Strawbridge et al. 2015, Hiles et al. 2012b, Hannestad et al. 2011).  
 
 Inflammatory correlates with depressive subtype 
6.1.5.1 Somatic symptom subtype assessment  
Concurrent high inflammation (TNFα and to a lesser extent IL-6, Mip1b and IL-7) is seen with 
somatic but not cognitive or emotional symptoms of depression in outpatient participants (Chapter 
4). This finding follows two previous reports: Duivis et al. (2012) reported higher IL-6 and CRP in 
participants with more severe somatic symptoms measured using the same criteria as in the 
present study; Einvik et al. (2012) similarly split the Beck Depression Inventory by somatic and 
psychological items (but did not include mood or anhedonia), finding negative correlations 
between somatic score (for TNFα, IFNγ and IL-7) and psychological score for Mip1b. However, 
we find Mip1b to be positively related to somatic score only.  
 
Accounting for somatic symptoms might help to explain conflicting results between studies in this 
literature but there are many possible methods of analysing clinical presentations which could 
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form the basis of an inflammatory subtype of depression. Comparisons of specific somatic-
depressive symptoms may specifically account for previous inconsistency between positive 
(Karlovic et al. 2012) and negative (Dahl et al. 2014) cytokine associations with melancholic and 
atypical subtypes. Many reports posit that a subgroup of depression exists for which inflammation 
is important (Raison and Miller 2011, Krishnadas and Cavanagh 2012, Vogelzangs et al. 2012) 
and some indicate that this might have a somatic basis (Penninx et al. 2013), but few strategic 
attempts have been made to characterise this group. It will be important to distinguish between 
patients with somatic symptoms as a generalised category, and those with a specific atypical 
subtype. 
 
6.1.5.2 Bipolar subtype assessment  
We find that participants with bipolar depression attenuated IL-4 in Chapter 4. Evidence has 
suggested that bipolar disorder is associated with increased inflammation in both depressive and 
manic episodes (Muneer 2016) but levels in euthymia may or may not exceed those of controls 
(Kim et al. 2004, Modabbernia et al. 2013). Direct comparisons of unipolar and bipolar depression 
are rare but Bai et al. (2014) proposed that euthymic bipolar disorder is associated with more 
pronounced inflammation (for CRP, MCP1, sTNF-R1 and sIL-6R) than major depression, while 
people with and without a history of (hypo)mania may have similar levels of inflammation in a 
depressive episode (Maes et al. 1995, Becking et al. 2015). In the current studies, type of 
medication taken (e.g. mood stabiliser use in bipolar disorder) could contribute for IM differences 
between groups, though this is more likely the case for the TRD inpatient study than outpatient 
therapy study. More pronounced differences between groups may alternatively be masked by 
small sample size or potential inaccuracies in bipolar categorisation and our samples are unlikely 
to represent the full spectrum of bipolar disorders. These possibilities are also true of previous 
investigations directly comparing depressed bipolar and unipolar patients (Maes et al. 1995, 
Becking et al. 2015). 
 
6.1.5.3 Treatment-resistant depression subtype assessment  
People with treatment-resistant depression have been proposed as more likely to have a bipolar 
spectrum disorder, physical illness comorbidities and to meet criteria for melancholic or atypical 
subtypes, which have been previously (albeit inconsistently) associated with inflammation 
(Raison et al. 2013a). TRD has also been linked with a greater severity or frequency of somatic 
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symptoms (Papakostas et al. 2003) that could associate prospectively with non-response to 
treatment. Maes et al. (1997a) have also posited that inflammatory abnormalities are greater in 
TRD. In the current studies, retrospectively defined treatment-resistance appears present 
alongside higher IM levels in inpatients but not the less refractory outpatients. Treatment-
resistance does not predict response, which was unexpected in light of previous findings using 
the MSM staging tool (Fekadu et al. 2009b, Fekadu et al. 2012); this may be partly attributable to 
small sample sizes and incomplete follow-up after treatment. Extent of treatment-resistance 
varies widely in both the TRD study (MSM score range 8-15) and the psychological therapy study 
(range 3-10). Many IMs are elevated in more refractory depression (TNFα, TNFβ, IL-16, Mip1b, 
IL-12 and CRP) within TRD inpatients but associations are weaker in outpatients who had less 
treatment-resistant depression. It is possible that inflammation increases more alongside a severe 
TRD illness and these effects might be greater if treatment-resistance is measured over lifetime 
rather than within-episode. In support of this, a significant effect is observed of higher IFNα in 
inpatients with an earlier age of depression onset. Many biomarker levels do appear higher in the 
more treatment-resistant sample. This is not found for all markers, which is likely attributable to 
methodological and population differences between studies. The cross-study comparisons are to 
be interpreted as indications only. Hospital inpatient settings are a unique environment which 
could systematically alter biochemical profiles especially within-subjects longitudinally: a 
notorious example of this was the “Pink Spot” phenomenon in inpatients with schizophrenia 
(Freeman 1967) which was later found to be caused by patients’ tea consumption in the unit. 
These findings should therefore be assessed in a range of settings.  
Numerous variables could cause a subset of depressed individuals to possess high IM levels and 
it is challenging to fully comprehend the contributors to inflammatory protein activity, especially 
using cross-sectional measurements. Future explorations of TRD as a potential inflammatory 
subtype must inspect its inter-connections with known modulators of inflammation such as aging, 
disability, ill-health and medication factors.  
 
 Modifiers of IM levels  
The other variables which most commonly affect inflammation across Studies 2 and 3 are age (9 
IMs correlating positively at p < 0.01), quality of life impairment (7 IMs with a positive correlation 
of p < 0.01), physical illness severity (5 IMs positively correlating at p < 0.01) and childhood trauma 
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severity (4 IMs correlating positively and 1, IFNγ, correlating negatively). Medication use relates 
to a number of IMs: in inpatients, positive correlations with intake are identified (particularly for 
CRP, IL-10, IL-16) while outpatients are taking less medication and medicated participants have 
lower IL-17 and IL-12p70. This raises the possibility that in general, low medication intake could 
attenuate inflammation but multiple medications may contribute to IM increases, although 
different pharmacotherapies clearly have distinct effects.  
While many of the above are known modifiers of immune activity, less biological factors such as 
quality of life and everyday functioning are not frequently documented in neurobiological research. 
It is certainly likely that physical illness and functional variables strongly influence each other, but 
in late-life depression a meaningful and bidirectional relationship specifically between quality of 
life and inflammation has been reported (Nowakowski 2014). Due to the distinct links between 
BMI and inflammation via adipocytes, obesity is considered important, as is gender (Howren et 
al. 2009) but are less strongly associated with IMs than health-related quality of life in current 
studies. The extent of childhood trauma experienced appears greater with higher levels of some 
markers (CRP, TARC, sICAM1, Eotaxin and IL-15), aligning with evidence that childhood trauma 
may precipitate low-grade chronic inflammation persisting into adult life (Danese et al. 2011). In 
some studies, experience of early-life trauma predicted a worse (Tunnard et al. 2014) or improved 
response (Nemeroff et al. 2003) to psychological therapy but is not predictive of response to 
inpatient treatment or psychological intervention in Chapters 3 and 4. This may be partly due to 
the measurement method utilised here, which did not categorise trauma (e.g. into physical or 
emotional abuse or neglect), or by using continuous scores on the CTQ measure rather than 
categorising participants. It may also be related to the non-standardisation of treatments 
undertaken.  
 
Levels of IL-6, CRP and TNFα correlate positively with TRD, age, functioning, physical illness 
(except CRP) and medication use (except TNFα) in the current investigations. The importance of 
accounting for these factors when assessing inflammation in mood disorders has been 
emphasised (Hiles et al. 2012a, Howren et al. 2009) but is not always examined in research. 
Medication, age and physical illness do not appear to independently affect treatment-response in 
our studies but are important to control for (as evidenced by the all subsets regressions). These 
factors may contribute to high IM levels separately from clinical outcome for biomarkers that differ 
based on treatment response. Chapter 4 indicates that functional or disability factors (primarily 
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occupational status and health-related quality of life) are inter-connected with both response to 
treatment and inflammatory markers. These are not measured in Chapter 3 but could help to 
explain variance between aging-related and clinical factors in their relationship to IM levels. 
Nevertheless, quality of life and cytokines TNFα and IFNγ, as well as baseline severity predict 
depression after psychological therapy independently of one another. Alcohol non-use also has 
a suggested predictive effect of more severe depression after treatment, but this may be partly 
related to current illness. It is not clear why those who consumed alcohol showed improved 
outcomes but rates of alcohol consumption are relatively low in the outpatient study.   
 
 
6.2 Our findings of inflammation and depression in context 
 Trait inflammatory markers of depression  
These data provide supporting evidence that a large range of inflammation-related proteomic 
markers are significantly higher in people with depression, including the novel biomarkers Tie2, 
Eotaxin-3 and TARC. Many biomarkers differing significantly between patient and control groups 
do so both before and after treatment (in both depressed groups IL-8, MCP4, IL-16, Eotaxin, 
TARC, Tie2, IP-10, Eotaxin-3, in outpatients IL-15 and IL-7, and in inpatients Mip1a, sICAM1 and 
sVCAM1). This set of markers includes a prominence of chemokine markers, all higher in 
depressed subjects; the presence of lower CAM markers in inpatients may implicate a key 
dysregulation between IM attraction and endothelial binding. The elevated T-cell growth factors 
IL-15 and IL-7 in outpatients could signal differential immune profiles between these populations. 
The main difficulty with assessing the exact mechanistic variations between outpatients and 
inpatients (in addition to methodological analytical issues) is the number of factors on which they 
differ. This does, though, suggest that many IMs might be trait markers of affective illness which 
persist into remission. A longer-term measurement of biomarkers would help to determine the 
relationship between inflammation and stable remitted depression.  
 
 State-alterations of inflammation in depression 
A number of markers appear to increase alongside treatment in at least one study, for the most 
part regardless of other measured factors (IL-10, IFNγ, MCP1, sICAM1, sVCAM1, IL-7, IL-15 and 
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IL-8). Inflammation was hypothesised to decrease with treatment. As discussed, many of these 
increases could either represent a process towards normalising levels towards those of the 
healthy comparison group or an increase in regulatory immune activity. Additionally, the increases 
seen could be attributed to enhanced behavioural activation or arousal resulting from 
psychological therapy. Arousal may transiently enhance cytokine activity and physiological 
signalling pathways (Morrison and Bennett 2009). A recent study identified cytokine increases 
during a psychosocial (singing) intervention which occurred alongside reduction in depressive 
symptoms and an increase in positive mood, in conjunction with reduced cortisol levels (Fancourt 
et al. 2016). A similar investigation found short-term increases of IMs, but overall decreases 
across six weeks of a group drumming intervention for mood disorders (Fancourt et al. 2015). 
Wellbeing-enhancing events such as exercise can lead to hormesis (Ambarish et al. 2012), where 
acute surges in inflammation are followed by more gradual and enduring reductions in protein 
levels.  
 
It is possible that a short-term increase in IM levels during treatment (potentially as a result of 
increased behavioural activation) could precipitate a more gradual reduction in inflammatory 
activity for people who maintain euythmia in the longer term. There is not yet data directly 
supporting this theory. However, both Studies 2 and 3 include interventions containing a 
psychological component (non-systematically in Study 2): this is in contrast to the previous 
literature as reviewed and meta-analysed in Study 1, where the majority of studies have assessed 
short-term antidepressant treatment (often in participants unmedicated at baseline) and find 
decreases particularly in IL-6 during treatment. This theory would also account for our data 
showing higher IMs alongside poorer depression outcomes. We observe tentatively significant IM 
reductions in bipolar depression for Tie2 and sVCAM1 which could suggest a different mechanism 
occurring in bipolar disorders during psychological therapy (see below, Section 6.2.5). In the latter 
study, outpatients’ post-treatment assessment took place approximately 2-4 weeks following 
completion of psychological therapy, while the inpatient investigation measured IMs at discharge 
(treatment endpoint). Different results might have been yielded if the post-treatment assessment 




 IMs predictive of treatment outcome 
In accordance with the above notion, the most frequent IM associations with outcome are 
predicting follow-up in the longer term in Study 2 (IL-8, Mip1a, CRP, TNFα, IL-6 and MCP4), while 
only CRP correlates with outcome cross-sectionally at discharge in this study. It is possible that 
measuring inflammation upon discharge from an inpatient unit affects IM levels as this can be a 
stressful event for patients. In contrast, the post-treatment measurement in Study 3 occurs in the 
weeks following treatment-end and may provide a more valid measurement. This might indicate 
why the outpatient study yields more significant IM predictions of response than the inpatient 
study: high TNFα, IL-6, sICAM1, SAA, MCP4 and TARC are all found with a poorer depression 
outcome in the weeks following treatment-end. The pre-treatment IM predictors are almost 
identical to these (except for TARC, but with the addition of Tie2 and low IFNγ in subsequent non-
responders). Indeed, post-therapy depression severity in outpatients can be >30% explained by 
poor quality of life, depression severity, low IFNγ and high TNFα levels at pre-treatment, as 
independent predictors. These initial findings provide highly promising indications for future 
translational research investigating the prospective identification of refractory depression.  
It is important to note that the IMs which correlate with depression outcomes are often inter-
correlated in Study 3; IL-6, TNFα and sICAM1 all inter-relate at p < 0.05, in line with their known 
biological functions. IFNγ was not related to any of these markers, and was not consistently inter-
correlated with IL-12.   
 
 Inflammatory modulators   
There are several inconsistencies within our findings, highlighting that inflammatory protein levels 
are affected by many factors that are not fully understood. The absence of reliable patient and 
control group differences in TNFα, CRP and IL-6 may be due to lifestyle and demographic factors, 
particularly age and medication. As well as age and BMI (matched between inpatients and 
controls), both groups of Study 2 participants had higher rates of medication use than outpatients. 
These have likely led to reduced group differences between TRD and control groups, despite 
attempting to account for age and BMI in the cross-study comparison. 
 
High TNFα and IL-6 both associate with retrospective, concurrent and prospective measures of 
treatment-resistance or outcome (severity or non-response) in at least one study. CRP also 
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relates with response concurrently and prospectively but is affected by medication. This acute 
phase protein is likely to be best placed as a marker of depression severity or potentially to stratify 
by specific treatment. It is likely that TNFα primarily represents a prospective marker of severity, 
which has been identified across studies. This effect may be mediated partially by improvements 
in functioning during treatment. IL-6 may be able to predict treatment response in conjunction with 
other factors, and might best represent the somatic symptoms of depression which can be 
modified with psychological treatment.  
  
 Identifying an inflammatory subtype  
No subtype of depression yet exists which predicts treatment response (Arnow et al. 2015). 
Treatment-resistant depression itself may represent a subpopulation of mood disorders in whom 
inflammatory responses are dysregulated (Raison et al. 2013a).  
Chapter 4 suggests that IMs are more closely correlated with somatic than non-somatic symptoms 
of depression (for TNFα but also IL-6, Mip1b, IL-12, sICAM1 and IL-7). It is possible that people 
with high somatic symptoms and inflammatory activity represent a more homogenous 
subpopulation of depressed individuals, for which particular treatments may be more beneficial 
or in whom IMs might better predict treatment-response in general.  
Bipolar depression has been posited as a potential subtype displaying altered inflammation 
(Baune et al. 2012); for many biomarkers this is not observed in the current studies, all of which 
contained a limited number of bipolar disordered participants and were exploratory in nature. 
Participants categorised as bipolar show reductions in sVCAM1 and Tie2 over time, in contrast 
to increases in unipolar depression. It is plausible that greater variation or sensitivity of 
inflammatory responses occur in bipolar than major depressive disorders, in relation to mood 
states. For example lower levels may be exhibited in euthymia than depression, and with 
accentuated cytokine release during mania as indicated by Tsai et al. (2012). A lack of further 
significant differences in the present studies may reflect diagnostic inaccuracy, small sample 




 Immune activation versus suppression   
The findings in this work do not denote a simple delineation between Th1 and Th2 markers of 
inflammation, or between innate and adaptive immune activity. There is conflicting opinion on how 
cytokines and similar proteins inter-relate under different conditions, and inter-correlations were 
not reliable for many IMs between studies. In Study 3, IFNγ only correlated with IP-10 (as 
expected, although IP-10 significantly elevated in patients than controls) and IL-10. The latter 
finding may not be expected, according to a pro- and anti-inflammatory dichotomy, but IFNγ has 
been demonstrated to increase in response to IL-10 anti-inflammatory activity (Cavaillon et al. 
2001) and are found amongst high concentrations of macrophages. Both increase alongside 
inpatient treatment, but only IL-10 is higher in inpatients than controls, while low IFNγ in 
outpatients predicts non-response to treatment. Furthermore, IL-10 tends to positively correlate 
with pro-inflammatory markers, particularly TNFα.  
 
Despite this, some clear patterns emerge in line with expectations. IL-7 regulates Th1 and Th2 
activity and can strongly stimulate innate cytokine production (IFNγ, TNFα and IL-12; Van Roon 
et al. 2003), working in conjunction with IL-15 as a T-cell growth factor. IL-7 and IL-15 show very 
similar effects in the comparisons made across studies. It would have been interesting to observe 
whether IL-2 also acted similarly in these investigations, had its detection been sufficient.  
Many chemokine markers were highly inter-correlated and demonstrated significant effects. 
MCP1 and MCP4 are an example of two highly inter-correlated proteins that show distinct effects: 
while MCP4 appears higher in depressed patients than controls, and more-so in non-responders, 
MCP1 is lower in treatment-resistant patients, slightly more in responders. The ratio of 
MCP4/MCP1 may be an interesting avenue in the search for a marker of treatment-resistance. 
Immunoglobulins sICAM1 and sVCAM1 were strongly correlated with one another, although 
sICAM1 may be more promising a biomarker in MDD, and with chemokine markers as anticipated. 
These markers also associated strongly with pro-inflammatory cytokine markers (especially IL-6) 
and acute phase proteins CRP and SAA.  
 
It seems probable that depressed patients simultaneously present with indications of both pro- 
and anti-inflammatory activity as part of a systemic imbalance or alterations in the function of 
specific markers (Blume et al. 2011). A recent report suggested that monocyte gene expression 
might indicate pro-inflammatory activity in older individuals, while proteomic monocyte markers 
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could be suppressed in patients without childhood trauma or high arousal and with a later 
depression onset (Grosse et al. 2015). Therefore, we can likely assume that inflammatory 
imbalances will vary across patients within heterogeneous populations. It could be that immune 
suppression occurs in the earlier stages of mood disorders and progressively inflammatory 
responses rise during a chronic illness.  
 
 
6.3  Methodological considerations  
Clearly these findings require replication in larger, well-defined samples. Study 3 (Chapter 4) 
elicits more frequent significant effects than Study 2 (Chapter 3) which may in part be attributed 
to increased sample size. Despite this, both studies suffer loss to follow-up of post-treatment 
biomarker data. The exploratory approach of these studies demonstrates the influence of 
numerous additional variables on inflammation but has not been able to stringently control for 
these factors. Clinical associations with inflammatory markers are likely mediated or moderated 
by constructs relating to illness or disability.  
 
 Definition of treatment response and treatment outcomes  
Response to treatment was defined as is typical in clinical research; a >50% score reduction on 
a standardised symptom measure of depression from pre- to post-treatment. Remission was not 
assessed in addition to response, primarily due to similarity of group compositions in conjunction 
with the number of comparisons and small numbers of remitted participants. In these studies 
remitters are classified as responders. Remission is arguably a more reflective measure of the 
ultimate clinical aim for treatments, although response assesses improvement with treatment, 
accounting for depression severity at baseline. The use of dichotomous comparisons is beneficial 
as responders are a clinically relevant set of individuals, but also succumbs to data-loss as 
depression is a complex phenomenon that occurs over a spectrum (Altman and Royston 2006). 
Depression severity is included as a secondary outcome and yields comparable (or in some cases 
stronger) effects with IMs than response in the current studies. Clinical outcome data in Chapters 
2 and 4 are based on depressive symptoms at a single time point only, so sustained wellbeing 
(or occurrences of relapse) are undetected in current as well as previous reports within this field. 
Alternative definitions of treatment success could include an average depression score over time 
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with treatment, the degree of fluctuation in depression scores (e.g. as a ‘change’ score), or 
discriminating between early-response and non-response during treatment to yield more valid 
outcome data. Assessing a longer duration of follow-up (as in Chapter 3) may be a practical 
solution that reflects enduring treatment success. IMs were not measured at long-term follow-up, 
so the theory that inflammatory reduction (or normalisation to control levels) might occur gradually 
after treatment-end (see Section 6.2.2) could not be tested. It may be that more robust 
inflammatory associations are found when assessing patient wellbeing either in the months after 
treatment-endpoint, or at multiple time points, to determine sustained wellbeing.  
There are also strengths and weaknesses of the measures used to assess severity: the PHQ9 
(utilised in Chapter 4) is self-rated and provides a subjective measure of depression experience 
which is convenient to complete and widely used in services. While the PHQ9 appears to 
sensitively detect improvements in depressive state (Kounali et al. 2016) the HAM-D (used in 
Chapter 3) has been praised for its objective measurement of depression but lacks sensitivity in 
detecting treatment efficacy (Tsapekos et al. 2016).  
 
 Definition of exploratory depressive subtypes   
Retrospective treatment-resistance is measured as a continuous score in this project, rather than 
by excluding participants based on treatment-failures or using commonly used staging models, 
which have been criticised for their unidimensional and hierarchical nature (Fekadu et al. 2009b). 
However, the MSM measure only assesses treatment-resistance in the current episode. In 
addition to MSM scores and depression severity scores at previous time points, inflammatory 
markers also correlate positively with broader indications of chronic or TRD depression such as 
age of onset (e.g. IFNα) in current findings. Assessing a summary of lifetime treatment resistance 
may enhance the ascertainment of TRD in research.  
To discriminate between depressed patients based on the extent of somatic compared with non-
somatic symptoms, the outpatient study (Chapter 4) replicates the method used in the only 
examination of this construct that considers all core depressive symptoms (Duivis et al. 2014). 
This is not, however, a standardised definition and the severity of somatic compared with non-
somatic depressive symptoms may be better assessed using a novel methodology; for example, 
using a greater array of somatic symptoms assessed by a count score (Carson et al. 2014) or 
visual analogue scales.  
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The delineation of bipolar disorder is defined using the criteria set by the MINI interview (and in 5 
participants in Chapter 4, using the HCL-16). While the supplementation of HCL-16 data enabled 
a complete set of data for this variable, it may reduce the validity of bipolar categorisation in this 
study. The MINI and HCL-16 may both over-detect bipolar symptoms in individuals with 
subclinical hypothymic tendencies (Phelps and Ghaemi 2006). Differences between unipolar and 
bipolar depression might be more pronounced where bipolar disorder is considered a specific 
study inclusion criterion or where medication can be accounted for. 
 
 Inflammatory biomarker measurement  
Measurement of biomarkers has progressed in recent times and the MSD (Meso Scale Discovery) 
chip utilised for IM analysis in sera provides an ultrasensitive measurement (Dabitao et al. 2011). 
Despite this, a number of markers were not well detected in these samples (notably Mip1a, IFNα, 
IL-1, IL-2, IL-4, IL-5 and GM-CSF). This resulted in a reduced sample of IMs examined across 
studies, limiting the scope within which the inflammatory response in depression can be 
inspected. IL-1β has recently been suggested as a particularly promising cytokine for predicting 
treatment-response in depression (Cattaneo et al. 2016). IL-2 appeared more likely undetected 
(low) in non-responders, and due to its functional closeness to IL-15 and IL-7 it may be that lower 
IL-2 predicted a poorer treatment outcome; this could not be assessed. Of the IMs analysed that 
included undetected datapoints, imputation of these values might have masked poignant effects 
in our studies, or have inflated differences. There is no universally accepted method of biomarker 
imputation although the technique used of imputing with a value half the detection limit has been 
recommended (Whitcomb and Schisterman 2008), where multiple imputation or LLOD/√2 are not 
appropriate methods (Croghan & Egeghy 2003). Other factors such as time of day of blood 
collection could not be assessed in the present studies, and subjects had not fasted beforehand. 
As discussed in Section 3.5.9, the duration of storage may have caused some degradation of 
cytokine levels. As all samples were less than 4 years old this effect is considered to be minimal, 
but some proteins may have been more susceptible to degradation (Zhou et al. 2010).  
A full examination of physical illnesses or medication usage, which affect inflammation, was not 
possible. Despite the large panel of inflammatory biomarkers investigated there are additional 
cytokines that have putative associations with depression (for example, TGFβ) that were not 
measured. Serum proteomic markers only represent one dimension of inflammatory responses; 
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gene expression (e.g. Cattaneo et al. 2016) or neuroinflammatory measurements (Janelidze et 
al. 2013) might provide a valid marker of clinically relevant inflammatory activity in depression. 
  
 Data analysis methodology  
Isolated biomarkers of a system as complex as inflammation could be less indicative of systemic 
activity than composite or index values incorporating a range of related and important markers. 
Ratios of specific pro- and anti-inflammatory cytokines (e.g. IFNγ/IL-4 or IL-6/IL-10) have been 
measured with mixed results (Dhabhar et al. 2009, Gabbay et al. 2009). A principal component 
analysis of IMs has suggested that neuroinflammatory levels of IL-6, IL-10, TNFα and CRP 
characterise a single factor in people who had attempted suicide. When these were aggregated, 
those with greater depressive symptoms showed higher levels than controls (Lindqvist et al. 
2011). Chapter 2 findings support these, in the first composite meta-analysis of pro-inflammatory 
markers in depression. As well as showing inflammatory elevations in depression compared to 
controls, the meta-analyses suggest that a composite measure of IM levels also predict later 
response to treatment to a small extent. A composite marker has not been analysed in Chapters 
3 and 4 due to sample sizes, which did not permit a sufficiently-powered component or factor 
analysis. Interactions between the 33 biomarkers inspected were highly complex. IL-6 seems to 
relate in a cluster with CRP, SAA and sICAM1, while another cluster comprising chemokines 
TARC, MCP4 and Eotaxin is indicated in both inpatient and outpatient studies. TNFα is widely 
related to many markers across clusters. Combining levels of certain biomarkers (for instance, IL-
6, TNFα, CRP, SAA and sICAM1) may be fruitful in detecting more robust inflammatory 
associations.  
 
Log-transformation of cytokines and a bootstrapping method were employed to minimise any 
effects of non-normally distributed data or the presence of outliers. It must be considered that 
outlier effects may have influenced the current findings. Exclusion of outliers may disregard 
relevant effects but also further reduces statistical power. Small sample sizes is an additional 
precaution in interpreting the findings in this thesis.  
 
In logistic regression analyses predicting non-response (versus response) or patient (versus 
control) group status, the Hosmer-Lemeshow test was used to determine goodness-of-fit of the 
models. On a few occasions, this indicated some deviation between observed and expected 
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inflammatory values in subgroups within the model. However, none of these indications were 
significant in both unadjusted and adjusted analyses, and where this occurred in the presence of 
a significant prediction by the model, the model was comparably significant between unadjusted 
and adjusted regression comparisons. Therefore, we consider it unlikely that false positive results 
arose as a consequence of poor model fit. 
 
For the all subsets comparisons, linear regression tests are used to predict post-treatment 
depression severity from pre-treatment assessments. These were selected instead of logistic 
regressions predicting response status (which was the primary outcome measure) to avoid 
information loss from dichotomising outcome. To a greater extent in Chapter 3, sample sizes 
reduce statistical power and potentially the ability to detect true differences. The large number of 
potential predictors required a system for variable selection for the multivariate model. There is 
no standard recommendation for model selection with these type of data; the all subsets 
regression takes an exploratory approach which is unlikely to exclude potentially important 
predictors but may contain bias, collinearity or overfitting (Rencher et al. 1980). Bias may also 
occur in the selection of the optimal model, and we were careful to incorporate criteria that appear 
to indicate optimal models in the selection process; i.e. BIC, AIC, r2, Durbin-Watson and 
theoretical or evidence-based justification of variables as proposed by Sullivan et al. (1989).  
 
Finally, a large number of comparisons have been undertaken in the present studies. While Simes 
control for multiple comparisons was undertaken for the main analyses, the exploratory analyses 
are potentially susceptible to type I error. Additionally, it is emphasised that false discoveries can 
not truly be detected and that Simes correction may have been over-conservative in its precaution 
against the risk of type I error, especially since not all IVs were inter-correlated. Due to the number 
of cases studied and comparisons undertaken, the present findings are to be interpreted as 
exploratory, initial findings.  
  
 Study and sample characteristics 
Despite the measurement of numerous comparisons, a plethora of factors exist that are likely to 
affect the relationship between inflammation and treatment outcomes in depression and could not 
be assessed in the present work. The naturalistic study design limits observation of specific 
intervention effects because participants were undertaking many different treatment 
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combinations. Any distinct influences of individual pharmacological or psychological treatments 
on inflammation will have been masked in the present studies. It is also means that inflammatory 
alterations in the complete absence of medication could not be assessed. The sample sizes and 
limitations to the scope of data collection meant that some factors could not be measured or 
accounted for. For example, more information regarding control participants’ health and 
medication use would have been useful. The possibility of acute infection or inflammation in 
participants could not be eliminated. A replication of these findings would help to determine 
whether these findings are robust. However, this project has enabled a comprehensive insight 
into the current evidence linking treatment-resistance with inflammation. The review and meta-
analysis in Chapter 2 identified areas of need for research and this facilitated two primary 
investigations addressing novel comparisons to address areas of uncertainty.  
 
 
6.4 Future Directions  
 Validation of results 
The findings from this project require replication in further samples. This is particularly true for 
novel biomarkers, such as TARC and Tie2 and for comparisons between somatic as well as 
bipolar and TRD subtypes. A large sample of participants undergoing a specific set of treatments 
will help to demonstrate the immuno-pharmacological effects of specific interventions, including 
purely psychological therapy investigations. 
 
 Individual treatment effects on inflammation and response 
 All commonly prescribed treatments for depression should be comprehensively assessed for 
their specific effects on inflammatory markers. This may enable constructs relating to biomarkers 
and symptom presentations to predict outcomes to a variety of antidepressant treatments in a 
more personalised fashion, and may be possible in the context of both unipolar and bipolar 
affective disorders. This is likely to be useful for specific anti-inflammatory medications as well as 




 Discovery of homogenous subtypes 
Taken together, the current evidence indicates that inflammatory profiles are definitively but 
abstrusely altered in a sub-population of individuals with mood disorders. This may be found 
within or across diagnostic categories, and would account for inconsistent findings that are 
observed in this literature. Identifying this subgroup more clearly may most effectively be 
facilitated by a large cluster analysis of IM levels in depression. This would illustrate within-
population variability in biomarker levels and latent class analyses could exhibit distinct clinical 
characteristics based on levels of inflammation. Additionally, principal component analysis might 
identify homogenous markers and could also inform the use of IM ‘composites’ in psycho-
immunological research, which may increase the homogeneity of future findings. 
 
 Prospective determination of treatment-response 
Use of the above techniques, in addition to more authentic and persistent measures of patient 
wellbeing (alongside other clinical, demographic, social and functional characteristics), is likely to 
result in an improved ability to forecast treatment-resistance prospectively. While it is unlikely that 
inflammatory activity alone can be used to distinguish treatment responders from non-responders, 
the present results suggest that concurrent measurement of wellbeing factors (e.g. everyday 
functioning or depression severity) and cytokine levels (particularly IL-6, TNFα and possibly IFNγ) 
are promising candidates for a predictive model of general non-response to treatments for people 
with depression. If a reliable model is developed to predict response (either for the depressed 
population or a subpopulation) and is validated retrospectively, a translational design can 
establish its applicability in a large controlled trial.  
 
 Stratified trial validation 
If validated, a stratified trial design could be employed to test a model to predict non-response 
and/or to determine where a patient needs to be triaged in a stepped care model. Patients would 
be recruited into the trial and classified as likely to achieve response or not respond, before 
beginning treatment. They would then be assigned to receive a standard or potentially ‘stepped-
up’ treatment program; these groups can be compared to inspect the efficacy of the model. This 
could be useful in both standardised and naturalistic treatment settings, across different types of 
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intervention. If treatment outcomes in individuals at risk for non-response can be improved then 
this could be used to refine treatment provision in clinical practice. This would have implications 
for cost-effectiveness as well as clinical benefits to patients. 
 
6.5 Clinical Implications 
The literature indicates that approximately two thirds of patients with depression do not achieve 
remission to an initial treatment and that the likelihood of non-response increases with the number 
of treatments trialled. Providing ineffective therapies has substantial consequences for individual 
and societal cost, including persistent distress and poor wellbeing, risk of suicide, loss of 
productivity and wasted healthcare resources. The results from this thesis indicate that 
inflammation is specifically associated with poor clinical outcomes and we suggest that these 
findings have the potential to improve the management and care of people with depression. 
Pending further research, translational implications may transpire through one or more of the 
following routes for enhancing treatment provision and effectiveness for people suffering from 
depression at the earliest practicable stage. 
 
 Clinical potential of a model to predict treatment response 
At present, patients with depression are not systematically directed to receive an optimised 
treatment program. Ultimately, a clinically viable model could be developed to provide individuals 
with the most appropriate treatment, to recognise those who are likely to develop refractory 
depression and supply enhanced care and monitoring to these patients. If a model (potentially 
containing both inflammatory and psychological markers) is validated in a translational research 
paradigm, routine screening at clinical assessments could optimise treatment for those vulnerable 
to treatment-resistance and monitor these patients more regularly following treatment. Based on 
current data, a putative model might include prominent experience of somatic symptoms, high 
levels of IL-6 or TNFα, more severe or chronic depression and poor health-related quality of life.  
 
 Treatment stratification to improve clinical outcomes 
A strata of depressed individuals predicted to be at-risk for treatment-resistance might be 
systematically prescribed concomitant psychological and pharmacological therapy, or with 
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combination pharmacotherapy. Potentially a cytokine or acute phase protein (such as IL-6 or 
CRP), or a panel of IMs could indicate the selection of specific treatments more likely to be 
effective. For example, people with depression but without high levels of inflammation might be 
indicated to receive psychological rather than pharmacological therapy. The current findings 
suggest that high levels of some pro-inflammatory markers (e.g. TNFα or IL-6) but low levels of 
others (e.g. IL-7 or IL-15) predict a poor response to psychological therapies but in the current 
samples inflammation is more strongly predictive of outcome in the outpatient study of 
psychological therapy than the inpatient multidisciplinary treatment investigation (though sample 
characteristics are also likely to influence these effects).  
A promising use of stratification might be for a subset of patients with high inflammation to receive 
treatments directly targeting inflammation; for instance, augmentation with an anti-inflammatory 
agent. There are an extensive array of treatment options for depression that may be influenced 
by inflammatory responses (see below, Section 6.5.4).   
 
 Personalised treatment using IMs 
While similar to stratification, more personalised treatment-selection strategies may be possible 
in the future. For example, a particular depressed individual might have markedly high TNFα 
levels but no elevations of other IMs, and could benefit from a TNFα antagonist such as infliximab 
(as found by Raison et al. 2013b). It is not clear whether cytokine suppressors might be beneficial 
in a subgroup or universally in depression. Personalised treatment may also entail monitoring IM 
levels during treatment such that a targeted adjunctive anti-inflammatory treatment could be 
introduced if biomarker levels increase or elevations persist. Possibly, the use of monitoring could 
additionally inform the length of continuation therapy (e.g. while inflammation remains high) or be 
used to detect early markers of relapse. Thus, personalised treatment using inflammatory proteins 





 Anti-inflammatory treatments for depression 
There are an extensive range of agents that might directly or indirectly reduce IM levels and 
depressive symptoms, including novel or repurposed interventions from other medical disciplines. 
These are categorised accordingly below.  
 
6.5.4.1 Direct cytokine or chemokine targets  
A number of known anti-inflammatory pharmacological agents have now been trialled examining 
their antidepressant potential. These include celecoxib (and other cyclooxygenase-2 inhibitors) 
which have showed promise at a meta-analytic level (Faridhosseini et al. 2014), and TNFα 
antagonists etanercept (Tyring et al. 2006) and infliximab (Raison et al. 2013b). The latter study 
illustrated particular benefits of infliximab for participants with elevated inflammation before 
treatment. Minocycline less specifically modifies inflammatory markers via MAPK pathways and 
shows promise as an antidepressant (Husain et al. 2015, Emadi-Kouchak et al. 2016). Similarly, 
aspirin may prove beneficial (Berk et al. 2013a). N-acetylcysteine (NAC) inhibits NFkB pathways 
and has shown preliminary efficacy for unipolar (Berk et al. 2014) and bipolar (Berk et al. 2008) 
depression. The short-term effects of these drugs have been examined in meta-analyses which 
demonstrate significant reductions in depressive symptoms (Köhler et al. 2014), depressive or 
manic symptoms in bipolar disorder (Rosenblat et al. 2016) and schizophrenia (Fond et al. 2014).  
Additional anti-cytokine medications have not yet been investigated for depression, such as 
anakinra, an IL-1 antagonist (Maes et al. 2012c). An IL-6 antagonist, tocilizumab, is now being 
trialled in TRD (Wolfe 2016).  
 
6.5.4.2 Novel targets indirectly affecting inflammation 
Antiglucocorticoid compounds have demonstrated modification of IM levels. Ketoconazole 
(Wolkowitz et al. 1999) and metyrapone (McAllister-Williams et al. 2016) are two such examples 
that have been investigated for depression, but both have drawbacks with their side effect profile, 
and the clinical utility of metyrapone is uncertain. Modafinil also interacts with HPA-axis activity 
and reportedly reduces depressive symptoms, particularly of fatigue, in unipolar and bipolar 
depression (Goss et al. 2013). Mifepristone (Gallagher and Young 2006) and corticosteroids such 
as fludrocortisone and spironolactone (Otte et al. 2010), dexamethasone and hydrocortisone 
(Ozbolt and Nemeroff 2013) may also be effective in depressive disorders, in the short-term.  
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The glutamate system appears dysregulated in depressive disorders (Arnone et al. 2015). 
Neuroinflammatory and glutamatergic systems interact with one another and NMDA receptor 
antagonists, including ketamine, might both interact with inflammation and represent efficacious 
treatments in depression (Walker et al. 2013). However, inflammatory involvement in ketamine’s 
mechanism of antidepressant action has not been assessed in clinical studies.  
 
6.5.4.3 Currently available antidepressant treatments 
As outlined in Section 1.5.3 of this thesis, different antidepressant medications demonstrate 
inconsistently varying inflammatory effects from one another and a better understanding of their 
distinct effects is likely to arise when clinical and demographic factors are accounted for. Initial 
indications suggest particularly that patients with high CRP might benefit more from nortriptyline, 
fluoxetine or venlafaxine, and improve less with escitalopram or psychological treatment (Harley 
et al. 2010, Chang et al. 2012, Uher et al. 2014).  
 
Newly-termed ‘somatic therapies’ target neuro-stimulation and show promise as interventions for 
depression; Transcranial magnetic stimulation (TMS), deep brain stimulation (DBS) and 
transcranial direct current stimulation (TDCS) may be advantageous for TRD (Kennedy and 
Giacobbe 2007) but are not well-established treatments at present (Cleare et al. 2015) and their 
effects on inflammation not understood. However, the traditional neuro-stimulatory treatment for 
TRD – ECT – might acutely increase cytokine levels followed by a subsequent reduction 
(Lehtimäki et al. 2008). It is possible that these treatments may interact with inflammatory 
responses in producing an antidepressant effect or have an attenuating influence on IMs in the 
long term.   
 
6.5.4.4 Complementary therapies  
Omega-3 polyunsaturated fatty acids have documented interactions with inflammation (Leonard 
and Maes 2012) and demonstrate some effectiveness for depression (Lespérance et al. 2010). 
In particular, high IL-1RA or CRP levels might predict subsequent non-response to 
eicosapentaenoic acid; EPA (Rapaport et al. 2016), which seems the most promising compound 




Other potential substances that may reduce depression and inflammation indirectly include 
curcumin (Tizabi et al. 2014), probiotics, folic acid or additional dietary alterations (Hastings et al. 
2016). Mindfulness, meditation, yoga (Black et al. 2013) and exercise (Gleeson et al. 2011) might 
also promote reductions in both depression and inflammation. However, it should be noted that 
few of these complementary treatments have been investigated using robust methodologies and 




6.6 Summary and Conclusions 
This project was undertaken to determine whether naturally occurring, circulating inflammatory 
protein levels are important in the relationship between depressive disorders and clinical 
response to treatments. Four principal questions were addressed and the summary of findings 
are delineated below.  
 
 Do inflammatory protein levels predict response to treatments?   
Previous research implies that a small, but potentially meaningful elevation in inflammation might 
precede poor response to antidepressant treatment (Strawbridge et al. 2015; Chapter 2). For both 
inpatients with TRD (Chapter 3) and depressed outpatients (Chapter 4), high TNFα and IL-6 are 
found to significantly predict a poor treatment outcome to intensive multidisciplinary and 
psychological interventions, respectively. To a lesser extent this is true also for CRP. The 
maintenance of depression after inpatient treatment in Chapter 3 is most strongly preceded by 
high pre-treatment levels of the pro-inflammatory chemokine TARC in conjunction with low levels 
of interleukins 7 and 15. Depression after psychological therapy in Chapter 4 is best predicted by 
high TNFα, low IFNγ, a poor health-related quality of life and more severe depression prior to 
treatment. Treatment duration averaged 6 months and achieved a response rate of approximately 
50% for both studies. 
 
 Are inflammatory markers related concurrently with clinical response?  
Chapter 2 was not able to address this uncertainty. Chapters 3 and 4 suggest that fewer 
inflammatory markers correlate with depression severity cross-sectionally than prospectively. 
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CRP and TARC levels appear the most reliably elevated after treatment in individuals who 
respond less well to interventions across studies. Additionally, IMs sICAM1, IL-6 and TNFα prior 
to treatment are higher alongside more severe depression in outpatients but not TRD inpatients.   
 
 Do inflammatory responses alter longitudinally with treatment for 
depression? 
Meta-analyses in Chapter 2 denote inflammatory decreases with antidepressant treatment, 
particularly for IL-6, TNFα in treatment-responders and CRP in unmedicated participants. 
Conversely, Chapters 3 and 4 find that inflammatory markers increase with treatment. IM 
increases are more frequent in the inpatient study (for IL-10, IFNγ, sICAM1 and MCP1) but the 
effects are stronger in outpatients (for IL-8, IL-15, IL-17 and IL-7). Further research investigating 
longer-term IM changes after treatment may determine whether a short-term rise in inflammation 
occurs before gradually reducing in people who do not relapse.  
 
 Is inflammation particularly aberrant in a subgroup of people with 
depression?   
Inflammatory markers tend not to differ between bipolar and unipolar depression in the present 
investigations. Participants in Study 2 (Chapter 3) are highly treatment-resistant, and TRD is 
associated with greater abnormalities in inflammatory activity, particularly with IL-8 and IL-10 
elevations, and sICAM1 and sVCAM1 attenuations. Chapter 4 suggests that IL-6 and TNFα are 
more highly expressed in the presence of somatic symptoms of depression, such as fatigue, 
appetite or sleep dysregulation. In particular, IL-6 or SAA may reduce alongside psychological 
treatment only in patients with a somatic subtype of depression.  
Previous evidence suggests that inflammation is only aberrant in a subset of people suffering 
from depression. Progress is gradually being made in better identifying this group, with the 





 Final Remarks  
In summary, IL-16, IL-8, IP-10, MCP4, Eotaxin, Eotaxin-3, TARC and Tie2 are all elevated in 
depressed patients both across studies and over time, while sVCAM1 and sICAM1 are 
consistently attenuated. Most of these biomarkers have not been well-studied in mood disorders. 
Due to the sheer complexity of inflammatory responses, examination of the full system and 
interactions between biomarkers is of considerable benefit. Optimising the measurement of both 
immunological occurrences and clinical measures of depression is likely to facilitate greater 
understanding. TNFα, IL-6 and CRP represent the most investigated IMs in mood disorders to 
date and show promise for predicting treatment response or resistance to specific treatments in 
a subgroup of patients with mood disorders. For these, and numerous other inflammatory markers 
measured, levels are influenced by many factors. Our findings highlight the importance of quality 
of life, age, physical illness, cognitive impairment and medication use in the relationship between 
inflammation and depression. These factors have been linked with treatment-resistance in mood 
disorders. The concurrent measurement of inflammatory and psychological data (including those 
listed above) may enhance the ability to prospectively identify those at risk for non-response to 
treatment. Further exploration and replication of our findings could have a number of translational 
implications: a) it may become feasible to use inflammatory biomarkers to individualise treatment 
choice, should a particular modality show differential efficacy in those with high levels of 
inflammation; b) we may identify at an earlier stage patients who are likely to run a more chronic 
or difficult to treat course of illness, allowing more intensive treatments to be used at an earlier 
stage; and c) we may identify patients in whom novel treatment strategies (e.g. direct anti-
inflammatory treatment) may be indicated. The identification of biological subgroups could also 
boost diagnostic accuracy and individualisation or stratification of treatments. These pathways 
have not been sufficiently explored, but complement recent research strategies to link clinical 
syndromes more closely to underlying neurobiological substrates (e.g. Insel 2014). As well as 
reducing heterogeneity this may facilitate a shift towards parity of esteem between physical and 
mental health. It is clear that although much work is needed, establishment of the relationship 
between inflammation and depressive disorders has substantial implications for reducing the 
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(LLOD / 2) 
% 
imputed 
IFNγ T1*  1 control   1.598 0.05 (0.025) 1.39%  
Eotaxin3 T1 5 controls   0.020 1.29 (0.645) 6.94% 
Mip1a T1 16 controls, 1  responder  0.352 2.28 (1.14) 23.6% 
IL-5 T1 17 controls, 2 responders, 1 non-responder 0.018 0.05 (0.025) 27.8% 
TNFβ T1 
T2** 








7 controls,6 responders, 1 non-responder 
4 responders, 1 non-responder 
0.005 
0.005 




20 controls, 3 responders, 3 non-responders 
 2 responders, 2 non-responders 
0.00003 
0.006 




6 controls, 13 responders, 6 non-responders 
5 responders, 4 non-responders 
0.015 
0.076 




28 controls, 10 responders, 3 non-responders  
3 responders, 4 non-responders 
0.0008 
0.009 




20 controls, 14 responders, 10 non-responders 
6 responders, 5 non-responders 
0.189 
0.491 




27 controls, 10 responders, 9 non-responders 
7 responders, 7 non-responders 
0.003 
0.026 




30 controls, 9 responders, 13 non-responders 
6 responders, 8 non-responders 
0.006 
0.006 




33 controls, 10 responders, 9 non-responders 
11 responders, 7 non-responders  
0.008 
0.037 
0.05 (0.025) 72% 
62.4% 
 
GM-CSF, IL-13, IL-1β, IL-2 and IL-1α were excluded from analyses as they had >50% data undetected at 
one or both time point.  
* T1 = Pre-treatment (baseline) measurement: n = 36 controls, n = 36 TRD (20 responders, 16 non-
responders) 
** T2 = Post-treatment (discharge) measurement: n = 29 TRD (17 responders, 12 non-responders). 
LLOD = lowest limit of detection. Data reported in pg/ml. 
All 20 other IMs had fully complete data. For the fully detected cytokines, manufacturer LLOD values (in 
pg/ml) are as follows, in ascending order: TNFα, IL-6, IL-10, IL-8 = 0.01; MCP1 = 0.06; IL-15 = 0.08; IL-7 = 
0.11; TARC = 0.17; IP-10, Mip1b = 0.22; IL-12 = 0.3; IL-17 = 0.45; sICAM1 = 0.46; CRP = 0.69; IL-16 = 0.88; 





 Supplementary Table 3.2   Pre-treatment IMs between TRD and control groups, adjusted 




Control group TRD group 
r2 OR 
95% CI 
Lower   Upper p cor. p lg-mean    SD lg-mean   SD 
TNFα 0.376 0.163 0.370 0.188 0.000 0.802 -3.871 3.392 0.878 0.910 
IL-6 -0.140 0.315 0.016 0.400 0.062 5.202 -0.130 3.058 0.031 0.058 
CRP 6.570 0.568 6.415 0.697 0.020 0.674 -1.496 0.288 0.345 0.460 
IL-10 -0.641 0.408 -0.498 0.300 0.056 3.561 -0.198 4.750 0.190 0.313 
IL-8 0.935 0.176 1.348 0.592 0.329 60.367 2.309 8.752 0.002 0.006 
IL-12 2.001 0.222 2.110 0.249 0.076 9.357 -0.111 4.964 0.044 0.077 
IL-7 1.165 0.222 1.142 0.183 0.004 0.573 3.775 2.171 0.647 0.725 
IL-15 0.319 0.093 0.341 0.135 0.013 6.019 -3.324 7.119 0.442 0.556 
IL-16 2.228 0.168 2.352 0.219 0.137 45.366 0.938 9.248 0.020 0.043 
IL-17 0.157 0.402 0.157 0.348 0.000 0.998 -1.290 1.754 0.987 0.987 
MCP1 2.406 0.188 2.313 0.159 0.108 0.024 -8.566 -0.707 0.031 0.058 
MCP4 1.800 0.222 2.135 0.252 0.452 372.803 3.842 11.089 0.001 0.003 
Mip1b 2.083 0.153 2.129 0.298 0.013 2.420 -1.480 4.325 0.457 0.556 
Eotaxin 1.969 0.179 2.252 0.166 0.570 31809.731 6.881 23.448 0.001 0.003 
sICAM1 5.824 0.267 5.577 0.134 0.364 0.002 -11.693 -4.035 0.001 0.003 
sVCAM1 5.905 0.289 5.602 0.128 0.480 0.000 -17.834 -5.143 0.001 0.003 
SAA 6.826 0.516 6.671 0.719 0.025 0.616 -1.879 0.347 0.305 0.500 
TARC 2.282 0.237 2.464 0.336 0.130 10.579 0.642 5.649 0.017 0.040 
Tie2 3.577 0.123 3.666 0.080 0.218 7958.018 4.342 19.730 0.002 0.006 
IP-10 2.200 0.166 2.533 0.206 0.609 23474.149 6.730 22.594 0.001 0.003 
IFNγ 0.740 0.310 0.752 0.265 0.001 1.177 -1.840 2.167 0.858 0.910 
Eotaxin3 0.315 0.491 1.252 0.279 0.876 299888.063 9.059 1318.294 0.001 0.003 
Mip1a 0.413 0.447 1.338 0.439 0.680 101.792 3.083 20.349 0.001 0.003 
IL-5 -1.110 0.627 -0.275 0.532 0.469 12.276 1.590 4.924 0.001 0.003 
TNFβ -0.990 0.439 -1.271 0.392 0.142 0.189 -3.341 -0.402 0.012 0.031 
IL-12p70 -1.214 0.524 -1.290 0.476 0.008 0.720 -1.427 0.734 0.524 0.611 
IL-4 -2.025 0.371 -1.964 0.762 0.004 1.196 -0.637 2.013 0.345 0.460 
IFNα -0.308 0.472 -0.429 0.262 0.041 0.360 -4.037 0.294 0.255 0.397 
 
Results of pre-treatment multivariate logistic regressions of inflammation (IV) on TRD versus control group 
(DV), adjusting for age, gender and BMI (covariates). Bold IM names and p values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons. 
Note that some of the OR’s are large; this is due to the levels at which markers were expressed and the 
variability across the sample.  





 Supplementary Table 3.3   Post-treatment IMs between TRD and control groups, 
adjusted for age, gender and BMI 
 
IM 
Control group TRD group 
r2 OR 
95% CI 
Lower   Upper P cor. p lg-mean    SD lg-mean   SD 
TNFα 0.376 0.163 0.413 0.182 0.020 3.932 -2.134 4.981 0.368 0.412 
IL-6 -0.140 0.315 0.040 0.323 0.117 8.666 0.249 4.980 0.025 0.044 
CRP 6.570 0.568 6.452 0.582 0.021 0.648 -1.783 0.631 0.356 0.412 
IL-10 -0.641 0.408 -0.376 0.278 0.213 22.104 0.779 10.695 0.087 0.135 
IL-8 0.935 0.176 1.562 0.695 0.492 140.003 2.825 12.503 0.006 0.015 
IL-12 2.001 0.222 2.139 0.217 0.145 32.778 0.967 7.519 0.010 0.022 
IL-7* 1.165 0.222 1.179 0.219 0.004 1.302 -2.658 3.851 0.840 0.840 
IL-15 0.319 0.093 0.348 0.127 0.027 13.022 -2.596 8.870 0.291 0.388 
IL-16 2.228 0.168 2.353 0.206 0.141 44.770 1.035 9.255 0.008 0.019 
IL-17 0.157 0.402 0.208 0.274 0.009 1.485 -1.043 2.737 0.664 0.715 
MCP1 2.406 0.188 2.397 0.171 0.006 0.601 -4.141 3.247 0.762 0.790 
MCP4 1.800 0.222 2.217 0.228 0.618 3912.782 5.763 21.586 0.001 0.003 
Mip1b 2.083 0.153 2.190 0.221 0.122 42.726 0.655 8.655 0.014 0.026 
Eotaxin 1.969 0.179 2.334 0.223 0.622 13151.451 6.542 28.503 0.001 0.003 
sICAM1 5.824 0.267 5.607 0.159 0.278 0.008 -9.735 -2.513 0.001 0.003 
sVCAM1 5.905 0.289 5.623 0.145 0.422 0.001 -14.654 -4.182 0.001 0.003 
SAA 6.826 0.516 6.661 0.539 0.041 0.492 -2.268 0.343 0.217 0.304 
TARC 2.282 0.237 2.537 0.336 0.236 33.244 1.142 8.811 0.014 0.026 
Tie2 3.577 0.123 3.684 0.084 0.279 19893.766 5.706 19.595 0.001 0.003 
IP-10 2.200 0.166 2.578 0.164 0.775 1399849.329 12.821 129.935 0.001 0.003 
IFNγ 0.740 0.310 0.878 0.276 0.080 5.752 0.003 4.308 0.054 0.089 
Eotaxin3 0.315 0.491 1.270 0.248 0.902 485738.104 9.944 812.697 0.001 0.003 
Mip1a 0.413 0.447 1.378 0.348 0.832 101334.401 7.677 1365.785 0.001 0.003 
IL-5 -1.110 0.627 -0.343 0.423 0.468 14.458 1.870 5.125 0.001 0.003 
TNFβ -0.990 0.439 -1.078 0.336 0.022 0.537 -2.207 0.791 0.320 0.407 
IL-12p70 -1.214 0.524 -1.099 0.593 0.025 1.628 0.640 4.145 0.342 0.412 
IL-4 -2.025 0.371 -1.663 0.417 0.244 11.406 1.194 5.396 0.002 0.006 
IFNα -0.308 0.472 -0.500 0.268 0.084 0.273 -4.196 -0.032 0.119 0.175 
 
Results of post-treatment multivariate logistic regressions of inflammation (IV) on TRD versus control group 
(DV), adjusting for age, gender and BMI (covariates). Bold IM names and p values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons. 
Note that some of the OR’s are large; this is due to the levels at which markers were expressed and the 
variability across the sample.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. When unadjusted for age, gender 
and BMI IL-7 regression model fit was satisfactory. All other regression models were adequately fitted 












Correlation (r value), significance (p value) 
 
TNFα r = 0.529, p = 0.003 
IL-6 n.s. 
CRP r = 0.695, p < 0.001 
IL-10 r = 0.507, p = 0.005 
IL-8 n.s. 
IL-12 r = 0.768, p < 0.001 
IL-7 n.s. 
IL-15 r = 0.764, p < 0.001 
IL-16 r = 0.434, p = 0.019 
IL-17 r = 0.376, p = 0.044 
MCP1 r = 0.418, p = 0.024 
MCP4 n.s. 
Mip1b r = 0.367, p = 0.049 
Eotaxin r = 0.497, p = 0.006 
sICAM1 r = 0.48, p = 0.008 
sVCAM1 r = 0.656, p < 0.001 
SAA r = 0.616, p < 0.001 
TARC r = 0.558, p = 0.002 
Tie2 n.s. 
IP-10 r = 0.552, p = 0.002 
IFNγ r = 0.496, p = 0.006 
Eotaxin-3 r = 0.51, p = 0.005 
Mip1a n.s. 






n.s. = p > 0.05.  
IMs from IFNγ onwards had non-detected values (in descending order of completeness prior to imputation). 
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 TNF r   .613 * .136 .412  .495 * .472 * .083 .096 .090 .440 * .434 * .317 .527 * .045 .061 .279 .042 .299 .176 .476 * .335  .273 .523 * .155 .466 * .214 .146 -.107 
p   .000 .428 .013 .002 .004 .632 .578 .603 .007 .008 .060 .001 .794 .724 .099 .808 .076 .304 .003 .046 .108 .001 .368 .004 .211 .396 .534 
 IL6 r .613 *   .593 * .423  .400  .382  .191 .165 .334  .353  .482 * .315 .302 .050 .258 .398  .592 * .344  .361  .309 .421  .149 .319 .277 .110 .223 .105 -.110 
p .000   .000 .010 .016 .022 .266 .335 .046 .035 .003 .061 .074 .770 .129 .016 .000 .040 .031 .067 .011 .386 .058 .102 .522 .190 .542 .525 
 CRP r .136 .593 *   .080 -.047 .387  .017 .382  .639 * .375  .304 .152 -.112 -.071 .475 * .325 .819 * .203 .053 .056 .188 .161 -.030 .300 .048 .296 .149 .011 
p .428 .000   .642 .787 .020 .923 .022 .000 .024 .071 .376 .517 .681 .003 .053 .000 .236 .758 .745 .272 .348 .863 .075 .783 .079 .385 .948 
 IL10 r .412  .423  .080   .311 .272 .118 -.081 .091 .377  .159 .108 .228 .012 -.029 .217 .246 .100 .068 .201 .174 .390  .386  .416  .003 .076 .176 -.394  
p .013 .010 .642   .065 .108 .494 .637 .596 .023 .353 .531 .180 .944 .869 .203 .149 .562 .694 .239 .311 .019 .020 .012 .988 .660 .305 .017 
 IL8 r .495 * .400  -.047 .311   -.228 .273 -.381  -.024 -.098 .207 .512 * .670 * .269 -.164 -.022 -.058 .418  .160 .025 -.042 .154 .661 * .040 -.080 -.077 .169 -.286 
p .002 .016 .787 .065   .180 .107 .022 .888 .570 .225 .001 .000 .112 .338 .898 .737 .011 .351 .887 .806 .369 .000 .819 .643 .655 .324 .091 
 IL12 r .472 * .382  .387  .272 -.228   .043 .447 * .201 .601 * .377  .025 .091 -.117 .286 .482 * .257 .025 -.073 .482 * .449 * .235 .001 .044 .433 * .159 .152 .035 
p .004 .022 .020 .108 .180   .804 .006 .239 .000 .023 .884 .597 .495 .091 .003 .130 .887 .673 .003 .006 .168 .993 .801 .008 .354 .376 .840 
 IL7 r .083 .191 .017 .118 .273 .043   .116 .005 .024 .099 .409  .299 .471 * -.251 .059 .038 .549 * .143 .310 .331  -.011 .044 -.218 .145 -.133 -.002 .056 
p .632 .266 .923 .494 .107 .804   .502 .975 .889 .565 .013 .077 .004 .139 .734 .826 .001 .406 .065 .049 .949 .801 .203 .400 .440 .992 .744 
 IL15 r .096 .165 .382  -.081 -.381  .447 * .116   .427 * .301 .256 -.065 -.217 -.079 .143 .299 .347  .058 .041 .208 .446 * .318 -.207 -.041 .373  .065 -.068 .215 
p .578 .335 .022 .637 .022 .006 .502   .009 .075 .132 .707 .204 .647 .406 .077 .038 .735 .813 .223 .006 .059 .226 .814 .025 .706 .695 .209 
 IL16 r .090 .334  .639 * .091 -.024 .201 .005 .427 *   .270 .360  .121 -.108 .023 .236 .133 .550 * .130 -.166 .207 .170 .433 * -.192 .297 -.014 .354  .072 .046 
p .603 .046 .000 .596 .888 .239 .975 .009   .112 .031 .482 .529 .892 .166 .440 .001 .451 .333 .227 .322 .008 .262 .078 .934 .034 .674 .790 
 IL17 r .440 * .353  .375  .377  -.098 .601 * .024 .301 .270   .088 .034 .036 -.212 .064 .072 .420  -.031 -.129 .157 .376  .312 -.032 .254 .458 * .385  .286 .008 
p .007 .035 .024 .023 .570 .000 .889 .075 .112   .612 .843 .834 .215 .712 .677 .011 .859 .452 .359 .024 .064 .854 .135 .005 .020 .091 .964 
 MCP1 r .434 * .482 * .304 .159 .207 .377  .099 .256 .360  .088   .434 * .311 .519 * .270 .412  .050 .389  .071 .544 * .358  .274 .139 .043 .138 -.011 -.092 .005 
p .008 .003 .071 .353 .225 .023 .565 .132 .031 .612   .008 .065 .001 .111 .012 .771 .019 .683 .001 .032 .106 .418 .802 .422 .951 .593 .975 
 MCP4 r .317 .315 .152 .108 .512 * .025 .409  -.065 .121 .034 .434 *   .489 * .618 * .030 .111 .031 .683 * .358  .161 .115 .352  .293 .086 .087 -.040 .322 .010 
p .060 .061 .376 .531 .001 .884 .013 .707 .482 .843 .008   .002 .000 .860 .518 .855 .000 .032 .350 .505 .035 .083 .617 .614 .816 .056 .953 
 Mip1b r .527 * .302 -.112 .228 .670 * .091 .299 -.217 -.108 .036 .311 .489 *   .406  -.101 .099 -.173 .443 * .108 .229 .179 .128 .596 * -.122 .288 -.150 .403  -.101 
p .001 .074 .517 .180 .000 .597 .077 .204 .529 .834 .065 .002   .014 .557 .567 .314 .007 .531 .179 .296 .458 .000 .477 .088 .384 .015 .558 
Eotaxin r .045 .050 -.071 .012 .269 -.117 .471 * -.079 .023 -.212 .519 * .618 * .406    -.070 .081 -.212 .522 * .229 .220 -.034 .206 .197 -.144 -.044 -.209 -.182 .019 
p .794 .770 .681 .944 .112 .495 .004 .647 .892 .215 .001 .000 .014   .685 .637 .214 .001 .178 .198 .844 .227 .249 .403 .798 .221 .289 .914 
slCAM1 r .061 .258 .475 * -.029 -.164 .286 -.251 .143 .236 .064 .270 .030 -.101 -.070   .689 * .336  -.167 -.160 .241 .065 .167 .000 .390  .095 .163 .007 .294 
p .724 .129 .003 .869 .338 .091 .139 .406 .166 .712 .111 .860 .557 .685   .000 .045 .329 .351 .156 .706 .330 .999 .019 .580 .341 .970 .082 




































































































































p .099 .016 .053 .203 .898 .003 .734 .077 .440 .677 .012 .518 .567 .637 .000   .054 .951 .337 .003 .038 .393 .260 .443 .425 .540 .935 .056 
 SAA r .042 .592 * .819 * .246 -.058 .257 .038 .347  .550 * .420  .050 .031 -.173 -.212 .336  .324   .100 .077 -.042 .255 .061 .007 .401  -.073 .290 .198 .012 
p .808 .000 .000 .149 .737 .130 .826 .038 .001 .011 .771 .855 .314 .214 .045 .054   .562 .656 .806 .133 .724 .970 .015 .673 .086 .248 .945 
 TARC r .299 .344  .203 .100 .418  .025 .549 * .058 .130 -.031 .389  .683 * .443 * .522 * -.167 .011 .100   .371  .042 .079 .135 .389  .095 .291 -.211 .108 .131 
p .076 .040 .236 .562 .011 .887 .001 .735 .451 .859 .019 .000 .007 .001 .329 .951 .562   .026 .808 .648 .431 .019 .583 .085 .216 .532 .446 
 Tie2 r .176 .361  .053 .068 .160 -.073 .143 .041 -.166 -.129 .071 .358  .108 .229 -.160 -.165 .077 .371    -.086 -.017 .009 .237 -.002 -.074 -.016 -.161 -.280 
p .304 .031 .758 .694 .351 .673 .406 .813 .333 .452 .683 .032 .531 .178 .351 .337 .656 .026   .616 .921 .959 .164 .989 .666 .927 .348 .098 
 IP10 r .476 * .309 .056 .201 .025 .482 * .310 .208 .207 .157 .544 * .161 .229 .220 .241 .478 * -.042 .042 -.086   .555 * .072 -.115 -.177 .291 .193 .044 .087 
p .003 .067 .745 .239 .887 .003 .065 .223 .227 .359 .001 .350 .179 .198 .156 .003 .806 .808 .616   .000 .678 .505 .301 .086 .260 .801 .614 
IFNγ r .335  .421  .188 .174 -.042 .449 * .331  .446 * .170 .376  .358  .115 .179 -.034 .065 .347  .255 .079 -.017 .555 *   .002 -.225 -.159 .377  .138 .192 .176 
p .046 .011 .272 .311 .806 .006 .049 .006 .322 .024 .032 .505 .296 .844 .706 .038 .133 .648 .921 .000   .989 .186 .355 .023 .422 .262 .305 
Eotaxin3 r .273 .149 .161 .390  .154 .235 -.011 .318 .433 * .312 .274 .352  .128 .206 .167 .147 .061 .135 .009 .072 .002   .184 .298 .164 .063 .163 -.140 
p .108 .386 .348 .019 .369 .168 .949 .059 .008 .064 .106 .035 .458 .227 .330 .393 .724 .431 .959 .678 .989   .282 .077 .338 .715 .344 .415 
Mip1a r .523 * .319 -.030 .386  .661 * .001 .044 -.207 -.192 -.032 .139 .293 .596 * .197 .000 .193 .007 .389  .237 -.115 -.225 .184   .165 .021 -.254 .121 -.199 
p .001 .058 .863 .020 .000 .993 .801 .226 .262 .854 .418 .083 .000 .249 .999 .260 .970 .019 .164 .505 .186 .282   .336 .902 .135 .483 .245 
IL5 r .155 .277 .300 .416  .040 .044 -.218 -.041 .297 .254 .043 .086 -.122 -.144 .390  .132 .401  .095 -.002 -.177 -.159 .298 .165   .029 .091 .080 -.141 
p .368 .102 .075 .012 .819 .801 .203 .814 .078 .135 .802 .617 .477 .403 .019 .443 .015 .583 .989 .301 .355 .077 .336   .868 .596 .644 .412 
TNFβ r .466 * .110 .048 .003 -.080 .433 * .145 .373  -.014 .458 * .138 .087 .288 -.044 .095 .137 -.073 .291 -.074 .291 .377  .164 .021 .029   .019 .175 .431 * 
p .004 .522 .783 .988 .643 .008 .400 .025 .934 .005 .422 .614 .088 .798 .580 .425 .673 .085 .666 .086 .023 .338 .902 .868   .912 .307 .009 
IL12p70 r .214 .223 .296 .076 -.077 .159 -.133 .065 .354  .385  -.011 -.040 -.150 -.209 .163 -.106 .290 -.211 -.016 .193 .138 .063 -.254 .091 .019   .075 -.074 
p .211 .190 .079 .660 .655 .354 .440 .706 .034 .020 .951 .816 .384 .221 .341 .540 .086 .216 .927 .260 .422 .715 .135 .596 .912   .665 .667 
IL4 r .146 .105 .149 .176 .169 .152 -.002 -.068 .072 .286 -.092 .322 .403  -.182 .007 .014 .198 .108 -.161 .044 .192 .163 .121 .080 .175 .075   -.142 
p .396 .542 .385 .305 .324 .376 .992 .695 .674 .091 .593 .056 .015 .289 .970 .935 .248 .532 .348 .801 .262 .344 .483 .644 .307 .665   .408 
IFNα r -.107 -.110 .011 -.394  -.286 .035 .056 .215 .046 .008 .005 .010 -.101 .019 .294 .321 .012 .131 -.280 .087 .176 -.140 -.199 -.141 .431 * -.074 -.142   
p .534 .525 .948 .017 .091 .840 .744 .209 .790 .964 .975 .953 .558 .914 .082 .056 .945 .446 .098 .614 .305 .415 .245 .412 .009 .667 .408   
  






































































































































TNFα r  .532* .210 .537* .677* .275 .130 .198 .423 .296 .315 .395 .751* .210 .163 .244 .080 .276 -.249 .363 .450 .292 .794* -.198 .124 .245 .530* .026 
p  .003 .275 .003 .000 .148 .502 .302 .022 .120 .096 .034 .000 .274 .398 .201 .679 .147 .194 .053 .014 .124 .000 .303 .520 .200 .003 .896 
IL6 r .532*  .591* .216 .449 .356 -.271 .233 .350 .452 .158 .263 .324 .035 .526* .362 .450 .180 -.248 -.012 .268 .247 .414 .074 .301 .486* .459 .131 
p .003  .001 .260 .015 .058 .154 .223 .063 .014 .413 .168 .087 .855 .003 .054 .014 .349 .195 .952 .160 .196 .025 .702 .113 .008 .012 .505 
CRP r .210 .591*  -.014 -.012 .384 .146 .190 .429 .466 .181 .362 -.114 .157 .815* .667* .764* .361 -.038 .178 .211 -.014 -.084 .247 .284 .204 .142 -.172 
p .275 .001  .944 .949 .040 .450 .324 .020 .011 .349 .054 .555 .417 .000 .000 .000 .055 .845 .355 .271 .943 .665 .196 .136 .288 .464 .382 
IL10 r .537* .216 -.014  .581* .055 -.045 -.148 .119 .310 .097 -.146 .494* .064 -.085 -.152 -.022 -.118 -.385 -.037 .072 .148 .635* -.049 .250 .354 .417 .027 
p .003 .260 .944  .001 .776 .816 .442 .539 .102 .615 .451 .007 .743 .659 .432 .909 .542 .039 .851 .712 .444 .000 .799 .191 .059 .025 .892 
IL8 r .677* .449 -.012 .581*  -.143 .032 -.138 .137 .178 .257 .280 .723* .161 -.089 -.166 -.131 .358 -.233 -.033 .214 .422 .840* -.126 .023 .553* .456 .054 
p .000 .015 .949 .001  .458 .869 .474 .477 .356 .179 .141 .000 .404 .646 .388 .499 .057 .224 .864 .265 .023 .000 .515 .907 .002 .013 .786 
IL12 r .275 .356 .384 .055 -.143  -.161 .259 .278 .262 .061 .049 .092 .041 .417 .462 .329 -.124 -.267 .378 .135 .157 .027 -.010 .350 -.107 .166 .086 
p .148 .058 .040 .776 .458  .404 .175 .144 .171 .751 .799 .635 .831 .024 .012 .082 .523 .161 .043 .485 .415 .889 .959 .063 .582 .390 .663 
IL7 r .130 -.271 .146 -.045 .032 -.161  .149 .503* .225 .290 .540* .157 .580* .084 .169 .039 .633* .033 .266 .089 .133 .071 .117 .003 -.091 .078 -.512* 
p .502 .154 .450 .816 .869 .404  .439 .005 .240 .127 .003 .417 .001 .664 .381 .840 .000 .867 .164 .647 .491 .715 .547 .989 .639 .688 .005 
IL15 r .198 .233 .190 -.148 -.138 .259 .149  .300 .265 .215 .319 -.003 .301 .332 .396 .254 .167 -.219 .377 .546* .107 .125 -.154 .202 .138 .128 .074 
p .302 .223 .324 .442 .474 .175 .439  .113 .165 .262 .092 .986 .113 .079 .034 .185 .386 .253 .044 .002 .581 .519 .424 .293 .475 .509 .708 
IL16 r .423 .350 .429 .119 .137 .278 .503* .300  .375 .103 .272 .222 .292 .407 .481* .584* .450 -.146 .185 .201 .094 .277 .201 .263 .108 .498* -.087 
p .022 .063 .020 .539 .477 .144 .005 .113  .045 .593 .154 .247 .124 .028 .008 .001 .014 .450 .338 .296 .627 .146 .296 .168 .577 .006 .662 
IL17 r .296 .452 .466 .310 .178 .262 .225 .265 .375  -.012 .133 .099 .159 .338 .240 .377 .211 -.337 .119 .200 -.085 .178 .094 .200 .227 .181 -.228 
p .120 .014 .011 .102 .356 .171 .240 .165 .045  .951 .492 .610 .411 .073 .210 .044 .272 .074 .538 .298 .662 .355 .629 .299 .236 .349 .243 
MCP1 r .315 .158 .181 .097 .257 .061 .290 .215 .103 -.012  .677* .274 .702* .194 .169 -.179 .252 -.044 .232 .020 .658* .249 -.074 .087 -.007 .032 -.001 
p .096 .413 .349 .615 .179 .751 .127 .262 .593 .951  .000 .150 .000 .313 .382 .354 .188 .819 .226 .917 .000 .192 .703 .652 .971 .870 .996 
MCP4 r .395 .263 .362 -.146 .280 .049 .540* .319 .272 .133 .677*  .313 .726* .312 .353 -.006 .660* .144 .348 .233 .512* .254 .073 .176 -.024 .220 -.290 
p .034 .168 .054 .451 .141 .799 .003 .092 .154 .492 .000  .098 .000 .100 .060 .974 .000 .458 .064 .224 .004 .184 .708 .362 .900 .252 .134 
Mip1b r .751* .324 -.114 .494* .723* .092 .157 -.003 .222 .099 .274 .313  .320 -.065 -.083 -.250 .264 -.319 .228 .316 .476* .814* -.333 .000 .197 .564* .112 
p .000 .087 .555 .007 .000 .635 .417 .986 .247 .610 .150 .098  .091 .736 .669 .192 .166 .092 .235 .095 .009 .000 .078 .999 .304 .001 .569 
Eotaxin r .210 .035 .157 .064 .161 .041 .580* .301 .292 .159 .702* .726* .320  .151 .187 -.082 .506* .002 .265 .103 .598* .191 -.082 .229 -.097 .172 -.277 
p .274 .855 .417 .743 .404 .831 .001 .113 .124 .411 .000 .000 .091  .433 .331 .671 .005 .990 .165 .595 .001 .320 .672 .232 .616 .372 .154 
slCAM1 r .163 .526* .815* -.085 -.089 .417 .084 .332 .407 .338 .194 .312 -.065 .151  .762* .624* .298 -.175 .289 .241 .073 -.176 .372 .287 .157 .247 .037 
p .398 .003 .000 .659 .646 .024 .664 .079 .028 .073 .313 .100 .736 .433  .000 .000 .116 .364 .128 .208 .708 .360 .047 .132 .417 .196 .852 
sVCAM 
1 
r .244 .362 .667* -.152 -.166 .462 .169 .396 .481* .240 .169 .353 -.083 .187 .762*  .566* .324 .003 .397 .370 .068 -.089 .271 .257 -.182 .008 .103 



































































































































SAA r .080 .450 .764* -.022 -.131 .329 .039 .254 .584* .377 -.179 -.006 -.250 -.082 .624* .566*  .208 -.041 .116 .262 -.301 -.107 .193 .315 .244 .220 .038 
p .679 .014 .000 .909 .499 .082 .840 .185 .001 .044 .354 .974 .192 .671 .000 .001  .279 .835 .549 .171 .112 .582 .317 .096 .201 .252 .846 
TARC r .276 .180 .361 -.118 .358 -.124 .633* .167 .450 .211 .252 .660* .264 .506* .298 .324 .208  .011 .139 .291 .265 .240 .122 -.024 .115 .254 -.338 
p .147 .349 .055 .542 .057 .523 .000 .386 .014 .272 .188 .000 .166 .005 .116 .086 .279  .953 .472 .125 .164 .210 .529 .904 .554 .184 .079 
Tie2 r -.249 -.248 -.038 -.385 -.233 -.267 .033 -.219 -.146 -.337 -.044 .144 -.319 .002 -.175 .003 -.041 .011  -.149 -.156 -.248 -.221 -.103 -.203 -.290 -.364 -.314 
p .194 .195 .845 .039 .224 .161 .867 .253 .450 .074 .819 .458 .092 .990 .364 .987 .835 .953  .440 .420 .195 .250 .593 .290 .128 .052 .104 
IP10 r .363 -.012 .178 -.037 -.033 .378 .266 .377 .185 .119 .232 .348 .228 .265 .289 .397 .116 .139 -.149  .613* .120 .121 -.143 -.003 -.182 -.041 -.128 
p .053 .952 .355 .851 .864 .043 .164 .044 .338 .538 .226 .064 .235 .165 .128 .033 .549 .472 .440  .000 .535 .532 .460 .987 .344 .833 .516 
IFNγ r .450 .268 .211 .072 .214 .135 .089 .546* .201 .200 .020 .233 .316 .103 .241 .370 .262 .291 -.156 .613*  -.027 .378 -.312 .117 .257 .109 .091 
p .014 .160 .271 .712 .265 .485 .647 .002 .296 .298 .917 .224 .095 .595 .208 .048 .171 .125 .420 .000  .890 .043 .099 .544 .178 .573 .645 
Eotaxin 
3 
r .292 .247 -.014 .148 .422 .157 .133 .107 .094 -.085 .658* .512* .476* .598* .073 .068 -.301 .265 -.248 .120 -.027  .410 .055 .192 .055 .149 .120 
p .124 .196 .943 .444 .023 .415 .491 .581 .627 .662 .000 .004 .009 .001 .708 .725 .112 .164 .195 .535 .890  .027 .776 .317 .777 .442 .545 
Mip1a r .794* .414 -.084 .635* .840* .027 .071 .125 .277 .178 .249 .254 .814* .191 -.176 -.089 -.107 .240 -.221 .121 .378 .410  -.294 .108 .418 .479* .027 
p .000 .025 .665 .000 .000 .889 .715 .519 .146 .355 .192 .184 .000 .320 .360 .646 .582 .210 .250 .532 .043 .027  .121 .577 .024 .008 .891 
IL5 r -.198 .074 .247 -.049 -.126 -.010 .117 -.154 .201 .094 -.074 .073 -.333 -.082 .372 .271 .193 .122 -.103 -.143 -.312 .055 -.294  .318 -.002 .111 .087 
p .303 .702 .196 .799 .515 .959 .547 .424 .296 .629 .703 .708 .078 .672 .047 .155 .317 .529 .593 .460 .099 .776 .121  .092 .991 .567 .661 
TNFβ r .124 .301 .284 .250 .023 .350 .003 .202 .263 .200 .087 .176 .000 .229 .287 .257 .315 -.024 -.203 -.003 .117 .192 .108 .318  .342 .321 .170 
p .520 .113 .136 .191 .907 .063 .989 .293 .168 .299 .652 .362 .999 .232 .132 .179 .096 .904 .290 .987 .544 .317 .577 .092  .070 .090 .387 
IL12p70 r .245 .486* .204 .354 .553* -.107 -.091 .138 .108 .227 -.007 -.024 .197 -.097 .157 -.182 .244 .115 -.290 -.182 .257 .055 .418 -.002 .342  .398 .039 
p .200 .008 .288 .059 .002 .582 .639 .475 .577 .236 .971 .900 .304 .616 .417 .345 .201 .554 .128 .344 .178 .777 .024 .991 .070  .032 .844 
IL4 r .530* .459 .142 .417 .456 .166 .078 .128 .498* .181 .032 .220 .564* .172 .247 .008 .220 .254 -.364 -.041 .109 .149 .479* .111 .321 .398  .097 
p .003 .012 .464 .025 .013 .390 .688 .509 .006 .349 .870 .252 .001 .372 .196 .967 .252 .184 .052 .833 .573 .442 .008 .567 .090 .032  .622 
IFNα r .026 .131 -.172 .027 .054 .086 -.512* .074 -.087 -.228 -.001 -.290 .112 -.277 .037 .103 .038 -.338 -.314 -.128 .091 .120 .027 .087 .170 .039 .097  
p .896 .505 .382 .892 .786 .663 .005 .708 .662 .243 .996 .134 .569 .154 .852 .603 .846 .079 .104 .516 .645 .545 .891 .661 .387 .844 .622  
 
* = p < 0.01 
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imputed   
TNFβ T1 * 
T2 ** 




0.04 (0.02) 7.3% 
6% 
Eotaxin-3 T1  
T2   








22 responders, 26 non-responders 
12 responders, 9 non-responders 
0.01 
0.002 




25 responders, 26 non-responders 
19 responders, 5 non-responders 
0.109 
0.134 




30 responders, 24 non-responders 
17 responders, 9 non-responders 
0.0009 
0.007 




30 responders, 29 non-responders 
20 responders, 9 non-responders 
0.0019 
0.007 




28 responders, 34 non-responders 
17 responders, 12 responders 
0.001 
0.002 




37 responders, 37 non-responders 
24 responders, 16 non-responders 
0.002 
0.003 




33 responders, 30 non-responders 
25 responders, 16 non-responders 
1.93 
3.63 




44 responders, 46 non-responders 
28 responders, 16 non-responders 
0.078 
0.031 




46 responders, 43 non-responders 
29 responders, 15 non-responders 
0.312 
0.024 
0.05 (0.025) 92.7%  
88% 
 
Only IMs with non-detected data are reported. IL-13, GM-CSF, IL-4, IL-2, IL-1α, Mip1a, IL-1β and IL-5 were 
excluded from analyses due to high rates of non-detection (>50%, at least one time point).   
* T1 = Pre-treatment measurement: n = 47 responders, n = 49 non-responders. 
** T2 = Post-treatment measurement: n = 31 responders, n = 18 non-responders.   
LLOD = lowest limit of detection. Data reported in pg/ml. 
The remaining 21 IMs were fully detected. Of these, the manufacturer LLOD values (in pg/ml) are as follows, 
in ascending order: TNFα, IL-6, IL-10, IL-8 = 0.01; IFNγ = 0.05; MCP1 = 0.06; IL-15 = 0.08; IL-7 = 0.11; 
TARC = 0.17; IP-10, Mip1b = 0.22; IL-12 = 0.3; IL-17 = 0.45; sICAM1 = 0.46; CRP = 0.69; IL-16 = 0.88; 






Supplementary Table 4.2    Pre-treatment inflammation in subsequent responders and 




lg-mean    SD 
Non-responder 
lg-mean     SD r2 OR 
95% CI 
Lower  Upper   P cor. p 
TNFα 0.289 0.108 0.348 0.111 0.121 0.006 -10.951 -0.645 0.026 0.268 
IL-6 -0.318 0.286 -0.170 0.276 0.115 0.154 -4.179 -0.117 0.035 0.268 
CRP * 6.201 0.539 6.388 0.557 0.079 0.526 -1.604 0.230 0.130 0.298 
IL-10 -0.732 0.407 -0.675 0.304 0.051 0.652 -1.848 0.969 0.403 0.904 
IL-8 0.951 0.182 0.979 0.165 0.045 1.246 -2.566 3.434 0.880 0.939 
IL-12 1.307 0.163 1.305 0.181 0.044 0.899 -2.145 1.764 0.870 0.939 
IL-7 1.967 0.222 1.968 0.278 0.046 1.665 -2.003 3.593 0.699 0.939 
IL-15 0.447 0.105 0.439 0.127 0.051 3.730 -2.601 5.208 0.469 0.904 
IL-16 2.325 0.177 2.329 0.162 0.044 0.866 -2.784 2.914 0.901 0.939 
IL-17 0.256 0.390 0.199 0.303 0.051 1.534 -0.979 1.799 0.503 0.904 
MCP1 2.457 0.152 2.470 0.172 0.051 2.844 -2.121 4.813 0.505 0.904 
MCP4 2.170 0.189 2.182 0.226 0.045 1.291 -2.331 2.636 0.804 0.939 
Mip1b 2.089 0.193 2.145 0.179 0.062 0.256 -4.569 0.973 0.218 0.904 
Eotaxin 2.296 0.208 2.326 0.223 0.046 1.523 -1.821 2.856 0.699 0.939 
sICAM1 6.481 0.415 6.546 0.353 0.096 0.013 -9.708 -0.073 0.034 0.268 
sVCAM1 5.668 0.097 5.717 0.111 0.046 0.444 -5.680 4.506 0.726 0.939 
SAA 5.775 0.097 5.785 0.085 0.048 0.739 -1.588 1.088 0.625 0.939 
TARC 2.472 0.226 2.526 0.297 0.050 0.599 -2.388 1.289 0.511 0.904 
Tie2 3.625 0.192 3.703 0.176 0.077 0.140 -6.726 0.953 0.265 0.904 
IP-10 2.326 0.154 2.368 0.241 0.045 0.708 -3.589 2.078 0.778 0.939 
IFNγ 0.707 0.285 0.592 0.249 0.105 5.664 0.195 4.411 0.049 0.282 
Eotaxin3 0.742 0.491 0.795 0.442 0.044 0.971 -1.124 1.070 0.939 0.939 
TNFβ -0.725 0.541 -0.663 0.428 0.052 0.706 -1.622 0.587 0.478 0.904 
 
Results of multivariate logistic regressions of inflammation (IV) on responder versus non-responder group 
(DV) before psychological treatment, adjusting for age, gender and BMI (covariates). Bold IM names and p 
values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.  
* Hosmer-Lemeshow test p < 0.05, indicating possible poor model fitting. When unadjusted for age, gender 
and BMI the CRP regression model fit was satisfactory. All other regression models were adequately fitted 





Supplementary Table 4.3   Post-treatment comparison of inflammation between 





lg-mean    SD 
Non-responder 
lg-mean     SD 
r2 OR 
95% CI 
Lower  Upper   
P cor. p 
TNFα 0.303 0.108 0.338 0.123 0.104 0.038 -13.274 4.453 0.369 0.644 
IL-6 -0.298 0.298 -0.079 0.299 0.198 0.057 -8.695 0.145 0.052 0.239 
CRP 6.172 0.506 6.599 0.568 0.204 0.234 -3.659 -0.015 0.023 0.199 
IL-10 -0.652 0.289 -0.567 0.259 0.128 0.180 -4.970 0.768 0.106 0.348 
IL-8 1.012 0.130 1.081 0.175 0.108 0.083 -11.254 2.768 0.346 0.644 
IL-12 1.359 0.144 1.415 0.180 0.076 1.437 -4.863 3.007 0.786 0.861 
IL-7 1.970 0.200 1.937 0.264 0.099 0.129 -9.156 2.822 0.390 0.644 
IL-15 0.481 0.115 0.530 0.105 0.104 0.035 -12.830 3.172 0.276 0.644 
IL-16 2.300 0.147 2.334 0.163 0.086 0.231 -8.023 3.409 0.530 0.695 
IL-17 0.309 0.347 0.288 0.279 0.081 1.648 -1.529 3.621 0.621 0.714 
MCP1 2.467 0.168 2.549 0.218 0.091 0.207 -10.524 3.261 0.574 0.695 
MCP4 2.142 0.151 2.272 0.220 0.204 0.014 -12.775 0.051 0.038 0.219 
Mip1b 2.115 0.159 2.117 0.135 0.074 1.169 -5.035 5.409 0.932 0.945 
Eotaxin 2.317 0.213 2.359 0.254 0.074 0.920 -3.849 4.050 0.945 0.945 
sICAM1 6.413 0.468 6.646 0.332 0.161 0.003 -15.928 1.601 0.070 0.268 
sVCAM1 5.684 0.100 5.758 0.124 0.144 0.005 -17.960 1.555 0.177 0.509 
SAA 5.782 0.092 5.825 0.114 0.113 0.374 -4.945 0.697 0.315 0.644 
TARC 2.451 0.266 2.720 0.336 0.258 0.039 -7.459 -1.344 0.001 0.023 
Tie2 3.607 0.223 3.682 0.231 0.090 0.300 -8.447 2.341 0.546 0.695 
IP-10 2.332 0.151 2.383 0.191 0.087 0.253 -6.823 3.675 0.568 0.695 
IFNγ 0.701 0.316 0.538 0.320 0.186 9.331 0.294 5.996 0.026 0.199 
Eotaxin3 0.743 0.496 0.916 0.404 0.100 0.387 -5.205 1.372 0.420 0.644 
TNFβ -0.664 0.469 -0.578 0.388 0.091 0.551 -2.627 0.951 0.395 0.644 
 
Results of multivariate logistic regressions of inflammation (IV) on responder versus non-responder group 
(DV), adjusting for age, gender and BMI (covariates) after psychological treatment. Bold IM names and p 
values indicate significant effects.  
lg-mean = log-transformed mean value, SD = standard deviation, r2 = model r-squared value, OR = odds 
ratio, equivalent to standardised beta coefficient, 95% CI = 95% confidence intervals, p = uncorrected p, 
before Simes control for multiple comparisons, cor. p = p value after Simes control for multiple comparisons.  














Correlation (r value), significance (p value) 
TNFα r = 0.687, p < 0.001  
IL-6 r = 0.686, p < 0.001 
CRP r = 0.705, p < 0.001 
IL-10 r = 0.798, p < 0.001 
IL-8 r = 0.582, p = 0.001 
IL-7 r = 0.495, p = 0.001 
IL-12 r = 0.817, p < 0.001 
Il-15 r = 0.591, p < 0.001 
IL-16 r = 0.435, p = 0.002 
IL-17 r = 0.679, p < 0.001 
MCP1 r = 0.755, p < 0.001 
MCP4 r = 0.766, p < 0.001 
Mip1b r = 0.842, p < 0.001 
Eotaxin r = 0.771, p < 0.001 
sICAM1 r = 0.662, p < 0.001 
sVCAM1 r = 0.342, p = 0.015 
SAA r = 0.539, p = 0.001 
TARC r = 0.853, p < 0.001 
Tie2 r = 0.913, p < 0.001 
IP-10 r = 0.591, p < 0.001 
IFNγ r = 0.555, p = 0.001 
Eotaxin-3 r = 0.558, p = 0.001 
TNFβ r = 0.298, p = 0.038 
 
 n.s. = p > 0.05.   
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TNFα r  .239 .311* .248 .345* .055 .151 -.129 .248 .093 .308* .222 .361* .217 .458* .290* .213 .177 -.007 .402* .140 .232 .110 
p  .019 .002 .015 .001 .596 .142 .212 .015 .368 .002 .030 .000 .034 .000 .004 .037 .084 .946 .000 .174 .023 .288 
IL6 r .239  .515* .221 .053 -.120 .147 .268* -.048 .142 .343* .325* .307* .196 .297* -.052 .368* .237 .161 .315* .047 .195 -.110 
p .019  .000 .031 .608 .244 .152 .008 .642 .167 .001 .001 .002 .055 .003 .617 .000 .020 .116 .002 .647 .058 .285 
CRP r .311* .515*  -.039 .118 -.154 .094 -.006 .024 .107 .149 .179 .159 .114 .431* -.105 .598* .209 .052 .210 -.008 .029 -.049 
p .002 .000  .705 .252 .135 .362 .953 .814 .299 .147 .081 .123 .269 .000 .308 .000 .041 .616 .040 .935 .777 .637 
IL10 r .248 .221 -.039  .100 .104 .050 .074 -.046 .080 .091 .249 .134 .084 .127 .038 .011 .014 .142 .081 .270* -.061 -.108 
p .015 .031 .705  .334 .314 .627 .471 .657 .441 .376 .015 .192 .416 .217 .715 .912 .893 .168 .431 .008 .558 .295 
IL8 r .345* .053 .118 .100  .061 .241 .090 .172 .131 .324* .191 .139 .401* .209 .184 .024 .105 .073 .106 -.019 .194 .082 
p .001 .608 .252 .334  .558 .018 .383 .094 .202 .001 .062 .175 .000 .041 .073 .820 .307 .481 .303 .853 .058 .430 
IL12 r .055 -.120 -.154 .104 .061  -.012 .167 .179 .394* .067 .179 .100 .015 .117 .228 -.133 -.078 .221 .274* .067 .173 .281* 
p .596 .244 .135 .314 .558  .908 .105 .081 .000 .514 .082 .333 .882 .258 .025 .198 .452 .030 .007 .519 .092 .006 
IL7 r .151 .147 .094 .050 .241 -.012  .096 -.133 -.062 .211 .151 .059 .244 -.031 -.087 .154 .134 -.037 .237 .181 .185 -.117 
p .142 .152 .362 .627 .018 .908  .350 .197 .548 .039 .143 .567 .017 .764 .400 .133 .193 .718 .020 .078 .071 .258 
IL15 r -.129 .268* -.006 .074 .090 .167 .096  .087 .174 .429* .421* .132 .316* .348* .093 .212 .370* .337* .133 -.124 .171 -.167 
p .212 .008 .953 .471 .383 .105 .350  .400 .090 .000 .000 .199 .002 .001 .365 .038 .000 .001 .196 .230 .096 .104 
IL16 r .248 -.048 .024 -.046 .172 .179 -.133 .087  .141 .132 .082 .188 .183 .203 .345* .055 .122 .099 .073 -.215 .319* .039 
p .015 .642 .814 .657 .094 .081 .197 .400  .170 .200 .430 .067 .075 .048 .001 .594 .237 .338 .479 .035 .002 .709 
IL17 r .093 .142 .107 .080 .131 .394* -.062 .174 .141  .238 .097 .113 .239 .112 .163 .089 .000 .151 .063 .003 .234 .242 
p .368 .167 .299 .441 .202 .000 .548 .090 .170  .020 .345 .275 .019 .278 .112 .388 .999 .142 .545 .977 .022 .017 
MCP1 r .308* .343* .149 .091 .324* .067 .211 .429* .132 .238  .372* .142 .615* .432* .195 .210 .285* .394* .365* .124 .402* -.132 
p .002 .001 .147 .376 .001 .514 .039 .000 .200 .020  .000 .168 .000 .000 .057 .040 .005 .000 .000 .230 .000 .201 
MCP4 r .222 .325* .179 .249 .191 .179 .151 .421* .082 .097 .372*  .358* .348* .317* .123 .209 .426* .286* .465* -.032 .162 .008 
p .030 .001 .081 .015 .062 .082 .143 .000 .430 .345 .000  .000 .001 .002 .231 .041 .000 .005 .000 .755 .114 .942 
Mip1b r .361* .307* .159 .134 .139 .100 .059 .132 .188 .113 .142 .358*  .210 .280* .219 .088 .160 .148 .223 -.031 .202 .087 
p .000 .002 .123 .192 .175 .333 .567 .199 .067 .275 .168 .000  .040 .006 .032 .393 .120 .150 .029 .764 .048 .400 
Eotaxin r .217 .196 .114 .084 .401* .015 .244 .316* .183 .239 .615* .348* .210 
 
.397* .349* .141 .426* .287* .427* .028 .501* -.002 
p .034 .055 .269 .416 .000 .882 .017 .002 .075 .019 .000 .001 .040 
 













































































































slCAM1 r .458* .297* .431* .127 .209 .117 -.031 .348* .203 .112 .432* .317* .280* .397*  .373* .405* .413* .242 .402* -.117 .244 -.009 
p .000 .003 .000 .217 .041 .258 .764 .001 .048 .278 .000 .002 .006 .000  .000 .000 .000 .017 .000 .258 .017 .932 
sVCAM
1 
r .290* -.052 -.105 .038 .184 .228 -.087 .093 .345* .163 .195 .123 .219 .349* .373*  -.007 .137 .038 .269* -.069 .277* .259 
p .004 .617 .308 .715 .073 .025 .400 .365 .001 .112 .057 .231 .032 .000 .000  .948 .183 .716 .008 .502 .006 .011 
SAA r .213 .368* .598* .011 .024 -.133 .154 .212 .055 .089 .210 .209 .088 .141 .405* -.007  .213 .106 .220 .020 .059 -.128 
p .037 .000 .000 .912 .820 .198 .133 .038 .594 .388 .040 .041 .393 .169 .000 .948  .038 .303 .031 .846 .569 .212 
TARC r .177 .237 .209 .014 .105 -.078 .134 .370* .122 .000 .285* .426* .160 .426* .413* .137 .213  .193 .304* -.208 .276* -.090 
p .084 .020 .041 .893 .307 .452 .193 .000 .237 .999 .005 .000 .120 .000 .000 .183 .038  .060 .003 .042 .006 .386 
Tie2 r -.007 .161 .052 .142 .073 .221 -.037 .337* .099 .151 .394* .286* .148 .287* .242 .038 .106 .193  .218 -.194 .105 -.007 
p .946 .116 .616 .168 .481 .030 .718 .001 .338 .142 .000 .005 .150 .005 .017 .716 .303 .060  .033 .059 .309 .946 
IP10 r .402* .315* .210 .081 .106 .274* .237 .133 .073 .063 .365* .465* .223 .427* .402* .269* .220 .304* .218  .201 .327* .197 
p .000 .002 .040 .431 .303 .007 .020 .196 .479 .545 .000 .000 .029 .000 .000 .008 .031 .003 .033  .050 .001 .054 
IFNγ r .140 .047 -.008 .270* -.019 .067 .181 -.124 -.215 .003 .124 -.032 -.031 .028 -.117 -.069 .020 -.208 -.194 .201  .029 .101 
p .174 .647 .935 .008 .853 .519 .078 .230 .035 .977 .230 .755 .764 .787 .258 .502 .846 .042 .059 .050  .777 .327 
Eotaxin
3 
r .232 .195 .029 -.061 .194 .173 .185 .171 .319* .234 .402* .162 .202 .501* .244 .277* .059 .276* .105 .327* .029  .021 
p .023 .058 .777 .558 .058 .092 .071 .096 .002 .022 .000 .114 .048 .000 .017 .006 .569 .006 .309 .001 .777  .841 
TNFβ r .110 -.110 -.049 -.108 .082 .281* -.117 -.167 .039 .242 -.132 .008 .087 -.002 -.009 .259 -.128 -.090 -.007 .197 .101 .021  
p .288 .285 .637 .295 .430 .006 .258 .104 .709 .017 .201 .942 .400 .985 .932 .011 .212 .386 .946 .054 .327 .841  
 
















































































































TNFα r  .423* .300 .348 .186 -.044 .085 -.017 .235 .224 .317 .289 .350 .177 .466* .292 .200 .332 .184 .510* .298 .002 .053 
p  .002 .034 .013 .196 .761 .556 .909 .101 .117 .025 .042 .013 .220 .001 .040 .165 .019 .202 .000 .036 .990 .716 
IL6 r .423*  .711* .229 .098 .010 .335 .401* .055 .204 .449* .390* .193 .249 .541* .056 .492* .182 .302 .352 .291 -.057 -.121 
p .002  .000 .110 .498 .945 .017 .004 .705 .155 .001 .005 .180 .082 .000 .698 .000 .207 .033 .012 .040 .696 .406 
CRP r .300 .711*  .240 -.080 -.022 .377* .198 .009 -.010 .278 .394* .175 .122 .516* -.064 .631* .242 .264 .344 .182 -.029 -.126 
p .034 .000  .093 .578 .880 .007 .169 .950 .943 .051 .005 .225 .399 .000 .659 .000 .090 .064 .014 .205 .842 .388 
IL10 r .348 .229 .240  .119 .212 .173 -.038 -.203 .297 .184 .089 .178 .157 .181 .007 .274 -.108 .226 .181 .285 -.154 .073 
p .013 .110 .093  .409 .140 .229 .792 .158 .036 .202 .541 .216 .275 .209 .962 .055 .455 .114 .209 .045 .291 .616 
IL8 r .186 .098 -.080 .119  -.027 .179 .275 -.008 .280 .448* .290 .081 .474* .187 .168 -.172 .103 .292 .110 -.250 .315 .308 
p .196 .498 .578 .409  .854 .214 .053 .955 .049 .001 .041 .574 .001 .193 .244 .233 .478 .040 .446 .080 .028 .032 
IL12 r -.044 .010 -.022 .212 -.027  .034 .148 -.012 .477* .024 .088 .011 -.028 -.038 .380* .112 -.122 .135 .253 .172 .001 .198 
p .761 .945 .880 .140 .854  .815 .304 .932 .000 .871 .544 .939 .849 .792 .007 .439 .399 .352 .076 .231 .995 .172 
IL7 r .085 .335 .377* .173 .179 .034  .286 -.069 .039 .251 .315 .281 .187 .299 .233 .248 .106 .185 .261 .086 .189 .100 
p .556 .017 .007 .229 .214 .815  .044 .634 .788 .079 .026 .048 .193 .035 .104 .083 .463 .198 .067 .553 .193 .495 
IL15 r -.017 .401* .198 -.038 .275 .148 .286  .145 .127 .324 .505* .132 .438* .552* .302 .348 .255 .425* .092 -.107 -.017 -.103 
p .909 .004 .169 .792 .053 .304 .044  .317 .380 .022 .000 .361 .001 .000 .033 .013 .074 .002 .525 .461 .907 .482 
IL16 r .235 .055 .009 -.203 -.008 -.012 -.069 .145  .041 .069 .067 .025 .105 .141 .324 .021 .354 .146 .063 -.151 .153 -.003 
p .101 .705 .950 .158 .955 .932 .634 .317  .776 .634 .643 .861 .467 .329 .022 .883 .012 .311 .665 .295 .295 .983 
IL17 r .224 .204 -.010 .297 .280 .477* .039 .127 .041  .270 .044 .210 .186 .133 .144 .101 .002 .339 .137 .060 .050 .195 
p .117 .155 .943 .036 .049 .000 .788 .380 .776  .058 .763 .144 .197 .358 .319 .487 .989 .016 .344 .678 .731 .179 
MCP1 r .317 .449* .278 .184 .448* .024 .251 .324 .069 .270  .465* .095 .658* .479* .207 .279 .407* .493* .427* .013 .350 -.036 
p .025 .001 .051 .202 .001 .871 .079 .022 .634 .058  .001 .511 .000 .000 .149 .050 .003 .000 .002 .930 .014 .807 
MCP4 r .289 .390* .394* .089 .290 .088 .315 .505* .067 .044 .465*  .294 .422* .484* .279 .302 .576* .353 .527* -.013 .118 .077 
p .042 .005 .005 .541 .041 .544 .026 .000 .643 .763 .001  .038 .002 .000 .050 .033 .000 .012 .000 .927 .419 .601 
Mip1b r .350 .193 .175 .178 .081 .011 .281 .132 .025 .210 .095 .294  .233 .369* .109 .231 .167 .186 .147 .129 .059 .136 
p .013 .180 .225 .216 .574 .939 .048 .361 .861 .144 .511 .038  .104 .008 .450 .107 .247 .196 .307 .373 .689 .350 
Eotaxin r .177 .249 .122 .157 .474* -.028 .187 .438* .105 .186 .658* .422* .233 
 
.548* .274 .277 .351 .352 .241 -.043 .307 .077 
p .220 .082 .399 .275 .001 .849 .193 .001 .467 .197 .000 .002 .104 
 













































































































slCAM1 r .466* .541* .516* .181 .187 -.038 .299 .552* .141 .133 .479* .484* .369* .548*  .457* .581* .403* .428* .388* .021 .122 .018 
p .001 .000 .000 .209 .193 .792 .035 .000 .329 .358 .000 .000 .008 .000  .001 .000 .004 .002 .005 .885 .404 .903 
svCAM1 r .292 .056 -.064 .007 .168 .380* .233 .302 .324 .144 .207 .279 .109 .274 .457*  .074 .227 .163 .373* .064 .296 .298 
p .040 .698 .659 .962 .244 .007 .104 .033 .022 .319 .149 .050 .450 .054 .001  .608 .113 .259 .008 .657 .039 .037 
SAA r .200 .492* .631* .274 -.172 .112 .248 .348 .021 .101 .279 .302 .231 .277 .581* .074  .231 .192 .359 .178 .146 -.261 
p .165 .000 .000 .055 .233 .439 .083 .013 .883 .487 .050 .033 .107 .051 .000 .608  .106 .182 .011 .216 .317 .071 
TARC r .332 .182 .242 -.108 .103 -.122 .106 .255 .354 .002 .407* .576* .167 .351 .403* .227 .231  .233 .263 -.130 .221 .020 
p .019 .207 .090 .455 .478 .399 .463 .074 .012 .989 .003 .000 .247 .012 .004 .113 .106  .104 .065 .368 .127 .891 
Tie2 r .184 .302 .264 .226 .292 .135 .185 .425* .146 .339 .493* .353 .186 .352 .428* .163 .192 .233  .184 -.013 -.022 .083 
p .202 .033 .064 .114 .040 .352 .198 .002 .311 .016 .000 .012 .196 .012 .002 .259 .182 .104  .201 .929 .883 .568 
IP10 r .510* .352 .344 .181 .110 .253 .261 .092 .063 .137 .427* .527* .147 .241 .388* .373* .359 .263 .184  .429* .111 .113 
p .000 .012 .014 .209 .446 .076 .067 .525 .665 .344 .002 .000 .307 .091 .005 .008 .011 .065 .201  .002 .446 .441 
IFNγ r .298 .291 .182 .285 -.250 .172 .086 -.107 -.151 .060 .013 -.013 .129 -.043 .021 .064 .178 -.130 -.013 .429*  -.016 .040 
p .036 .040 .205 .045 .080 .231 .553 .461 .295 .678 .930 .927 .373 .765 .885 .657 .216 .368 .929 .002  .914 .787 
Eotaxin3 r .002 -.057 -.029 -.154 .315 .001 .189 -.017 .153 .050 .350 .118 .059 .307 .122 .296 .146 .221 -.022 .111 -.016  .096 
p .990 .696 .842 .291 .028 .995 .193 .907 .295 .731 .014 .419 .689 .032 .404 .039 .317 .127 .883 .446 .914  .518 
TNFβ r .053 -.121 -.126 .073 .308 .198 .100 -.103 -.003 .195 -.036 .077 .136 .077 .018 .298 -.261 .020 .083 .113 .040 .096  
p .716 .406 .388 .616 .032 .172 .495 .482 .983 .179 .807 .601 .350 .600 .903 .037 .071 .891 .568 .441 .787 .518  
 
* = p < 0.01 
